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Alkaptonuria (AKU) is an ultra-rare, autosomal recessive metabolic disease caused by 
a deficiency of HGD enzyme leading to increased circulating homogentisic acid 
(HGA). HGA is deposited as ochronotic pigment in connective tissues, leading to 
multisystemic involvements including severe arthropathy and cardiovascular 
calcification. 18F-NaF PET/CT is a sensitive imaging modality which can offer unique 
and accurate information concerning the radiotracer activity at the ROI using PET 
semiquantitative assessment methods such as standardised uptake value (SUV). 
 
The main aims of this thesis were to investigate the utility of 18F-NaF PET/CT as an 
imaging biomarker for detecting the early stage of bone involvement, early disc 
degeneration, and the early stage of microvascular calcification for AKU patients. Part 
of this thesis aimed to assess the progression of the disease and the response of therapy 
over four years for SONIA 2 patients by evaluating the changes in 18F-NaF PET/CT 
scans. 
AKU patients who were enrolled in the SONIA 2 trial and underwent 18F-NaF PET/CT 
were included in the analysis in this thesis. HUmean and SUVmax were measured from 
lumbar vertebrae, femoral head, and lumbar disc. SUVmax, TBRmax, and HUmean were 
measured for the main cardiac arteries.  
 
The studies presented in this thesis show four key findings: 
First, high 18F-NaF uptake and low HUmean values were detected in the lower spine and 
hip lesions from 18F-NaF PET/CT scan, indicating active bone turnover and low bone 
density in AKU patients. Bone HUmean and SUVmax values in the spine consistently 
decrease with age, indicating decreased bone density, decreased osteoblastic activity, 
and reduced spine perfusion which may be assiocated with ochronosis and ageing. 
Second, disc degeneration was strongly associated with increased SUVmax in PET 
images and high Pfirrmann scores in MR images in AKU patients. Lumbar disc 
SUVmax increased gradually with age followed by a decline in the later years, which is 
related to the disease progression. In the advanced disc degeneration, less binding sites 
would be available to bind with 18F-NaF and was therefore associated with low SUV.  
Third, there were no significant differences between the nitisinone-treated and non-
treated patients in the adjusted mean change in 18F-NaF PET/CT quantitative values 
for the spine. Minimal changes in the SUVmax and HUmean over the visits have been 
noted in both groups, suggesting that nitisinone may not directly affect spinal tissues 
or the impact of nitisinone needs more time to be noticeable. In fact nitisinone might 
slow the progression of ochronosis by stopping further pigmentation, but it is unlikely 
to reverse ochronosis or treat severe damage, specifically in the lumbar spine regions. 
Fourth, cardiac involvements appeared as increased 18F-NaF uptake and local dense 
areas in 18F-NaF PET/CT images, indicating cardiovascular calcification in AKU 
patients. Calcified vessels were detected in PET images due to the strong biological 
similarities between bone formation and vascular calcification as the main structural 
component in both events is hydroxyapatite; the 18F-NaF uptake mechanism in the 
calcified vessels is similar to that in bone tissues. 
 
Overall, this thesis reveals that 18F-NaF PET/CT scan is a promising imaging 
technique to identify early musculoskeletal and cardiovascular involvements in AKU 
patients. This thesis proposed novel and reliable 18F-NaF PET/CT semiquantitative 
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Alkaptonuria (AKU) is a rare multi-system genetic disorder caused by the 
accumulation of homogentisic acid (HGA) in connective tissues due to mutation in a 
specific enzyme 1. It is now known that the cause of AKU is a deficiency of 
homogentisate 1,2-dioxygenase (HGD; EC 1.13.11.5), an enzyme in the pathway for 
metabolising ingested phenylalanine and tyrosine 1. The deficiency of HGD in the 
tyrosine metabolic pathway leads to an inability to metabolise HGA to 
maleylacetoacetic acid (Figure 1.1). Over time, HGA accumulates and undergoes 
oxidation, hypothesised to result in a melanin-like polymer, which appears as a dark-
brown pigment in connective tissues, termed ochronosis (Figure 1.2). HGA is excreted 
from the body via the urinary system. The high urinary concentration of HGA in AKU 
causes urine to darken upon standing or following exposure to air. HGA deposition as 
an ochronotic pigment in cartilage, joints, and bones leads to them to become brittle 
and black-brown in colour over time, which is why AKU is also known as ‘black bone 
disease’. Pigmentation of cartilage is the direct cause of an early-onset, severe 
osteoarthropathy, termed ochronotic arthropathy, which is one of the central 










Figure 1.1. The tyrosine metabolic pathway. 
The diagram illustrates the phenylalanine and tyrosine degradation pathway. The biochemical 
defect in alkaptonuria is the deficiency of the enzyme homogentisate 1, 2 dioxygenase (HGD). 
HGA is not metabolised as a consequence of HGD deficiency, and over time HGA 
accumulates in connective tissues as ochronotic pigment. The drug nitisinone inhibits the 
enzyme 4-hydroxyphenylpyruvic acid dioxygenase, blocking the production of homogentisic 
acid and downstream metabolites (adapted from reference 2). In non-AKU, significant HGD 









Figure 1.2. Formation of ochronotic pigment. 
Dietary protein is metabolised via homogentisic acid (HGA) to maleylacetoacetate. Deficiency 
of the enzyme homogentisic acid 1, 2-dioxygenase in alkaptonuria leads to increased HGA. 
Oxidative conversion of HGA to benzoquinone acetic acid leads to the production of 
ochronotic pigment, which becomes bound within the connective tissue extracellular matrix 




AKU holds an iconic place in medical history, as the first disease shown to conform 
to Mendelian principles, with an autosomal recessive mode of inheritance 1. The 
earliest case of AKU has been dated to 1500 BC, from the study of an Egyptian 
mummy named Harwa. Both biochemical and radiographical examination of the spine, 
knee, and hip of the mummy established the diagnosis 4. It has been noted that the 
mummy joints were narrowed and pigmented. Clinically, the first AKU case was 
reported by Scribonius in 1584 in a healthy child whose urine was ‘black as ink’ 
coining the term black urine disease 5. In 1609, Schenck reported the same clinical 
finding in a Carmelite monk. Subsequently, several cases were reported by Zacutus 




the first to use the term ‘alcapton’, which described the discolouration of urine when 
alkali was added 1,5. Boedecker gave the substance responsible for darkening the name 
‘alkapton’, derived from Arabic alkali, and the Greek word meaning ‘to suck up 
oxygen greedily', which refers to the property of acid oxygen uptake in alkaline 
solution 5. The term ‘ochronosis’ was first used by Virchow in 1866 to describe a case 
of a 67-year old male patient characterised by black pigmentation in the articular 
cartilage, tendons, ligaments and arteriosclerotic plaques 6. The patient died of 
congestive heart failure, and the pigmented tissue which was examined 
microscopically, appeared as yellow/brown (ochre) in colour. Three decades later in 
1891, Wolkow and Bauman identified 2,5-dihydroxyphenylacetic acid (HGA), the 
chemical species of the causative agent of AKU 1.  
 
In 1902, Albrecht proposed an association between AKU and ochronotic arthropathy. 
A few years later, Osler diagnosed ochronosis clinically in two AKU patients. In 1908, 
Archibald Garrod first discribed AKU as an ‘inborn error of metabolism’, after finding 
that many affected individuals were the offspring of consanguineous parents. In 1909, 
he suggested that the deficiency of a specific enzyme that splits the aromatic ring of 
HGA was the cause of AKU. After more than fifty years, La Du confirmed this theory 
when he established that HGD, the enzyme involved in the tyrosine and phenylalanine 
pathway in the liver, was missing in a patient with AKU 5.   
 
1.1.2 Epidemiology  
 
AKU is classified as an ultra-rare disease; today, the incidence of AKU is estimated to 
range from one out of 250,000 to one out of 1,000,000 births worldwide 7. However, 
there are specific hotspots where the incidence rate is much higher, such as in Slovakia 
and the Dominican Republic, where it is estimated to be one out of 19,000 8,9. Since 
1962 1, the cases documented amount to roughly 600 patients from 35 countries. 
Nowadays, more than 1000 patients have been identified with AKU worldwide 10. 
According to a worldwide review on AKU, cases have been recorded in other 
countries, including the United States 11, Saudi Arabia 12, Turkey 13, India 6, Sudan, 
France 14, United Kingdom 15, Germany, Lebanon, and Jordan 16. Jordan has been 
recently identified as one of the hotspots for AKU, including the diagnosis of 40 cases 




Several possible explanations exist for the high incidence in some world regions. 
Living in isolated hamlets may cause genetic isolation and the founder effect, leading 
to increased local transmission of genetic variants, including defective alleles, from a 
common ancestor 9. A possible reason for increased incidence in Arabic countries and 
India is a consanguineous marriage, which is more common in Arabic, Muslim and 
Indian cultures 5. It is believed that there are likely many unidentified patients with 
AKU, particularly in countries where consanguineous marriages are more common, 
and in regions where healthcare challenges limit accurate diagnoses of AKU.  
 
1.1.3 Clinical presentation 
 
1.1.3.1 Homogentisic acid 
 
Despite the rarity of the AKU, signs of the disease can be recognised from birth. 
Children with AKU are usually asymptomatic, but the main pathognomonic 
characteristic of the disease appears at birth and persists throughout life, which is 
black-brown urine (Figure 1.3.A). Darkening of urine in diapers (nappies) is often the 
first feature of AKU to be identified in infant patients. However, in some cases, 
darkening of urine may take several hours, and therefore go unnoticed by the parent or 
patient. In this case, an additional test may be required to confirm the AKU diagnosis, 
which involves adding sodium hydroxide (NaOH) to the fresh urine sample. Adding 
this step will lead to immediate darkening of the urine 12. This incident can be 
explained by the oxidisation of a high HGA concentration in the urine by air or 
alkalinisation, which leads to urine discolouration. The oxidisation process converts 
the HGA to benzoquinone acetic acid (BQA) turning the urine black. Oxidisation of 
other bodily fluids, including sweat, also occurs, which can lead to noticeable 
discolouration of clothing in areas such as under arms.  
 
1.1.3.2 Ochronosis  
 
Besides the black-brown urine, the overt clinical manifestations of AKU usually do 
not appear until the third-fourth decades of life, due to the slow progressive nature of 
the disease. The non-excreted HGA by the urinary system results in increased HGA 
accumulation in tissues throughout the body over many years, which leads to a 




pigment appears in the skin, as brown sclera pigmentation in the eyes and as blue-
black discolouration in the pinna of the ear (Figure 1.3.C). Ear pigmentation has been 
reported in 70% of AKU patients, and eye pigment been noticed in 50% of AKU 
patients. Discolouration of other parts, including the gums, hands, and nose, has also 
been documented 14,18. 
 
In the third-fourth decades of life, HGA pigment accumulates in the articular cartilage 
in addition to skeletal, cardiovascular, genitourinary, respiratory, ocular and cutaneous 
tissues. The advanced stage appears between 50 and 60 years, with rapid disease 
progression 19. The symptoms worsen with age due to several reasons. One of the 
major reasons is decreased kidney function with age, causing a decrease in HGA urinary 
excretion. Another possible explanation is the cartilage degradation that occurs as part 
of the natural ageing process in later life, which exacerbates the existing joint damage 
caused by ochronosis 20.  
 
 
Figure 1.3. Ochronotic pigmentation features.  
A. Dark urine of AKU. B. External ear cartilage pigmentation. C. Dark pigmentation of the 
temporal aspect of the sclera in the right eye with vessels coursing superficial to pigmentation. 




 Ochronotic arthropathy  
 
The most severe complication of ochronosis is musculoskeletal and joint 
involvements, which is also known as ochronotic arthropathy (see Figure 1.4). The 
musculoskeletal involvement primarily affects the axial skeleton and weight-bearing 
joints, causing lower back and joint pain. Usually, spinal symptoms appear by the age 
of 30 and progress with age 19.  
 
Ochronotic arthritis closely resembles general osteoarthritis (OA) with pain and 
damage to the large joints and spine. Clinically, both conditions exhibit similar 
abnormal morphostructural radiological changes of joints and the spine. In contrast to 
OA, in which osteophytic changes and lumbosacral changes are predominant, the 
sacroiliac joint changes are not as evident in ochronotic osteoarthropathy. The spinal 
degeneration changes for ochronosis include narrowing of the intervertebral discs 
(IVDs) with severe disc calcification, sclerosis of the endplate, osteophytosis, bony 
bridges, and spondylitis and disc herniation. The intervertebral vacuum phenomenon 
is one of the common disc degeneration findings in AKU patients. Vacuum 
phenomenon is a degenerative disc disorder which usually appear as gaseous 
collection in the IVD space and within vertebral bodies 22. The ochronotic pigment is 
deposited in hyaline cartilage and both annulus fibrosis and nucleus pulposus at 
multiple IVD levels. The nucleus pulposus probably becomes ossified in advanced 
cases, which is readily recognised on spine images 23. In 20% of ochronotic 
spondylosis cases, the initial presenting symptom appears as an acute rupture of the 
nucleus pulposus. 
 
Although the entire spine is usually affected, lumbar spine symptoms usually occur 
first, followed by the thoracic then cervical regions 3. These changes result in 
predominant back pain, limitation of movement, stiffness and primarily physical 
disabilities. In some cases, the IVD collapses and fuses at multiple spinal levels, 
causing possible loss of physiological curves and resulting in decreased height. In 
advanced cases, the IVD and synovial joints are often found to contain dark brown to 
black material on discectomy, most likely due to ochronotic pigment deposition in 
cartilage and ligaments. In a previous study examining 163 AKU patients, most 




and hip involvement 3. In fact, large weight-bearing joint involvement usually appears 
several years after the spine involvement. In ochronotic arthritis, upper extremity 
involvement is less commonly recognised, except in the shoulder, compared to 
multiple lower extremity involvement, which is more common 24. Large peripheral 
joints, such as knees and hips, are most commonly affected by ochronosis. Hand, 
elbow and wrist involvement is rare in AKU, but numerous cases of multi-upper joint 
involvement have been reported, including carpal, metacarpal and distal 
interphalangeal joints 24.  
 
Additionally, tendon also can be pigmented 5. Numerous tendon-related pathologies 
have been reported in AKU, including radiographic findings of tendon calcification, 
which causes increased thickness of the tendon 14. In the advanced stage, full-thickness 
tears may also be recognised in ochronotic patients who may need a casting with the 
ankle in the talipes equinus position or surgical repair. 
 
It is important to highlight that the interactions with environmental factors such as gait 
and abnormal load-bearing can affect the extent of bone and joint involvement in 
AKU. Typically, joint degeneration and its associated symptoms become more 







Figure 1.4. Features of ochronotic arthrophathy in human joint tissue.  
A, Markedly ochronotic bulging intervertebral discs and the vertebral body is seen from within 
the abdominal cavity. B, spine seen from posterior or dorsal aspect showing ochronotic 
pigment. C, Dark pigmentation seen in arthroscopy of knee joint showing fibrillary blackened 
cartilage. D, appearance of pigmented head of femur showing uniform pigmentation. E, Hip 
joint showing rim of cartilage and marked cartilage loss with exposure of underlying bone. F, 
unstained cut section of femur condyle showing little pigment on left side progressing to full 





 Cardiac ochronosis 
 
Connective tissues of the cardiovascular system are particularly susceptible to damage 
by ochronosis (see Figure 1.5). Although the pathogenesis of cardiovascular 
ochronosis is unclear, the extensive extracellular deposits of ochronotic pigment in the 
cardiac tissues are present 25. The accumulation of ochronotic pigment within cardiac 
connective tissues acts as a trigger for dystrophic calcification. The cardiac arteries 
can be affected by thickening and calcification of the arterial walls in ochronotic 
patients leading to aortic stenosis and mixed cardiac diseases. Although many clinical 
factors can be associated with calcified aortic valve disease in AKU, there is no clear 
statistical correlation between aortic stenosis and plasma HGA level 26,27. This can be 
explained by the fact that plasma HGA level is a snapshot of the disease at the time of 
measuring, while the severe cardiovascular involvements are due to ochronotic 
pigments which deposited years ago. 
 
Cardiovascular manifestations in AKU patients are common. There are numerous case 
reports of cardiac involvement in AKU, including coronary artery disease, aortic root 
disease, and aortic stenosis 28–32. In very severe cases, patients may require a heart 
transplant 25. AKU has been diagnosed intra-operatively during aortic valve 
replacement, due to presence of ochronotic pigmentation in the heart 25,33. A partial or 
entire arterial wall can be covered with black patches and may be extended into the 
endothelium, causing valve involvement. 
 
Fifty-eight AKU patients were evaluated to delineate the natural history of AKU by 
Phornphutkul et al. 7. In that study, cardiac involvement appeared at the mean age of 
54 years, with no clear sign of cardiac abnormality before the age of 40. Additionally, 
50% of patients were found to have severe cardiovascular involvement after 59 years 
of age. In that study, coronary artery calcification was detected from computed 
tomography (CT). Interestingly, elevated serum cholesterol level was not correlated 
with coronary artery calcification in these patients.  
 
In the UK National Alkaptonuria Centre (Liverpool), a systematic cardiovascular 
evaluation was performed to understand the cardiovascular changes for patients with 




patients from 14 families using full electrocardiographic, echocardiographic, and 
coronary angiography. They found that more than 40% of AKU patientts had a 
significant burden of aortic valve disease by the fifth decade of life, with no explicit 
finding of a substantial burden of mitral valve disease or coronary artery disease. 
Another study by Hawaida et al. 27 evaluated the presence of valvular heart disease 
and vascular calcification for 76 AKU patients using echocardiographic screening and 
CT scans. In that study, a subgroup of 40 patients was enrolled in a nitisinone treatment 
study and underwent a non-contrast CT scan; only 17 scans were suitable for cardiac 
evaluation and coronary and valvular calcification evaluation. Coronary and valvular 
calcification was noted in CT images and scored using the Agatston cardiac scoring 
system at coronary, intracardiac, and aorta regions. It was found that 18% of the 
patients showed coronary calcification, 47% of the patients showed valvular 
calcification, and 65% showed aortic calcification. All patients had substantial 
evidence of intracardiac calcification by the age of 60. A modest relationship was also 




Figure 1.5. Features of cardiovascular ochronosis in human tissue.  
A. Longitudinal cut section of the abdominal aorta and common iliac bifurcation, showing 
more pigment at bifurcation and branch point orifices. B, Low-pressure pulmonary trunk and 
valve showing little pigment. C, Aortic root and valve with marked pigmentation. Figure from 
21. 
 
1.1.4 Mechanism underlying AKU and connective tissue change 
 
In AKU, excessive HGA production leads to an increase in HGA level in circulating 
and tissue concentrations, but the accumulation of pigment and ochronosis throughout 




all connective tissues over the body. Joint cartilage is particularly susceptible to 
ochronosis, which results in weakness and brittleness of the joint tissues 35. HGA-
derived pigment is most heavily deposited in large weight-bearing joints such as the 
hip, shoulder, elbow and knee. Within fibrocartilaginous tissues, pigmentation has 
been identified in the annulus fibrosis of IVDs and pubic symphysis. Pigmentation is 
also found within the elastic cartilage of the external ear and epiglottis. Ochronotic 
pigment is also deposited in non-cartilaginous tissues; it can be found in the skin, eye, 
brain, tendons, ligaments, perichondrium, synovial membrane and periosteum. 
Pigmentation has been identified in the cardiovascular system within heart valves, 
chordae tendineae, major coronary arteries and aortic artery.  
 
The pathogenesis of ochronosis is still not fully understood, nor is the exact mechanism 
of pigment formation from HGA. Although there are still many unexplained questions 
about ochronosis, the initiation of pigmentation within human cartilage was 
elucidated. Taylor et al. carried out a number of investigations to investigate the 
initiation and progression of ochronosis in AKU 36,37. Taylor et al. demonstrated that 
early ochronotic pigment were associated ultrastructurally with collagen periodicity 36. 
Histological exanimation of an alkaptonuric hip joint capsule showed that the presence 
of extracellular pigmentation was associated with the collagen fibres and intracellular 
pigmentation within fibroblasts. Taylor et al. also identified that initial pigmentation 
appears as pericellular and intracellular pigmentation of chondrons within the calcified 
articular cartilage. Mechanical and biochemical damage caused by mechanical 
loading, chemical attack, and ageing could significantly increase the possibility of 
ochronosis in cartilage. It has been hypothesised that the collagen fibres may have sites 
where HGA can bind, and that these sites in a healthy collagen fibres are protected by 
proteoglycans that prevent HGA from binding. Proteoglycans can be lost due to 
mechanical or biochemical damage as part of age-related wear and tear, which exposes 
these sites to binding of HGA. 
 
Following the initial binding of HGA, it is hypoethezsied that rapid deposition of HGA 
will occur as an ochronotic polymer resulting in stiffening of the collagen fibre. This 
process results in further mechanical damage leading to progressive ochronosis 20. It 
is important to mention that collagen damage also occurs naturally in the absence of 




Ochronotic pigments is extensively deposited in connective tissue, which contains type 
1 collagen. HGA accumulation may alter the cross-linking structure and integrity of 
collagen and interactions of the macromolecules by physical binding. Chemically, 
HGA is oxidised to a melanin-like polymer by an enzymatic process via BQA 24. The 
oxidation process leads to the formation of free radicals in connective tissue, which is 
also associated with tissue damage by inciting inflammation in the cartilage. Tendon 
can be considered a pigment deposition site as it richly contains type 1 collagen 5,38. 
The ochronotic process eventually causes degradation of cartilage and joint 
degeneration in the axial and appendicular skeleton, which leads to premature arthritis, 
bone fracture, osteopenia and muscle and tendon ruptures 38.  
   
1.1.5 Prevention and treatment options for AKU 
 
Although AKU was described over a hundred years ago, the prevention and treatment 
for AKU patients was focused on symptomatic treatment and limiting the progression 
of ochronosis symptoms. Ascorbic acid (vitamin C), low protein diets, classic 
analgesic drugs, physiotherapy, joints replacement were used as a possible treatment 
option for AKU patients. However, these treatments were clinically ineffective and 
had no effect on the intrinsic cause of ochronosis. Recently, in 2020, nitisinone has 
been licenced for treating AKU patients 39.What follows is a description and review of 
past and current therapy options for AKU patients. Table 1.1 summarises all the 
prevention and treatment options that have been tested and reported for AKU patients. 
 
1.1.5.1 Ascorbic acid  
 
It has been assumed that antioxidant therapy would have a powerful effect in treating 
AKU patients by inhibiting the oxidation of HGA to BQA, an intermediary product in 
the formation of ochronotic pigment in connective tissues. From this point, it has been 
hypothesised that using ascorbic acid (vitamin C); a powerful antioxidant agent, as a 
treatment option for AKU patients, would prevent ochronosis by inhibiting the 
oxidative conversion of HGA to BQA (Figure 1.1 and Figure 1.2). Interestingly, based 
on previous studies, the most unexpected finding was that ascorbic acid has no 




In 1940, Sealock et al. 40 administrated ascorbic acid (1 to 4 gram/day) to AKU patients 
without getting any effect on the excretion of HGA. It had been presumed that 
preventing the oxidation of HGA using ascorbic acid could delay the darkening of 
urine only. Another study was done by Wolff et al. 41 who investigated the effect of 
administrating vitamin C to AKU patients, testing the effect of vitamin C in both adult 
and infant. Wolff et al. reported that a high dose of vitamin C could possibly reduce 
urinary BQA and free radical formation; however, it appeared not to affect HGA 
excretion. Furthermore, it was suggested that vitamin C increased the levels of HGA 
in the urinary system, contributing to the formation of renal oxalate stones, which 
could be an unsuitable treatment for young infants. Additionally, several studies 
highlighted that antioxidant ascorbic acid therapy was not clinically useful 3,18. 
 
1.1.5.2 Low protein diet 
 
Another possible treatment option was lowering tyrosine in the diet, which would 
prevent the formation of BQA by the degradative HGA pathway. Approximately 6% 
of dietary protein is degraded via the HGA pathway. The idea is that reducing the 
dietary intake of phenylalanine and tyrosine will reduce the amount of HGA produced 
and therefore prevent ochronotic pigmentation. Hasas et al. 42 investigated the 
effectiveness of protein restriction in 16 AKU patients aged between 3 to 27 years old. 
In that study, Hasas noted that protein restriction resulted in a significant reduction of 
HGA urinary excretion in 12 years old and younger. The result was less evident for 
older age patients, suggesting that protein intake restriction may be useful for younger 
AKU children only. It has also been reported by Phornphutkul et al. 7 that no 
significant change in urinary HGA level been noted with protein restriction in AKU 
patients. Another study showed relief of joint pain in children after restricting protein 
intake 43. Indeed, it is challenging to restrict a low protein diet for life, as it needs 
intensive specialist supervision during growth and is difficult to maintain 3. 
 
1.1.5.3 Nitisinone  
 
Presently, the most promising treatment for AKU patients is inhibiting 4-
hydroxyphenylpyruvic acid dioxygenase (HPPD), the second enzyme in the tyrosine 




(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC), is a HPPD 
inhibitor which can block the conversion of 4-HPPA into HGA (Figure 1.1). The 
regulatory agencies have approved nitisinone for the treatment of hereditary 
tyrosinemia type 1 (HT-1). Hereditary tyrosinemia type 1 (HT-1) is another inborn 
tyrosine metabolism disorder which results in chronic liver and kidney disorder due to 
the accumulation of toxic metabolites that are downstream of HGA in the tyrosine 
pathway. Data from several sources have identified the reduction of HGA levels and 
ochronotic pigment associated with nitisinone intake.  
 
In 1998, Anikster et al. 44 suggested using nitisinone to treat AKU patients as it would 
reduce the production of HGA. One year later, Suzuki et al. 45 investigated the effect 
of nitisinone in an AKU mouse model, and he found a reduction in urinary output of 
HGA. The evidence from that study suggests that nitisinone could be a possible 
pharmacotherapeutic agent for AKU. In 2002, two patients were treated with oral 
administration of nitisinone, 0.35-1.4 mg/day, twice a day, for 10 and 9 days 7. In that 
study, urinary HGA excretion reduced after the course of treatment, from 6.4 g to 1.7 
g per day after nine days and 2.9 to 0.13 g per day after ten days. Initial observations 
suggested that there may be a link between taking nitisinone and reducing ochronosis 
for AKU patients.  
 
In addition to the clinical experiments, preclinical experiments of nitisinone in AKU 
mice were performed. Preston et al. 46 studied the therapeutic effect of long-term 
treatment with nitisinone in the AKU mouse model, examining the plasma HGA level 
and knee joint pigmentation. A considerable reduction in plasma HGA was reported, 
as well as joint ochronosis inhibition in those mice treated with nitisinone compared 
to non-treated mice. 
 
Since 2005, the National Institutes of Health (NIH) has investigated the safety and 
efficacy of nitisinone in AKU. Suwannarat et al. 47 evaluated 9 AKU patients who 
received oral doses of nitisinone with a regular diet, starting with 0.35 mg for eight 
days, then followed by 1.05 mg for three months. In that study, it was noted that urinary 
HGA concentration reduced by 95% from 4 g/day to 0.2 g/day, and tyrosine levels 
increased significantly from 68 μmol/L to 760 μmol/L. Additionally, Suwannarat 




had reported lower pain in their affected joints. A longer-term trial then followed, with 
a larger sample group, including treatment and non-treatment groups, between 2005 
and 2009. In a 3-year randomised therapeutic trial, Introne et al. 48 investigated the 
effect of 2.1 mg/day nitisinone on 40 AKU patients including 20 patients in the 
treatment group and 20 patients in the non-treatment group. This study showed a 
sustained and marked reduction in urine HGA by 98% and plasma HGA levels by 95% 
throughout the study. To examine the clinical efficacy of the drug, Introne et al. used 
hip rotation examination, which did not show a statistically significant difference in 
the range of motion between the treated and untreated groups reporting an inconclusive 
outcome. These results would seem to suggest that it is possible that the joint 
degeneration started early in AKU patients and is irreversible even with the reduction 
of HGA.  
 
The agreement of using nitisinone in AKU patients by the regulatory agency, was 
recently approved in 2020 39,49. Nitisinone has been used off-label at the National 
Alkaptonuria Centre (NAC) since 2012 for patients attending the Royal Liverpool 
University Hospital, using 2 mg/day, the same dose given in the NIH study. In 2018, 
NAC results were published, confirming the biochemical efficacy of nitisinone in 
AKU 38. The NAC study reported that nitisinone can effectively reduce the urinary 
HGA level, slow morbidity progression, and may partially reverse ochronosis after 
taking nitisinone.   
 
DevelopAKUre founded a series of international clinical trials to investigate the 
efficacy and safety of nitisinone in order to obtain marketing authorisation for the 
treatment of AKU, which has now been approved by the European Medicines Agency. 
The main three research sites are Royal Liverpool University Hospital, Liverpool, UK, 
the National Institute of Rheumatic Diseases, Piestany, Slovakia and Hospital Necker 
and Institute Necker in Paris, France. Three studies were involved; the first study was 
to assess the dose-response and was called ‘Suitability of Nitisinone in Alkaptonuria 
1’ (SONIA 1), the second study was to determine the efficacy of nitisinone and called 
‘Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2), and the last study was a cross-






In 2013, the Royal Liverpool University Hospital and the National Institute of 
Rheumatic Diseases, Piestany, started the first trial (SON1A 1). The SONIA 1 trial 
aimed to identify the most appropriate nitisinone dose in patients with AKU over a 
period of four weeks by investigating the effect of different doses in reducing urinary 
HGA excretion 51. Forty patients were grouped into five groups; each group received 
a different daily nitisinone dose, 0 mg, 1 mg, 2 mg, 4 mg, and 8 mg. The most effective 
dose which reduced urinary HGA down by 98.8% and  serum HGA to < 3.1 μmol/L 
was shown in the group treated with the highest amount of daily dosage of nitisinone 
8 mg. No serious adverse events were reported in the SONIA 1 study.  
 
In 2014, a longer-term trial called SONIA 2 started and finished in 2019. The primary 
objective of the SONIA 2 trial was to analyse the effectiveness of nitisinone in AKU 
after four years of treatment. In addition to this, the study intended to confirm whether 
nitisinone is safe for use by most AKU patients. All the participants engaged in SONIA 
2 were recruited from all across Europe and Jordan. The SONIA 2 study was based at 
three different clinical sites, including Paris (France), Liverpool (UK) and Piestany 
(Slovakia). These sites are chosen based on the fact that there are experts in AKU and 
support from AKU society. In total, 138 AKU patients were identified and randomly 
divided into two equal groups. Out of these, 69 were treated with nitisinone reciving 
10 mg/day, and the other 69 were not given nitisinone. The impact of nitisinone on the 
HGA level excreted into the urine and overall disease progression in the whole-body, 
including bone and joints, was observed over four years. Each patient attended their 
allocated test centre for a total of six visits. From SONIA 2 data, it would be possible 
to determine the effectiveness and impact of nitisinone and define whether nitisinone 
is safe to be used for the long term.  
 
In 2017, the SOFIA trial started, including 30 AKU patients with a mean age of 38 
years who visited the Royal Liverpool University Hospital. The objective of the 
SOFIA trial was to determine when microscopic and macroscopic ochronosis can be 
identified, and the ideal age to begin nitisinone treatment 52. SOFIA encompassed five 
age groups, 4 patients in each group. A series of clinical tests and examinations were 
performed, including urine tests, blood tests, MRI, ear biopsy, eyes/ear photography 
and gait analysis. SOFIA data showed that ear pigmentation could be identified in the 




a 22 years old patient, while ear pigmentation was first detected in a 34 years old 
patient. Interestingly, MRI results did not show significant changes in the spine and 
joints before 30 years, however gait data showed abnormal results in all patients, 
including the young AKU patients. It was concluded from the SOFIA trial that 
ochronosis could begin before the age of 20 years, suggesting a paediatric study to 
identify when ochronosis first initiates is needed. 
 
Ranganath et al. 53 tested the relationship between bone density and nitisinone therapy 
for 87 AKU patients who attended the NAC between 2007 and 2020 and underwent 
serial clinical evaluations, including DEXA and CT densitometry. In that study, 
patients were grouped into three groups, nitisinone-treatment group, nitisinone plus 
antiresorptive treatment group, and non-treatment group. The changes in regional bone 
density values from DEXA and CT were evaluated to detect the effect of treatment. 
The study focused on three body sites; the femoral neck, hip and lumbar spine. 
Ranganath et al. reported that the group of AKU patients who undertook 2 mg/day 
nitisinone showed a significant reduction in CT values measured at femoral neck and 
hip sites (P < 0.05 and 0.01, respectively), and slightly increase lumbar CT value (P > 
0.05). Only patients on nitisinone plus antiresorptive had improved bone density 
values at all measured ROI (P < 0.001), and surprisingly had significantly more 
fractures than nitisinone-treatment group and non-treatment group. Ranganath et al, 
are suggesting the co-therapy is required to prevent bone loss in AKU patients. 
 
1.1.5.4 Other treatment options 
 
Although lifestyle counselling is also underused and can improve the life quality of 
AKU patients, the existing literature on this area have not been addressed yet 18. 
Minimising joints load and avoiding hard exercises caused by active occupations, 
activities, or hobbies can likely have a positive impact on ochronotic arthropathy 
symptoms. Pain control is tackled by undertaking a variety of classic analgesic drugs 
such as paracetamol, non-steroidal anti-inflammatories, opioids, local anaesthetics, 
anticonvulsants and gabapentin; however, it is only palliative treatment and not 
completely effective. Physiotherapy can also help in reducing joint pain and improve 
mobility. At the advanced stage of ochronotic arthropathy, palliative surgery may be 




replacement, spine surgery and tendon repair may also needed in some cases. It has 
been suggested that liver transplant would successfully eradicate HGA from the body 
54. Organ replacement could improve the metabolic symptoms of AKU however it is 
not justified in a disease with a relatively normal lifespan. Therefore, liver or kidney 
transplant is not used to treat patients with AKU. 
 
Although using nitisinone showed very successful results, it is not a perfect option as 
it can affect the tyrosine levels. Missing enzyme replacement would be the ideal 
treatment for AKU patient. Hypothetically, replacing the missing HGD enzyme with 
gene/enzyme therapy will prevent HGA accumulation and appearance of ochronosis 
in connective tissues. However, clinically, this treatment is not possible yet but may 
be available in the future 3.  
 
Table 1.1. Current and future treatment options available for AKU.  
Adapted from reference 3,18. 
Treatment options Summary 
Ascorbic Acid (vitamin C) 
Efficacy unproven increases HGA production may 
exacerbate the condition 
Low protein diets Efficacy in adults unproven, compliance difficult 
Lifestyle counselling Underused, lack of evidence base 
Physiotherapy Underused 
Surveillance Lack of knowledge prevents utilisation 
Pain control Widely used, palliative, incompletely effective 
Palliative surgery Effective but invasive,  not universally available 
Organ replacement/ Liver 
transplant 
Unjustified in a disease with normal lifespan, lack of 
evidence base 
Reverse pigment binding Not yet available 
Nitisinone Not shown to alter outcomes, increases tyrosine 
Enzyme replacement Not yet available 








1.2 Skeletal system  
 
1.2.1 Anatomy and physiology   
 
The skeleton system consists of bone and connective tissues, which generates the body 
frame, and protects the vital organs 55. Bone is characterised by its strength, rigidity, 
and capacity to heal and rebuild itself regularly. Bone is made up of an inorganic 
mineral phase of crystals bound to protein, mostly collagen 56. The crystals contain a 
composite called hydroxyapatite, which consists of calcium, phosphate and hydroxyl 
ions. Normal bone is in a continuous state of remodelling by resorbing osteoclasts from 
the old and microdamaged bone to mechanically stronger and thicker new bone, which 
adapts to the mechanical stresses of everyday life. The bone turnover process can also 
be triggered or accelerated by pathological conditions like fractures, infections, bone 
tumors or metastases. 
 
The skeleton is comprised of two portions: the axial and the appendicular parts. The 
axial skeleton composes the skull, the thoracic cage and the vertebral column, while 
the appendicular skeleton composes the shoulder girdle, the upper limbs, the pelvic 
girdle, and the lower limbs. This is an essential distinction since many disorders favour 
either the axial or the appendicular portions.  
 
Anatomically, bone is composed of two components: cortical bone, also called 
compact bone, and trabecular bone, also called spongy or cancellous bone (see Figure 
1.6). Both cortical and trabecular bone have similar matrix compositions, but with 
different layout and distribution. Cortical bone is restricted to the outer layer of the 
bone and makes up around 75% of total bone volume. Trabecular bone is restricted to 
the inner layer, having a much larger surface area, around 60%. Although cortical bone 
is a greater mass per unit volume compared to trabecular bone, the metabolic rate in 
trabecular regions is ten times higher than in cortical regions 55. In total, around 5-10% 
of the skeleton is annually renewed. 
 
Besides the bones, the human skeleton comprises of tendons, ligaments and cartilage 
that link the bones together. Articular cartilage is the highly specialised connective 




coefficient which allows joint motion 57. Articular cartilage is structurally devoid of 
blood circulation, lymphatics, and nerves and is strongly influenced by a harsh 
biomechanical and physiological environment. The most significant feature of 
articular cartilage is that it has little ability for healing and repairing. Usually, treatment 
and repair of cartilage damage are challenging for the patient and clinician; therefore, 




Figure 1.6. Anatomy of a bone.  
The femur with its soft tissue, including articular cartilage, blood vessels, bone marrow and 
periosteum. Image performed by BioRender.com 
 
 
1.2.1.1 Spine  
 
The spinal column consists of bones, ligaments and intervertebral discs, functionally 
coordinated to allow upright movement and protect the spinal cord. The bony spinal 
column comprises generally of 33 vertebral bodies that are stacked from the skull to 
the coccyx, one on top of the other 58. The spine consists of 33 vertebral bodies that 
create 5 different sections with their own distinctive features in the normal 




vertebral bodies, 5 sacral vertebral bodies which are fused together to form the sacrum 
and 4 vestigial vertebral bodies which are fused to form the coccyx, see Figure 1.7. 
 
The spine consists of segments consisting of a vertebral body and IVD that adjacent 
surfaces of the vertebra. These discs are at risk of inflammatory and degenerative 
diseases. Ligaments and muscles act as a connective tissue between spinal segments, 
allowing for flexion, tilt, extension, and rotation.  
 
Each IVD forms a fibrocartilaginous joint which consists normally in young and healthy 
IVD of three components: the annulus fibrosus, nucleus pulposus and the cartilaginous 
endplate 59, see Figure 1.8. Annulus fibrosus is the thick outer ring of fibrous cartilage 
that surrounds the nucleus pulposus. The annulus fibrosis is composed of 15–25 
concentric layers that composed of type I and type II collagen. The nucleus pulposus is 
soft and gel-like structure within the disc functioning as a buffer between the end plates 
and transfers hydrostatic pressure. The cartilaginous endplate is a thin horizontal layer 
usually less than 1mm thick of hyaline cartilage that attaches to the border of the 

















1.3 Cardiovascular system 
 
1.3.1 Anatomy and physiology  
 
The cardiovascular system composes of principle components: the heart, blood, blood 
vessels, and the lymphatic system 62,63. The heart is a cone-shaped muscular organ 
located wihtin the central region of the thoracic cavity, called the mediastinum. The 
cardiac muscle is supplied by different branches of coronary arteries. The blood 
vessels transfer blood throughout the body tissues via bulk flow. The main components 
of the vascular system are arteries, arterioles, capillaries, venules, and veins. The 
largest artery in the body is the aorta, divided into ascending aorta, descending aorta, 
and abdominal aorta. All the arteries branch from the aorta and divide into smaller 
vessels. The four main coronary artery branches are the left coronary artery or left 
main stem (LCA), left anterior descending artery (LAD), left circumflex artery (CA), 
and right coronary artery (RCA). There are two major veins: the inferior vena cava, 
which is located below the level of the heart and the superior vena cava, located above 
the heart.  
 
The functional anatomy of the coronary arteries changes throughout the lifespan of 
humans. With ageing coronary arteries become thicker due to calcium deposition 62. 
These changes typically appear in the elderly, causing detrimental cardiac damage, 
myocardial ischemia, and in some cases, it can cause death.  
 
1.4 Medical imaging  
 
Medical imaging is a process of performing a visual representation of different body 
parts for clinical evaluation. Structural and functional information can be established 
by different medical imaging techniques identifying anatomical and physiological 
abnormalities. Moreover, medical imaging may help address important concerns that 
occur during the drug development phase. 
 
Diagnostic imaging includes multiple non-invasive imaging modalities, each with its 
own set of technology, equipment and protocol. Diagnostic imaging techniques 




resonance imaging (MRI), echocardiogram, ultrasound (US), and nuclear medicine 
imaging techniques such as single-photon emission computed tomography (SPECT) 
and positron emission tomography (PET).  
 
Both physicians and AKU researchers are aware of the increased importance of 
different imaging techniques for detection, evaluation, and follow up of disease stages. 
With numerous ongoing research efforts involving large-scale imaging investigations, 
more advanced imaging would inevitably find its place in the clinical management of 
AKU patients. For the diagnosis of ochronosis, radiographic assessment and imaging 
evaluation play a critical role to identify and assess pathological changes caused by 
ochronosis. Therefore, imaging modalities would be a crucial part for enhancing and 
growing our awareness of the natural history of AKU.  
 
1.4.1 Radiographic evaluation of ochronotic arthropathy using different imaging 
modalities  
 
The radiographic features of ochronotic arthrosis should be considered carefully to 
avoid miss diagnosis with other arthrosis disorders such as OA. In the past, the 
relatively uncommon and unrecognised skeletal manifestations of ochronotic 
arthropathy have perhaps contributed to the scarcity of investigations performed in this 
disease area as it is a rare genetic disease 12,64,65. Early diagnosis of ochronotic arthritis 
has a long-term impact on the patient as it allows early detection of structural bone and 
joint damage. The radiographic features of bone involvement in ochronotic cases were 
previously reported in many AKU cases 22,66–70. Most of the AKU radiographic 
features were particularly similar to those which can be noted in other musculoskeletal 
disorders 15,71–75. 
 
What follows is a brief description of medical imaging techniques that are mainly used 
to diagnose bone and bone-related disorders. 
 
1.4.1.1 Conventional X-ray radiography 
 
X-ray is the simplest, least expensive imaging modality, which is usually used as a 




limited sensitivity and specificity as it creates a two-dimensional (2D) anatomical 
image, which may fail to depict abnormalities on individual lesions where specific 
views including obliques are required. X-ray also has low sensitivity to assess the 
changes in bone loss at a follow-up imaging. It has been estimated that plain 
radiography cannot identify bone loss until it exceeded 25-30% of its density, which 
means severe damage has occured by that time 76.  
 
While X-ray images may not show as much detail as other imaging modalities, it is usually 
performed at the first of nearly all musculoskeletal disorders to decide the next steps. 
Spinal X-ray is not recommended to be repeated frequently every year as it may not 
provide additional information, however, it can be used for monitoring structural 
damage over a long-term period 72. The characteristic X-ray imagery associated with 
AKU can show significant calcification of the IVD, and joint narrowing 72.  
 
1.4.1.2 Ultrasound (US) 
 
Although evaluation of bone involvement and periphery of joints abnormalities in 
general by US is restricted, nowadays, US examination offers acceptable results in the 
assessment of ochronotic arthropathy 15,74. US can permit an evaluation of bone and 
joint turnover for AKU patients as it can offer an image of the structural lesions and 
inflammatory changes during the early and late stages of ochronotic arthropathy 15. It 
is important to point out that the quality of US images depends on the frequency of 
sound waves and the type of transducer. It deserves to be mentioned that evaluating 
the level of joint inflammation, abnormal bone and cartilage structure mainly depends 
on the experience level of the sonographers. 
 
1.4.1.3 Dual Energy X-ray Absorptiometry (DEXA) 
  
Clinically, bone densitometry or dual energy X-ray absorptiometry (DEXA) is a gold 
standard method to diagnose osteoporosis by measuring bone mineral density (BMD) 
from two different intensity X-ray beams 77. The basic principle of DEXA is to 
calculate the absorption of the X-ray of high and low-energy transfer within the body, 
assuming that the body consists of two compartments: bone tissue and soft tissue. The 




site containing bone, the other site containing soft tissue only, then the soft tissue 
attenuation ratio will be subtracted away, leaving only bone attenuation ratio.  
 
DEXA is usually measured in the anteroposterior view of the lumbar spine (L2-L4) 
and proximal femur. Although BMD is measured in g/cm2, the DEXA report is more 
commonly referred to as T-score and Z-score. T-score is density value expressed as 
the standard deviation below or above the mean BMD of a healthy young reference 
population at the site of the same gender and the ethnicity of the patient. Z-score is the 
difference between the measured bone density and someone from an aged-matched 
cohort. Diagnoses based on bone density value measurements have been guided by a 
World Health Organisation (WHO) report. The WHO report recommended using a T-
score equal or below -2.5 as diagnostic of osteoporosis, between -2.5 and -1 as 
osteopenia and equal or above -1 as normal. Table 1.2 summarises the WHO 
classification criteria for T-scores. 
 
Table 1.2 WHO classification criteria for T-score from DEXA scan.  
Level T-score 
Normal > -1 
Osteopenia Between - 1 and - 2.5 
Osteoporosis < −2.5 
 
In AKU, the ochronotic pigment in cartilage may contribute to bone mineral density 
loss. An imbalance between bone formation and bone resorption caused by ochronosis 
may increase bone fracture risk in patients with AKU. Therefore, evaluating bone 
density for AKU patients could be an essential diagnostic tool to assess patients at risk 
and who may need clinical intervention. Numerous studies found a strong inverse 
association between BMD measured from DEXA and joint damage, suggesting that 
the pathophysiological processes of osteoporosis seem to be expected for the local 
bone loss of individual joints 77.  
 
Although DEXA has been successfully employed in many musculoskeletal disorders, 
it is not the best method fo choice for AKU patients. Yu et al. 78 evaluated bone density 
from DEXA scans in patients with a spinal degeneration condition, and he found that 




degeneration. This means that severe IVD calcification significantly over-estimates 
the value of lumbar bone density in DEXA scans. In ochronotic patients, extensive 
disc degeneration could influence the spinal DEXA measurements; therefore, the 
results may not reflect a true representation of bone density 79. On the other hand, it 
has been reported previously that hip BMD is usually lower than spinal BMD in 
osteoarthritic patients, suggest that spinal BMD is not considered a significant marker 
for spinal osteoporosis 48,79. Therefore, lumbar bone density measured from DEXA 
results in AKU patients must be interpreted with caution. A previous study reported 
low bone mineral density in DEXA scan at the hip region in ochronotic patients that 
had normal spine density 75. 
 
1.4.1.4 Computed Tomography (CT) 
 
Computed tomography (CT) is a medical imaging procedure using a rotating gentry 
with X-ray tubes performing cross-sectional images of a specific body part. CT is 
superior when compared with conventional osseous radiography as it offers a high-
resolution tomographic analysis of osseous changes and soft tissue structure. CT 
images translate the X-ray attenuation of various body structures, demonstrating 
precisely bone details, hence making it the preferred choice to evaluate bone 
anatomical structures 80.  
 
In the 1970s, bone mineral density analysis was proposed using the quantitative CT 
technique 81. However, drawbacks such as high cost, the need for a large dose of 
ionizing radiation, comparatively long scanning duration, and the advent of DEXA 
contributed to the restricted use of CT in the areas of musculoskeletal research, not 
withstanding its initial introduction and precision. Diagnostic imaging technology has 
recently advanced steadily, and CT is growing considerably in both quality and 
quantity in clinical areas. The benefit of CT over DEXA gained interest for the second 
time with the development of diagnostic imaging technology. 
 
It has been described previously in many studies when CT scans were obtained for 
routine clinical measurements in preoperative examinations; the images would be 
considered a valuable source of information and can be used to assess osteoporosis for 




mineral density and evaluating the risk of fractures for AKU patients using CT images 
from a PET/CT scan without any additional cost or radiation exposure. The 
information delivered by quantitative measurements can notify the physician to initiate 
future investigations. 
 
 Semiquantitative CT assessment 
 
With technological advances in CT systems and imaging software, CT usage was 
remarkably increased in bone quantitative fields, specifically for those patients who 
have not undergone DEXA scanning. In 2011, Hounsfield unit (HU) from the CT scan 
was introduced by Schreiber et al. 83 to predict regional spinal BMD, with several 
concurrent studies examining its effectiveness in predicting fracture risk.  
 
HU is a quantitative value obtained from the linear attenuation coefficient describing 
radiodensity of tissues, named after Sir Godfrey Hounsfield 83. HU are generated from 
the total linear X-ray absorption coefficient, which is calibrated to the water X-ray 
attenuation coefficient. Based on the Hounsfield scale, water is assigned a value of 0 
HU, air a value of -1000 HU, bone a value of +300 to +3000 83, soft tissue a value 
between +20 and +100, and fat value of around -50 HU. Metal devices have 
demonstrated high HU values (≥3000), which will cause marked attenuation of the 
radiation beam 83. Table 1.3 shows the HU values for different body components and 
common joint replacement implant component. Modern imaging software allows 
identifying HU value for any ROI from CT scans. HU values are calculated based on 





  1000  83,84 
 
 is the X-ray linear attenuation coefficient of the selected ROI  







Table 1.3 Hounsfield value of body components and medical implant component 
measured from CT scan. 
Substance HU value 
Air -1000 
Fat Around -50 to -120 
Water 0 
Bone +300 to +3000 
Metal ≥ 3000 
Soft tissue Between +20 to +100 
 
The relationship between densitometry and diagnostic CT scan semiquantitative 
values has been widely investigated 81,83–85. Recently, a number of studies have shown 
a significant correlation between BMD and T-score measured from DEXA scan and 
HU values measured from the diagnostic CT scan. These studies described the role of 
diagnosis of osteoporosis by measuring lumbar spine bone density from diagnostic CT 
scans. Previous investigations have proved a linear correlation between HU values and 
bone density values (BMD and T-score) 81,83–86.  
 
A considerable amount of literature has been published, estimating bone density from 
diagnostic CT imaging. According to the published data in this area, the average HU 
value that indicates a strong risk of osteoporosis was below 60. Table 1.4 summarises 
HU values measured from CT scans for normal, osteopenic and osteoporotic patients 
stratified according to WHO criteria from literature. Lee et al. 81 reported that patients 
with normal bone density at lumbar vertebra levels had a mean HU value of 120.8, 
osteopenic patients had a mean HU value of 78.8, and osteoporotic patients had a mean 
HU value of 54.7. In another study, Batawil et al. 85 pointed out that HU value of 100 
and below demonstrated 100% sensitivity for osteoporosis in a study analysing 252 
patients. Another significant study in 1867 patients showed a strong correlation of the 
range HU values of 110-160 at lumbar vertebrae and osteoporosis 87. Other researchers 
question whether HU measurements from different body parts correlate with BMD 
from the DEXA scan. Pervaiz et al. 88 investigated the correlation between HU 
measurements in the proximal humerus and hip DEXA measurements. They identified 
a significant correlation between humerus HU values measured from CT images and 





Considering all of these findings, it seems that HU measurements could provide such 
a promising tool to assess regional bone density. However, it is premature to say that 
HU values will operate as a replacement indicator for bone mineral density. As noted 
in Table 1.4 there is some overlap in the HU values between the classified groups. 
Unlike the WHO criteria for T-score from DEXA scan, the standard classification for 
BMD from HU quantification has not yet been established. However, such values can 
be used as comparison points for evaluating acceptable HU ranges which can identify 





Table 1.4. The mean HU values measured from diagnostic CT scan for normal, 
osteopenic, and osteoporotic patients from the literature.  
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92.1 ± 29.1 
 
 
1.4.1.5 Magnetic Resonance Imaging (MRI) 
 
More recently, there has been increased usage of MRI in a variety of musculoskeletal 
disorders. MRI is regarded as a pivotal modality for accurate assessment of arthropathy 
as it is sensitive, safe and painless scan which is mostly used for symptomatic patients 
with joint pain. A powerful magnetic field and radio waves are used in an MRI scanner 
to obtain detailed images of the body part. Although the MR scan is non-invasive as 
there is no ionising radiation, it is an expensive procedure with some contraindications, 




pain or those with neurodegenerative disorders to fit in the scanner and remain stable 
for a long time without moving 76.  
 
There are a number of a published AKU case reports describing the imaging features 
which have been noted in MR images 66–68. These findings introduce the advantage of 
MRI for detecting structural alteration and functional contrasts in soft tissue at an early 
stage of ochronotic arthritis, which may be difficult with other imaging techniques  
 
 MRI disc scoring system  
 
Quantifying disc degeneration which appears in MRI is can be used as an sensitive 
assessment method. An easy, reliable and comprehensive MRI scoring system with 
sufficient reproducibility is needed to quantify disc degeneration in order to reflect the 
disc damage and disease progression. In the literature, a number of MRI assessment 
methods based on morphological change have been proposed to evaluate lumbar IVD 
degeneration. The most common MRI scoring system used to quantify degenerative 
disc disease is the Pfirrmann grading system which was introduced in 2001 by 
Pfirrmann et al. 90.  
 
Pfirrmann disc degeneration system is one of the morphological disc degeneration 
scoring systems using T2-weighted MRI sequences 90. The system mainly depends on 
the signal intensity from sagittal MRI sections of disc degeneration unit, IVD structure, 
the distinction between nucleus and anulus, and IVD height 90. Initially, the Pfirrmann 
grading system was introduced with five scales. Although the Pfirrmann scoring 
system using five levels shows good discrimination and responsiveness, it may be non-
discriminatory in elderly patients 91. The main difference between Pfirrmann scales is 
the brightness and distinction of nucleus pulposus (NP) to disc membrane 92. Indeed, 
using a five graded Pfirrmann disc degeneration scale can easily vary between different 
investigators or observers. Griffith et al. noted difficulties when scoring lumbar spine 
disc degeneration, specifically in the aged population 89. Most of the discs were scored 
having third or fourth grade, and ambiguity was encountered. Griffith splits some 
scores, adding a privilege on using the Pfirrmann score system to increase its 
discriminatory power. The Pfirrmann grading system has been modified from five 




method. The third Pfirrmann grade was expanded to two scores, and the fourth 
Pfirrmann grade was expanded to three scores, adding three additional scores in total. 
The first, second and the fifth Pfirrmann grades were not changed. The modified 
Pfirrmann method expanded the visual representation of the disc and minimised 
ambiguity. In general, both five and eight Pfirrmann classifications of lumbar disc 
degeneration have reported a substantial to excellent intra- and inter-observer 
agreement rate in the literature 93–95. The overall findings of the previous studies 
suggest that MRI can be used to detect and monitor degenerative alterations in the 
discovertebral joint, which are associated with ochronotic pigment in AKU patients.  
 
1.4.1.6 Radionuclide bone imaging  
 
Nuclear medicine is an alternative medical imaging field which can provide a regional 
assessment of bone formation, avoiding some drawbacks of other imaging techniques. 
Radionuclide bone scan is considered the preferred clinical method to identify bone 
metastasis, which often offers representations of the whole body with a single session. 
The widespread availability of nuclear medicine and molecular imaging scanners 
enhances the role of this imaging technique for diagnosing various musculoskeletal 
disorders 96. Radionuclide bone scan also called scintigraphy. Nowadays, scintigraphy 
is one of the common imaging technique evaluating the pathophysiology of metabolic 
bone conditions, including infection, inflammation, trauma, benign and malignant 
tumor 97–99. Scintigraphy is the most efficient imaging modalities assessing early 
changes in bone when correlated with other related imaging techniques such as X-rays, 
CT and MRI. Radionuclide bone imaging is a sensitive bone technique however it is 
non-specific. The abnormal uptake can be shown in the skeleton for several reasons 
such as fracture, infection, inflammation or even tumor depending on the osteoblastic 
activity and local blood flow. 
 
The whole-body skeletal assessment in scintigraphy offers unique information 
reflecting active bone turnover, which can be assessed by qualitative and quantitative 
imaging methods. Besides whole skeleton evaluation, these imagery methods are 
flexible. It can analyse and quantify any selected region of interest within the whole 




articular cartilage, in the literature, several bone radiotracers have been used in 
advanced joint disorders 101.  
 
 Bone radiopharmaceuticals  
 
Bone-seeking radiopharmaceuticals are primarily analogs similar to the basic mineral 
components of bone like hydroxyapatite, hydroxyl groups, or phosphate. In the 1960s, 
sodium fluoride labelled with fluorine-18, also known as 18F-NaF was first proposed 
by Blau et al. as a radioisotope agent for bone imaging and was later approved for 
clinical use by the US FDA in 1972 97. Despite early awareness of the superior 
diagnostic efficiency of 18F-NaF, the tracer was not used extensively because of its 
limited availability, comparatively high cost, and the technical issues relating to high-
energy photons using the equipment which was available at that time. The introduction 
of the radioisotope technetium-99m (99mTc) contributed to the search for an alternative 
imaging marker which can be labelled with 99mTc presenting better physical 
characteristics than 18F-NaF using conventional gamma cameras 55. In the mid-1970s, 
99mTc-labelled diphosphonate compounds was introduced by McAfee and 
Subramanian. Since then it has been widely employed for imaging both benign and 
malignant bone disorders 55. Besides the suitability for imaging by a gamma camera, 
the radiotracer was more available with low cost and was simpler to prepare in the 
nuclear medicine department. For those reasons, the FDA withdrew its approval of 
using 18F-NaF as a bone imaging radiotracer in 1975.  
 
In the mid-1990s, gamma-cameras with thick crystals and high-energy collimators 
were implemented. In the late 90s, bone scan with 18F-NaF came into its own with 
improved performance in PET scanners renewing the application of 18F-NaF 
specifically for oncological imaging. The increasing number of PET scanners foster 
high-resolution skeletal imaging to be applied widely in various skeletal conditions 102. 
In 2000, the FDA re-approved the use of 18F-NaF as a bone imaging radiotracer. Since 
then, 18F-NaF became the most commonly preferred bone imaging agent in nuclear 
medicine once again. A few more tracers are candidates for skeletal imaging however 
short half-life radiotracers are always the most recommended bone radiotracer in the 
clinical field to reduce radiation to the patients and clinical staff. In general, all bone-




Over the last decade, numerous radionuclide bone scan applications have been 
apparent in skeletal disorders using gamma photon tracers or positron emission tracers. 
Bone scintigraphy using both 18F-NaF and 99mTc-Methylene diphosphonate (99mTc-
MDP) has been found to be a useful technique for assessing disease activity in  patients 
with OA 103. Although both imaging techniques are sensitive, many technological 
advantages motivate the usage of 18F-NaF PET scan as a superior imaging tool over 
99mTc-MDP SPECT scan. The comparison between 18F-NaF and 99mTc-MDP has been 
widely investigated. It has conclusively been shown that positron emission bone 
radiotracer has a superior ability to diagnose bone disorders compared to gamma bone 
radiotracer. In 2015, Beheshti et al. 104 compared the results of the conventional 99mTc-
MDP bone scan and 18F-NaF PET scan in detecting bone metastases in patients with 
prostate cancer. Beheshti reported that 18F-NaF PET is more superior in terms of 
specificity and sensitivity compared to 99mTc-MDP in detecting the presence of 
malignant bone diseases. Lee et al. 103 compared the clinical utility of 18F-NaF PET/CT 
with that of conventional 99mTc-MDP scintigraphy for 24 patients with 
temporomandibular disorder. In that study, 18F-NaF PET/CT was reported having 
higher sensitivity and accuracy than 99mTc MDP scintigraphy to diagnose OA. Table 
1.5 summarises and compares the characteristics of 99mTc-labelled diphosphonate 
compounds and 18F-NaF PET bone scintigraphy. The following section reviews the 
pharmacokinetics of bone radiotracer and describes the main characteristics of 99mTc-





Table 1.5. Comparison of 99mTc-labelled diphosphonate compounds and 18F-NaF PET 
bone scan.  
(Modified from 55,105)  
Characteristic 
99m





Radiotracer physical half-life 6 hr 110 min 
Protein binding in the blood Yes No 
Types of emissions Gamma 
Positron, annihilation 
gamma 





The spatial resolution of the 
scanner (mm) 
4–15 3–6 
Organ receiving the highest 
dose 
Bone Bladder 
Mechanism of localisation 
Binds to bone matrix 
Glomerular 
Binds to bone matrix 
Glomerular 
Usual administered activity 
600 MBq (planar) 




Effective dose (mSv/MBq) 0.0057 0.024 
Patient dose (mSv) 4.2 – 6.3 4.4 – 8.9 
Imaging time after injection 3 – 6 hr 30 – 60 min 
Advantages 
 Inexpensive 
 Easily prepared on-site 
from generator 
 Well studied 
 
 High spatial resolution 
of PET 
 Simple to prepare from 
cyclotron 
 No binding to plasma 
proteins. 
Limitations 
 Poorer spatial 
resolution of SPECT 
 Not a single chemical 
entity 
 Protein binding delays 
clearance 
 Instability of complex 
 Expensive 






1.4.1.6.1.1 Mechanism of radiopharmaceutical uptake 
 
The pharmacokinetics of bone searching radiotracers rely fundamentally on the rate of 
bone absorption and the elimination from the body circulation by kidney excretion. 
99mTc- labelled diphosphonates and 18F-NaF are imaging radiomarkers for bone 
turnover and bone perfusion. The principal mechanism for the uptake of these 
radiotracers is absorption into or on the crystalline hydroxyapatite bone structure. After 
intravenous administration, the radiotracer distributes from the vascular to 
extravascular space, taking around 2 to 4 minutes 106. The delivery of the tracer to the 
bone lesion mainly depends on the blood flow, regional osteoblastic activity, exposed 
bone surface area, and extraction rate of the tracer 97,107. Therefore, the changes in 
radiotracer kinetics relate mainly to bone vascularity, osteoblastic activity, and kidney 
function 107. In musculoskeletal disorders, it has been reported that there is an abnormal 
increase in vascularity and bone turnover in the affected site. 106. 
 
Radionuclide bone imaging can be acquired at three imaging phases; first imaging 
phase is radiotracer angiography, immediately with the bolus injection; second phase 
is soft tissue phase or blood pool phase, and the third imaging phase is a delay phase 
or bone imaging phase 55. Table 1.6 illustrates the movement of bone radiotracer 
during the three imaging phases. 
 
Table 1.6. The movement of bone tracer during the three imaging phases. 
Phase 1 Radionuclide angiography Tracer intravascular administration 
Phase 2 Soft tissue or blood pool phase imaging 
Tracer distribute in the extravascular 
extracellular spaces 
Phase 3 Delayed or metabolic imaging Tracer accumulates in bone tissue 
 
In scintigraphy, bone activity must be high, while soft tissue activity must be low at 
the delay imaging phase, reflecting the amount of circulating radiotracers in the blood 
pool. In adults, the distribution of bone tracers throughout the skeleton is generally 
uniform 55. Bone lesions with increased or decreased tracer uptake reflects abnormal 




by the skeleton, extraskeleton tissue absorption can also be observed in scintigraphy 
55. These observations may be coincidental, because in some cases, it may indicate 
clues to other underlying diagnoses. Therefore, the accurate interpretation of 
scintigraphy relies on understanding the pathophysiology of the underlying condition 
and tracer absorption mechanisms in both bone and extraskeleton tissue. Some chronic 
diseases might alter regional bone formation or affect renal extraction causing the 
abnormal distribution of the bone radiotracer throughout the body. Furthermore, 
technical factors, such as formulation and quality of the radiopharmaceutical might 
also alter the tracer biodistribution causing abnormal accumulation of the tracer in 
extraskeleton tissues. 
 
1.4.1.6.1.2 99mTc- labelled diphosphonate 
 
Both 99mTc-MDP (99mTc-Methylene diphosphonate) and 99mTc-HMDP (99mTc-
hydroxymethylene diphosphonate) decay with a half-life of 6 hours, emitting 140 keV 
gamma-photons, generated from a 99Mo/99mTc generator at the nuclear medicine 
department. 99mTc-MDP and 99mTc-HMDP have a similar molecular structure to 
etidronate, one of the first bisphosphonates used to treat osteoporosis 100. In 
applications of nuclear medicine, substances with a P-C-P bond are typically referred 
to as diphosphonates. The simplest diphosphonates structures are preferred for 
scintigraphy due to their fast plasma clearance and a high urinary excretion, making a 
significant contribution to the better contrast between the bone and the soft tissue. Both 
99mTc-MDP and 99mTc-HMDP undergo protein binding, rising over time from 
approximately 25% immediately after injection to around 50% at 4 hours after 
injection 97. Protein binding complicates the bone scans, and only the non-protein-
bound component or free 99mTc-MDP in plasma will be taken up by bone 97,100. The 
kidneys excrete an average of 35% of the dose injected by glomerular filtration after 
three hours in a normally hydrated patient. Around 30 to 40% of the injected dose is 
accumulated within the bones, 10 to 15% in the soft tissues, and around 5% in the 
blood 106. Usually, bone imaging with 99mTc-labeled diphosphonates is requested at 
three phases during the bone scans; immediately with the bolus injection, within 5 






1.4.1.6.1.3  Sodium fluoride labelled with 18F (18F-NaF) 
 
18F-NaF is a positron emission radionuclide which decays with a physical half-life of 
110-minutes, emitting a gamma photon at high energy of 511 keV. 18F-NaF is 
produced on-site from medical cyclotron by bombarding Oxygen-18 enriched water 
(18O-H2O) with high energy protons 
55. Following IV administration, 18F-NaF is 
rapidly cleared from the plasma. It has a high bone affinity, resulting in better tissue-
to-background ratios leading to a high imaging quality. A minimal protein-bound 
fraction of 18F-NaF causes fast clearance from blood. When 18F-NaF gets into the 
bones, the inhilitation of fluoride and hydroxide ions occurs. 18F– ion exchanges for 
hydroxy1 groups (OH-) on the surface of the hydroxyapatite matrix of bone-forming 
fluoroapatite (see Figure 1.9): 
 
Ca5 (PO4)3OH+ F− → Ca5 (PO4)3F + OH− 
 
18F-NaF is accumulated at high osteoblastic sites, where fluoride ions bind to the new 
bone formation. About 50% of the 18F-NaF injected dose is absorbed into the bone 108, 
and around 30% of the tracer goes into the red blood cells. The 18F-NaF in the red 
blood cells has no effect on bone absorption of radiotracer since it easily spreads 
transversely through the cell membrane 108. One hour after 18F-NaF is injected, just 
about 10% of the administered dose remains in the bloodstream. Any remaining traces 
are excreted from the body through the renal system about 6 hours after being injected. 
This characteristics ensure proper absorption of 18F-NaF, allowing the images to be 
performed 45-60 minutes after injection. 
 
Radiotracer excretion is primarily through the kidneys and the urinary tract. In 
instances of renal insufficiency, the kidneys, and the ureters are usually visible in 
PET/CT image 108. The localization of urinary tract level depends on the urine 
functionality, the level of hydration, and the time interval between injection and 
imaging. Localisation close to the site of construction will increase in the presence of 
urinary outflow obstruction. Soft tissue uptake indicates the amount of 18F-NaF present 
in the blood during imaging and under normal circumstances, which should be 
minimal. 18F-NaF uptake by the skeleton is homogeneous for adults with generally 







Figure 1.9. Incorporation of 18F from NaF into the hydroxyapatite crystals of the mineral 
bone matrix to form the radioactive fluorapatite crystals.  










In 2010, the Society of Nuclear Medicine (SNM) proposed an international guideline 
for skeletal positron emission imaging with 18F-NaF 109. The paper summarised the 
most common clinical indications for 18F-NaF PET scan, providing recommendations 
for patient preparation and precautions, the injection dose, imaging protocols and 
imaging acquisition, interpretation criteria, image processing, quality control, patient 
education concerns, infection control and radiation safety. 
 
 Imaging technology: instrumentation  
 
Since the domain of nuclear medicine instrumentation is too broad to cover in this 
thesis, certain essential topics of instrumentation will be discussed in the following 
sections. 
 
1.4.1.6.2.1 Gamma camera 
 
The gamma camera imaging technique is designed to detect the decay of 99mTc atoms, 
which emit 140-keV gamma-rays and conversion electrons in low abundances during 
the radioactive decay process 111. The gamma camera is built out  of a large thin crystal, 
recording each gamma-ray arrival. In front of the crystal is a collimator made up of a 
dense lead block perforated by thousands of fine holes, which enables gamma-rays to 
pass precisely through the centre of the holes, forming an image of the distribution of 
the 99mTc atoms throughout the body 100. Most modern gamma cameras have two 
heads, which allow the simultaneous acquisition of both anterior and posterior images. 
A two-dimension whole body image can be performed in a single scan taking 20-30 
minutes. In some cases, confirming the presence of arthropathy may be a challenge 
with a 2D view as the planar image cannot precisely localise the site of an abnormality 
due to overlap and low resolution, specifically in joints 112. By rotating the gamma 
camera around the ROI and taking a sequence of step-by-shoot images from multiple 
angles through a complete 360°, a three-dimensional (3D) image is created, a 
technique known as single-photon emission computed tomography (SPECT). 
Recently, SPECT has emerged as a useful imaging tool allowing higher accuracy 
localisation of suspicious lesions by separating the overlaying radiotracer activity into 




allowing a significantly higher reflection of early bone changes compared to 2D mages 
112.  
1.4.1.6.2.2 PET scanner  
 
18F atom decays into a neutron by emitting positrons which are particles similar to 
electrons but with a positive electric charge rather than a negative charge 100. The 
positron constantly looses kinetic energy through interactions with the surrounding 
tissue atoms and deflects from its original path; usually it travels no more than 1mm 
through matter following emission from the nucleus. The positron finally combines 
with free electron and annihilates emitting two 511-keV photons which travel in 
opposite directions 180o apart (see Figure 1.10). 
 
A PET scanner consists of a large number of small crystal detectors which are 
organised as rings around the body. The fundamental measurement in the PET system 
is based on recording two photons simultaneously which emit from positron 
annihilation by two opposing detectors. When positron annihilate, the two 511-keV 
gamma rays are detected on the opposite sides of the ring detectors, which indicate 
that the 18F atom decayed in the line between these two detectors 100. This line is 
referred to as line of response (LOR). A detailed image of ROI can be built up after 
detecting millions of pairs of coincident gamma rays, which infer the distribution of 
18F atoms in the body of the patient. Most of the new PET systems are made of more 
than 12,000 detectors which have the ability to generate a 3D distribution image of 18F 
atoms decaying within 15-20 cm-wide sections of the body 100,111. By using a step-by-
shoot technique, it is possible to produce an entire body image in about 40 minutes by 






Figure 1.10. Basic principles of 18F-NaF-PET/CT.  
The figure shows the processing principles of a positron emission tomography (PET). The 
image illustrates how a positron (e +) is emitted from the nucleus of the radioisotope (18F-) 
and attaches with an electron (e –), which results in the annihilation event that transforms their 
mass into two 511 keV gamma photons emitted in diametrically opposite directions. These 
photons are registered by the scanner’s detector (the green-coloured ring). After the 
registration, the data is forwarded to a processing unit which determines if the two registered 
events are coincidence events (occurring at the same time) or not. All coincidences are 
forwarded to the image processing unit where the final image is produced via mathematical 




1.4.1.6.2.3 Hybrid scanner  
 
Although a radionuclide bone scan is a sensitive imaging technique in detecting 
metabolic bone disorders, it delivers limited details on bone morphological 
information. Uptake of 18F-NaF is a marker of  specific diagnosis when the pattern of 
uptake is detected while the level of tracer uptake does not distinguish between benign 
and malignant bone lesions 114. For this reason, the relationship between anatomical 
imaging and functional imaging may be critical to drawing a line in the middle of 
malignant and benign lesions.  
 
Dual imaging modality, also known as hybrid imaging modality, provides several 
benefits for the clinical decision by combining functional and structural information 
in single scanning session 55. Hybrid images can offer a precise localisation and size 
of lesion 115. Previous investigations in this field have demonstrated the benefits of 
hybrid imaging for a wide range of clinical applications 114.  
 
Over that last decade, PET scanners have been combined with anatomical imaging 
modalities such as CT or MRI in a single imaging system. In the same line, 
considerable attention has been devoted to increase the diagnostic accuracy of SPECT 
by combining a gamma camera with an anatomical scanner 116. Hybrid imaging 
modalities which are available nowadays include SPECT/CT, SPECT/MR, PET/CT 
and PET/MR scans. These advance scanners offer satisfactory delineation of bone and 
soft tissues throughout the whole-body, providing well-detailed disease assessment. 
Although high 18F-NaF uptake in subchondral bone does not always correspond to 
abnormal observations on MRI or CT images and vice versa, the abnormalities that 
can be observed separately in single imaging performance would notify the clinician 
to initiate further investigation 117. 
 
It is hoped that hybrid imaging will provide useful information for AKU patients by 
evaluating structural and functional information in a single scanning session. 
Understanding the link between anatomical or molecular information will improve the 






 Qualitative and quantitative radionuclide assessment methods  
 
Quantitative and semi-quantitative methods are significant, and an important aspect to 
consider during disease diagnoses, assessing disease progress, and evaluating 
treatment response. In the clinical field, there are two types of quantitative methods: 
imaging and non-imaging methods. Both techniques can provide useful information to 
detect early abnormal bone formation and assess accurate therapeutic response. 
Nowadays, there are a number of quantitative and semiquantitative imaging methods 
to diagnose, predict bone and joint abnormalities, and evaluate treatment response. 
Most of those quantitative methods are sensitive with good reliability; however, the 
best quantitative method has not been confirmed yet and will certainly change in the 
future. This will facilitate the determination of which technique is the most efficient 
for addressing regional bone turnover and joints degeneration for some rare disorders 
such as AKU. 
 
Even though bone biopsy is regarded as the gold standard for quantifying bone 
turnover, it is restricted to one location at the iliac crest, making it reasonably 
complicated, invasive and expensive to execute, and may fail under considerable 
measurement mistakes 118. Practically, one of the widely used methods for measuring 
bone turnover is biochemical bone markers or bone turnover markers (BTM). BTMs 
can estimate bone turnover from urine and serum, offering a practical and convenient 
alternative tool 119,120. Different biochemical markers of bone resorption and bone 
formation have been studied, showing a significant association between the early 
change in BTM and predicting bone density response in clinical trials of osteoporosis 
treatment 119,120. Although BTMs appear to be the most practical tool for evaluating 
bone turnover, they represent the global function of the skeleton. Therefore, BTMs 
cannot provide information on the regional bone sites or differentiate the effect of 
treatment in trabecular and cortical bone regions. A recent investigation showed an 
increase in bone resorption in AKU patients. Bone loss leads to high urinary excretion 
of type 1 collagen N-telopeptide 24. Early results have demonstrated increased 
inflammation, bone resorption and cartilage remodelling among AKU patients 





Radioisotope quantitative methods are a powerful approach in the medical imaging 
field that provide an alternative technique to avoid some of the drawbacks of other 
bone quantitative methods. The broad usefulness of PET in research and in the clinical 
fields has led to efforts to simplify quantitative approaches which are comparatively 
reliable, and easy to use as a practical tool in the daily use of this modality. As 
mentioned earlier, the absorption of bone radiotracers throughout the entire skeleton 
should be almost equal and any discrepancies either lower or higher reflecting a change 
in bone metabolism. Those abnormal uptakes can be quantified using reliable 
radionuclide quantitation methods. Research studies involving radiotracers 
concentrate either on plasma clearance or bone uptake measurements. While a variety 
of radionuclide quantitative methods were defined in the literature, it is important to 
identify the best approaches based on study protocols, patient acquisition, processing 
time, and the availability of the software. Usually, each researcher or clinician chooses 
their preferred quantitation method considering it as the best method for the purpose 
of their study. Thus, the best radionuclide quantitation technique for clinical use will 
certainly improve as time goes. Hoekstra et al. 122 addressed nine classes of PET 
analytical approaches which have been used in literature for diagnosing, predicting, 
and evaluating the response to therapy.  
 
At the moment, radionuclide quantitation can be approached by several methods from 
graded visual evaluation to complex kinetic assessments of dynamic imaging 
acquisition and blood collection. The following paragraphs briefly outline the main 
radionuclide quantitation methods which been described in literature. 
 
1.4.1.6.3.1 Visual measurement 
 
The simplest radionuclide assessment method is dichotomous visual inspiration; either 
a positive or negative scan. Clinically, bone scintigraphy interpretation is qualitative 
based primarily on  visible assessment 123. Visual inspection of a PET/CT image 
mainly depends on the opinion of the nuclear medicine physician who will look for 
signs of abnormal bone metabolism during the evaluation of the bone scan, however 
it is a subjective assessment method. Generally, positive bone lesions are detected 
visually by noting abnormal radiotracer uptake at any skeletal lesion. These regions 




spots" in the area of less tracer. Some theories are widely agreed as a reference when 
viewing 18F-NaF PET images. Hot areas may point out tumor, infection, trauma, 
fibrous dysplasia, fracture, inflammation, Paget’s disease, myositis ossificans or an 
arthritis, while cold areas may point out some certain types of cancer or lack of blood 
flow to the bone 107,124. The viewer has two main challenges in deciding if a change in 
the absorption site is a normal tracer biodistribution and/or the degree of absorption is 
too high or low to support their final conclusion 125. The expert observer will precisely 
determine whether an increasing or decreasing uptake at the specific site is likely to be 
related to bone disorder based on anatomical information, age, medical history and 
previous observations of the 18F-NaF distribution throughout normal skeleton. 
However, it is difficult for even expert observers to accurately assess the degree of 
tracer uptake. The three theories are not descriptive on the meaning of normal, high or 
low tracer uptake throughout the skeleton. While more studies are carried out, it is 
clear that the concepts of normal, high and low tracer absorption vary from different 
bone disorders and clinical settings 125. 
 
In 2011, an AKU study was performed seeking to describe practical methods to 
quantify the disease burden in a patient with AKU 70. An alkaptonuria severity score 
index (AKUSSI) was used to score disease severity by performing systematic clinical 
evaluations, combining clinical assessment, imaging assessment, and questionnaires. 
Bone and joint lesions were subjectively scored by pain score and visual evaluation of 
abnormal radiotracer accumulation in the whole skeleton using 99mTc-MDP bone 
scanning 126. A score system was used for whole body scintigraphy; 1 for a positive 
joint lesion and 0 for a normal region. The previous study led to the critical clinical 
imaging question of whether it is possible to quantify bone lesions by radionuclide 
bone imaging for AKU patients specifically and for arthropathy patients in general.  
 
On the other hand, visual inspection might be graded to enhance the sensitivity and 
specificity. Many studies have graded the accumulation of radiotracer which was 
somewhat better 125. In high resolution PET/CT images, the abnormality can be graded 
on a 4 or 5-point score level relative to normal bone structure. For instance, regional 
bone sites can be scored as: 0, normal; 1, mild; 2, moderate; 3, between moderate and 
high intense uptake; 4, high intense uptake; and 5, very high intense uptake. This gives 




score between observers until explicitly established guidelines for abnormal regional 
level are performed. Using this approach, Vinjamuri et al. 76 addressed this hypothesis 
by visually scoring various lesions in whole-body 99mTc-MDP bone scans. Vinjamuri 
et al. quantified the radioisotope activity in AKU patients in order to create a reliable 
tool that might be used later to assess the response of treatment for those patients who 
will take nitisinone. The most affected OA bone and joint lesions were evaluated using 
a four-score level starting from 0 for normal, to 3 for the advanced degenerative site. 
In fact, the score scale was mainly based on his personal experience and might differ 
between clinical observers.  
 
The scoring system based on visual assessment can be influenced by physical and 
physiological factors. Development of a non-subjective assessment method that 
demarcated the boundary between the normal distribution of radiotracer and increased 
tracer uptake in the skeleton is clinically required. Various research has focused on 
quantifying abnormal lesions to develop the best radionuclide quantitative method 
which can precisely measure radiotracer uptake and evaluate the treatment response.  
 
1.4.1.6.3.2 Standardised uptake value (SUV) 
 
Since 1941, tracer uptake normalisation was used as a technique to supplement visual 
interpretation which was described as a percentage of the injected dose divided by unit 
of body weight 127. In 1980s, it was defined as the differential absorption ratio (DAR) 
and was being employed in PET scans evaluation. Occasionally, in the literature 
aliases like the differential uptake ratio (DUR) and a standardised uptake ratio (SUR) 
are also identified 123. Currently, this is applied as standardised uptake value (SUV).  
 
Nowadays, SUV is the most commonly employed semi-quantitative method owing to 
its popularity in clinical PET studies in comparison to other quantitative approaches. 
In many articles, this approach is addressed in detail 123,127,128. SUV is represented as 
the tracer concentration in the tissue, divided by the injection dose normalised to body 





In practical application, SUV is measured automatically using commercial PET 
scanner software by dividing the ROI concentration of the radiotracer (kBq/mL), by 
the injecting dosage (kBq) divided by body size 123. The basic SUV equation is: 
  
SUV =  





Usually body size measurement is based on either lean body mass (LBM), body 
surface area (BSA) or total body weight (TBW) of the patient 123. In fact, TBW is the 
most regularly used body size method which is used to calculate SUV values.  
 
When radioactivity is retained and equally distributed throughout the body, the SUV 
in every part of the body will be found to be 1g/ml irrespective of the patient size and 
amount of tracer injected. SUV values have no dimensions and take the assumption 
that 1ml of tissues has a weight of 1g 129.  
 
SUV was described as the best measurement method to adopt by many researchers and 
clinicians for PET investigations because of its attractive features 130,131. The main 
advantage of SUV measurement is the fact that it is computationally simple to apply 
and can be used to quantify any site of the skeleton from only a single injection. 
Another advantage of SUV is that it needs substantially less scanner time than other 
complex acquisition protocols. Measuring the SUV value requires either a whole body 
scan or a static image for the chosen ROI rather than applying dynamic one-hour 
imaging for each region. Additionally, complex requirements such as blood sampling 
and blood analysis are not needed to calculate SUV values.  
 
The reliability of SUV may be influenced by biological and physical/technical factors 
123,127,129. Some of these factors may lead to overestimation or underestimation of the 
SUV value if not considered carefully during image acquisition and image processing. 
Table 1.7 illustrates some of these factors 123,127,130. Many consensus groups addressed 
these factors and established protocol guidelines in order to overcome the errors in 
such a broader sense. In 2010, Adams et al. 130 reviewed the main biological and 




The article provided an overview recommendation to minimise the error during 
calculating SUV values in order to assess a precise response of the therapeutic plan 
and detect early degenerative changes. In another study done by Win et al. and his co-
workers 107, the effect of several factors that can influence the uptake of 18F-NaF uptake 
through the normal skeleton were tested including kidney function, patient age, height 
and weight. Although younger patients in that study had higher SUV values, they have 
not found a considerable correlation between age and the mean SUV value. On the 
other hand, they noticed a relationship between the mean bone SUV values and both 
height and weight of the patient in certain bone regions. Win also reported that there 
was no correlation between SUV value and serum creatinine because all the patients 
who were involved in his study had normal serum creatinine. The findings might have 
been far more relevant if the author had included patients with abnormal renal 
functions to find the relationship between the SUV values and serum creatinine levels.  
 
In the literature, there are two popular existing ways of reporting SUV calculation 
within the ROI: maximum and mean SUV value (SUVmean and SUVmax) 
130. SUVmean 
incorporates multiple voxel information, which makes it less sensitive to the noise 
surrounding the ROI. Nevertheless, the calculated SUVmean can differ depending on 
the voxels that are included within the ROI. It is therefore sensitive to the ROI 
definition, making it subject to intra-and interobserver variability 130. In contrast, 
SUVmax is the maximum voxel value within the ROI and thus does not depend on the 
definition of ROI, assuming that there will be inclusion of the voxel having the highest 
activity concentration, however it is more susceptible to background activity and 
image noise. Therefore, it is important when measuring SUVmax to carefully avoid 
including areas of high radioactivity accumulation, like the urinary bladder. In PET 
research, SUVmax is the most convenient way of calculating SUV values making it the 
most popular employed method due to the fact that it more reproducible and less 
observer-dependent compared to SUVmean 
129,130. Several clinical studies have revealed 
that SUVmax
 is a reliable method for evaluating treatment response specifically when 
serial images were analysed and compared in different occasions 129. Usually, 
researchers prefer to use SUVmax to avoid underestimation of the radioactivity as the 
ROI may be misplaced. It is important to mention that radiotracers such as 18F-NaF 
have high signal-to-noise ratio in bone, so that the soft tissues uptake is usually not 




In this case, even slight region misplacement may result in significant drop in the mean 
measure of radioactivity uptake. It has been reported previously that there are no 
substantial variations between mean and maximum SUV values which have been 
measured from normal skeleton and extraskeleton tissue in negative or positive 18F-
NaF scans 132. 
 
Data from several sources have identified the average SUV values for normal bone 
sites, trying to establish a threshold for normal bone SUV values. Win et al. 124 
examined the data from 11 patients without a history of metabolic bone disease or 
cancer who underwent 18F-NaF PET/CT bone scans. In that study, 31 bone sites 
throughout the axial and appendicular skeleton were analysed. Win et al. reported that 
mean SUVmax of cervical vertebrae was 6.84, thoracic vertebrae was 7.36, lumbar 
vertebrae was 7.27, femoral head was 2.22, humeral head was 1.82, mid sternum was 
5.51, and parietal bone was 1.71. In another study, Puri et al. 131 quantified hip and 
lumbar spine lesions for 12 healthy postmenopausal women using six quantification 
methods including SUV measurement. In that study, normal SUV value for hip site 
was 2.324 ± 0.734, while for the lumbar spine was 6.005 ± 1.47. Similarly, Sabbah et 
al. 132 found that axial skeleton lesions had a significant higher SVUmax values (7.8 ± 
2.0) compared with appendicular skeleton (2.9 ± 1.0). Together, these studies outline 
that each bone site has a different normal 18F-NaF uptake measurement. 
 
A considerable amount of literature has been published on using this approach to 
assess progression of disease and evaluate response to treatment. It is now well 
established from published studies that SUV can be used to quantify active lesions 
which can be noted in positive 18F-NaF PET/CT scans. SUV has been extensively 
employed to detect bone metastases; it has recently been used in the degenerative joint 
disorder field 133,134. Kobayashi et al. 133 measured the SUV at the hip joints and 
observed an accelerated rate of bone remodelling in various stages of OA. In his study, 
SUV values were compared with radiographic findings in MRI and the severity of pain 
scale. Kobayashi et al. pointed out that positive lesions in a PET scans had a SUVmax 
of 6.5 and higher. The authors reported also that the positive joint lesions were more 
detectable in PET scans in comparison to MRI (47 in PET vs 25 in MRI) suggesting 
that PET can identify abnormal bone turnover earlier than MRI in OA of the hip. 




damage from 18F-NaF PET and MRI in patients with patellofemoral pain. The authors 
found that high SUVmax does not often relate to bone or cartilage structural damage 
which can be seen on MRI. Additionally, increased SUV showed a positive correlation 
with patient pain. These findings indicate that high radiotracer uptake in PET scans 
could indicate an early stage of a metabolic change, which may lead to joint 
degeneration. 
  
To compare the distribution of 18F-NaF uptake in normal, benign and malignant bone 
lesions, Sabbah et al. 132 compared SUV measurements from different skeleton lesions. 
Sabbah et al. reported that there was statistically significant difference in SUVmax 
between normal regions and benign bone lesions (P < 0.0001). Similarly, there was a 
statistically significant difference between SUVmax in bone metastases and SUVmax in 
the normal skeleton (P < 0.0001). Interestingly, when Sabbah compared the SUVmax 
in benign bone lesion with SUVmax in bone metastases, there was no statistically 
significant differences at any bone lesion (P > 0.05). Other authors argues that 18F-NaF 
PET/CT scan may not be effective to differentiate between benign and metastatic bone 
lesions, however it still played a critical role in distinguishing between normal bone 
and benign or possibly malignant bone lesions 137. Several other studies provided 
evidence that there is a definite difference in regional SUV values when comparing 
the values for normal lesions with abnormal findings in bone disorders or metastases 
lesions. 
 
In the treatment field, 18F-NaF PET is considered a promising tool to monitor the 
treatment response not only in cancer cases but also for various types of 
musculoskeletal diseases 138. There is recent evidence indicating that serial 
measurements of SUV may discriminate between respondents or non-respondents to 
therapy as proposed by several researchers 139–142. Frost et al. 138,140,141 carried out a 
number of investigations evaluating regional 18F-NaF uptake before and after 
treatment for patients with osteoporosis. In his series of quantitative studies, Frost et 
al. noted a change in SUV values during treatment period which were different at 
various skeletal locations 141. Installe et al. monitored the treatment in Paget’s disease 
of bones by evaluating the changes in kinetic modelling, SUVmax, and biochemical 
markers of bone remodelling. In that study Installe et al. reported that SUVmax was an 




the need of dynamic acquisition or blood sampling. In another study, Uchida et al 143 
found that both lumbar spine SUV and femoral neck SUV reduced significantly (P < 
0.01) as a consequence of alendronate treatment, which correlated with an 8.2% rise 
in lumbar spine bone mineral density. All the studies reviewed here support the 
hypothesis that PET/CT semiquantitative radionuclide methods including SUV 
measurements can be used as an imaging biomarker to assess early changes in bone 
formation and detect evidence for nitisinone treatment response for AKU patients. 
 
Table 1.7. Technical and biological factors influencing SUV determinations at ROI .  
Factors  
Technical/ physical  
factors  
Residual dose in the syringe 
Inter-scanner variability 
Injected radioactivity 
CT contrast material 
Imaging protocols 
Size of ROI  
Partial volume effect  
Attenuation correction and reconstruction methods  
Quality control point 
Biological factors  Age  
Body size  
Uptake time  
Respiratory motion 
Kidney function  
 
1.4.1.6.3.3 Other quantitative assessment  
 
In addition to SUV, there are more accurate radionuclide quantitative approaches 
which are somewhat more complicated such as Hawkins method, and graphical Patlak 
analysis 125. Despite their efficacy, previous methods have suffered from considerable 
methodological limitations. A major limitation of these methods is that each site or 
ROI needs a single bolus injection followed by a 60-minute dynamic scan 119,120. It 
means that, if more than one region needs to be quantified, a patient needs to get 
another injection in order to quantify that ROI. Another drawback of these techniques 




view. Also, these quantitative approaches require blood collection and analysis, 
making it a long, complex, and costly procedure. Because of the reasons above, these 
techniques are impractical to be used in day to day clinical studies but have been 
widely performed by researchers in experimental studies. 
 
1.4.2 Radiographic evaluation of cardiac calcification using different imaging 
modalities 
 
Atherosclerotic plaques may contain lipids, inflammatory cells or calcium, which 
usually remain asymptomatic until cardiovascular complications and events clinically 
appear without warning, such as myocardial infarction or stroke 98. While 
cardiovascular imaging techniques are continuously improving, it is still challenging 
to efficiently detect atherosclerotic lesions at high-risk of rupture. These high-risk 
plaques, identified as vulnerable plaques, have key histopathological features 
including inflammation and early-stage microcalcification. It is proposed that intact 
high-risk plaques will demonstrate certain pathophysiological characteristics prior to 
the clinical rupturing incident so that detection of these features could have 
prospectively valuable information on plaque vulnerability. Moreover, early 
predicting of vulnerable patients could avoid serious consequences. 
 
Although numerous studies have been trying to understand the mechanism of vascular 
calcification, it still remains elusive. Naturally, vascular calcification occurs during a 
two-phase process: the initial microcalcification stage and the subsequent macroscopic 
formulation of calcium, also known as macrocalcification 144. Although there are no 
standardised sizing criteria of the plaque, there is a common agreement that 
microcalcification and macrocalcification are classified based on < 50 μm and ≥ 50 
μm nodules, respectively. Microcalcification, a more clinically relevant representation 
of vascular mineralisation, describes the early phases of intimal calcium deposition 
and amplifying mechanical stress on the fibrous plaque surface, which can directly 
lead to its rupture. With incremental calcification of plaque, the inflammatory plaque 
becomes pacified with a necrotic core wall blocking off the blood flow. Therefore, 
later phases of macrocalcification include plaque stabilisation and a reduced 




microcalcification and macrocalcification in vessels. The pathophysiological 
progression and vascular calcification imagery techniques are seen in Figure 1.11. 
 
 
Table 1.8. Key differences between microcalcification and macrocalcification.  
(Table from 145) 
Characteristic Microcalcification Macrocalcification 
Size <5 μm ≥ 5 μm 
Stage of calcification Early Late 
Inflammation Persistent Healed 
Surface area High Low 
Exposed hydroxyapatite High Low 




18F-fluoride binding on 
positron emission 
tomography 







Figure 1.11. The link between inflammation, microcalcification, and macrocalcification. 
A large necrotic core, a thin fibrous cap, and an intense inflammation are key precipitants of 
acute plaque rupture and myocardial infarction. Intimal calcification is thought to occur as a 
healing response to this intense necrotic inflammation. However, the early stages of 
microcalcification detected by 18F-fluoride positron emission tomography are conversely 
associated with an increased risk of rupture. In part, this is because of residual plaque 
inflammation and in part because microcalcification itself increases mechanical stress in the 
fibrous cap further increasing propensity to rupture. With progressive calcification, plaque 
inflammation becomes pacified, and the necrotic core walled off from the blood pool. The 
latter stages of macrocalcification detected by computed tomographic are therefore associated 
with plaque stability and a lower risk of that plaque rupturing (Illustration credit: Ben Smith). 





Imaging cardiac calcification may be crucial in terms of understanding the mechanism 
of vascular calcification, which may be associated with plaque rupture and adverse 
events. Conventional diagnostic modalities such as invasive coronary angiography and 
myocardial stress testing have consistently been unsuccessful in recognising such 
plaques, leading to an increase in the probability of having other factors than only the 
degree of luminal arterial stenosis which can relate to plaque rupture 145. MRI 
angiography and US have also been used previously to detect atherosclerotic plaques 
98,145. Clinically, cardiac CT is a gold standard imaging technique for identifying 
macrocalcification in coronary arteries by providing a coronary artery calcium (CAC) 
score 147,148. The advanced phase of calcification is conveniently imaged by CT 
angiography, which is assumed to show plaque stability. However, CT cannot detect 
microcalcification nor distinguish between active and inactive cardiovascular 
calcification. It has been argued by many researchers that CT can detect the irreversible 
stage of the atherosclerotic process but failed to prevent the evolution of vascular 
calcification as it cannot detect the earlier phase of microcalcification 148–150.  
 
In nuclear imaging, different positron radiotracers have been used to detect and 
identify calcified vessels and improve cardiovascular risk prediction. To date, the 
majority of cardiovascular studies have employed 18Fluorine- labelled 
fluorodeoxyglucose (18F-FDG) as an inflammation imaging radiomarker and 18F-NaF 
as microcalcification imaging radiomarker 98. Previous studies have used 18F-FDG to 
quantify the extent of atherosclerosis and to determine therapeutic response 98,146,151. 
In practice, imaging coronary arteries using 18F-FDG is problematic as there is 
adjacent background myocardium uptake, which usually causes coronary signal 
obscuration 148. Motion correction algorithms can help to address this problem by 
switching myocardial metabolism away from glucose 145. Furthermore, the partial 
volume effect (PVE) restricts the use of 18F-FDG-PET 98. PVE contributes to a 
substantial underestimate of tracer absorption in structures smaller than the spatial 
resolution of PET system, which needs to be corrected when evaluating arterial 
inflammation.   
 
Recently, positron bone agent 18F-NaF has been proposed as a sensitive method to 
track microcalcification and active vascular calcification. There has been substantial 




been employed before to evaluate vascular calcification within the coronary arteries 
150, the aorta 154,155, femoral arteries 155, and carotid arteries 149. Several clinical and 
preclinical works are investigating the use of 18F-NaF as a vascular microcalcification 
biomarker 156. 
 
As mentioned earlier, the mechanism of 18F-NaF uptake includes the exchange 
between the fluoride ions and the hydroxyl group of hydroxyapatite after incorporating 
it into hydroxyapatite crystals forming the fluorapatite. The uptake of 18F-NaF is 
associated with local blood flow, the surface area, and the permeability of the capillary 
system 97. In atherosclerosis, vascular calcification commonly appears as 
hydroxyapatite deposits in the vascular wall sharing the same histological components 
of ectopic bone such as the existence of osteoclast-like and osteoblast-like cells. There 
is a high possibility that the same mechanism that underlies the 18F-NaF uptake in 
osseous tissue is also occurring in the calcified vessels due to the strong biologic 
similarities between vascular calcification and bone formation 157. Although the nature 
of vascular tissue is different to bone, in which there is constant blood supply via them, 
it is not likely to be considered as an active factor 145.  
 
As it is in bone tissue, the essential structural component of the calcified vessels is 
hydroxyapatite. The arterial uptake is likely related to the fluoride ion deposition on 
hydroxyapatite crystals in the available surface area of the arterial wall 98. In the 
subsequent stage of calcification or macrocalcification most hydroxyapatite is 
internally distributed and cannot be bound to 18F-NaF. Furthermore, 18F-NaF cannot 
penetrate to deeper vascular layers; 18F-NaF can only bind to the outer surface 144. 
Thus, macrocalcification cannot be precisely defined by 18F-NaF PET scan. 
 
In the literature, there are various assessment methods used to identify and quantify 
vascular calcification in 18F-NaF PET/CT scans, such as visual assessment, SUV, 
target to background ratio (TBR), and entire myocardiac calcification measurement. 
In 2010, Derlin et al. described vascular 18F-NaF uptake and arterial calcification in 
major arteries in a retrospective analysis of 75 patients with malignancy 155. Both 
qualitative and semiquantitative analysis was performed. In that study, Derlin noted 
increased radiotracer uptake in femoral arteries, abdominal aorta, thoracic aorta and 




calcification sites, which have been detected from CT images, have shown an 
increased radiotracer uptake in PET images. The study indicated the feasibility of 18F-
NaF PET/CT for the imaging of mineral deposition in arterial wall alterations at the 
early stage of calcified plaques, providing different information to the CT images. A 
series of investigations were carried out by the same author in which he and his co-
workers studied the vascular 18F-NaF uptake 158–160. 
 
In 2011, Beheshti et al. 152 created a unique method reflecting cardiac calcification in 
the entire heart structure. In that study, heart and aorta calcification were evaluated and 
quantified for 51 patients who underwent 18F-NaF PET/CT scan for whole-body 
skeletal evaluation. For the quantitative analysis, the ROI was placed on a CT slice 
over the main cardiac arteries and then corresponded to PET images to measure SUV. 
After that, the molecular calcification score for each slice was estimated by 
multiplying the SUVmean of each ROI by slice volume. The global cardiac calcification 
score (GCCS) was calculated by adding the previous molecular calcification scores for 
the entire ROIs. In that study, a strong correlation was noted between the age of 
patients and increased 18F-NaF uptake. Beheshti provided a valuable insight into the 
detection of calcification from the large surface area of the cardiovascular structure, 
including the entire myocardium, to avoid miss diagnosis of patients at high-risk of 
cardiac events.  
 
Irkle et al. 149 and his co-workers published a paper in 2015, which focused on the 
mechanism of 18F-NaF uptake in the cardiovascular system. In that study, an electron 
microprobe was used on carotid atherosclerotic plaques to measure the presence of 
18F-NaF tracer directly within the calcified areas during carotid endarterectomy 
surgery. The authors noted that the binding of 18F-NaF to the calcified areas was 
exceptionally specific. Also, the degree of 18F-NaF absorption was seen to be strongly 
dependent upon the calcification surface area and was only able to absorb through the 
outer calcification layer without a deeper penetration. These results indicate that 18F-
NaF-PET/CT can detect microcalcifications since, with regard to its size, 
microcalcifications have large surface areas while macrocalcifications have limited 
surface areas. Several other researchers recorded similar conclusions which resulted 
in expanded interest for using 18F-NaF to identify the microcalcification phase and 




On the other hand, data from several studies have identified that the increased 18F-NaF 
uptake in PET images was associated with coronary calcium score (CAC). Dweck et 
al. 148 noted that patients with CAC scores of 0 had low 18F-NaF activity versus patients 
with CAC > 1000 (TBRmax ± SD; 1.23 ± 0.24 vs 1.64 ± 0.49, P = 0.003). In another 
study which set out to detect coronary atherosclerosis and evaluate the correlation 
between 18F-NaF PET and CT quantitative assessments, Kitagawa et al. 150 classified 
his patients into four groups based on CT angiography results and HU values to; 
calcified plaque (CP), non-calcified plaque (NCP), partially calcified plaque (PCP), 
and high-risk features (HU < 30 and vascular remodelling index >1.1). In that study, 
TBRmax value for the PCP group was higher than the NCP and CP groups (1.17 ± 0.19 
versus 1.00 ± 0.24 and 0.92 ± 0.18, respectively, P < 0.0001), and TBRmax value 
measured from high-risk lesions was higher than those in the other groups (1.20 ± 0.21 
vs 1.02 ± 0.20, P =  0.0011). 
 
It is important to point out that imaging of coronary artery disease using 18F-NaF 
PET/CT scans has some limitations. The spatial resolution of the advanced PET 
system is around 4–5 mm, thus the target ROI has to be at least 8–10 mm in size in 
order to be observed 98. This is especially relevant when imaging atherosclerotic 
plaques, since these plaques typically are a few millimetres in size. Moreover, cardiac 
motion and breathing rate are a significant cause of concern in attempts at imaging 
arteries. In order to overcome the limitations outlined, measuring uptake at the large 
vessels or global cardiac uptake enable better identification of cardiovascular 
inflammation or calcification 152. 
 
Current evidence in the literature and ongoing studies strongly demonstrate the 
essential role of 18F-NaF PET/CT imaging in assessing molecular calcification in the 
major vessels and coronary arteries. Overall, previous results clearly support the 
hypothesis that 18F-NaF tracer can be used as an imaging marker to identify 
microcalcification and no doubt of becoming an intensive subject in future studies. 
Due to the substantial similarity between cardiac disorders and cardiovascular 
involvement in AKU, cardiac imaging modalities for identifying early vascular 
calcification could be utilised to diagnose and detect cardiac ochronosis. SONIA 2 




images could be also used to detect early vascular calcification in AKU patients 
without adding extra radiation or cost.   
 
1.5 Aims and objectives 
  
This thesis provided an important opportunity to advance the understanding of the 
disease state and disease progression in AKU patients. The experimental works 
presented here in this thesis mainly investigates whether 18F-NaF can be used as an 
imaging biomarker for evaluating early changes in bone tissue, identifying early 
calcification in the IVD area, and detecting early microvascular calcification in the 
main arteries for AKU patients. The impact of some biological factors such as age and 
gender that may influence the 18F-NaF PET/CT semiquantitative values are also be 
tested. Part of this thesis seeks to investigate the relationship between semiquantitative 
radiographic values from different imaging modalities. Also, the progression of the 
ochronotic arthrophathy and the treatment response is investigated during the course 
of therapy. The specific objectives are as follows:  
 
1. Assessment of bone involvement in the lumbar spine and hip regions for AKU 
patients by measuring Hounsfield units (HU) from CT and standardised uptake 
values (SUVmax) from 
18F-NaF PET. 
 
2. Determine the link between structural disc changes and molecular changes in 
the lumbar disc area by comparing MRI disc degeneration grade and 18F-NaF 
uptake in PET scan.  
 
3. Evaluation of the changes in 18F-NaF PET/CT semiquantitative values across 
five visits in order to track the progression of the disease and/or assess the 
response of treatment in the long term for AKU patients who treated with 
nitisinone for four years.  
 
4. Using 18F-NaF PET/CT images as a valuable imaging method to identify early 
cardiovascular calcification and assess future cardiovascular risk without 




The thesis is divided into seven chapters. The first chapter began by providing 
background information on AKU and medical imaging modalities, and reviewing the 
academic literature concerning the main findings in the radiographic evaluation of 
bone and cardiac involvements. The second chapter describes the methodology which 
was employed for this thesis. The overall structure of the experimental study takes the 
form of four chapters, form Chapter 3 to Chapter 6. Each experimental chapter 
examines one of the listed objectives, which was pointed out above. Each results 
chapter begins with a brief introduction and ends with a summary of the main findings, 
limitations of the study, suggestions for further research and followed by the 
conclusion. The final chapter gives a brief summary and discusses the overall findings, 
key methodological limitations, highlights the main contributions made by this thesis, 
reflects on the overall implications of the results for future research, and finally 























2.1 Ethical approval  
 
Ethical approval for the SONIA 2 clinical trial was given by the National Research 
Ethics Service, and the patients provided written informed consent (REC reference: 
13/NW/0567), dated 17/9/2013.  
 
2.2 Patient group 
 
2.2.1 SONIA 2 patients 
 
SONIA 2 has fully recruited 138 AKU patients over three sites: in Liverpool, United 
Kingdom; Paris, France, and Piešťany, Slovakia. The trial took place over four years, 
starting in 2014 and finishing in 2019. Each participant was required to make up to six 
visits to their nearest clinical site; at the baseline, after three months, after one, two  
and three years, and the final visit after four years. The participants were randomly 
divided into two equal groups of 69. The first group took nitisinone, 10 mg/day, and 
the second group was a control group. The comparison between the treatment and the 
non-treatment groups was aimed at identifying the effectiveness and the impact of 
nitisinone and provide evidence for nitisinone slowing the progression of AKU.  
 
Only the patients who attended the Royal Liverpool University Hospital, Liverpool, 
England, for evaluation at the baseline in mid-2014/ early 2015 were included in the 
studies which were done here in this thesis. On the initial cohort of 41 adult AKU 
patients, 25 were males, and 16 were females with a mean age of 51 ± 10.9. The 
participants were aged between 30 and 68 at the beginning of the SONIA 2 trial. All 
patients underwent a number of clinical and biochemical tests, including the following; 
clinical eye photographs, ear cartilage biopsies, echocardiograms, blood samples, 
urine samples, X-Ray, ultrasound, spine MRI, DEXA, and 18F-NaF PET/CT. Only 18F-
NaF PET/CT imaging data were analysed for the purpose of this thesis. The baseline 
18F-NaF PET/CT image was analysed for investigating ochronotic arthrophathy and 
cardiac ochronosis in Chapter 3, Chapter 4, and Chapter 6. The serial images from 
baseline through to the final visit were analysed and compared in Chapter 5. Data from 
other imaging modalities such as DEXA scan and MRI were compared with 18F-NaF 
PET/CT findings in order to assess the correlation between different imaging 
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modalities in Chapter 3 and Chapter 4. Error! Reference source not found. showed 
the number of SONIA 2 patients, gender, age and standard deviation (SD) who were 
analysed in each result chapter. 
 
Baseline 18F-NaF PET/CT images at Visit 1 were available for all 41 patients. Only 32 
AKU patients from the Liverpool site (78%) completed Visit 6. In SOINA2, 9 patients 
withdrew from the SONIA 2 trial after Visit 1 and before completing the rest of the 
scheduled visits. In practice, analysing some of the images was problematic for several 
reasons. Some of the patients had undergone 99mTc-MDP bone scans instead of 18F-
NaF PET/CT bone scans due to the failing production of 18F-NaF on the scanning day. 
Another source of uncertainty in the analysis was that some of the patients had 2D 18F-
NaF PET/CT static images in specific body regions instead of 3D whole-body18F-NaF 
PET/CT scans due to technical issues in the PET scanner on the day of imaging. In 
this thesis, neither 99mTc-MDP bone scans nor 18F-NaF PET/CT static images were 
analysed or compared with the 3D 18F-NaF PET/CT semiquantitative values. 
 
SONIA 2 data was anonymised to protect the personal information of the patients. 
Limited data were shown while analysing the 18F-NaF PET/CT images, such as gender, 
date of birth, weight, height, the amount of the administered dose, time of the scanning 
and imaging protocol. 
 
Some SONIA 2 participants were excluded from some parts of this thesis. These 
include the patients who have lumbar disc implants, hip joint replacements, and those 
with very high bone density values. in Chapter 3, 2 SONIA 2 patients were excluded 
from the analysis; patient number 36 had multilevel spinal surgery, and patient number 
38 had abnormally high bone density values, so that it was difficult to quantify the 
spine lesion for those patients. Patient number 16 had one lumbar disc implant placed 
between T12 and L1; this patient was included in this thesis by analysing the regions 
between L2-L5 levels instead of L1-L5. 
 
Patients with a metal stem placed into the femur were excluded from femoral 
measurement only. In total, 5 patients had a right hip joint replacement and 9 patients 
had a left hip joint replacement; these patients were excluded from hip measurements 
in Chapter 3. The reason for excluding patients with metal implants is because, in CT 
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scans, X-rays would be completely absorbed by metal, causing streak artifacts which 
cause significant sources for error. 
 
Table 2.1. SONIA 2  patients who were analysed in each result chapter. Y; included N; 
not included.  
Patient 
number 
Gender Age Chapter 3 Chapter 4 Chapter 5 Chapter 6 
1 Male  42 Y Y Y Y 
2 Male  49 Y Y Y Y 
3 Male  62 Y Y Y Y 
4 Male  51 Y Y Y Y 
5 Male  65 Y N N Y 
6 Female  59 Y Y Y Y 
7 Female  53 Y Y Y Y 
8 Male  33 Y Y Y Y 
9 Female  45 Y Y Y Y 
10 Female  34 Y Y Y Y 
11 Female  43 Y Y Y Y 
12 Male  43 Y Y Y Y 
13 Male  39 Y Y Y Y 
14 Male  41 Y Y Y Y 
15 Male  47 Y Y Y Y 
16 Male  59 Y Y N N 
17 Male  46 Y Y Y Y 
18 Female  37 Y Y Y Y 
19 Female  55 Y Y Y Y 
20 Male  61 Y Y N Y 
21 Male  57 Y Y Y Y 
22 Male  65 Y N Y Y 
23 Female  37 Y Y Y Y 
24 Male  52 Y Y Y Y 
25 Female  56 Y Y Y Y 
26 Female  68 Y N N Y 
27 Female  54 Y Y N Y 
28 Male  44 Y Y Y Y 
29 Female  47 Y Y Y Y 
30 Male  67 Y N Y Y 
31 Female  64 Y Y Y Y 
32 Male  60 Y N Y Y 
33 Male  52 Y Y Y Y 
34 Female  68 Y Y Y Y 
35 Male  30 Y Y Y Y 
36 Male  55 N N N Y 
37 Female  30 Y Y Y Y 
38 Female  44 N Y Y Y 
39 Male  44 Y N Y Y 
40 Male  62 Y Y Y Y 









2.3 18F-NaF PET/CT procedure  
 
Figure 2.1. illustrates the consecutive methodological steps for whole body 18F-NaF 
PET/CT bone scan.  
 
2.3.1 Patient preparation and precautions  
 
1. Based on the Society of Nuclear Medicine (SNM) and European Association 
of Nuclear Medicine (EANM) Procedure Guideline for 18F-NaF PET/CT Bone 
Scans 104,109, pregnant and breastfeeding patients were not involved in this 
study.  
 
2. Before the schedule, the patient was informed about the procedure, and on the 
arrival day, one member of the PET/CT staffing team explained the process to 
the patient. 
 
3. To decrease the radiation dose and improve image quality, patient was well 
hydrated one hour before the injection. Patients were asked to drink more than 
200 ml (8-oz or two glasses) of water to promote the rapid renal extraction of 
the radiopharmaceutical.   
 
4. Patients were asked to drink a second time, consuming more than 200 ml of 
water after receiving the 18F-NaF injection to improve image quality and 
reduce background activity.  
 
5. Patients emptied their bladder frequently and immediately before starting the 
scan to avoid high intense tracer activity in the urinary bladder, which could 
confound the interpretation of findings in the pelvis and degrade image quality. 
 
6. Patients removed any metal objects to prevent attenuation artifacts. 
 






Figure 2.1. Illustrates 18F-NaF PET/CT imaging produce.  
One hour before the imaging, patient must be hydrated. After administration of the 18F-NaF, patients must wait for around 60 minutes. During this waiting 
time, patients must drink water and empty his/her bladder. The patient lies supine in the scanner bed with a hand on the side. CT scan is acquired immediately 
before PET scan. Image workstation is used to display and analysis PET/CT images. Figure done in Biorender.com.
71 
 
2.3.2 Radiopharmaceutical and dose administration  
 
Patients were intravenously injected with 185-370 MBq (5-10 mCi) of 18F-NaF by an 
intravenous catheter. Based on the SNM and EANM Procedure Guideline for 18F-NaF 
PET/CT bone scans 104,109, the higher activity which could be used for obese patients 
was 370 MBq (10 mCi). 
 
2.3.3 18F-NaF PET/CT protocol and imaging acquisition  
 
18F-NaF PET/CT images of the whole skeleton was performed 60 minutes after IV 
administration of 18F-NaF in patients with normal renal function to ensure rapid 
localisation of radiotracer in the skeleton and rapid clearance from the soft tissues and 
circulation. Patients were placed in a supine position with their arms at the sides for 
whole-body imaging from the head to toes. Patients were asked to minimise their 
movements as much as possible during the scan. 
 
The 18F-NaF PET/CT images were performed using a GE Discovery 690 PET/CT 
scanner (General Electric Medical System, Waukesha, WI, USA). Two images were 
preformed; the first one from the vertex of the skull to one third of the way down the 
thigh, and the second one from the lower thigh to the toes. Low dose CT images 
without contrast media were acquired immediately before the PET scan for of the 
whole-body, for attenuation correction of emission images and lesion localisation 
purpose using X-ray tube current 30 mA, voltage of 120 kVp and rotation of 0.5 
seconds. The duration of CT imaging was approximately 30 seconds. 
 
The PET images were acquired by three-dimensional (3D) mode to ensure that higher 
count rates compensate for the shorter acquisition times, which were required for 
imaging a large imaging surface. The PET imaging parameter was matrix 128 x128, 
and the slice thickness was 2.5 mm. The acquisition time was 2 minutes per bed 
position. PET images were reconstructed using a 3D ordered-subset expectation-
maximization algorithm (OSEM) which is ideal with iterative reconstruction. The 
duration of PET imaging was around 20 minutes.  
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2.4 Imaging display and processing 
 
CT, PET, and co-registered fused PET/CT images were displayed and analysed using 
the PET/CT workstation. To ensure and facilitate lesion detection, maximum-intensity 
projections (MIP) was generated. Images were reconstructed in trans-axial, coronal 
and sagittal projections and interpreted from a workstation. 
 
2.4.1 Image software 
 
2.4.1.1 Hermes software 
 
The 3D 18F-NaF PET/CT images were displayed to identify any abnormalities in the 
whole skeleton and analysed the images using Hermes hybrid software (version 1.4) 
(Hermes medical solutions, Stockholm, Sweden). Hermes Hybrid Viewer is a 
molecular imaging software that displays the images which were generated for 
PET/CT and archives the data. Hermes software can display different images from 
different imaging modalities, which provides functional and morphological 
information. It is a fast and reliable software for PET/CT images, where the datasets 
are loaded simultaneously and processed. The trans-axial, coronal and sagittal PET, 
CT and fused PET/CT images can be viewed together. Hermes Hybrid Viewer also 
has a consistent and reproducible tool for a quantification purpose. Besides, it can save 
the quantitative values and export them as XML for further statistical analysis. 
 
Hermes workstation was used to analyse data in Chapter 3 only. The 18F-NaF PET/CT 
images were processed, analysed and quantified at the Department of Nuclear 
Medicine in the Royal Liverpool University Hospital Trust, England. Data were also 
analysed at Sheikh Jaber AlAhmad AlSabah Nuclear Medicine and Molecular Imaging 
Centre, Kuwait, using Hermes software. 
 
2.4.1.2 Horos software 
 
The second medical imaging software, which was used to display, and analyse the 18F-
NaF PET/CT data in this thesis, was Horos software. Horos software is a free medical 
imaging processing application for Mac dedicated to DICOM images produced by 
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different imaging modalities such as PET/CT. Horos viewer is based upon OsiriXTM 
as well as other open-source medical imaging libraries. 18F-NaF PET/CT data were 
downloaded from Hermes workstation in Royal Liverpool Hospital and uploaded in 
Horos software in MacBook Pro laptop. Horos software has the same imaging analysis 
tools that are available in Hermes software. It can display whole-body PET, CT and 
fused PET/CT images simultaneously. Like Hermes software, it can quantitative ROI, 
save the quantitative values and export them as XML for statistical analysis 
 
Horos and OsiriXTM Software have been selected by many researchers for their 
advantages as well as its reliability. One advantage of Horos software is that it can be 
used anytime, anywhere, without being in the hospital or clinical department. Using 
Horos software instead of Hermes software saved a lot of time and avoided using the 
imaging workstation during busy clinical weekdays. This software was used to view, 
analyse, and quantify 18F-NaF PET/CT images in Chapter 4, Chapter 5, and Chapter 
6.  
 
2.5 Semiquantitative measurement for bone  
 
2.5.1 Hounsfield unit (HU) 
 
To date, various methods have been developed and introduced to assess osteoporosis 
by measuring bone density from different techniques. Each technique has its 
advantages and disadvantages. In this thesis, the linear attenuation coefficient 
measured from the CT scan was proposed to capture bone density from specific 
skeletal sites. Regional bone radiodensity was quantified from 3D CT images by 
measuring mean HU from specific ROI, without using phantom. In recent years, 
measuring HU have been employed to determine bone density in the lumbar spine 
using non-contrast CT image 81,83,85. CT is mainly used in hybrid PET/CT scans for 
attenuation correction of emission images and lesion localisation. However, in this 
thesis, CT data was quantified to estimate regional bone density. Measuring bone 
density from the PET/CT image delivers an additional quantitative bone value without 
adding additional radiation or costs to the patients from data which are available but 
used for other purposes. PET/CT softwares calculated the average, minimum, and 
maximum HU values from the selected ROIs. In Chapter 3 and Chapter 5, mean HU 
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value was considered in order to assess regional bone density in the lumbar spine and 
femoral head, assess the progression of ochronotic arthropathy in the spine, and 
evaluate the regional efficacy of treatment over four years. 
 
 
2.5.1.1 Lumbar vertebral body measurement  
 
Lumbar spine density was quantified by measuring HU from lumbar vertebrae, from 
L1 to L5. Previously, CT scans have been used by many reserchers to assess 
osteoporosis using HU measurement from the lumbar spine. Across this research area, 
different authors have estimated lumbar bone density from diagnostic CT 81,83,85. In 
this thesis, the CT lumbar quantitative assessment technique was based on the previous 
evidence in literature related to its reliability and validity. The HU measurement at 
each lumbar vertebral body was obtained using previously described protocols 81,83,85. 
 
The following steps were done to evualate and quantify lumbar vertebrae bodies: 
1. Displaying whole body CT, PET and PET/CT images side-by-side in sagittal, 
coronal and axial plans on one screen for easy viewing. 
2. Scrolling through the images and adjusting the three orthogonal views to align 
with the appropriate spine till the best view of the spine at sagittal, coronal and 
axial plans is reached which is usually vary between the patients. 
3. Placing the cursor over the intersection of the axes crosshairs in any image 
which will produce a cursor that translates the two axes in unison.  
4. Draging the crosshair in to the centre of the spine which will automatically co-
regisiter it in the three spine planes. Clicking on a location on one of the views 
will focuse the other two views on that specific location. Some patient may not 
laying straight ahead during the scan, causing the axial, coronal and sagittal 
reconstructions of the spine not being parallel to the the axial, coronal and 
sagittal planes of the body. 
5. Use the magnifier tool to adjust the image size. 
6.  Placing the crosshairs on the sagittal plane for each lumbar vertebrae at three 
locations; superior to the inferior endplate, in the middle of the vertebral body 
and immediately inferior to the superior endplate (Figure 2.2).  
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7. In the axial CT images, the largest possible elliptical ROI was drawn covering 
the trabecular area only to prevent volume averaging from cortical margins. 
Note that the cortical bone region of the vertebrae is denser than the trabecular 
bone region which will show as a lighter area in CT images.  
 
Following the steps above, the HU values were generated in the CT image for each 
ROI. Then the average value for each lumbar vertebral level was performed from the 
three axial slices. For for each patient, the average lumbar value of HUmean was also 
performed, presenting the L1-L5 bone density value. 
 
This method was used in Chapter 3 to assess the bone density for the baseline data and 
correlate the results with bone mineral density measured from the baseline DEXA 
reports. This method was also repeated throughout the serial data from Visit 1 to Visit 
6, in Chapter 5, to assess the progression of disease and treatment response over four 
years.  
 
2.5.1.2 Head of the femur measurement 
 
The following steps were done to evaluate and quantify the head of the femur: 
1. Magnifying the image using the magnifier tool to adjust the image size and 
maximise the view at the hip area. 
2. In the coronal CT image, placing the crosshairs at the centre of each head of 
the femur.  
3. Adjusting the three orthogonal views to align with the appropriate head of the 
femur till the best view of the ROI at sagittal, coronal and axial plans are 
reached. 
4. In the axial images, round ROI was drawn around the head of the femur at ech 
side. 
 
Following the previous steps, the HU values were generated in the CT image for both 
femoral sides (Figure 2.3). The average value of HUmean for both the right and left head 
of the femur was calculated to give the mean HU value for each patient. In some 
patients, only one hip side was measured because the second hip joint was replaced 
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with artificial joint. The exclusion criteria for femoral measurement included bilateral 
hip replacements. 
 
2.5.2 Standardised uptake value (SUVmax) 
 
It was decided that the best method to adopt in this thesis for quantifying bone and 
joint involvements was using SUV measurement. The exact ROI, which was drawn at 
the CT image to measure HU, was copied to the PET image to measure SUV at the 
lumbar spine and femoral head sites, as shown in Figure 2.2 and Figure 2.3. Both 
Hermes and Horos software were used to calculate: average standardised uptake value 
(SUVmean), minimum standardised uptake value (SUVmin), and maximum standardised 
uptake value (SUVmax) value for the ROI. In the literature, it has been argued that the 
chosen value for any study would vary depending on the aim of the study. In this thesis, 
SUVmax was considered because the main objective of the investigation was to assess 
the progress of the disease and treatment response for AKU patients. The average value 
of SUVmax from the three axial slices was calcuated to provide the mean SUVmax for 
each lumbar vertebra. The average value of SUVmax for the lumbar vertebrae bodies 
for each patient was also performed. The average value of SUVmax of the right and left 
head of the femur was ued to calculate the mean SUVmax for the hip site. This method 




Figure 2.2. 3D 18F-NaF PET/CT scan of the spine.  
The images illustrate the methods for determining the Hounsfield unit (HU) values from CT scan and SUV from PET scan using an elliptical region of interest 
function. (a) Shows the vertebral bodies in a sagittal slice of 18F-NaF PET/CT scan. In the panel, three axial locations are selected (b) immediately superior to 
inferior endplate slice (c), middle of the vertebral body, and slice (d), inferior to the superior endplate. The same region which was placed on the CT image at 




Figure 2.3. 18F-NaF PET/CT axial slice of the head of the femur.  
The image illustrates the analysing method for determining the HU and SUV values of the femoral head using round ROI function. The HUmean and SUVmax 





2.6 DEXA scan  
 
Clinically, bone mineral density can be assessed by a dual-energy X-ray 
absorptiometry (DEXA) scan. All SONIA 2 patients underwent DEXA scanning 
annually to investigate the changes in bone density over the course of treatment. 
DEXA reports within the same year of performing 18F-NaF PET/CT scan were 
evaluated. Bone density values were extracted from the baseline DEXA report to 
compare the data with semiquantatitive values which have been measured from 
baseline 18F-NaF PET/CT scans. Based on the World Health Organisation (WHO) 
criteria, SONIA 2 patients have been classified into three groups according to T-score 
values. AKU patients who had a T-score -1 or greater were considered as normal, who 
had a T-score less than -1 and greater than -2.5 as osteopenia, and who had a T-score 
-2.5 or less as osteoporosis. Lumbar and femoral T-score values were compared with 
gender and age in Chapter 3. The relationship between 18F-NaF PET/CT 
semiquantitative values and T-score was investigated in Chapter 3. Lumbar T-score 
value were correlated with mean lumbar HUmean values and SUVmax values, whereas 
femoral T-score values were correlated with the head of the femur HUmean and SUVmax 
values.  
 
2.7 Semiquantitative measurement for discovertebral unit (DVU) 
 
It was not possible to quantify IVDs because they were too thin and difficult to 
delineate. Thus, ROI including the IVD was used that included part of bone of the 
adjacent vertebrae to make it large enough to ensure that the cartilage region was 
placed within the drawn ROI. However, the measured value was not reflective of the 
disc alone, and so was referred to as the discovertebral unit (DVU). The concept of 
DVU delineation is based on covering the region between two horizontal lines at the 
middle point of two adjacent vertebrae, including the disc and endplates of the two 






2.7.1 Standardised uptake value (SUVmax) 
 
Six lumbar discovertebral units (DVUs) from segment T12/L1 to segment L5/S1 were 
quantified at three consecutive sagittal slices from 18F-NaF PET/CT images in order 
to assess and detect the extent of disc degradation in all three dimensions.  
 
The following steps were done to evaluate and quantify the lumbar DVUs : 
1. Displaying whole body CT, PET and PET/CT images side-by-side in sagittal, 
coronal and axial plans on one screen for easy viewing. 
2. Scrolling through the images and adjusting the three orthogonal views to align 
with the appropriate spine till the best view of the spine at sagittal, coronal and 
axial plans is reached which is usually vary between the patients. 
3. Placing the cursor over the intersection of the axes crosshairs in any image 
which will produce a cursor that translates the two axes in unison.  
4. Draging the crosshair in to the centre of the spine which will automatically co-
regisiter it in the three spine planes.  
5. Magnifying the image using the magnifier tool to enhance the disc view.  
6.  Placing the crosshairs on the coronal plane for each lumbar IVD. 
7. In the three sagittal CT images, ROI were drawn for each lumbar level covering 
the DVU area as shown in Figure 2.4. 
8. Copying the same ROI which was drawn the the CT to PET images to measure 
the SUVmax. 
 
Following the spteps above, the SUVmax values were generated in the PET image for 
each ROI. Then the average value for each lumbar vertebral level was performed from 
the three sagittal sections. This method was used to identify disc degeneration for AKU 
patients in Chapter 4, and to evaluate the disease progression and treatment response 





Figure 2.4. 18F-NaF PET/CT for the lower spine.  
The images illustrate the semiquantitative measurement method for the lumbar disc region. Upper images show the CT images, and lower images show 18F-
NaF PET images. A. coronal section with three different horizontal lines corresponds to the three sagittal sections in image B. 
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2.7.2 MRI scoring system  
 
A spine MRI was performed for all SONIA 2 patients annually to investigate the 
changes in spine lesions over the course of treatment and assess the progression of the 
disease. Baseline MRIs were evaluated and analysed by an MRI consultant radiologist, 
experienced in musculoskeletal MRI, Dr Alpesh Mistry. Six regions of lumbar 
discovertebreal unit (DVUs) from segment T12/L1 to segment L5/S1 were scored 
using a validated MRI scoring system. The relationship between disc degeneration 
identified from MRI and 18F-NaF PET/CT scan was investigated in Chapter 4. 
 
2.7.2.1 MR imaging protocol 
  
The MR images of the spine were performed on a 1-T scanner (Siemens Impact Expert; 
Siemens Medical Systems, Erlangen, Germany). The standard MR imaging protocol 
for degenerative disc disease included sagittal T1-weighted spin-echo (repetition time 
[TR] 700 msec/echo time [TE] 12 msec) and T2-weighted FSE (TR 5000 msec/TE 
130 msec) images including the following parameters: matrix, 512x225; FOV, 
225x300 mm; slice thickness, 4 mm; interslice gap, 0.8 mm; number of excitations, 4 
 
T2-weighted images were used to allow a thorough view of disc anatomy. The T2-
weighted sagittal images were utilised to evaluate the lumbar vertebral bodies, lumbar 
IVDs, the ligaments, facet joints, spinal canal and spinal cord and intervertebral 
foramen. Also, the STIR images were usually performed in the sagittal plane to detect 
bone marrow changes.  
 
2.7.2.2 Pfirrmann scoring system 
 
Various MRI scoring systems are available in the literature to classify disc 
degeneration. The Pfirrmann scoring system is one of the most common methods for 
lumbar disc degeneration. In this thesis, the Pfirrmann scoring system was selected by 
an MRI consultant to quantify disc degeneration for its reliability and validity. Lumbar 
DVUs were scored using a modified eight-level MRI based Pfirrmann scoring system. 
Table 2.2 describes the pertinent features of each Pfirrmann grade using T2-weighted 
sagittal plane. The reference images comprise 24 images, which reflect the changes in 
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the disc at each grade. The eight scores represent a progression of the disc degeneration 
from grade 1, which corresponds to healthy disc structure, to grade 8 for the end-stage 
of disc degeneration. The MR images were assessed and scored using a reference sheet 
of the Pfirrmann grading system. Figure 2.2 shows the images which were used as a 




Table 2.2. The eight-level grading scale of lumbar disc degeneration on sagittal MRI  (T2-
weighted) proposed by modified from five Pfirrmann grading system.  
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Figure 2.5 Algorithm for the modified Pfirrmann grading system for the assessment of 
lumbar disc degeneration, and the images of IVDs at each level.  
Images cited from 89. The image reference panel shows the eight-level modified grading system 
from three sagittal MRI T2-weighted images reflecting the inherent variability across each 
level. Table 2.2 describes the pertinent features at each disc degeneration level.  
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2.8 Semiquantitative measurement for cardiovascular arteries 
 
Many SONIA 2 patients had dense areas in CT images and abnormal distributions of 
18F-NaF tracer in the PET images within the heart area was noted. A cross-sectional 
study was carried out for the baseline 18F-NaF PET/CT data to capture the complexities 
of the phenomenon and allow a deeper understanding of cardiac involvements in AKU 
patients. 
 
The main coronary arteries were visually recognised in CT images. The CT image was 
evaluated for abnormal focal density in the cardiac area. CT density for the calcified 
vessels was identified having high attenuation coefficient values. 18F-NaF PET images 
were evaluated for increased bone radiotracer uptake in the main coronary arteries 
area. 
 
In this thesis, the calcification of the main coronary and aortic artery was quantified in 
order to investigate the cardiac calcification in AKU patients. What follows is the 
description of the cardiovascular measurement method, which was used in Chapter 6.  
 
2.8.1 Semiquantitative measurement for main coronary arteries 
 
For the coronary arteries analysis, the four main branches of coronary arteries, 
including left coronary artery-left main stem (LCA), left anterior descending artery 
(LAD), left circumflex artery (LCA), and right coronary artery (RCA), were evaluated 
and quantified from the baseline 18F-NaF PET/CT images for SONIA 2 participants.  
 
The following steps were done to evaluate and quantify the main coronary arteries: 
1. Displaying whole body CT, PET and PET/CT images side-by-side in sagittal, 
coronal and axial plans on one screen for easy viewing. 
2. Scrolling through the images and adjusting the three orthogonal views to align 
with the appropriate view of the heart at sagittal, coronal and axial plans which 
is usually vary between the patients. 
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3. Placing the cursor over the intersection of the axes crosshairs at the centre of 
the heart in the coronal section which will produce a cursor that translates the 
two axes in unison.  
4. Magnifying the image using the magnifier tool to enhance the the view of the 
main arteries.  
5. Placing an individual circular ROI on axial CT slices in each arterial region 
over the four main coronary branches, as shown in Figure 2.6.  
6. The HUmean will be generated from the main coronary regions.  
7. Copying the same ROI which was drawn in CT image to the PET image to 
measure mean, maximum and minimum SUV values (see Figure 2.6). It could 
be challenging to identify the exact border of cardiac arteries on non-contrast 
18F-NaF PET/CT images, so measuring the mean SUV value would not present 
the accurate uptake values. Because of that, measuring maximum SUV values 
for each ROI was the best option to choose in order to identify the active 
cardiovascular lesion in PET images and to predict future heart events. SUVmax 
from each coronary artery was generated individually.  
8. To precisely evaluate the 18F-NaF uptake at the arteries, it would be essential 
to extract the background 18F-NaF activity from the blood pool, which could 
influence the arterial SUV measurements. To do that, blood pool SUV must be 
measured by placing three circular ROIs at the centre of inferior vena cava 
(IVC) and superior vena cava (SVC) on axial images. 
9. Generating the maximum target to background ratio (TBRmax) for each ROI. 
TBR is also referred to us as tissue to background ratio or tumour to 
background ratio in the literature. TBRmax is calculated by dividing the SUVmax 
for each ROI with an averaged SUVmean of the blood pool 














2.8.2 Semiquantitative measurement for aortic arteries 
 
Aortic calcification was assessed by quantifying the ascending aorta (AA) and 
descending aorta (DA) from 18F-NaF PET/CT images. The following steps were done 
to evaluate and quantify the aorta: 
1. Displaying whole body CT, PET and PET/CT images side-by-side in sagittal, 
coronal and axial plans on one screen for easy viewing. 
2. Scrolling through the images and adjusting the three orthogonal views to 
align with the appropriate view of the aorta at sagittal, coronal and axial plans 
which is usually vary between the patients. 
3. Magnifying the image using the magnifier tool to enhance the aotra view.  
4. Drawing an individual circular ROI on CT slices covering the maximal area 
just beyond the discernible border of the aortic artery at the axial CT slices. 
5. The same principle, which was applied for coronary artery measurement (in 
section 2.8), was applied to generate HUmean, SUVmax and TBRmax form 
18F-





Figure 2.6. 18F-NaF PET/CT scan of the chest illustrating the methods of determining the HU values from CT scan and SUV from PET scan for the 
main coronary arteries using a manual circle region of interest function.  
The left panel shows CT images, middle 18F-NaF PET image and right fused 18F-NaF PET/CT image. The upper panel shows a coronal 18F-NaF PET/CT slice 
of the chest. The lower panel shows an axial CT, PET, and fused 18F-NaF PET/CT slice of the heart showing the main coronary arteries. Blue, RCA: right 
coronary artery; yellow, LAD: left anterior descending artery; red, LCA: left coronary artery-left main stem; purple, CA: left circumflex artery. The ROI was 
first drawn in the CT images to determine HUmean was then copied to 18F-NaF PET images to determine SUVmax. Horos imaging software automatically calculates 




Figure 2.7. 18F-NaF PET/CT scan of the chest illustrating the methods of determining the Hounsfield unit (HU) values from CT scan and SUV from 
PET scan for ascending aorta and descending aorta using a manual circle region of interest function.  
The left panel shows CT images, middle PET image and right fused 18F-NaF PET/CT image. The upper panel shows a coronal PET/CT slice of the chest. Lower 
panel shows CT, PET, and fused 18F-NaF PET/CT axial slices of the heart, showing the ascending aorta and descending aorta. Blue, DA: descending aorta, and 
purple, AA: ascending aorta. The ROI was first drawn in the CT image to determine HUmean, then copied to PET images to determine SUVmax. Horos imaging 
software automatically calculates the HUmean and SUVmax values for each ROI. 
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2.9 Statistical analysis 
 
Descriptive data were generated for all variables. Statistical analysis and data 
management were performed using IBM SPSS Statistics software (version 24.0, 
Armonk, NY). Parametric tests were used to analyse data with a normal distribution. 
Non-parametric tests were used to compare data that was not normally distributed. 
Linear and non-linear regression were carried out to analyse numerical data and 
examine the linear relationship between two or more independent variables. 
Polynomial regression was applied, seeking for better correlation between age and the 
measured quantitative values. The data were presented as mean  standard deviation 
(SD), minimum, maximum, median and percentage. 
 
A Pearson correlation analysis was conducted to assess the relationship between all 
variables. A P value < 0.01 was considered strongly significant and P < 0.05 was 
considered significant. Pearson correlation was carried out to assess the correlation 
between the two variables. A correlation R-value of +1 is considered a perfect positive 
linear relationship between variables, -1 considered a perfect negative linear 
relationship and 0 considered no relationship.   
 
Independent sample t-tests were used to compare the means values of two independent 
groups regarding the same variable to assess the statistically different variables, such 
as the difference between genders. The differences in variable values between the age 
groups were compared using one-way analysis of variance (ANOVA).   
 
Statistical analysis comparing treated and control SONIA 2 groups was undertaken by 
Matt Gernall, medical statistician, Department of Liverpool Clinical Trials Centre 
LCTC. Because of missing values, data were analysed using the Kruskal-Wallis test 
for Chapter 5. In that chapter, a Kruskal-Wallis test was used to investigate the changes 
between the visits; pre-test, during-test, and post-test. A Kruskal-Wallis test is also 
known as one-way ANOVA on ranks. A Kruskal-Wallis test is a rank-based non-
parametric test analog to the independent samples that is used to investigate whether 
there are statistically significant differences between two or more groups on the 
continuous dependent variable. Kruskal-Wallis test is an alternative test to the one-
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way ANOVA and an extension of the Mann-Whitney U test, which compares more 
than two independent groups. The result of these tests provided P-values. A P-value < 




















3 Cross-sectional study of bone involvement at baseline in 
alkaptonuria patients from the SONIA 2 study using 18F-NaF 









This part of the thesis proposes a molecular imaging methodology which allows better 
quantitative assessment of regional bone formation for patients with AKU using 18F-
NaF PET/CT scans. The primary aim of this study is to assess bone involvement in the 
lumbar spine and hip regions for AKU patients by measuring Hounsfield units 
(HUmean) from CT and standardised uptake value (SUVmax) from 
18F-NaF PET scans. 
The secondary aim is to assess the impact of some biological factors such as gender 
and age in these semiquantitative values for AKU patients. This study also set out to 
determine if SUVmax and HUmean obtained from PET/CT system correlate with each 
other and/or correlate with bone mineral density values measured from DEXA scans.  
This chapter is subdivided into three sections. The first section identifies and quantifies 
bone involvements from CT images. The second section identifies and quantifies bone 
involvements from 18F-NaF PET images. The third section investigates the 
relationship between semiquantitative radiographic values measured from different 
imaging modalities.  
 
The diagnosis of ochronotic arthropathy may be technically and clinically challenging, 
especially in its early stages; however, it is an essential aspect to understand the 
pathophysiology of this rare metabolic disease. The spine and large joints have been 
found to be the most affected sites in patients with AKU. Several cases have required 
physical therapy and multiple joint replacements 10,12,64,65,162. 
 
Radiographic imaging modalities utilised for evaluating ochronotic arthropathy must 
be sensitive in order to detect early bone and joint involvement. 18F-NaF PET/CT scan 
is a promising imaging approach which has been widely employed for identifying early 
bone and joint abnormalities in various arthropathic conditions 76,101,103,131,163.  
 
18F-NaF is a positron bone radiotracer which is rapidly cleared from the plasma and 
has a high bone affinity resulting in better tissue-to-background ratio 108. On the 
surface of the bone matrix where hydroxyapatite crystals are concentrated, 18F-ion 
exchanges rapidly with the hydroxyl groups forming fluoroapatite. Sixty minutes after 
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injection, most of the 18F-NaF administration dose deposits in areas of rich osteoblastic 
activity in the newly mineralising bone 55.  
 
Increased 18F-NaF uptake in PET images reflects abnormal manifestations, which can 
be detected in vivo by quantitative and qualitative measurement methods. Visual 
inspection of a positive lesion in a PET/CT image mainly depends on the opinion of 
the nuclear medicine specialist; therefore, it is a subjective method. Development of a 
non-subjective method that demarcated the boundary between the normal distribution 
of radiotracer and increased tracer uptake in the skeleton is clinically more needed. 
Standardised uptake value (SUV) is one of the simplest and reliable PET 
semiquantitative measurements that can be used to quantify active abnormal bone 
lesions throughout the whole skeleton from non-dynamic 18F-NaF PET scans 
101,103,131,163. The accumulation of 18F-NaF in the skeleton could be attributed to several 
factors such as regional osteoblastic activity, exposed surface area, blood flow, and 
renal function 107,108.  
 
Over the few decades, most of the PET scanners have been combined with CT offering 
better functional and anatomical information. Although CT scanning is mainly 
acquired during PET imaging for lesion localisation purposes, valuable information 
can be extracted from CT images. Clinically, DEXA is a gold standard method for 
diagnosing osteoporosis by measuring bone mineral density value (T-score). As found 
previously in many studies, diagnostic CT scans shows the ability to estimate bone 
density, and predict fracture risk 81,83–85. In this study, CT data were used to determine 
bone density in AKU patients by measuring HU without additional radiation or costs. 
 
As part of the SONIA 2 clinical trial, whole-body 18F-NaF PET/CT and DEXA scans 
were carried out annually at the Royal Liverpool University Hospital for each 
participant to evaluate bone and joint involvements (see section 2.2.1). It is hoped that 
this study will contribute to a deeper understanding of the disease state and progression 






3.2 Design of study 
 
3.2.1 Patient group 
 
In this study, a total of 39 AKU patients including 24 males and 15 females were 
analysed, with a mean age of 50.8 ± 10.8 years (range, 30 - 68-years old) at the 
beginning of the trial. No significant age differences were found between male and 
female groups (see Table 3.1). Patients with spinal surgery were excluded from the 
lumbar spine analysis, and those with hip replacement were excluded from the hip 
analysis. Although patient number 16 had one lumbar disc implant placed between 
T12 and L1, this patient was included by using the data from L2-L5 segments instead 
of L1-L5. In this chapter, 2 SONIA 2 patients were excluded from this study; patient 
number 36 had multilevel spinal surgery, so that it was difficult to quantify the lumbar 
bodies. Patient number 38, a 44-year-old female, had abnormally high bone density 
values in DEXA report, indicating a degenerative disorder, so she was excluded from 
this chapter analysis. On the other hand, patients who had at least one femoral 
replacement were excluded from hip measurements. 
 
The patients were stratified by gender and decade of life, forming two and four groups, 
respectively, as shown in  
 
 
Table 3.2. In this chapter, 7 patients (17.94%) were between 30 and 39 years old, 12 
(30.77%) were between 40 and 49 years old, 10 (25.64%) were between 50 and 59 
years old, and 10 (25.64%) were above 60 years old. 
 
Table 3.1. Demographic baseline characteristics of AKU patients who were part of the 
SONIA 2 clinical trial. 




Age ± SD 
years 
Age range  
Total 39 50.8 ± 10.8 30 – 68 
Male 24 (61.5%) 51 ± 10 30 – 67 







Table 3.2. The number of AKU patients at the beginning of the SONIA 2 clinical trial 
classified by gender and age.  
The participants were stratified by the decade of life into four age groups 30-39, 40-49, 50-59 
and ≥ 60 years old. 
Age group Gender Patient no. 
30 – 39 years old 
Total  7 
Male 3 
Female 4 
40 49 years old 
Total  12 
Male 8 
Female 4 
50 – 59 years old 
Total  10 
Male 6 
Female 4 
≥ 60 years old 






3.2.2 Image analysis 
 
Baseline data for SONIA 2 patients who had undergone 18F-NaF PET/CT between 
2014 and 2015 were retrospectively reviewed (see section 2.2.1). 18F-NaF PET/CT 
images were viewed using Hermes hybrid software (see section 2.4.1.1). The 18F-NaF 
PET/CT images were evaluated on a 3D fusion Hermes software imaging station. HU 
was measured from CT images from the lumbar spine and hip sites. For the lumbar 
spine measurement, the HUmean was obtained from each lumbar vertebral body (L1-
L5) at three different locations from axial CT slices by drawing the largest possible 
elliptical ROI covering the trabecular region (see a Figure 2.2). The average value of 
HUmean for each lumbar level was generated. For the hip measurement, the HUmean was 
obtained from the heads of the femurs, a circular ROI was drawn at the axial CT slice, 
and the HU generated from the right and the left head of the femur (see Figure 2.3). 
All the ROIs which obtained from the CT images were correlated to PET images to 
measure maximum SUV (see section 2.5.1.2). The average lower spine and hip 




3.2.3 Correlation  
 
DEXA reports within the same year of performing the 18F-NaF PET/CT scan were 
compared. Among the enrolled patients, 37 patients were included in the comparison 
section. T-score values from the lumbar spine (L1-L4) were correlated with HUmean 
and SUVmax values of lumbar vertebrae measurements (L1-L4), and T-score value 
from the femoral region was correlated with HUmean and SUVmax values of the head of 
the femur.  
 
The differences in the measured quantitative values between gender and age were 
investigated using the Pearson correlation coefficient and multiple linear regression. 
Polynomial regression was also applied, seeking for better correlation between age and 
the measured values. The differences between age groups were investigated using one-
way ANOVA. Correlations between the semiquantitative values were evaluated also 
using the Pearson correlation coefficient.  
 
 
3.3 Results  
 
3.3.1 HU mean measurements  
 
The first section aimed to measure attenuation coefficients of bone regions from CT 
images at the lumbar spine and hip sites in order to estimate bone density from AKU 
patients, without adding extra radiation to the patients. All the measured data are found 
in the appendix section (Table 9.1), displaying the mean, minimum, and maximum HU 
values at each region of interest (ROIs).  
 
3.3.1.1 Lumbar vertebrae body 
 
The results of the mean HU value at each lumbar vertebrae level for 39 SONIA 2 
patients are shown in Figure 3.1. The average HUmean was obtained from the three 
levels of each lumbar vertebrae (L1, L2, L3, L4, and L5). The mean HU was 139.94 ± 
60.06 at L1, 141.22 ± 63.85 at L2, 133.06 ± 53.67 at L3, 146.04 ± 61.92 at L4, and 
182.41 ± 64.95 at L5 (see Table 9.1 in the appendix). Closer inspection of the data 
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show that the mean HU value measured at the lowest lumbar vertebrae body (L5) was 
statistically higher than the rest of lumbar vertebrae bodies (R = 0.726, R = 0.720, R = 
0.723, R = 0.812, respectively and P < 0.001).  
 
Figure 3.2 shows some examples of bone involvements in the lumbar spine in AKU 
cases, which were identified from spine CT images. The table below the images 
summarises the HU values measured from CT images for those patients. Closer 
inspection of the cases show that in normal cases, uniform high intensity area was 
noted throughout the skeleton in CT images, indicating normal bone density. In 
contrast, in abnormal cases, low bone intensity was noted in the skeleton indicating 
low bone density and weak and fragile bone lesions. 
 
 Lumbar vertebrae body HUmean values and gender  
 
Figure 3.1 and Table 9.1 (appendix) compare the mean HU values across the lumbar 
vertebrae (L1, L2, L3, L4, and L5) for each gender group. The mean HU value across 
L1 to L5 was 145.46 ± 54.33 (range 29.86 - 238.78) for males and 152.4 ± 59.77 (range 
25.88- 221.05) for females. The mean HU was 138.25 ± 57.00 at L1, 133.02 ± 5 4.66 
at L2, 130.05 ± 52.56 at L3, 145.31 ± 63.56 at L4, and 183.87 ± 69.80 at L5 for the 
male patients. While the mean HU was 142.52 ± 66.47 at L1, 154.33 ± 76.54 at L2, 
137.87 ± 56.91 at L3, 147.22 ± 61.37 at L4, and 180.08 ± 58.62 at L5 for the female 
patients. The measured HU values across the lumbar vertebrae were very similar in 
both genders. The female patients had slightly higher HUmean values across the lumbar 
vertebrae compared to the male patients. Independent t-tests were used to analyse the 
relationship between HU values and gender at each lumbar level. No statistically 
significant differences in the mean HU values between the two groups was found at 






Figure 3.1. HUmean obtained from CT scan at the lower spine and femoral sites for 39 AKU patients who were part of SONIA 2 clinical trial stratified 
by gender.  
The results show the analysis of the baseline CT data for 24 males and 15 females, which have been measured from each lumbar vertebrae level (L1, L2, L3, 
L4, and L5), average lumbar levels (L1-L5), right femoral head (RTF), left femoral head (LTF), average femoral head (RT+LT F) for male and female patients. 
Table 9.1 (appendix) shows the statistical correlation between gender at all ROI. Independent t-tests revealed no statistically significant differences in HU values 
at L1, L2, L3, L4, L5, L1-L5, RTF nor RT+LF F between males and females (P-value was 0.83, 0.32, 0.66, 0.93, 0.86, 0.68, 0.23, and 0.09, respectively). A 
significant difference was found between male and female groups at the LTF site only (P = 0.04). *Groups which showed significant difference (P < 0.05). In 





L1 186 157 117 141 2 
L2 164 146 90 182 32 
L3 199 152 85 130 22 
L4 222 144 74 166 28 
L5 220 190 122 184 66 
L1-L5 198 158 98 161 30 
Figure 3.2. Coronal, sagittal, and axial spine CT images for AKU patients.  
Age and gender of the each patient display above each image. The table below illustrates HUmean values for all lumbar levels. 
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 Lumbar vertebrae body HUmean values and age  
 
The relationship between HUmean and age was tested. The mean lumbar vertebrae (L1, 
L2, L3, L4, and L5) HUmean was plotted against age for all patients, as shown in Figure 
3.3. A clear reduction in HUmean measurements with age was noted in AKU patients. 
Multiple linear regression was applied to demonstrate the trend in HUmean at each 
lumbar level with age. On average, age was seen to have a statistically significant 
negative effect across the all lumbar vertebrae HU L1-L5 values (R = -0.545, R =-
0.588, R = -0.624, R = -0.646, R =-0.489; all P < 0.05). Using polynomial regression, 
the correlation coefficient was not substantially improved (see Table 9.2 in the 
appendix). 
 
The average HUmean values measured from all lumbar ROI were stratified into four age 
groups, and subgroup analysis was performed, as shown in Figure 3.4, and Table 9.3 
(appendix). The average HU mean for L1-L5 was 181.95 ± 26.28 for 30-39 age group 
patients, 177.59 ± 45.9 for 40-49 age group patients, 142.44 ± 48 for 50-59 age group 
patients and 94.8 ± 50.27 for ≥ 60 years old patients. The youngest age group patients 
were shown to have the highest HU mean values in most of the lumbar vertebrae levels 
(L1, L2, L3 and L4) and the oldest age group patients were shown to have the lowest 
HUmean values. For all lumbar vertebral levels, the mean HUmean values decreased 
consistently by increasing decade of life, ranging from 181.95 HU mean in the 3
rd decade 
of life to 94.8 HU mean in the 6
th decade of life and above. Looking at Figure 3.4, it is 
apparent that the mean HUmean value in the average vertebral levels changed slightly 
from the 3rd to the 4th decade of life, and from the 4th to the 5th decade of life. Subgroup 
analysis using one-way ANOVA revealed that the differences were not statistically 
significant (all P > 0.05). Statistically, there was a significant difference in the average 
lumbar levels (L1-L5) between the 50s and 60s age groups only (P = 0.045). 
Interestingly, in the L5 level, HUmean increased from the 30s to 40s age groups, then 
decreased; however, the differences were not statistically significant (P > 0.05). This 






Figure 3.3. Scatter plots illustrating the correlation between age and HUmean obtained from baseline CT scan at the lower spine and femoral sites for 
39 AKU patients who were part of SONIA 2 clinical trial.  
The results display HUmean of each lumbar vertebrae level (L1, L2, L3, L4, and L5), average lumbar levels (L1-L5), right femoral head (RT_F), left femoral 
head (LT_F), average femoral head (RT+LT F) in individual AKU cases with age. Multiple linear regression analysis identified a negative statistically significant 


















































Figure 3.4. HUmean for all lumbar vertebrae level among four decadal age groups measured from baseline CT scan for AKU patients who were part of 
SONIA 2 clinical trial. 
Table 9.3 (appendix) shows the lumbar levels and four age groups which indicated a statistically significant difference between subgroup analyses. Lumbar 
HUmean values show decreases as age increases. Statistically, there was a significant difference in the average L1 value between the 50s and 60s (P = 0.005) and 
in the average lumbar levels (L1-L5) between the 50s and 60s age groups (P = 0.045) only. *Groups which showed significant difference (P < 0.05). In box and 





3.3.1.2 Head of the femur  
 
Figure 3.1 displays the results of HU measurements at the head of the femurs for AKU 
patients. All the head of the femur data is found in Table 9.1 and Table 9.3 (appendix). 
The average head of the femur density measurement for all AKU patients was 240.00 
± 50.20 HU and ranged from 154.00 to 341.30 HU. The mean HU was 235.08 ± 59.78 
at the head of the right femur, and ranged from 127.91 to 334.16; 244.42 ± 48.98 at 
the head of the left femur, and ranged from 154.5 to 348.44. Figure 3.1 shows the 
differences in HU value between right and left femoral sides. From this data, it is 
evident that the HU values of the right and left head of the femur was similar with no 
significant differences. On the other hand, as can be seen in the Figure 3.1, the femoral 
HU values were significantly higher than the lumbar HU values (R = 0.516, P = 0.002). 
 
Figure 3.5 shows hip CT images for the same AKU patients which were decribed 
previously in the spine section (section 3.3.1.1). Likewise, in the spine area, uniform 
high intensity regions with high HU values were detected in femoral heads for young 
patients, indicating dense bone area, while the low intensity regions with low HU 
values were detected in the elderly patients indicating low bone density area.  
 
 Head of the femur HUmean values and gender  
 
Figure 3.1 demonstrates the mean HUmean measured at the head of the femur in males 
and females. The mean head of femur HUmean value was  229.00 ± 52.07 and ranged 
from 154.00 to 295.00 for the male patients and 257.00 ± 51.08, and ranged from 
178.00 to 341.00 for female patients. The head of the femur HUmean was 227.55 ± 
52.54 at the right side and 311.52 ± 143.8 at the left side for males, while it was 247.02 
± 59.25 at righ side and 334.16 ± 127.91 at left side for females. There was no 
statistically significant difference between male and female group on the right side, 
but there was a statistical difference on the left sideHead of the femur HUmean values 
and age 
 
The mean head of femur HUmean was plotted against age for all AKU patient in Figure 
3.3. As noted in the lumbar vertebrae section, a noticeable trend demonstrating an 
apparent reduction in femur HU measurements with age in AKU patients was 
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observed. Multiple linear regression reflects the trend in HUmean in the femoral region 
with age. Age had a statistically significant effect on the average head of femur HUmean 
values (R = -0.558, P < 0.05).   
 
As shown in Figure 3.6 and Table 9.3 (appendix), the average HUmean for the head of 
the femur was 280.05 ± 38.68 for 30-39 age group patients, 229.83 ± 42.36 for 40-49 
age group patients, 224.77 ± 50.71 for 50-59 age group patients and 184.46 ± 51.85 
for ≥ 60 years old patients. On average, the youngest age group patients were noted to 
have the highest mean HU values in the head of the femur, and the oldest age group 
patients were observed to have the lowest HU values. The mean HU values decreased 
by age in the femoral area. Statistically, there was a significant difference in the 
average head of femur values between the 30s and 40s age groups only (P = 0.02). No 
statistically significant differences between the 40s and 50s age group or between the 
50s and 60s age group were noted (P = 0.806 and P = 0.159, respectively). Separating 
out male and female findings indicates that there were very little changes in femoral 
HUmean values for AKU male subjects between the age groups, while femoral HUmean 





RT F 334.16 244.28 258.11 201.14 116.6 
LT F 348.44 222.38 293.33 217.43 - 
R+L F 341 233 276 209 - 
Figure 3.5. Coronal, sagittal, and axial hip CT images for AKU patients.  
Age and gender of each patient displayed above each image. The table below illustrates the HUmean value for each femoral side. 65 years old male patient had 









Figure 3.6. HUmean for femoral heads among four decadal age groups measured from CT scan for AKU patients who were part of SONIA 2 clinical 
trial. 
Table 9.3 (appendix) shows the right (RT), left (LT), and average femoral sites (RT +LT) and age groups, indicating a statistically significant difference between 
subgroup analyses. Femoral HUmean values show slight decreases as age increases. Statistically, there was a significant difference in left femur value between 
the 30s and 40s (P = 0.007), and in the average femoral sites between the 30s and 40s age groups (P = 0.02) only. *Groups which showed significant difference 
(P < 0.05). In box and whisker, x is the mean value, and the line is the median. 






Figure 3.7. HUmean for femoral heads among four decadal age groups for male (top row figures) and female (bottom row figures) measured from CT 




3.3.2 SUVmax measurement  
 
The second section aimed to measure 18F- NaF uptake from PET images at the lumbar 
spine and femoral sites from AKU patients. All the data are displayed in detail in the 
appendix section (Table 9.4 and Table 9.6), showing the mean, minimum, and 
maximum SUVmax values at each ROI for each gender and age group.  
 
3.3.2.1 Lumbar vertebral body 
 
The results of SUVmax measurements at each lumbar vertebrae level for SONIA 2 
patients are shown in Figure 3.8. The mean lumbar SUVmax values for all AKU patients 
across L1 to L5 was 10.54 ± 2.17 (range, 5.20 – 15.91). The mean SUVmax was 10.19 
± 2.30 at L1, 10.67 ± 3.15 at L2; 10.08 ± 2.15 at L3, 10.59 ± 2.55 at L4, and 11.15 ± 
2.62 at L5. It can be seen from the data in Figure 3.8 and Table 9.6 that mean SUVmax 
of L5 was slightly higher than the rest of the lumbar levels. Overall, the mean SUVmax  
value for all lumbar vertebrae levels were similar, with no statistically significant 
differences between the lumbar level values (all P > 0.05).  
 
Figure 3.9 shows the spine 18F-NaF PET images for some AKU cases. SUVmax values 
for L1-L5 are summarised in the table below the images. Figure 3.10 shows the fused 
18F-NaF PET/CT images for the patients shown in Figure 3.8. From these data, it can 
be seen that homogeneous distribution of 18F-NaF tracer throughout the skeleton was 
noted in young patients at all spinal levels, indicating normal tracer uptake. In the 
abnormal AKU cases, unclear disc area and increased radiotracer uptake were noted, 
indicating metabolic bone disorder.  
 
 Lumbar vertebrae body SUVmax values and gender  
 
Figure 3.8 illustrates the SUVmax across the lumbar vertebrae (L1, L2, L3, L4, and L5) 
in both gender groups. The mean lumbar SUVmax values across L1 to L5 was 10.92 ± 
2.1 (range, 7.07 – 15.91) for males and 9.93 ± 2.22 (range, 5.2 – 14.64) for females. 
The mean SUVmax was 10.68 ± 2.27 at L1, 10.97 ± 3.20 at L2; 10.45 ± 2.25 at L3, 
11.06 ± 2.45 at L4, and 11.43 ± 2.73 at L5 for the male patients. The mean SUVmax 
was 9.43 ± 2.21 at L1, 10.18 ± 3.11 at L2, 9.47 ±1.91 at L3, 9.84 ± 2.61 at L4, and 
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10.70 ± 2.47 at L5 for female patients. Looking at Figure 3.8, it is apparent that the 
SUVmax across all lumbar vertebrae levels of the male group was slightly higher than 






Figure 3.8. SUVmax obtained from the baseline 18F-NaF PET scan at the lower spine and hip sites for 39 AKU patients who were part of SONIA 2 
clinical trial stratified by gender.  
This figure shows the analysis of 18F-NaF uptake for 24 males and 15 females, which have been measured from each lumbar vertebrae level (L1, L2, L3, L4, 
and L5), average lumbar levels (L1-L5), right femoral head (RTF), left femoral head (LTF), average femoral head (RT+LT F) for male and female patients. 
Lumbar SUVmax values tend to be higher than femoral values in both male and female patients. The SUV value for all lumbar vertebrae levels were similar, with 
no statistically significant differences between the lumbar level values (P > 0.05). Likewise, The SUV value for the right and left femoral side was similar with 
no statistically significant differences (P > 0.05). Table 9.4 (appendix) shows that there are no significant differences between male and female patients at any 
ROI. P-value was 0.1, 0.045, 0.17, 0.15, 0.41, 0.17, 0.7, 0.25, 0.71 at L1, L2, L3, L4, L5, L1-L5, RTF, LTF, RT+LF F, respectively. In box and whisker, x is 




L1 8.98 8.66 12.9 12.57 4.87 
L2 9.01 8.12 12.24 19.93 6.77 
L3 9.27 7.24 11.22 13.10 6.99 
L4 8.42 7.98 12.32 15.54 7.79 
L5 8.92 12.17 12.93 14.56 8.93 
L1-L5 8.92 8.83 12.16 15.2 7.07 
Figure 3.9. Coronal, sagittal, and axial spine 18F-NaF PET images for AKU patients.  




Figure 3.10 Coronal, sagittal, and axial spine fused 18F-NaF PET/CT images for AKU patients.  





 Lumbar vertebrae body SUVmax values and age 
 
The results of the mean SUVmax across all lumbar vertebrae was plotted against age in 
Figure 3.11. Multiple linear regression was conducted to analyse the trend in the 
lumbar vertebrae SUVmax with age.  The average SUVmax of L1-L5 was reduced with 
increasing age (R = -0.438, P = 0.005). Looking at each level individually, age was 
noted to have a statistically significant effect at L1, L3, L4 and L5 levels, with 
correlation coefficients of R = -0.332,  R =-0.391, R = -0.416, and R = -0.432, 
respectively; all P < 0.05. Polynomial regression did not substantially improve the 
correlation coefficient (see Table 9.5 in the appendix). 
 
The average SUVmax from the lumbar vertebrae across the L1 level to the L5 level for 
each age group was generated. The subgroup analysis results were compared and 
summarised in Figure 3.12 and Table 9.6 (appendix). Generally, young patients had 
higher SUVmax at all vertebrae bodies compared to older patients. As can be seen from 
the Figure 3.12, the average SUVmax values for all measured vertebrae body levels 
were decreased slightly by decade of life ranging from 11.86 ± 2.34 in the 3rd decade 
of life to 9.01 ± 2.60 in the 6th decade of life and above. Although the reduction in 
SUVmax was noted in the average lumbar levels, subgroup analysis using one-way 
ANOVA revealed that those differences between age groups were not statistically 
significant (P > 0.05). The only statistically significant differences between age groups 
has been noted between the 50s and 60s age groups in the L1 (P = 0.025) and between 
the 40s and 50s age group in the L5 (P = 0.02). As was found in the HU results, the 
measured values from the L5 level was increased from the 30s to 40s age group then 
decreased consistently in the 50s and 60s age group; however, these differences were 





Figure 3.11. Scatter plots illustrating the correlation between age and SUVmax obtained from 18F-NaF PET scan at the lower spine and femoral sites for 
39 AKU patients who were part of SONIA 2 clinical trial.  
The results display SUVmax of each lumbar vertebrae level (L1, L2, L3, L4, and L5), average lumbar levels (L1-L5), right femoral head (RTF), left femoral head 
(LTF), average femoral head (RT+LT F) in individual AKU cases with age. Multiple linear regression analysis identified a negative statistically significant 
correlation (P < 0.05) between age and SUVmax values measured from L1, L3, L4, and L5. Statistically, no significant correlation between SUVmax at L2 and 













































Figure 3.12. SUVmax for all lumbar vertebrae level among four decadal age groups measured from baseline 18F-NaF PET scan for AKU patients who 
were part of SONIA 2 clinical trial.  
Table 9.6 (appendix) shows the lumbar level, which indicated a statistically significant difference between subgroup analyses. Lumbar SUVmax values show 
slight decreases as age increases. Statistically, there was a significant difference in L1 value between the 50s and 60s (P = 0.025), and in the L5 between the 40s 





3.3.2.2 Head of the femur 
 
Figure 3.8 and Table 9.4 (appendix) summarise the SUVmax results of the femoral 
regions. The mean SUVmax measured from the head of the femur was 4.50 ±  2.55 and 
ranged from 2.2 to 8.36. The mean SUVmax was 5.63 ± 2.36 at the head of the right 
femur and  4.34 ±1.57 at the head of the left femur for all patients. As shown in Figure 
3.8, there was no statistically significant differences between right and left head of 
femur SUV measurements (P > 0.05). On the other hand, the mean head of femur 
SUVmax value was significantly lower than the average lumbar SUVmax value. 
 
Figure 3.13 and Figure 3.15 show 18F-NaF PET and fused 18F-NaF PET/CT images, 
respectively for the hip regions for AKU cases. As noted from the figures and data, a 
normal femoral head structure had uniform distribution of 18F-NaF throughout the 
bone, while increased 18F-NaF uptake was noted in the abnormal hip lesions.  
 
 Head of the femur SUVmax values and gender  
 
Figure 3.8 demonstrates the SUVmax of the head of the femur in males and females. 
The mean SUVmax measured from the head of the femur was 4.5 ± 2.08, ranged from 
2.82 to 8.36 for males, and was 4.92 ± 1.92, ranged from 2.2 to 8.15 for females. From 
the Figure 3.8, it is clear that the male group had a higher SUVmax on the right side 
while the female group had higher values on the left side. For the average femoral 
value, males had higher values than females. However, the independent t-test 
identified that the differences were not statistically significant (P > 0.05). Previously 
in this chapter, HU measurements also showed that there was no evidence that gender 
has an influence on the average head of femur values.  
 
 Head of the femur SUVmax values and age  
 
The results of the mean SUVmax of the head of the femur was plotted against age in 
Figure 3.16. Multiple linear regression was applied to analyse the trend in femoral 
SUVmax measurements with age. In contrast to the previous result in section 3.3.2.1.2, 
age was not found to be a statistically significant factor affecting the mean head of 
femur SUVmax (R = 0.214, and P = 0.217). 
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Subgroup analysis of the femoral measurement is shown in Figure 3.16 and Table 9.6 
(appendix). The average SUVmax for femoral sides was 4.13 ±  2.34 for 30-39 age 
group patients, 4.57 ± 1.48 for 40-49 age group patients, 4.57 ± 1.31 for 50-59 age 
group patients, and 6.84 ± 6.51for ≥ 60 years old patients. In contrast to the lumbar 
level findings, the oldest age group patients had the highest SUVmax values, and the 
youngest age group patients had the lowest values. The mean SUVmax at the average 
head of the femur increased consistently by decade from 3rd decade of life to the 6th 
decade of life; however, there were no significant differences between any of the age 
groups at femoral sites (P > 0.05). Separating out male and female as shown in Figure 
3.17 indicates that femoral SUVmax values  for male subjects increased by age from 
30s to the 60s age groups, while there were very little changes in femoral SUVmax 




RT F 1.9 5.45 3.19 4.47 4.0 
LT F 2.9 4.88 3.35 2.69 - 
RT+LT 
F 
2.25 5.12 3.27 3.58 - 
Figure 3.13. Coronal, sagittal, and axial hip 18F-NaF PET images for AKU patients.  





Figure 3.14. Coronal, sagittal, and axial fused 18F-NaF PET/CT images for the hip region for AKU patients.  








Figure 3.15. Coronal, sagittal, and axial fused 18F-NaF PET/CT images for the hip region for AKU patients.  
Age and gender of each patient displayed above each image.  










Figure 3.16. SUVmax for femoral heads among four decadal age groups measured from baseline 18F-NaF PET scan for AKU patients who were part of 
SONIA 2 clinical trial.  
Table 9.6 (appendix) shows the right (RT), left (LT), and average femoral sites (RT +LT) and age groups, indicating a statistically significant difference between 
subgroup analyses. The mean SUVmax at the average head of the femur increased consistently by decade from 3rd decade of life to the 6th decade of life; however, 
statistically, there were no significant differences between any of the age groups at femoral sites (P > 0.05). In box and whisker, x is the mean value, and the 





Figure 3.17. SUVmax for femoral heads among four decadal age groups for male (top row figures) and female (bottom row figures) measured from 




3.3.3 DEXA bone density values  
 
T-scores were extracted for each patient from the DEXA report to investigate the 
correlation between bone mineral density values and the semiquantitative values 
measured from the 18F-NaF PET/CT image. The results of T-score values from the 
lumbar spine and hip sites reported from the DEXA scan were investigated, and the 
mean values displayed in Figure 3.18. All the data are summarised in Table 9.7 
(appendix). The mean lumbar T-score values across L1 - L4 was 0.52 ± 1.79 (range, -
3.2 – 5.4) and femoral T-score was -1.5 ± 1.06 (range, -3.1 – 1.3). The mean lumbar 
T- score was 0.9 ± 1.77 (range, -1.6 to 5.4) for male patients and -0.09 ± 1.7 (range, -
3.2 to 3.5) for female patients while femoral T-score was -1.72 ± 0.9 (range, -3.1 to 
0.3) for males and 1.27 ± 1.22 (range, -3.1 to 1.3) for females. Independent t-tests 
indicated a significant difference between the T-score values of males and females 
measured from L4 only (P = 0.04). No significant difference in the T-score values 
between males and females measured from the average lumbar spine and hip site was 
found (P = 0.1 and P = 0.25, respectively).  
 
Based on World Health Organisation (WHO) criteria, AKU patients were stratified 
into three groups according to T-score values: normal when T-score is -1 or greater, 
osteopenic when T-score is less than -1 and greater than -2.5, and osteoporotic when 
T-score is -2.5 or less. According to WHO criteria, 81% of all patients were normal in 
the lumbar spine and 32.4% in the proximal femur, 16.2% of all patients had the 
diagnosis of osteopenia in the lumbar spine and 40.5% in the proximal femur, and 
2.7% of all patients had a diagnosis of osteoporosis in lumbar spine and 21.6% in the 
proximal femur. It is apparent from the DEXA report that femoral T-scores seem to 
have a lower bone mineral density compared to the lumbar spine T-scores indicating 
the diagnosis of osteopenia and osteoporosis in AKU patients. Table 3.3 displays the 
T-score values for those patients described previously in the HU and SUV sections.  
 
The mean T-score values measured from DEXA scans from the lumbar spine and left 
proximal femur were plotted against age in Figure 3.19. Multiple linear regression was 
applied to analyse the correlation of bone density values with age. No significant 
correlation was found between lumbar T-score and age at all levels L1-L4 (R = 0.032, 
R = -0.311, R = -0.158, and R = -0.009, respectively, all P > 0.05 ). In contrast, strong 
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correlation between femoral T-score and age was found (R= 0.571, P < 0.05). 
Polynomial regression did not improve the correlation coefficient (see Table 9.8 in the 
appendix). Looking at subgroup age analysis in Figure 3.20 and Table 9.9 (appendix), 
young patients had a normal T-score range, representing healthy bone density values, 
while most of the older patients, above 40 years old had osteopenia T-score range. For 
all lumbar vertebral levels, the mean T-score values increased consistently by 
increasing the decade of life from the 3rd decade of life to the 5th decade of life, then 
decreasing from the 5th decade of life to the 6th decade of life and above. Subgroup 
analysis using one-way ANOVA revealed that the differences were only significant at 
the L2 level between the 50s and 60s age groups (P = 0.006). 
 
For the femoral site, the T-score values decreased consistently by increasing the 
decade of life, ranging from -0.486 in the 3rd decade of life to -2.186 in the 6th decade 
of life. There was a significant difference in the femoral T-score between the 30s and 
40s age groups only (P = 0.028).  
 
 
Table 3.3. lumbar and femoral T-score values for those patients in Figure 3.2, Figure 3.5, 
Figure 3.9 and Figure 3.11. 
Age 30 45 52 62 65 
Gender Female Female Male Male Male 
L1 0.6 -1.2 -0.4 -0.7 1.4 
L2 1.0 -1.5 -0.6 -2.5 -0.3 
L3 1.3 -1.0 -2.0 0.5 0.5 
L4 0.4 -1.4 -1.6 0.6 1.3 
L1-L4 0.8 -1.3 -1.4 -0.4 0.6 







Figure 3.18. T-score obtained from baseline DEXA scan at the lower spine and femoral sites for 37 AKU patients who were part of SONIA 2 clinical 
trial stratified by gender.  
The results show bone density analysis for 23 males and 14 females, measured from each lumbar vertebrae (L1, L2, L3, and L4), average lumbar levels (L1-
L4), and the left proximal femur for male and female patients. Table 9.7 (appendix) shows significant differences in mean T-score value between male and 
female groups at L4 only (P = 0.04). No statistically significant differences in the T-score values were noted between males and females at the L1, L2, L4, or 
femoral site (P-value was 0.06, 0.39, 0.35, 0.10, 0.25, respectively). *Groups which showed significant difference (P < 0.05). In box and whisker, x is the mean 





Figure 3.19. Scatter plots illustrating the correlation between age and T-score obtained from baseline DEXA scans at the lower spine and femoral 
regions for 37 AKU patients who were part of SONIA 2 clinical trial.  
The results display the T-score of each lumbar vertebrae level (L1, L2, L3, and L4), average lumbar levels (L1-L4), and the left proximal femur in individual 
AKU cases with age. Femoral T-score values show consistent decreases as age increases (P < 0.001). Multiple linear regression analysis identified no statistical 



































Figure 3.20. T-score for all lumbar vertebrae level and femoral regions measured from baseline DEXA scans among four decadal age groups for AKU 
patients who were part of SONIA 2 clinical trial.  
Table 9.9 (appendix) shows the ROI, which indicated a statistically significant difference between subgroup analyses. *Groups which showed significant 
difference (P < 0.05). Statistically, there was a significant difference in L2 value between the 50s and 60s (P = 0.006), and in femur between the 30s and 40s 





3.3.4 Correlation between the quantitative values  
 
In this section, the relationship between the different quantitative values measured 
from different bone imaging techniques were addressed. The correlation between the 
semiquantitative values measured from CT, PET and those extracted from the DEXA 
report was tested. Simple statistical analysis was used to evaluate the relationship 
between HUmean and T-score, between HUmean and SUVmax, and between SUVmax and 
T-score.  
 
3.3.4.1 Hounsfield Unit value (HUmean) and (T-score) value 
 
The relationship between the HU values measured from CT and T-score values 
measured from DEXA was evaluated for each lumbar level separately and compared, 
as shown in Figure 3.21. Moderate correlations were noted between the average 
lumbar level (L1-L4) HU value and the T-score value (P < 0.05 and R = 0.503). The 
R values were 0.398 for the L1 vertebra; 0.605 for L2; 0.563 for L3; 0.448 for L4. A 
strong correlation was found between HU values and T-score values in the femoral 
site with statistically significant values (P < 0.01, R = 0.796). 
 
Based on DEXA scans, AKU patients were stratified into three groups according to T-
score values; normal, osteopenic, and osteoporosis. Table 3.4 and Figure 3.22 
summarised the mean HU value for each group. In the lumbar spine site, the mean HU 
value for normal patients was 152.93 ± 52.677 (95% CI, 133.26 to 172.6 ), and for 
osteopenic patients was 92.67 ± 33.44 (95% CI, 57.57 – 127.76 ). Only one patient 
had an osteoporotic T-score value in L1-L4 with HU 19. Using the t-test, the 
differences in mean HU values of L1-L4 between normal and osteopenic was 
significant (P = 0.011).  
 
In the femoral site, the mean HU values for normal T-score patients was 270.53 ± 
39.11 (95% CI, 245.68 to 295.38), for osteopenic patients was 231.37 ± 35.49 (95% 
CI 211.7 to 251.03), and for osteoporotic patients was 161.59 ± 31.596 (95% CI, 13.36 
to 190.81) (Table 3.4). The differences in mean HU value of the head of the femur 
between normal and osteopenic, and between osteopenic and osteoporotic were 
statistically significant (P = 0.012, P < 0.0001, respectively). 
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Overall, patients who reported low HU values were also reporting low T-score. As 
noted from the examples in Table 3.3, Figure 3.2, and Figure 3.5, there is positive 
correlation between T-scores and HU values. This results indicate that normal T-score 
values can be detected in area with high HU values at both lumbar and femoral regions 
in the young 30 years old AKU patient. While low HU values in CT images were 





Figure 3.21. Scatter plots illustrating the correlation between HUmean obtained from CT scan and T-score obtained from DEXA scan for each lumbar 
vertebrae level, and femoral site for AKU patients who were part of SONIA 2 clinical trial.  



























































































Table 3.4. Mean ± SD and 95% confidence intervals of HUmean values for normal, 
osteopenic and osteoporotic AKU patients who were part of SONIA 2 clinical trial.  
Based on WHO criteria, AKU patients were stratified into three groups according to lumbar 
and femoral T-score values. Pt no. = patient number, CI = confidence intervals. 
T-score Pt no. Mean HU ± SD 95% CI 
Lumbar spine 
Normal -1 or greater 30 152.93 ± 52.677 133.26 – 172.6 
Osteopenic 
Less than -1 and 
greater than -2.5 
6 92.67 ± 33.44 57.57 – 127.76 
Osteoporotic -2.5 or less 1 19  
Femur 
Normal -1 or greater 12 270.53 ± 39.11 245.68 – 295.38 
Osteopenic 
Less than -1 and 
greater than -2.5 
15 231.37 ± 35.49 211.7 – 251.03 





Figure 3.22. The HUmean values for normal, osteopenic and osteoporotic AKU patients 
who were part of SONIA 2 clinical trial at the lumbar spine and femoral sites.  
Based on lumbar T-score measurements, 30 patients were normal, 6 were osteopenic and 1 
was osteoporotic. Based on femoral T-score, 12 patients were normal, 15 were osteopenic and 
7 were osteoporotic. In box and whisker, x is the mean value, and the line is the median.   
133 
 
3.3.4.2 Hounsfield Unit value (HUmean) and standardised uptake value (SUVmax) 
 
The relationship between HU values measured from CT and SUVmax values measured 
from 18F-NaF PET were evaluated for lumbar spine and head of the femur, as shown 
in Figure 3.23 and Figure 3.24. It is apparent from Figure 3.23 and Figure 3.24 that 
there was a moderate correlation between the average lumbar HUmean value and 
SUVmax with a correlation coefficient of 0.373, and P-value of 0.02. Regionally, there 
was statistical significant correlation between HUmean value and SUVmax at L1, L2, and 
L4. The correlation coefficients and (P-value) was 0.517 (P = 0.001) for the L1 
vertebra; 0.492 (P = 0.001) for L2; 0.13 (P = 0.429) for L3; 0.32 (P = 0.047) for L4 
and  0.254 (P = 0.119) for L5. No significant correlation was found between HUmean 
values and SUVmax values in the average femoral site R = -0.277 and P = 0.113. 
 
As was shown in the examples in Figure 3.2 and Figure 3.9, younger AKU patients, 
had uniform high dense calcium areas in CT images with high HU values and 
homogeneous distribution of 18F-NaF throughout the skeleton in PET images. 
Increased lumbar SUVmax values were noted in the area of low HU values in the 52 
years old patient. On the other hand, the 65 years old AKU patient had very low HU 
values and low SUVmax at all lumbar level. Similar findings were noted in the hip 







Figure 3.23. Scatter plots illustrating the correlation between mean HUmean obtained from CT scan and SUVmax obtained from 18F-NaF PET scan for 
each lumbar vertebrae level for AKU patients who were part of SONIA 2 clinical trial.  
At L1, L2 and L4, there was a statistically significant correlation between HUmean and SUVmax (P = 0.001, P = 0.001, and P = 0.047,  respectively). No statistically 
significant correlation was noted at L3 and L5 levels (P = 0.429, and P = 0.119, respectively). In average lumbar levels, there was statistical correlation between 
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Figure 3.24. Scatter plots illustrating the correlation between HUmean obtained from CT scan, and SUVmax obtained from 18F-NaF PET scan for the 
femoral site AKU patients who were part of SONIA 2 clinical trial.  



















3.3.4.3 Standardised uptake value (SUVmax) and T-score value 
 
The relationship between SUVmax values measured from PET and T-score measured 
from DEXA was evaluated for each lumbar level, as shown in Figure 3.25. Data show 
that there was no correlations between SUVmax values and the T-score at the average 
lumbar vertebrae levels (P = 0.684) with a correlation coefficient (R) of 0.069. 
Regionally, the correlation coefficients and (P-value) was -0.292 (P = 0.085) for the 
L1 vertebra; 0.178  (P = 0.293) for L2; -0.096 (P = 0.572) for L3 and 0.047 (P = 0.781) 
for L4. Likewise, no significant correlation was found between femoral SUVmax value 
and femoral T-score value (P = 0.339, R = -0.166). 
 
Based on WHO criteria for osteoporosis, mean SUVmax value for normal lumbar T-
scores was 10.76 ± 2.22 (95% CI, 9.92 to 11.59 ), SUVmax value for osteopenic was 
9.37 ± 2.62 (95% CI, 6.61 – 12.12), as summarised in Table 3.5 and presented in Figure 
3.26. Only one patient had an osteoporotic T-score value in L1-L4 with SUVmax of 
8.15. The differences in mean SUVmax value of L1-L4 between the normal and 
osteopenic group was not significant (P = 0.183).  
 
In regard to the femoral site, mean SUVmax value for normal T-scores was 4.63 ± 1.96 
(95% CI, 3.39 to 5.88), for osteopenic was 4.45 ± 1.34 (95% CI, 3.74 – 5.17), and for 
osteoporotic was 6.54 ± 6.66 (95% CI, 0.38 – 12.70). No statistically significant 
differences in the SUVmax value between normal and osteopenic nor between 
osteopenic and osteoporotic groups was found (P = 0.782, P = 0.231, respectively). 
 
From Table 3.3, Figure 3.9, and Figure 3.11, it is clear that high SUVmax values in the 
PET image overlay with with low T-score values in DEXA image. From this data, it 
can be seen that the young AKU patient had normal T-score values at both spine and 
hip regions and low SUV values compared to 52 years old patient and 62 years old 
patients. The 45 years old AKU patient had a normal lumbar T-score value but an 
osteopenic femoral T-score value. In that patient, increased SUVmax values were noted 
in the lumbar vertebrae and femoral head.  It was noted that the osteoporosic cases had 
low 18F-NaF absorption in low-density areas. Although the 62 and 65 year old male 
patients had normal T-score values at the lumbar spine and osteoporotic T-score values 
at the femoral head, there was a significant difference in SUVmax values between the 
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two cases. The 62 year old patient had a very high SUVmax value, while the 65 years 





Figure 3.25. Scatter plots illustrating the correlation between SUVmax obtained from an 18F-NaF PET scan, and T-score obtained from DEXA scan for 
each lumbar vertebrae level, and femoral site for 37 AKU patients who were part of SONIA 2 clinical trial.  
No statistically significant correlation between SUVmax and T-scores was found at neither lumbar nor femoral sites (all had P > 0.05).
R = 0.292































































































Table 3.5. Mean and 95% confidence intervals of SUVmax for normal, osteopenic and 
osteoporotic AKU patients who were part of SONIA 2 clinical trial.  
Based on WHO criteria, AKU patients were stratified into three groups according to lumbar 
and femoral T-score values. Pt no. = patient number, CI = confidence intervals. 
T-score Pt no. Mean SUVmax ± SD 95%  CI 
Lumbar spine 
Normal -1 or greater 30 10.76 ± 2.22 9.92 – 11.59 
Osteopenic 
Less than -1 and 
greater than -2.5 
6 9.37 ± 2.62 6.61 – 12.12 
Osteoporotic -2.5 or less 1   
Femur 
Normal -1 or greater 12 4.63 ± 1.96 3.39 – 5.88 
Osteopenic 
Less than -1 and 
greater than -2.5 
15 4.45 ± 1.34 3.74 – 5.17 





Figure 3.26. Figures show the mean SUVmax values for normal, osteopenic and 
osteoporotic AKU patients who were part of SONIA 2 clinical trial at the lumbar spine 
and femoral site.  
Based on lumbar T-score measurements, 30 patients were normal, 6 were osteopenic, and 1 
was osteoporotic, while based on femoral T-score, 12 patients were normal, 15 were 
osteopenic, and 7 were osteoporotic. In box and whisker, x is the mean value, and the line is 
the median.    
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3.4 Discussion  
 
The current study is one of the few studies evaluating bone involvements for AKU 
patients quantitatively. The study set out to assess regional bone formation at the most 
affected skeletal sites for AKU patients using 18F-NaF PET/CT scans. In this chapter, 
novel molecular imaging assessment methods have been introduced to quantify active 
bone turnover and estimate bone density at the lumbar spine and hip sites. The current 
study establishes a quantitative framework for detecting the early stage of ochronotic 
arthropathy in AKU patients using 18F-NaF PET/CT semiquantitative methods. 
 
3.4.1 HU measurements   
 
Throughout this study, bone density for AKU patients was approximated by measuring 
HU from non-contrast CT scans. In the literature, several reports have identified 
patients at risk of fracture and those with bone density disorders by determining spine 
HU values from diagnostic CT systems when it is performed for other clinical purposes 
81,83,85,164. The results of this study showed that AKU patients had low HU values in 
the lumbar vertebrae and head of the femur, indicating low bone density. It is more 
likely that low bone density in AKU patients is associated with ochronosis. Several 
studies reported low bone desnity in patients with AKU 48,75. It is more likely that 
ochronotic pigment in the joints cause unusual transmission of mechanical loading to 
the subchondral bone, which may alter bone remodelling in AKU patients. 
 
As data showed in Figure 3.1, the mean HU measured at the lowest lumbar level (L5) 
was statistically higher than the rest of the lumbar levels. This suggests that the density 
of lumbar vertebrae may be different depending on the anatomical level. From lumbar 
HU values in both genders, females seem to have slightly higher HU values at all 
lumbar levels compared to male patients; however, there was no evidence that gender 
significantly influences the measured values. This suggests that the differences 
between HU values may not related to gender; instead, the effect may occur due to the 
individual difference between the measured patients. A previous study evaluating the 
relationship between lumbar HU values and sex for 18 females and 7 males  supported 
the findings in this chapter 83.  Although the mean age of AKU patients in this chapter 
was 50.8 years old compared to 71.3 years old in Schreiber’s study, similar findings 
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was found in both studies.  Schreiber et al. found that male patients had slightly higher 
HU values compared to female patients; however, the differences were not statistically 
significant 83. The measured HU values throughout L1-L4 by Schreiber were 175.7, 
173.3, 169.5, 170.9 and 165.3, 165.1, 164.0, 164.4 for males and females, respectively, 
while in this chapter it was 138.25, 133.02, 130.05, 145.0 and 142.52, 154.33, 137.87, 
147.00 for males and females, respectively. The differences between the results here 
and Schreiber study may be due to the small sample size and different mean age. 
Different CT systems may also influence the HU values, so caution must apply when 
comparing the quantitative values with the literature.  
 
Regarding the head of the femur HU measurements, no data were found in the 
literature. Most of the published work has concentrated on lumbar spine 
measurements. In fact, the spine is considered as one of the best skeletal sites for 
quantitative assessment of bone metabolism by many researchers for several reasons. 
First of all, spinal bone turnover is usually greater than those detected at other bone 
sites. Anatomically, spine vertebrae is rich in trabecular bone, which is less dense but 
highly vascularised compared to cortical bone 107. Cortical bone represents the 
minority of the bone mass, whilst trabecular bone accounts for the majority of bone 
turnover, which is associated with bone remodelling. Second of all, the spine is the 
primary weight-bearing region in the body, which is subjected to high mechanical 
stress, causing osteoblast differentiation and stimulation. As a result of these factors, 
bone turnover and osteoblastic activity will be increased in the spine area 124. In the 
current study, the head of the femur result is consistent with lumbar spine findings 
where no significant differences between males and females were found. A possible 
explanation for this might be that the effect of losing bone tissues and developing 
osteoporosis in both genders is similar throughout the entire skeleton. These results 
may be due to menopause triggers in women, and physical inactivity in men. 
Therefore, hormonal changes in female and physical inactivity in men may cause an 
equal effect on bone density for AKU patients.  
 
In relation to the age effect, it was noted that HU values obtained at L1-L5 decreased 
significantly with increasing age (P < 0.01, R = -0.632; Figure 3.11.). The differences 
in average lumbar levels HU values among different age groups were statistically 
significant between the 5th and 6th decade of life (P = 0.045), following the predictably 
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decreasing trend with increasing age. Femoral HU results seem to be consistent with 
lumbar HU results, where a significant decrease in the HU values with ageing was 
found (P < 0.001, R = 0.558). This finding broadly supports the work of other studies 
in this area linking low HU values with age. Batawil et al. measured HU in lumbar 
vertebrae (L1-L4) for 114 women who underwent an abdominal CT scan 85. In that 
study, a strong correlation between decreased HU values at L1-L4 and increasing age 
was found; lumbar spine HU values were significantly decreased from 182 HU at the 
4th decade to 82 HU at the 8th decade. Lee et al. 81 reported HU values in lumbar 
vertebrae L1-L4 in 128 female patients (mean age 66.4) with low back pain who 
underwent a CT scan. Lee et al. and his co-worker also found a decreasing trend at L1, 
L2, L3 and L4 with increasing age (R = 0.673, R = 0.794, R = 0.766, R = 0.713, 
respectively) 81; subgroup analysis showed significant differences between the 50s and 
60s groups, and between 70s and 80s groups at L1-L3. At the L4 level, a difference 
was noted between the 60s and 70s. Lee et al. also reported no significant differences 
between the 40s and 50s at any lumbar vertebrae levels. It is encouraging to compare 
the findings among age groups in this chapter with that found by Lee et al.81, who 
found that the average lumbar HU values in the 40s were 175.0 ± 48.9, in 50s was 
150.2 ± 40.4 and in 60s was 97.5 ± 39.7. Interestingly, a similar finding has been 
detected in this chapter where the average lumbar HU value was 177.59 ± 45.92, 
142.44 ± 48.39, and 94.8 ± 50.27 among the 40s, 50s and 60s, respectively. These 
results reflect those of Batawil et al. 85 also who found very similar HU values among 
these age groups. Schreiber et al. also found linear decreasing HU values in the lumbar 
spine by decade, ranging from 225.1 HU in the 2nd decade of life to 78.7 in the 8th 
decade of life 83. In this chapter, lumbar HU values followed a similar decreasing trend 
confirming the strong correlation between HU values and age.  
 
There are several possible explanations of the age influence on HU measurements. 
These results may be explained by the fact that the structure of bone changes as ageing 
occurs, and causes a loss of bone tissue, calcium and other minerals, and therefore loss 
of bone mass 165. Another possible explanation for this is the physical inactivity which 
will cause bone loss. Hormonal changes related to ageing may also be connected to 
losing bone tissue. From this point, decreased HU value in bone with age can be 
explained by bone mineral density reduction. In fact, it is more likely that the overlap 
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between ageing and ochronosis in AKU patients lead to more bone loss compared to 
the general population.  
 
3.4.2 SUV measurements  
 
This study is the first study that has investigated skeletal involvement for patients with 
AKU using semiquantitative 18F-NaF PET assessment method. The results of this 
study showed abnormal 18F-NaF uptake at lower spine and hip sites, refelecting bone 
turnover in AKU patients. Low SUVmax values in the lumbar vertebrae and head of the 
femur indicate low hydroxypeptite crystals which may be associated with ochronosis 
in AKU patients. High SUVmax values were detected in an area of early and active 
bone changes in AKU patients due to increased -18F binding sites in the area of active 
bone formation. In fact, the accumulation of 18F-NaF in the lumbar spine is associated 
with increased hydroxyapatite crystals of newly formed bone which reflects the active 
bone formation and bone remodelling lesions and can be identified as areas of 
increased SUV value. It is more likely that bone turnover and bone remodelling is 
associated with ochronotic pigment which deposited in the cartilage tissues. Although 
there was no previous PET quantitative data for patients with AKU in the literature to 
compare our reults with, it is more likely that AKU patients have abnormal 18F-NaF 
measurements due to ochronotic arthropathy compared to the general population.  
 
There are several published studies which reported bone SUV measurements from the 
normal cases and for those patients with bone disorders. Win et al. 124 reported the 
maximum SUV values from normal skeletons for 11 patients without a history of 
cancer or metabolic bone disease using 18F-NaF -PET/CT bone scans. In that study, 
the mean SUVmax of the lumbar vertebrae (L1-L5) was 7.27 and ranged from 7.04 to 
7.72, while lumbar SUVmax for AKU  patients in this study was 10.54 and ranged from 
5.2 to 15.91. Puri et al. 131 also reported lumbar spine SUV in 12 healthy 
postmenopausal women mean age 62.6 years, and found that SUV was 6.005 ± 1.47, 
significantly lower than the findings in this chapter. Although the findings of the 
current study do not match with literature, the differences in the values were expected 
due to the differences in the sample size and the nature of bone tissues between AKU 
patients and non-AKU patients. AKU patients more likely have degenerative bone and 
joint disease, therefore high SUV values in active and ongoing bone turnover area was 
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expected. This observation may support the hypothesis that HGA deposition in bone 
tissues may be correlated with increased bone resorption rate, leading to accelerated 
bone loss in patients with AKU. These damages would more likely increase the -18F-
NaF binding sites, therefore high SUVmax would be detected. 
 
The results in this study showed that mean SUVmax values throughout L1-L5 were 
similar, with no statistically significant differences between the measured levels. The 
results reflect those of Win et al, who also found that lumbar levels have similar 
SUVmax values 
124. This suggests that the radiotracer uptake in the spine may be similar 
in all lumbar vertebrae levels.  
 
In terms of quantifying the femoral site, similar mean SUVmax values were measured 
from both the right and left site which are far above those observed by Win et al. and 
Puri et al. The average SUVmax value at the femoral region in this chapter was 4.71, 
compared with 2.22 and 2.32 in literature. These differences are interesting, but also 
not surprising. These results may reflect differences in bone turnover between AKU 
patients and the general population. The comparison here appears to support the 
assumption that bone turnover increased 18F-NaF uptake throughout whole skeleton in 
those patients with metabolic bone disorders compared to general population. 
 
The findings of other osteoarthropathy studies confirm that the deposition of 
radiotracer in bone turnover lesions is higher than in healthy sites. Hip OA has been 
evaluated at various stages using SUV and compared with X-ray images and pain 
scale. The progressive OA stages showed significantly high SUVmax compared to the 
early-stage cases 166. Even early OA stage cases without OA radiographic findings, but 
with pain showed a radiotracer accumulation in the affected sites 167. Kobayashi et al. 
133 assessed the SUV at the hip joints and he observed an accelerated bone remodelling 
rate in various stages of OA; SUV values were compared with radiographical findings 
in MRI and the severity of pain. Kobayashi et al. pointed out that positive lesions in 
PET scan had a SUVmax of 6.5 and higher. The authors reported that the positive joint 
lesions were more detectable in PET scans in comparison to MRI (47 in PET vs 25 in 





As shown in Figure 3.8, the mean SUVs of all lumbar vertebrae levels were 
significantly higher than the mean SUVs of the femur regions (10.45 ± 2.17 and 4.94 
± 3.25, respectively). Comparing the findings with those of other studies confirms that 
18F-NaF uptake in the spine is higher than in the femoral bones. These results are 
consistent with that found by Win et al. 124, who reported that mean SUVs of the 
femoral bones are lower than the mean SUVs of the spine. This also accords with Puri 
et al. 118 findings who demonstrated higher bone turnover at the spine than the 
proximal femur. Therefore, a higher deposition of 18F-NaF in the vertebrae compared 
to the head of the femur was expected and normal. This is a positive finding providing 
confidence in the quality of the outcomes reported in this study, and the measurement 
methods which have been used to quantify ROI in this study. 
 
In reviewing the literature, no data were found on the question of sex effect on the 
bone SUV values measured from 18F-NaF PET/CT scans. The results of this study 
found that there is no significant differences in lumbar and femoral SUVmax between 
males and females. Although male patients had slightly higher SUVmax values, it was 
not statistically significant (P > 0.05). This study produced results which corroborate 
the findings of Kaneta et al. 168. Kaneta measured SUV in the normal vertebrae for 29 
patients including 8 females and 21 males who underwent 99mTc MDP SPECT/CT 
scan. He reported that male patients had higher SUV values in the spine compared to 
the female patients, suggesting that these findings reflect differences in bone mineral 
density which is higher in males compared to females.  
 
The results of this chapter found that age seems to affect 18F-NaF uptake in the lumbar 
vertebrae in patients with AKU. As data showed, lumbar vertebrae SUVmax values 
decreased with age (P = 0.006, R = 0.432). This also accords with earlier observations 
in the HU (section 3.3.1.1.2), which showed a reduction in HU values with age in the 
lumbar vertebrae. The similar finding in both HU and SUV values could be linked. A 
reduction in HUmean reflects low bone density which means less hydroxyapatite, 
resulting in a low 18F-NaF uptake. Another possible explanation for this result may be 
related to spine perfusion. It was hypothesised that blood flow and osteoblastic activity 
reduced with age. Therefore, it is likely that the reduction in spine perfusion as a result 
of ageing would reduce the 18F-NaF transfer to the spine vertebrae 118. This finding 
may explain the decline in 18F-NaF uptake with age. Therefore, it is not surprising that 
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a negative trend in lumbar levels SUVmax with age has been noted. In elderly patients, 
inactive or stable bone turnover lesions which were established years before might 
have fewer 18F-ion binding sites, therefore decreased 18F-NaF uptake, which can be 
identified as an area of low SUV values. Several studies have shown the same negative 
trend between lumbar SUV and age. Win et al. 107 examined the age effect in the 
normal spine, and he found a reduction in SUVmax in spine vertebrae at different levels 
with age; however, the reductions were not statistically significant. Ayubcha et al. 169 
also reported a negative trend in lumbar spine SUVmean with age but also without 
statistical significance.   
 
In contrast to the earlier lumbar vertebrae findings, no significant reduction in the 
values were found between femoral SUVs and age. However, these findings are 
broadly consistent with those observed by Win et al. 107, who reported that age did not 
significantly affect the 18F-NaF uptake in healthy bone regions. The findings of this 
chapter revealed that SUVmax of the femoral head had a similar trend with age as in the 
normal skeleton, suggesting that generalised rates of bone turnover in the hip region 
for AKU patients and normal patients are very similar. Although in this section no 
direct trend between SUVs and age was found, the results were limited to the number 
of patients who had not undergone femoral head replacement. Most of the eldery AKU 
patients had a metal stem placed into the femoral hollow centre; therefore, it is likely 
that these unmeasured cases could account for some aspect of findings here, causing a 
possible source of error.  
 
Looking more deeply among age groups, patients in their 30s and 40s are more likely 
to have normal osteoblastic activity and normal blood supply to the spine and hip area; 
therefore, SUV measurement reflects the normal distribution of 18F-NaF through the 
spine and femoral head in these AKU patients. In contrast, patients in their 50s and 
60s tended to have a severe joint pain and disability. In older patients, they are more 
likely to have inactive osteoblast activity due to ageing and abnormal blood flow to 
the spine and hip area, which will cause fewer binding sites, leading to low 18F-NaF 
deposition in bone. In general, most of pathological bone diseases are associated with 
an increase in local bone remodelling and vascularization 170. On bone scans, this 
associated bone response is shown as a concentration of accelerated radioactive tracer 
absorption. The advance stage of bone or joint disorder provide minimal bone 
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remodelling and a disturbance in blood flow; therefore, in the late stage of bone and 
joints degeneration, the bone image findings are characterised by low radiotracer 
uptake area 171.    
 
From the results of SUV values at each age group, young AKU patients were seen to 
have higher SUVmax values in the lumbar spine (L1-L5) compared to older patients. 
The average SUVmax in lumbar vertebrae levels decreased from the 30s to the 60s. 
Although the differences in the SUVmax for the average lumbar levels between age 
groups were only statistically significant between 50s and 60s, this result supports the 
idea of the association between ochronosis and age. It is probably that bone turnover 
is active in AKU pateints at the late 40s and can be detected in PET scans at the early 
50s showing the peak bone turnover process.  
 
3.4.3 T-score measurements 
 
In this study, lumbar and femoral T-score values from DEXA reports were analysed 
and compared with gender and age. Statistically, no significant differences in T-score 
values between males and females were noted at neither lumbar spine nor the proximal 
femur (P = 0.1 and P = 0.25, respectively). These findings agree with HU and SUV 
results, suggesting that gender has no significant effect on bone radiographic 
quantitative values for AKU patients. As mentioned in the HU section, previous 
studies have reported that there are no significant differences in bone density values 
between males and females in non-AKU patients 83. Therefore, it seems that this also 
applies to AKU patients. In contrast, Daly et al. 172 compared age and gender-specific 
changes in bone mineral density (BMD) over ten years of study, and found that the 
annual loss in BMD for female patients was significantly higher than male patients 
aged 60 years and older (0.5-0.7% greater).  
 
In the current study, no correlation was noted between lumbar T-score and age for 
AKU patients (Figure 3.20), suggesting that there is no direct correlation between bone 
mineral density measured from DEXA scan and age. A reduction in lumbar T-score 
with age was expected due to bone loss with ageing; however, this trend was not 
evident in this part of the investigation. In contrast to the earlier lumbar spine T-score 
findings, there was a strong correlation between femoral T-score and age (R= 0.571, 
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P < 0.05). Young AKU patients had healthy femoral T-score ranges representing 
normal bone density, while most of the older patients had an osteopenic T-score range. 
There is no debate that bone density is reduced with age; but the results in this sections 
showing no statistically significant correlation between lumbar T-sore values and age 
which could also be related to the disease severity in AKU patients. It has been widely 
agreed that bone turnover is coupled very tightly in the first three decades of life to 
maintain a steady-state between bone formation and bone resorption. Around the age 
of 20 years in women and older in men, bone mass reaches a peak; after that, bone 
turnover continues causing a gradual bone mass reduction 173.  
 
In AKU cases, bone density measurements may be problematic as extensive disc 
degeneration complicate bone densitometry in ochronotic patients. Spinal DEXA 
measurements may be influenced by severe disc calcification, and the results may not 
reflect a true representation of bone density. It has been reported previously that, hip 
BMD can be lower than spinal BMD due IVD calcification and the formation of 
osteophytes 48. The spine calcification in conjunction with reactive arthritic changes 
mainly concentrates at the edges of vertebral bodies as osteophyte formation, which 
substantially alters spinal measurements and overestimate the measured bone density 
values in DEXA scan 48. Abdominal aortic calcification, which is also common in 
AKU cases, can also cause a false high bone mineral density. For this reason, some 
articles suggested measuring bone density at the central or mid vertebral body rather 
than the posterior-anterior or lateral vertebral body to represent accurate vertebral 
density 48. 
 
A number of large studies in this area suggest that spinal BMD from DEXA scan is 
not considered a significant surrogate marker for spinal osteoporosis in osteoarthritic 
patients. In some cases, DEXA reports may indicate normal spinal bone density while 
the patient is osteoporotic. This might be related to the DEXA imaging technique. In 
DEXA, bone density values represent the estimated amount of all mineral density in 
the path of X-ray beam between L2-L4 levels. Therefore, calcified regions within the 
X-ray path could interfere the lumbar bone density values.  
 
In patients with ochronosis, IVD calcification is highly expected due to ochronotic 
deposition between the vertebrae. Therefore, this calcification and osteophyte 
149 
 
formation may likely influence the lumbar density measurements in a DEXA scan 
resulting in high T-score values. Therefore, lumbar bone density values measured from 
DEXA scans in AKU patients must be interpreted with caution. Furthermore, BMD 
assessment in ochronotic patients shows low bone mineral density at the hip region, 
while lumbar value was within or higher than the values of the control group 75. In the 
current study, most of the AKU patients had lower femoral T-score values compared 
with the lumbar T-score values, giving a diagnosis of osteopenia and osteoporosis. 
According to the lumbar T-score, 81% of the AKU cases were diagnosed as normal, 
while only 32.4% of those cases were diagnosed as normal based on femoral T-score. 
These results are in agreement with Aliberti et al. 75 findings who investigated skeletal 
involvement in ochronotic patients. Aliberti et al. evaluated lumbar spine and femoral 
bone mineral density (BMD) from DEXA scans for 7 AKU patients (5 males and 2 
females), age range from 26 to 82 years. In that study, Aliberti found that one patient 
had normal bone density at the femoral site, three patients were osteopenic, and three 
patients were osteoporotic. He reported that lumbar bone density provided 
overestimated T-score results caused by IVD  calcification and osteophyte formation. 
 
In general, DEXA measurements have several limitations. First, DEXA results reflects 
both cortical and trabecular bone, however, bone turnover appears earlier in the 
trabecular bone compared to cortical bone. Therefore, DEXA values may possibly fail 
in detecting early osteoarthropathy in the spine. Second, DEXA measurement is 
affected by the size of patient. Therefore, overweight and obese patients may have 
false T-score values. Notwithstanding these limitations, at present, T-score from 
DEXA scan is the only accepted method by WHO to diagnose osteopenia and 
osteoporosis. However, searching for more accurate diagnostic tools to estimate bone 
density is needed.   
 
3.4.4 Correlation between HU and T-score 
 
Throughout this study, a moderate correlation between HU values obtained from CT 
scans across lumbar vertebrae and bone mineral density values measured by DEXA 
scans was demonstrated with a R = 0.503 and P = 0.002 (Figure 3.22). This finding is 
consistent with that of Schreiber et al., who found a moderate correlation between HU 
values and T-score throughout L1-L4 (R= 0.48, P < 0.0001) 83. This also accords with 
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Barawil et al. 85 observations, who reported correlation coefficients between HU and 
T-score throughout L1-L4 to be 0.509, 0.473, 0.492, and 0.525, respectively, similar 
to the results in this chapter. These findings significantly supported the results in this 
chapter. 
 
On the other hand, several reports have shown that HU values measured from CT had 
a strong correlation with bone mineral density values (T-score and absolute BMD 
values) measured by DEXA scans throughout the lumbar levels. Lee et al. 81 reported 
a strong correlation across L1-L4 between HU and T-score with correlation 
coefficients of 0.673, 0.794, 0.766, and 0.713, respectively, and between HU and BMD 
with correlation coefficients of 0.657, 0.774, 0.737 and 0.673, respectively. Another 
clinically relevant finding was also found between HU measured from CT and BMD 
measured by quantitative computed tomography (QCT); a more complex CT 
technique. In a previous study of 30 healthy patients, Gerety et al. 164 reported a 
significant correlation between HU and QCT BMD measured from L1 level (R = 0.83, 
P > 0.005).   
 
Since 2011, several studies have been published comparing HU values from CT scans 
with bone density measurement values from DEXA scans 83. An initial objective of 
current and ongoing studies is to identify the sensitivity and specificity of HU values 
obtained from CT for the detection of osteopenia and osteoporosis. These findings 
might help us and others to establish the range of HU values that can be used to 
represent normal, osteopenia and osteoporosis. In the present study, AKU patients with 
normal T-score values in lumbar vertebrae had a mean HU value of 152.93 ± 52.677, 
and those with osteopenia had a mean HU value of 92.67 ± 33.44. It was difficult to 
represent and estimate the HU value for the osteoporotic group due to a limited number 
of patients who had osteoporosis T-score values at L1-L4.  Only one patient had an 
osteoporotic T-score value of 19 HU, making this finding uncertain.  
 
Although several studies suggested HU thresholds that represent high sensitivity and 
specificity for detecting normal, osteopenia and osteoporosis 81–85,87,89,164, these results 
should be interpreted with caution. Each study suggested a different range of HU 
values representing normal, osteopenia and osteoporosis cases (see Table 1.4). These 
results are likely to be related to bone radiodensity which can be influenced by several 
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factors. Vertebral bone density measurement from the CT scanner is dependent mainly 
on the CT system, the tube voltage (energy of the photons) and the imaging protocol. 
Therefore, the differences in the literature are expected as each CT department have 
their local CT system and use different imaging parameters. To develop a full picture 
in this area, additional work would be needed.  
 
Regarding the femoral site, the head of femur HU values has a strong correlation with 
the femoral T-score (R = 0.796, P < 0.001), as shown in Figure 3.22. In the present 
study, AKU patients with normal T-score values in the proximal femoral head had a 
mean HU value of 270.53 ± 39.11, those with osteopenia had a mean HU value of 
231.37 ± 35.49, and those with osteoporosis had a mean HU value of 161.59 ± 31.59. 
 
Although no previous data were found on the correlation between femoral HU and T-
score in the literature, the findings reported in this chapter are particularly interesting 
and encouraging. These findings suggest that the head of femur HU values can predict 
bone density at the femoral site. Therefore, it is a promising finding which introduces 
that HU values could be used to diagnose osteoporosis for those AKU patients who 
have not undergone a DEXA scan and had CT, SPECT/CT, or PET/CT scan for 
another reason.  
 
3.4.5 Correlation between HU and SUV 
 
To our knowledge, no study has investigated the correlation between bone HU values 
measured from CT and SUV values measured from 18F-NaF PET. This study is the 
first study to examine the association between HU values and SUV values at lumbar 
and femoral bone regions. The results in this study showed an association between 
HUmean values and SUVmax for average lumbar vertebrae levels (R = 0.373, P = 0.002). 
However, looking at each lumbar level individually in Figure 3.23, the significant 
correlations were noted only at the L1,L2 and L4 with a correlation coefficient of 
0.517, 0.492 and 0.320, respectively and all had P < 0.05. At the same time, there was 
no significant correlation at L3, and L5 in which the correlation coefficients were 
0.130, and 0.254, respectively, and all had P > 0.05. This inconsistency between the 
lumbar levels might be related to mechanical forces acting on the lumbar spine. It is 
possible that upper lumbar levels had increased axial forces acting upon them due to 
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its flexibility; therefore, the active bone turnover can be detected earlier in PET scan 
at those levels.  
 
On the other hand, no significant correlation was noted between HU and SUV at the 
femoral site as shown in Figure 3.24. (R = 0.277, P = 0.113). This finding may be 
somewhat limited by the number of patients who were involved in this section. As 
mentioned earlier, patients who underwent joint replacement were excluded from the 
femoral measurements. So, these unmeasured cases may account for some aspects of 
the results. 
 
Taken together, a correlation between the regional bone attenuation coefficient and 
regional 18F-NaF uptake was expected due to strong correlation between bone density 
and hydroxyapatite sites. In fact, high-density area has higher HU values and therefore 
higher hydroxyapatite sites for 18F-NaF to bind with, leading to high SUV. Further 
investigations are needed to confirm whether bone HU values obtained from CT 
correlate with 18F-NaF uptake from PET scan or not.  
 
3.4.6 Correlation between SUV and T-score 
 
This study demonstrates no clear correlation between SUVmax values obtained from 
18F-NaF PET across lumbar vertebrae and bone mineral density values measured by 
DEXA scan with correlation coefficient 0.069 and P = 0.684. Similar findings have 
been noted in the femoral site, which also showed no correlation between the head of 
the femur SUVmax and femoral T-score (R = 0.166, and P = 0.339). Based on WHO 
criteria, in the present study, AKU patients with normal T-score values in lumbar 
vertebrae had a mean SUVmax value of 10.76 ± 2.22, and those with osteopenia had a 
mean SUVmax value of 9.37 ± 2.62. The SUVmax for an osteoporotic T-score is not 
certain as it is reflecting the value of one patient only who had lumbar vertebrae T-
score below -2.5 and had 8.15 SUVmax. On the other hand, AKU patients with normal 
T-score values in the proximal femoral head had a mean SUVmax value of 4.63 ± 1.96, 
those with osteopenia had a mean SUVmax value of 4.45 ± 1.34, and those with 




The weak association between T-score and SUVmax was unexpected. The findings of 
the current study do not support the previous hypothesis, which suggests that low bone 
density is associated with low 18F-NaF uptake in the bone. Following the expected 
correlation between HU and SUV, it was also expected to see a strong relationship 
between T-score values and SUV values due to limited hydroxyapatite sites in a low-
density lesion. A possible explanation for this might be that the measurements of bone 
density value in DEXA scans is obtained from the trabecular and cortical bone regions, 
while in the current study, SUV values was measured from the trabecular areas only. 
It is possible that these unmeasured areas could account for some aspects of the 
relationship. The other possible reason could be explained by the fact that DEXA 
results are overestimated due to IVD calcification and vascular calcification, which 
may not represent true information about bone density.  
 
As noted from the examples, patients who reported decreased SUVmax values had 
either very low or normal T-score values. The reason for this is not clear, but it may 
have something to do with bone formation and the stage of disease. For example, in 
case of active bone turnover or bone remodelling, it would be expected to detect high 
SUV values, and after that when the affected area becomes inactive or stable, the 18F-
NaF uptake in that area could become low. This could explain what was noted in this 
chapter.   
 
3.5 Summary  
 
In AKU patients, ochronotic pigment can cause unusual transmission of mechanical 
loading to the subchondral bone, which may alter bone remodelling. 18F-NaF PET/CT 
is a sensitive and accurate imaging technique which can detect early bone metabolism 
and joint arthropathy throughout the entire skeleton, including high-risk regions such 
as the spine and hip. The present study proposes a novel radiographic semiquantitative 
method which can be used to assess the progression of skeletal involvement in the 
spine and hip regions for AKU patients. The results from this study contribute to a 
deeper understanding of the disease state and progression in AKU patients.  
 
The accumulation of 18F-NaF in PET images is associated with hydroxyapatite crystals 
of newly formed bone which can be identified as areas of increased SUV value. In 
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addition to performing CT for attenuation correction purpose, CT data can be used as 
a diagnostic tool alerting the physician to investigate abnormal bone density 
specifically for those patients with rare metabolic bone diseases which may not 
otherwise be suspected.  
 
IVD calcification is highly expected in AKU patients due to ochronotic deposition 
between the vertebrae. This calcification and osteophyte formation may likely result 
in unusually high bone mineral density and T- score values in DEXA scans. Because 
of this, spinal DEXA measurements may not reflect a true representation of bone 
density for ochronotic patients. 
 
Based on the significant correlation between vertebral and femoral HU values 
measured from PET/CT scan and T-score values measured from DEXA scan, HU 
measurements can be used to estimate bone mineral density and detect bone disorders 
without adding extra radiation or cost to the patient. These results may also help others 
to find new ways of quantifying and extracting valuable data which are available but 
has rarely been used for identifying patients at high risk of fracture. Although positive 
HU findings were noted in this study, these results are not strong enough to suggest 
the replacement of DEXA with CT for bone mineral density assessment purposes. 
 
Spinal HU and SUV measurements from lumbar vertebrae consistently decrease with 
each decade of life studied here in AKU patients due to reduced bone density mass 
and active bone turnover which might be associated with ochronosis and ageing. 
However, a moderate correlation between the average HU of lumbar bodies and 




This study has some limitations which must be considered. First, interobserver and 
intraobserver reliability have not been tested due to limited time and collaboration. 
Second, only two skeletal sites were evaluated in the current study which may not 
represent the global disease progression. Third, a non-AKU control group was not 
studied to statistically compare the quantitative bone values for general population 
subjects with AKU patients. Fourth, in this study, HU values obtained from CT images 
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included only trabecular bone density, while T-score values from the DEXA reports 
represented both cortical and cancellous bone. Three axial sections may not precisely 
summarise the density of cancellous bone as it is a heterogeneous tissues. Although 
trabecular bone is more important than cortical bone in order to determine fracture 
risk, it is possible that HU results from CT images underestimate the true bone mineral 
density 81. Therefore, in the current study, the correlation between T-scores and HU 
values may represent some error.  
 
3.7 Future work  
 
Future investigations are required to confirm and validate the findings which were 
found in this study. First, interobserver and intraobserver reliability of the SUV and 
HU values need to be tested. This would strongly support the PET/CT measurement 
methods which were proposed in this study. Second, other bone sites such as the 
shoulder, tibia and humerus bone need to be assessed and quantified, in order to 
evaluate the impact of ochronotic pigment in multiple skeleton sites. Third, a non-
AKU control group is needed to statistically compare the results of AKU patients with 
the general population. Also, it would be interesting to establish HU thresholds for 
normal, osteopenia and osteoporosis in patients under local imaging protocols in the 




This chapter has shown that: 
 
 18F-NaF PET/CT scan is a promising imaging technique which can help to 
detect early ochronotic arthropathy. 
 AKU patients had low HU values in the lumbar vertebrae and head of the femur 
indicating low bone density. 
 The accumulation of 18F-NaF in a PET image is associated with increased 
hydroxyapatite crystals of newly formed bone which reflects the active bone 
formation and bone remodelling lesions and can be identified as areas of 
increased SUV value. 
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 In elderly AKU patients, inactive or stable bone turnover lesions which were 
established years before might have low -18F ion binding sites, and therefore 
decreased 18F-NaF uptake, identifying as an area of low SUV value. 
 Bone HU and SUV values in the lower spine consistently decrease with age, 
indicating decreased bone density and osteoblastic activity with age. 
 The reduction in spine perfusion as a result of ageing would also reduce the 
18F-NaF transfer to the spine vertebrae. 
 There were no significant differences between the 18F-NaF PET/CT 
semiquantitative values nor DEXA measurement of males and females at 
neither spine nor femoral sites. 
 Spinal DEXA measurements are influenced by severe disc calcification in 
AKU patients, and thus the results may not reflect a true representation of bone 
density.  
 There was a strong correlation between vertebral and femoral HU values 
measured from PET/CT scans and T-score values measured from DEXA scans, 
suggesting that HU measurements can be used to estimate bone mineral density 
without adding extra radiation to the AKU patient. 
 There was a moderate correlation between the average HU and SUVmax of the 
























4 Cross-sectional study of lumbar intervertebral disc degeneration 
at baseline in alkaptonuria patients from the SONIA 2 study 








In the previous chapter, regional bone formation in the lumbar spine and hip sites were 
quantitatively assessed in AKU patients from the SONIA 2 study by measuring HUmean 
from CT and SUVmax from 
18F-NaF PET images. Also, the measured values were 
correlated with bone density values from DEXA reports. As pointed out in Chapter 3, 
18F-NaF PET/CT is a promising imaging technique which can successfully detect early 
bone involvements reflecting accelerated bone remodelling in ochronotic patients.  
 
This chapter of the thesis is performed to detect and identify the lumbar joint changes 
for AKU patients. The present study is one of the first investigations to focus 
specifically on disc degeneration for ochronotic patients using two advanced 
molecular imaging modalities. The main aim of the current study is to evaluate the link 
between early molecular disc changes detected from 18F-NaF PET/CT scans and the 
structural disc changes identified from MRI within lumbar spine. This study designed 
to identify lumbar intervertebral disc 18F-NaF uptake by measuring SUVmax from PET 
images and identify disc structural changes by measuring the Pfirrmann score from 
MRI. Part of this study aimed to test the effect of gender and age on the SUVmax and 
disc degeneration score in AKU patients.  
 
This study is divided into three sections. In the first section, lumbar disc degeneration  
is identified and quantified using 18F-NaF PET/CT scans. In the second section, lumbar 
disc degeneration is scored from MRI. In the third section, the correlation between 18F-
NaF PET/CT and MRI results is investigated.  
 
During the development of ochronosis, ochronotic pigment accumulates in the joints 
and articular cartilage, causing ochronotic arthropathy. In the spine, ochronotic 
pigment causes vertebral bone changes and joint degeneration, resulting in increased 
blood flow to spine, and accelerated bone remodelling in the affected area 3,35. 
Ochronotic spinal changes manifest similar to spine arthritis through vertebral disc 
herniation, disk space narrowing, severe disc calcification, sclerosis, osteophytosis, 
and spondylitis 13,16. In the early stages of disc degeneration, the interaction between 
the vertebral body and the IVD is critical not only to determine the disease profile but 
also to assess early changes in the spine.  
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Although there are no specific radiopharmaceuticals to image the articular cartilage, 
the 18F-NaF radiotracer has been widely used to detect the changes relating to 
osteoarthritis and other joints disorders 101,103. Early joint degradation assiocated with 
joint calcification is more likely be visible on 18F-NaF PET imaging before other 
imaging techniques. The uptake of the bone radiotracer in the joint can be quantified 
using PET quantitative measurement methods such as SUV. 
 
The principle of the MR scanner provides a clear separation between bone and soft 
tissues in vivo, offereing high-resolution images. The modified 8 level Pfirrmann 
grading system, is a simple, non-invasive, and convenient MRI method which can 
assess morphological changes and provide a visual evaluation of lumbar intervertebral 
disc degeneration; however, it is a subjective qualitative assessment method which can 
be inadequate for evaluating the end stage of disc degeneration 90,174.  
 
4.2 Design of study 
 
4.2.1 Patient group 
 
In this chapter, a total of 34 AKU patients who were part of the SONIA 2 trial with a 
mean age of 48.38 ± 10.04 years old, ranging from 30 to 68 years old, were reviewed. 
These patients comprised of 19 males with a mean age of 48.68 ± 9.45 years, ranging 
from 30 to 62 years, and 15 females with a mean age of 48 ± 11.07 years, ranging from 
30 to 68 years, with no statistical age difference between the groups (P > 0.05). The 
demographic characteristic of this population is summarised in Table 4.1. Patients with 
metal implants were not able to do an MRI and have been excluded from this analysis. 
Only patients who had both 18F-NaF PET/CT and MRI within the same year were 
included in this study. Patients were grouped into four age groups, as shown in Table 
4.2. In this study, 7 patients (21%) were between 30 and 39 years old, 12 (35%) were 
between 40 and 49 years old, 10 (29.3%) were between 50 and 59 years old, and 5 






Table 4.1. Demographic characteristics of 34 AKU patients who were part of SONIA 2 
clinical trial and involved in this study classified by gender.  
Data displayed as number of patients and percentage in each group. Age of the patients 
displayed as mean ± SD, minimum and maximum. 
Gender Patients no. (%) Age ± SD (years) Age range  
Total 34 48.38 ±10.04 30 - 68  
Male 19 (55.9%) 48.68 ±9.45 30 – 62 
Female 15 (44.1%) 48.00 ±11.07 30 - 68 
 
 
Table 4.2. The number of AKU patients at the beginning of the SONIA 2 clinical trial 
who underwent both 18F-NaF PET/CT and MRI stratified by decade of life. 
Age group Gender Patient no. 
30 - 39 years old 
Total  7 
Male 3 
Female 4 
40 - 49 years old 
Total  12 
Male 8 
Female 4 
50 - 59 years old 
Total  10 
Male 6 
Female 4 
≥ 60 years old 






4.2.2 Image analysis 
 
Baseline 18F-NaF PET/CT images were displayed using Horos software. The images 
were analysed and interpreted, blinded to the MR images or results. As explained 
earlier in the Methods Chapter, (section 2.7) it was difficult to draw a ROI around the 
disc region only due to the advanced disc degeneration in most AKU cases; therefore, 
a ROI covering the disc area and the endplate of the two adjacent vertebrae was used 
and termed discovertebral unit (DVU).  
 
Six regions of lumbar DVU from segment T12/L1 to segment L5/S1 from 18F-NaF 
PET/CT and spine MR images were analysed. A total of 203 lumbar intervertebral 
discs were quantified as described in the Methods Chapter (see section 2.7). Patient 
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number 16 had metallic disc support at T12/L1, so only five DVUs were analysed for 
this patient.  
 
18F-NaF uptake within DVUs were quantitatively identified from PET images at three 
consecutive sagittal slices to assess and detect the extent of disc degradation. CT 
images were used in this chapter for attenuation correction and anatomical localisation 
of the disc area only. The ROI was drawn in CT image first to delineate the DVU 
clearly, than the same ROI was copied to PET image for SUVmax measurement. 
Lumbar discs from spine T2 weighted MR images were scored by a musculoskeletal 
radiologist, Dr. Alpesh Mistry, using the eight-level modified Pfirrmann grading 
system, blinded to the 18F-NaF PET/CT images (see section 2.7.2).  
 
4.2.3 Correlation  
 
Differences in lumbar disc SUVmax values and Pfirrmann scores between gender and 
age were tested using the Pearson correlation coefficient. Multiple linear regression 
and polynomial regression were used, to assess the relationship between the 
quantitative values and age. Subgroup age analysis was investigated using one-way 
ANOVA. Within each lumbar DVU level, the SUVmax from the 
18F-NaF PET/CT scan 
and Pfirrmann score from MR images were compared to assess the relationships 
between 18F-NaF PET/CT and MRI results using the Pearson correlation coefficient. 
 
4.3 Results  
 
4.3.1 SUVmax measurements  
 
This section aimed to identify 18F-NaF uptake by measuring SUVmax from PET images 
at the lumbar disc region to detect disc calcification for AKU patients. Figure 4.1 
shows the lumbar SUVmax values, which were obtained from the lumbar DVUs across 
the T12/L1 segment to the L5/S1 segment for 34 SONIA 2 patients. Lumbar DVUs 
results from 18F-NaF PET/CT scan and MRI 
 
Table 9.10 (appendix) displays the mean, minimum, and maximum SUVmax at each 
ROI. The mean SUVmax value of average lumbar DVU segments for all 34 AKU 
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patients was 15.12 ± 4.13, (range 6.93 – 23.84). Average SUVmax was 14.38 ± 5.10 
(range 6.72 – 25.91) at T12/L1; 15.84 ± 6.41 (range 7.12 – 33.41) at L1/L2; 14.78 ± 
5.2 (range 6.95 – 25.76) at L2/L3; 14.23 ± 5.01 (range 6.25 – 30.02) at L3/L4; 14.46 
± 5.06 (range 5.44 – 24.65) at L4/L5 and 17.11 ± 5.90 (range 7.14 – 27.20) at L5/S1. 
The highest mean SUVmax was detected at the lowest lumbar DVU (L5/S1) segment, 
as shown in Figure 4.1. Statistically, the SUVmax value of the L5/S1 segment was not 
significantly higher than to the rest lumbar segments (P > 0.05). 
 
Figure 4.2 and Figure 4.3 show spine 18F-NaF PET/CT images for four AKU patients. 
As noted from the images and the measured data in the table below the images, it 
appears that there is a clear separation between the vertebrae bodies with low 18F-NaF 
uptake at DVUs in 18F-NaF PET/CT images for young AKU patients. In contrast, in 
the elderly patients, focal hot areas were noted between the vertebrae with high 
SUVmax values.  
 
4.3.1.1 Lumbar DUV SUVmax values and gender  
 
Figure 4.1 and Table 9.10 (appendix) compare the SUVmax across the lumbar disc 
levels for each gender group. The mean SUVmax value for all lumbar DVUs across the 
T12/L1 segment to the L5/S1 segment was 16.15 ± 3.19 (range 8.59 - 21.58) for males 
and 14.11 ± 4.96 (range 6.93 – 23.84) for females. The SUVmax across the lumbar 
levels were very similar in both genders. Male patients had slightly higher SUVmax at 
all DVU levels than female patients except at L1/L2 level; the females had higher 
SUVmax value. However, statistical analysis using an independent t-test indicated that 
there was significant confounding differences between SUVmax for males and females 
at the L5/S1 level only (P = 0.02), while there were no statistically significant 







Figure 4.1. Mean SUVmax obtained from 18F-NaF PET scan at each lumbar DVU for 34 AKU patients who were part of SONIA 2 clinical trial stratified 
by gender.  
The results show the analysis of the baseline PET data for 19 males and 15 females AKU patients from six  lumbar DVU regions from segment T12/L1 to 
segment L5/S1. SUVmax showed the highest value at the L5/S1 segment. Total DVUs; average DVU segments from T12/L1 to segment L5/S1. Table 9.10 
(appendix) shows the statistical correlation between gender at all lumbar DVU segments. Males had slightly higher mean SUVmax at T12/L1, L2/L3, L3/L4, 
L4/L5 and L5/SI levels than females. By contrast, females tended to have slightly higher SUVmax at L1/L2 level only. The independent sample t-test revealed 
no statistically significant differences between males and females at T12/L1, L2/L3, L3/L4, L4/L5 (P = 0.07, P = 0.67, P = 0.62, P = 0.44, and P = 0.3, 
respectively). Statistically, AKU males had higher SUVmax value than the females at L5/S1 only (P = 0.02). In box and whisker, x is the mean value, and the 






T12/L1 L1/L2 L2/L3 L3/L4 L4/L5 L5/S1 Total DVU 
SUVmax Grade SUVmax Grade SUVmax Grade SUVmax Grade SUVmax Grade SUVmax Grade SUVmax Grade 
Pt #1 8.57 1 9.88 1 9.62 1 8.78 1 9.67 1 8.61 1 9.19 6 
Pt #2 10.34 2 13.36 2 14.25 2 12.65 2 10.99 2 18.01 3 13.27 13 
Figure 4.2. Coronal sections of CT, PET, and 18F-NaF PET/CT for the lower spine for 30 years old and 45 years old AKU patients. 





T12/L1 L1/L2 L2/L3 L3/L4 L4/L5 L5/S1 Total DVU 
SUVmax Grade SUVmax Grade SUVmax Grade SUVmax Grade SUVmax Grade SUVmax Grade SUVmax Grade 
Pt #3 25.91 8 28.2 8 13.65 5 18.38 5 16.12 7 27.2 8 21.58 41 
Pt #4 8.51 8 12.6 8 13.4 8 12.76 8 15.96 8 23.83 8 16.01 48 
Figure 4.3.Coronal sections of CT, PET, and 18F-NaF PET/CT for the lower spine for 52 years old and 62 years old AKU patients.  
The SUVmax and Pfirrmann score (grade) for all lumbar DUV are displayed in the table below the images. 
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4.3.1.2 Lumbar DUV SUVmax values and age   
 
In this section, the effect of age on disc calcification was evaluated by examining the 
correlation between 18F-NaF uptake and age at lumbar disc areas for AKU patients. 
Figure 4.4 shows the SUVmax against age for all AKU patients at each lumbar DVU. 
Multiple linear regression and polynomial regression were used, seeking for the best 
statistical correlation between SUVmax at each lumbar segment and age. The values of 
SUVmax increased gradually with age following by a declined in the later years. Young 
AKU patients had low SUVmax , below 15, then after the age of 40 years, the SUVmax 
values increased, reaching a maximum around the age of 44/50 years. From here, a 
general reduction in SUVmax measurements can be seen at most of DVU levels where 
the elderly AKU patients had a reduction in SUVmax measurements, decreasing to 
values comparable to that in young AKU patients.  
 
Multiple linear regression indicated that SUVmax values were not significantly 
correlated with age at all DVU levels (R = -0.124, R = -0.034, R = -0.296 , R = -0.01 
, R = -0.202, R= 0.143, respectively; all P > 0.05). As it is clear from Figure 4.4, a hill 
shaped trend in the data was noted at most of the lumbar disc levels; therefore, 
polynomial regression was fitted to the SUVmax data. The differences between multiple 
linear regression and polynomial regression analysis at each level is shown in Figure 
4.4. When polynomial regression was applied, the R values were improved 
significantly in all DVU levels (R = 0.57, R = 0.44, R = 0.6 , R = 0.51 , R = 0.49, R= 
0.52).  
 
The mean SUVmax from the lumbar DVUs across the T12/L1 segment to the L5/S1 
segment for each age group was measured, and subgroup analysis was performed as 
shown in Figure 4.5 and Table 9.11 (appendix). The average SUVmax for all lumbar 
levels was 12.99 ± 3.92 for 30-39 age group patients, 17.67 ± 3.97 for 40-49 age group 
patients, 15.45 ± 2.65 for 50-59 age group patients and 11.34 ± 3.6 for ≥ 60 years old 
patients. Generally, the youngest and oldest age group patients had low SUVmax in all 
DVU segments. Mean SUVmax values at all lumbar DVU segments increased from the 
3rd decade of life to the 4th decade of life, where the highest mean SUVmax was detected 
at the average lumbar disc levels. Moreover, SUVmax values in the 5
th decade patients 
were remarkably high. The SUVmax values started to decrease between the 50s and 60s 
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age groups in all lumbar disc levels. One-way ANOVA revealed that in the L2/L3, 
L4/L5 levels, there was a significant difference between the 30s and 40s age groups (P 
= 0.035 and P = 0.025, respectively). In L2/L3 and L4/L5 levels, there was significant 
differences between the 40s and 50s age groups (P = 0.002 and P = 0.003, 
respectively). In T12/L1 and L3/L4 levels, there was a significant difference in SUVmax 
values between the 50s and 60s age groups (P = 0.037 and P = 0.029, respectively). 
Interestingly, linear regression analysis showed that age did not affect the SUVmax, but 
was found to be significant between the age subgroups at some of the measured lumbar 
disc levels. Therefore, in this section of the thesis, it was more precise to use 
polynomial regression rather than multiple linear regression to correlate SUV values 





Figure 4.4. Scatter plots illustrating the correlation between SUVmax obtained from 18F-NaF PET/CT and age at the lumbar DVU segments for 34 AKU 
patients who were part of SONIA 2 clinical trial.  
The results display SUVmax of lumbar DVUs from T12/L1 segment to the L5/S1 segment in individual AKU patients with age. Linear regression analysis (blue 
dotted line) identified no statistically significant correlation between SUVmax and age in AKU patients at all DUV levels P > 0.05 (R = -0.124, R = -0.034, R = 
-0.296, R = -0.01, R = -0.202, R = 0.143, respectively). Polynomial function (order 2 polynomial line: red dotted line) was fitted to the AKU data (R = 0.57, R 
= 0.44, R = 0.6 , R = 0.51 , R = 0.49, R = 0.52, respectively).  










































































































Figure 4.5. SUVmax for all lumbar DVU levels among four decadal age groups measured from baseline 18F-NaF PET/CT scan for AKU patients who 
were part of the SONIA 2 clinical trial. 
Table 9.11 (appendix) shows the lumbar DVU levels and age groups, indicating a statistically significant difference between subgroup analyses. *Groups which 
showed significant difference (P < 0.05). The difference between the 30s and 40s age groups SUVmax values were noted at L2/L3 and L4/L5 levels (P = 0.035, 
P = 0.025, respectively). The difference between the 50s and 60s age groups SUVmax values were noted at T12/L1 and L3/L4 levels (P = 0.037, P = 0.029, 
respectively). No significant differences were found in SUVmax values between any age group at level L1/L2 nor L5/S1. In box and whisker, x is the mean value, 
and the line is the median. 







Figure 4.6. SUVmax for the average lumbar DVU level among four decadal age groups measured from baseline 18F-NaF PET/CT scan for AKU patients 
who were part of the SONIA 2 clinical trial. 
Table 9.11 (appendix) shows the lumbar DVU levels and age groups which indicated a statistically significant difference between subgroup analyses. No 
significant differences were found in SUVmax values between any age group at the average six lumbar DVU  (P > 0.05). In box and whisker, x is the mean value, 





SONIA 2 patients were separated into four age groups by decade to look at the 
individual differences between the patients at each age group. 18F-NaF uptake of 
individual cases was sensitive to the SUVmax measured at each lumbar DVU level. 
Substantial variation of SUVmax resulted in the classification of the individual patients 
into their absolute age at each DVU level, as highlighted in Figure 4.7. In the 30 to 39 
age group (Figure 4.7), there was wide variation associated with the SUVmax 
measurement between the oldest patient in the group whose age was 39 years old and 
the rest of the patients whose ages were between 30 to 37 years old. The SUVmax values 
for that patient was closer to those patients in the 40s age group. It is evident that the 
patients in the 40s  and 50s age groups had more differences between their values than 
in the other age group patients. In the age group 40-49 and 50-59, high SUVmax values 
were noted compared with the two other groups. The highest SUVmax (SUVmax = 33) 
was identified in a 44-year-old female, followed by a 59-year-old female with SUVmax 
= 30. The patients in the oldest age group (≥ 60 years old) mostly had low SUVmax 
values in all DVUs. The lowest SUVmax value was identified in a 68-year-old patient 
where the range of SUVmax values was 6.25 - 7.43 at lumbar DVU levels. The findings 
in this study show low SUVmax in the youngest patients in the 30s, followed by an 
exponential increase up to the end of the 50s, followed by a steady reduction in the 






Figure 4.7. SUVmax measured from 18F-NaF PET/CT scan at each lumbar DVU level for 
each individual 34 AKU case based on the age of patient.  
In this chapter, 7 AKU patients in 30-39 years old group, 12 in 40-49 years old group, 10 in 
50-59 years old group, and 5 in ≥ 60 years old group. Total SUV = average SUVmax across the 
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4.3.2 Pfirrmann grading score 
 
The second section of this chapter aimed to assess disc degeneration from MR images 
at the lumbar spine region using Pfirrmann disc degeneration score for AKU patients. 
The results of Pfirrmann disc degeneration grade for 34 AKU patients are shown in 
Figure 4.8, and found in detail in Table 9.12 in the appendix section. The mean 
Pfirrmann score across the T12/L1 segment to the L5/S1 segment for all 34 AKU 
patients was 6.47 ± 2.65. There were no statistical differences between the average 
Pfirrmann score among lumbar disc levels (P > 0.05). Applying the modified 8 grade 
levels, 5 patients (14.7%) were classified as grade 1, 1 patient (2.9%) as grade 2, 1 
patient (2.9%) as grade 3, 1 patient (2.9%) as grade 5, 1 patient (2.9%) as grade 6, 2 
patients (5.9%) as grade 7 and 23 patients (67.6%) as grade 8 at the level of T12/L1; 
4 patients (11.8%) were classified as grade 1, 1 patient (2.9%) as grade 2, 1 patient 
(2.9%) as grade 3, 1 patient (2.9%) as grade 5, 1 patient (2.9%) as grade 6, 3 patients 
(8.8%) as grade 7 and 23 patients (67.6%) as grade 8 at the level of L1/L2; 4 patients 
(11.8%) were classified as grade 1, 2 patients (5.9%) as grade 2, 1 patient (2.9%) as 
grade 3, 1 patient (2.9%) as grade 5, 1 patient (2.9%) as grade 6, 2 patients (5.9%) as 
grade 7 and 23 patients (67.6%) as grade 8 at the level of L2/L3; 5 patients (14.7%) 
were classified as grade 1, 2 patients (5.9%) as grade 2, 1 patient (2.9%) as grade 3, 1 
patient (2.9%) as grade 5, 1 patient (2.9%) as grade 6, 1 patient (2.9%) as grade 7 and 
23 patient (67.6%) as grade 8 at the level of L3/L4; 5 patients (14.7%) were classified 
as grade 1, 2 patients (5.9%) as grade 2, 1 patient (2.9%) as grade 3, 4 patients (11.8%) 
as grade 7 and 22 patients (64.7%) as grade 8 at the level of L4/L5; 3 patients (8.8%) 
were classified as grade 1, 2 patients (5.9%) as grade 2, 2 patients (5.9%) as grade 3, 
4 patients (11.8%) as grade 7 and 25 patients (73%) as grade 8 at the level of L5/S1. 
No disc was scored as grade 4 for any of AKU patients, see Table 4.3.  
 
According to the total Pfirrmann score at all IVD disc levels (Table 4.4), 2 AKU cases 
(5.9%) scored one at all lumbar IVD levels indicating normal discs in the lumbar spine. 
Also, 2 AKU patients (5.9%) had a total Pfirrmann score of 7, indicating that the 
overall lumbar disc structure was normal in height with a clear distinction between 
inner and outer fibers but without horizontal bands at only one lumbar disc level. On 
the other hand, 26 patients (76.4%) of SONIA 2 patients had a total Pfirrmann score 
of more than 40, indicating severe disc degeneration, while 20 (58.8%) had a total 
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Pfirrmann score of 48, having scored eight at all lumbar IVD levels, indicating 
collapsed disc space at all lumbar regions. 
 
Table 4.3. Pfirrmann disc degeneration grade at each lumbar intervertebral disc scored 
from baseline MRI for 34 AKU patients who were part of SONIA 2 clinical trial. 
Results displayed as the number of patients and % at each lumbar DVU level from segment 
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Table 4.4. Shows the total Pfirmman score for all lumbar DVU levels from T12/L1 to 
L5/S1 scored from baseline MRI for 34 AKU patients who were part of SONIA 2 clinical 
trial.  
The minimum overall score for all DVUs is 6, indicating normal DVU at all lumbar levels, 
and a maximum score is 48 indicating abnormal DVU at all lumbar levels. 
Total Pfrrmann score Number of patients % 
6 2 5.9 
7 2 5.9 
13 1 2.9 
17 1 2.9 
18 1 2.9 
21 1 2.9 
41 1 2.9 
43 1 2.9 
44 1 2.9 
45 2 5.9 
46 1 2.9 




4.3.2.1 Pfirrmann score and gender  
 
Figure 4.8 demonstrates the Pfirrmann score across the lumbar disc levels in males and 
females. For both genders, there was no clear difference between the values across the 
lumbar disc levels. Males tended to have a greater Pfirrmann score than females at 
most of the lumbar disc levels. The average Pfirrmann score for average lumbar discs 
for male patients was 7.3 ± 1.7 and for female patients was 5.4 ± 3.3. Independent t-
test identified that male patients had significantly higher Pfirrmann scores than female 
patients at the average lumbar DVU levels (P = 0.035). Regionally, there were 
significant differences between male and female patients at T12/L1, L1/L2, L3/L4 and 
L4/L5 levels with P-values of 0.021, 0.015, 0.046, 0.029, and 0.029, respectively. In 
contrast at L5/S1, there was no statistically significant difference between male and 
female scores (P = 0.071).  The total Pfirrmann score across all lumbar disc levels for 
male patients was 43.0 ± 9.5, ranging from 17 to 48 compared to 32.3 ± 19.2, ranging 
from 6 to 48 for female patients. This means that the healthy lumbar disc structure was 
only noted in two female patient. Independent t-tests revealed statistically significant 






Figure 4.8. The Pfirrmann scoring values at each lumbar DVU values scored from baseline MRI for 34 AKU patients who were part of SONIA 2 
clinical trial for each gender. 
No difference in Pfirrmann score between the values across the lumbar disc levels were found. Table 9.12 (appendix) shows the statistical correlation between 
gender at most of the lumbar DVU segments. Male patients had statistically higher Pfirrmann scores compared to female patients at T12/L1, L1/L2, l2/l3, L3/L4 
and L4/L5 (P = 0.021, P = 0.015, P = 0.046, P = 0.029, and P = 0.29, respectively). No statistically significant differences between male and female patients 
was noted at L5/S1 (P = 0.071). In box and whisker, x is the mean value, and the line is the median. 





Figure 4.9. The Pfirrmann scoring values for the total lumbar DVUs values scored from baseline MRI for 34 AKU patients who were part of SONIA 
2 clinical trial for each gender.  
There was statistically significant differences in total Pfirrmann score across all lumbar DUV between male and female patients (P = 0.027). In box and 





4.3.2.2 Pfirrmann and age  
 
The results of the Pfirrmann score across all lumbar discs was plotted against age in 
Figure 4.10. Multiple linear regression and polynomial regression were conducted to 
examine the trend in the Pfirrmann score with age. From the graph below, it is clear 
that the Pfirrmann score of all lumbar discs was increased with age. Younge AKU 
patients had the low Pfirrmann score at most spinal levels that are in line with the 
Pfirrmann score of the normal disc structure in healthy non-AKU individuals. 
However, from the age of 39, the Pfirrmann score can be seen to increase sharply, 
reaching the maximum Pfirrmann score of 8. Linear regression revealed a strong 
correlation between the average Pfirrmann score and age at the average DVU levels 
(R = 0.662 and P < 0.001). Looking at each lumbar disc individually, age was noted 
to have a statistically significant effect at T12/L1, L1/L2, L2/L3, L3/L4, L4/L5, and 
L5/S1 levels, correlation coefficients R = 0.602,  R = 0.605, R = 0.642, R = 0.666, R 
= 0.684 and R = 0.681, respectively, and all had P < 0.001. On the other hand, non-
linear regression using polynomial function slightly improved the correlation 
coefficients at all disc levels (R = 0.66, R = 0.67, R = 0.73, R = 0.75, R = 0.78, and R 
= 0.80, respectively) 
 
The Pfirrmann score across all lumbar discs from T12/L1 level to the L5/S1 level for 
each age group was performed. Figure 4.11 and Figure 4.12 illustrate the mean 
Pfirrmann score for the lumbar levels among the four age groups. There was a 
noticeable trend demonstrating a clear increment in Pfirrmann score with age between 
the age groups. Generally, the youngest patients had normal discs with low mean 
Pfirrmann scores of 2.9 ± 2.3 at the lumbar disc regions. Subgroup analysis indicated 
that age had a significant confounding effect on all lumbar DVUs between the 30s and 
40s age groups (P = 0.007). The total Pfirrmann score for the patients in the 30-39 age 
group was 17.7 ± 13.6 compared to 41.2 ± 14.9 for the patients in the 40-49 age group. 
On the other hand, between the 40s and 50s, and 50s and 60s age groups, there was no 
significant difference in Pfirrmann score at any of the DVU levels. The mean 
Pfirmman score at all lumbar disc levels for 40-49 and 50-59 age group was 6.9 ± 2.5 
and 7.7 ± 0.4, respectively. All the patients in the older age group had the highest 
Pfirrmann score (score of 8) at all lumbar disc levels and a total of 48 Pfirrmann scores 
at all levels, indicating the end stage of disc degeneration. Generally, the Pfirrmann 
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score increased with age, but it was statistically significant only between the youngest 
two age groups.  
 
Figure 4.13 demonstrates the individual differences in the lumbar disc Pfirrmann score 
in four age groups. Substantial variation in the MRI graded score in the classification 
of the individual patient based on the absolute age was only noted in the 30s age group 
(Figure 4.13). It is evident from the graphs that young patients had healthy disc 
structure compared with the other patients. Most of the young patients (≤ 37 years old) 
had a Pfirrmann grade of 3 or lower at most of the lumbar levels except for a few 
exceptions. The oldest patient in the youngest age group who is 39 years old, had 
markedly different results from the rest of the 30-39 year old group patients, with a 
maximum Pfirrmann score at all lumbar disc levels. The majority of the cases in the 
40s and 50s had grade 7 and 8 at most lumbar disc levels, which corresponded to 
having severe disc degeneration and collapsed disc spaces at most of the DVU levels. 
In the 40-49 age group, 2 patients had 1 and 2 Pfirrmann scores at most lumbar levels, 
indicating healthy lumbar disc structures in contrast to the rest of their age group. On 
the other hand, all elderly patients (≥ 60 years old) had collapsed lumbar disc space at 
all lumbar levels with the maximum Pfirrmann grade at all levels. It is clear that the 
youngest age group had the lowest Pfirrman score, and the oldest age group had the 





Figure 4.10. Scatter plots showing the correlation between Pfirrmann score values obtained from MRI and age for all lumbar disc levels.  
Linear regression line (blue dotted line) shows that age have a strong positive statistically significant effect in Pfirrmann score at T12/L1, L1/L2, L2/L3, L3/L4, 
L4/L5, and L5/S1 levels, all had P < 0.0001 and correlation coefficients R = 0.602, R = 0.605 , R = 0.642, R = 0.666, R = 0.684 and R = 0.681, respectively. 





















































































































Figure 4.11. Pfirrmann score for all lumbar DVU level among four decadal age groups measured from baseline MRI for AKU patients who were part 
of the SONIA 2 clinical trial.  
High Pfirrmann scores were noted at 40-49, 50-59, and ≥ 60 age groups at most of the disc levels. Table 9.13 (appendix) shows the lumbar DVU levels and age 
groups, indicating a statistically significant difference between subgroup analyses. The strong statistical differences in the Pfirrmann score were only found 
between the 30s and 40s age group patients (P < 0.001) at all lumbar disc levels. In box and whisker, x is the mean value, and the line is the median.   
* * * 






Figure 4.12. Pfirrmann score for the average lumbar DVU level among four decadal age groups measured from baseline MRI for AKU patients who 
were part of the SONIA 2 clinical trial.  
High Pfirrmann scores were noted at 40-49, 50-59, and ≥ 60 age groups at the average lumbar disc levels. Table 9.13 (appendix) shows the lumbar DVU levels 
and age groups, indicating a statistically significant difference between subgroup analyses. The statistical differences in the Pfirrmann score were only found 
between the 30s and 40s age group patients (P = 0.004) at the average lumbar disc level. P-value between the 40s and 50 was 0.315, and between 50s and 60s 







Figure 4.13. Pfirrmann score measured from MRI at each lumbar disc level for each 
individual 34 AKU case based on the age of each patient.  
In this chapter, 7 AKU patients in 30-39 years old group, 12 in 40-49 years old group, 10 in 
50-59 years old group, and 5 in ≥ 60 years old group. All patients in the 60s age group had the 
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4.3.3 Correlation between SUVmax and Pfirrmann score 
 
The third section examines the relationship between semiquantitative values measured 
from 18F-NaF PET and disc degeneration scores measured from MRI at the lumbar 
spine. Among the enrolled patients, the correlations of SUVmax values from PET 
images with MRI Pfirrmann score values were evaluated separately for each lumbar 
DVU level. Figure 4.14 shows the correlation between Pfirrmann score values and 
SUVmax at each lumbar DVU level. The Pearson correlation coefficients between the 
SUVmax value and Pfirrmann score for the T12/L1, L1/L2, L2/L3, L3/L4, L4/L5, and 
L5/S1 DVU were 0.358, 0.367, 0.282, 0.355, 0.371, and 0.472, respectively. All 
obtained correlations were statistical significant (P < 0.05) at all disc levels except at 
L2/L3, where there was no significant correlation (P = 0.11). Correlation between the 
total Pfirrmann score at the total lumbar disc levels and the average SUVmax at all 
lumbar DVU levels was also investigated. Figure 4.15 shows a positive, statistically 
significant correlation, which was identified between the total Pfirrmann score at all 
lumbar disc levels from T12/L1 segment to L5/S1 segment and the average DVUs 
SUVmax (R = 0.459 and P = 0.006). 
 
From Figure 4.14, and the examples which were highlighted in section 4.3.1, it can be 
seen that the patients with low Pfirrmann scores had low SUVmax values. The young 
AKU patient with Pfirrmann score equal to 1 at all DVU levels, had SUVmax below 10 
at all ROIs. The patient with Pfirrmann scores equal to 2/3 at lumbar levels, had an 
average SUVmax of 13.27; higher than the previous patient. On the other hand, the 
patient with Pfirrmann scores between 5 to 8 had a very high SUVmax value, even 
higher than those who had Pfirrmann scores equal to 8 at all lumbar levels. 
Interestingly, the 62 year old patient, who had end-stage disc degenerative had low 
SUVmax values. In this study, it was noted that elderly patients with grade 8 Pfirrman 
discs showed decreased SUVmax corresponding to low 
18F-NaF uptake on PET/CT at 






Figure 4.14. Scatter plots showing the correlation between SUVmax obtained from 18F-NaF PET/CT scan and Pfirrmann score values obtained from 
MRI for all lumbar DVU levels for 34 AKU patients who were part of the SONIA 2 clinical trial. 
SUVmax increased significantly as Pfirrmann score increased. Level T12/L1, L1/L2, L3/L4, L4/L5, and L5/S1 showed positive, statistically significant correlation 












































































































Figure 4.15. Scatter plots showing the correlation between the mean lumbar DVU SUVmax obtained from 18F-NaF PET/CT scans and total Pfirrmann 
score values obtained from MRI for all lumbar DVU levels from T12/L1 to L5/S1 for 34 AKU patients who were part of the SONIA 2 clinical trial. 
The minimum total Pfirrmann score is 6, indicating normal IVDs at all lumbar region, and the maximum Pfirrmann score is 48 indicating severe disc degeneration 
at all lumbar IVD regions. Mean lumbar DVU SUVmax increased significantly as Pfirrmann score increased (R = 0.459, P = 0.006). In some cases, the patient 























This study is one of the first studies evaluating joint involvements for AKU patients 
by quantifying lumbar disc degeneration using advanced molecular imaging 
modalities. In this study, the relationship between molecular and morphological 
lumbar IVD changes was investigated by comparing the SUVmax from 
18F-NaF PET 
scans with the modified eight level Pfirrmann score from MRI. Although identification 
of early disc degeneration in AKU patients may be challenging using conventional 
imaging modalities, this study introduces a novel and sensitive semiquantitative 18F-
NaF PET/CT method which might detect disc calcification at its early stages, before 
its become symptomatic.  
 
4.4.1 SUVmax measurement for lumbar DVUs 
 
Abnormal scan manifestations at lower spine joints were noted in AKU patients as an 
area of increased 18F-NaF uptake, reflecting disc abnormalities. Disc calcification was 
observed in the area between vertebrae having bone-like intensity in 18F-NaF PET/CT 
scans. In reviewing the literature, no data were found on quantifying IVD changes in 
AKU patients using 18F-NaF PET/CT scans. It was hypothesised that disc degeneration 
is associated with ongoing mineral deposition in the IVD area. Usually, disc 
degeneration in AKU patients occurs as lamellar calcification of the nucleus pulposus 
in the lumbar region and ascending to the rest of the spine region 175. Jebaraj et al. 175 
suggested that biochemical alteration of AKU can cause disc calcification. This 
pathological process will increase calcium hydroxyapatite crystals or calcium 
pyrophosphate dihydrate crystals in the disc area.  
 
The mechanism of 18F-NaF uptake in calcified discs and other calcified joints can be 
explained from the mechanism of 18F-NaF uptake in bone tissues due to the strong 
biological similarities between joint calcification and bone formation. In fact, the main 
structural component in both events is hydroxyapatite crystals. After administration of 
18F-NaF, -18F deposits in calcium-rich tissues including those in calcified joints. 
Therefore, it is not surprising that high radiotracer accumulation was identified 




The changes in 18F-NaF uptake at the disc area is strongly associated with disc 
degeneration stages, which may differ between the individual. In early and ongoing 
disc disease stages, 18F-NaF mainly binds to the newly laid down hydroxyapatite in 
DVUs due to increased binding sites, therefore high 18F-NaF uptake would be detected. 
In advanced disc degeneration, the calcified disc become stable and inactive causing 
low calcium hydroxyapatite crystal, therefore low 18F-NaF uptake would be detected. 
In a separate study done in Kuwait, low 18F-NaF uptake was noted in IVD regions for 
non-AKU patients (Alawadhi, unpublished). This can strongly suggest that disc 
degeneration in AKU patients is following different patterns compared to the general 
population. 
 
As mentioned previously in the literature, there is a correlation between joint 
degeneration and increased 18F-NaF uptake in the affected area. Kabayahi et al. 
evaluated 18F-NaF uptake at the hip for various of OA stages and then compared the 
results with other clinical and radiographic findings 166. Kabayahi found that the 
advanced stage of OA had a significantly higher SUVmax than early-stage OA. It was 
also noted that even patients with early-stage OA and without OA radiographic X-ray 
features had a significant 18F-NaF accumulation at the hip joint. Interestingly, most of 
those patients had severe pain scores. This may strongly suggest that the early stages 
of disc degeneration in AKU patients could be identified as an area of increased 18F-
NaF uptake even before it becomes symptomatic.  
 
Part of this chapter examines the gender effect on the value of SUVmax at the lumber 
DVUs for AKU patients. From Figure 4.1 and Table 9.10, it appears that females had 
slightly lower SUVmax values at most of the lumber DVU levels. However, the 
difference was not statistically significant at most of the levels except at the lowest 
lumber DVU level (L5/S1), where the most pressure may be experienced by the spine. 
Although there is no published study testing the gender effect in the disc regions, these 
results can be explained. A possible explanation could be that females generally weigh 
less than males, which will reduce the pressure on the lower spine region. Win et al. 
107 tested some factors which may affect the 18F-NaF uptake for normal patients at the 
spine. Win found that weight was one of the factors that affect the SUV measurements 
by putting mechanical stress on the spine, causing increased osteoblastic activity and 
therefore increased 18F-NaF uptake. In another study, males showed higher bone SUV 
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values than female patients due to having a higher bone density than females 168. These 
theories may possibly explain the slightly higher SUVmax in the male patients 
compared to female patients in this chapter.  
 
Regarding the age effect, this study described that SUVmax across the lumbar disc 
increased gradually with age following by a decline in later years. This finding is 
contrary to the previous finding reported by Chanchairujira et al. who found that disc 
calcification noted by conventional radiography was linearly associated with age 176. 
Close inspection between subgroup age showed that the youngest and oldest patients 
had lower SUVmax compared with other middle age group patients (Figure 4.5 and 
Table 9.11). Statistically, there was significant differences in the measured SUVmax 
values between some of the age groups. The average SUVmax of DVUs increased from 
the age of 30 to 59 years; after that, the SUVmax tended to reduce again. Several theories 
could explain this observation. With increasing age, disc changes in structure and 
calcium start to build up in the disc. In the 30s, it is more likely that AKU patients 
have healthy spine structures due to normal blood supply to the spine and therefore 
normal distribution of 18F-NaF tracer would be noted in the spinal bone and disc. 
Interestingly, in this study, the oldest AKU patient in the youngest age group who was 
39 years old, had significantly higher SUVmax values similar to the average SUVmax 
for those patients in their 40s. This means that the increased bone remodelling  at the 
disc regions in AKU patients is more likely developed around the age of 38 and 40. It 
was reported previously during the late 30s, the onset of arthritic pain started in AKU 
patients specifically at the lower spine 3. Patients in their 40s and 50s tended to have 
high SUVmax, in contrast to the other two age groups which indicates an active and 
ongoing calcification in the intervertebral space. This could be due to abnormal blood 
supply to the spine or it may be related to ochronosis.  
 
Although the elderly patients tended to have disability and severe spinal pain, the 
SUVmax was low for the eldest patients, which is more likely due to inactive 
calcification in the disc space. By the 60s, the spine discs tend to be collapsed, and the 
calcification may become stable indicating end stage disc degeneration. Additionally, 
reduced perfusion to the bone as a result of ageing would result in reducing the 
radiotracer transfer to the spine regions, including those in vertebrae and the IVDs 118. 
A similar finding was also observed in Chapter 3, an old AKU patient also had low 
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SUVmax at lumbar verebrae. These findings may explain the decline in 
18F-NaF uptake 
in the bone and calcified disc with age in general. Additionally, it has been widely 
described that bone mineral density reduces with age. Riggs et al. 165 investigated the 
differential changes in bone mineral density of the appendicular and axial skeleton 
with ageing. Riggs found that bone diminution from the vertebrae began in young 
adulthood and was linearly increased by ageing. This also accords with earlier 
observations in Chapter 3, which showed a significant reduction in lower spine HUmean 
with age, indicating decreased bone density and osteoblastic activity with age. From 
this point, the reduction in SUVmax with age may be explained by the reduction of bone 
mineral density in the vertebrae, which would reduce the -18F ion binding sites in the 
whole spinal structure including bone and disc.  
 
Overall, the results in this section support the proposed theory that 18F-NaF uptake 
corresponds to the deposition of hydroxyapatite crystals at disc areas which may be 
strongly associated with the deposition of ochrontic pigment in IVDs. These findings 
suggest that 18F-NaF can be used as novel imaging marker to detect the early stage of 
ochronotic arthropathy by identifying early-stage disc calcification.  
 
4.4.2 Pfirmann score 
 
The second aim of this chapter was to evaluate lumbar intervertebral disc degeneration 
in MRI using the Pfirrmann scoring system. In this study, most of the lumbar discs for 
AKU patients were scored as grade 8, and ambiguity was encountered for the end disc 
degeneration stage. Although the MRI radiologist who scored the lumbar disc in this 
study suggested adding an extra grading score to separate the end stages of disc 
degeneration (very narrow intervertebral space and collapsed space); he preferred at 
that moment to score the lumbar disc degeneration for SONIA 2 patients using a 
validated MRI grading method. 
 
Regarding the effects of gender on Pfirrmann score, this study demonstrated that male 
AKU patients have a strong tendency to develop more severe lumbar disc degeneration 
than their female age-matched counterparts (Figure 4.8 and Table 9.12). These results 
support the general clinical perception that females are less likely to have disc 
degeneration compared to males. From radiographic evaluation, males were more 
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likely to develop osteophytes, which appeared with greater frequency than females 177. 
MRI data in this study confirms the previous radiographic findings, which showed a 
greater severity and frequency of osteophytes in men than women 177,178. A possible 
explanation for the severity and greater frequency of disc abnormailites in the male 
patients, as mentioned earlier in section 4.4.1, may be due to the higher weight and 
higher bone mineral density in men.  
 
In contrast to findings in this chapter, there are several studies that have suggested that 
females seem to be more susceptible to instability, structural deterioration, reduced 
lumbar disc height, and malalignment due to hormonal changes and menopause 179,180. 
Although De Schepper et al. 177 found that osteophytes were the most frequent 
radiographic feature observed in males, he also noted that disc space narrowing was 
more frequent in females. On the other hand, Wang et al. 181 found that elderly female 
patients had slightly higher Pfirrmann scores than male patients indicating more severe 
disc degeneration at all lumbar levels. These results differ from the findings in this 
study, which show males tend to develop more severe disc degeneration than females. 
In general, degenerative disc changes can be observed in both genders, and 
concentrating on a specific gender may change the finding in some studies.  
 
It was clear from Figure 4.10 that there are positive, statistical significant relationships 
between the Pfirrmann score and age in all lumbar disc levels (P < 0.05). However, 
this result has not previously been noted in this chapter when SUVmax was correlated 
with age. These results are likely related to the severity of the disc calcifications and 
whether the calcification is active or inactive in the IVD area. Looking at the subgroup 
age analysis in Figure 4.11 and Figure 4.12, the Pfirrmann score was statistically 
different between the 30s and 40s age groups only at all lumbar disc level (P < 0.05). 
As is shown in Figure 4.13, the individual changes in Pfirrmann score across the 
lumbar disc levels were noted for SONIA 2 patients. The youngest 6 SONIA 2 patients 
had low Pfirrmann scores with no score greater than 6. The majority of the patients 
after the age of 37 were graded with a grade 8, which indicated the end stage of the 
disc degeneration with totally collapsed disc spaces. Only, 1 patient in the late 30s had 
the maximum total Pfirrmann score at the lumbar disc levels, in which the values have 
nearly matched the results of the older age groups. The other three age groups had 
similar results with high Pfirrmann scores with insignificant differences between them. 
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Only a few individual differences were noted between cases within the 40s and 50s 
age groups. All the patients in the 60s age group had the highest possible total 
Pfirrmann score at all lumbar levels indicating the end stage of disc degeneration at all 
lumbar levels. It is somewhat surprising that some young AKU patients may had 
Pfirrmann grades of 7 and 8. The results show that even patients in their 30s and 40s 
have narrowed and collapsed disc spaces indicating advanced disc degeneration, likely 
due to the advanced ochronotic arthropathy stage.  
 
4.4.3 Correlation between SUVmax and Pfirrmann score 
 
The third objective in this study was to determine whether bone metabolic activity 
from 18F-NaF PET images corresponded to the disc degeneration noted in MRI for 
AKU patients. When the SUVmax at each lumbar DVU was plotted against the 
Pfirrmann score (Figure 4.14 and Figure 4.15), a positive, statistically significant 
correlation was identified between SUVmax and Pfirrmann score at most of the lumbar 
DVUs (R > 0.36 and P < 0.05). This result demonstrates that high SUVmax is usually 
associated with a high Pfirrmann scores. However, the relationship between increased 
tracer uptake and disc damage was asymmetric at the end-stage of disc degeneration. 
This indicates that increased 18F-NaF uptake on PET images may not always 
correspond to the structural damage in the discs which can be detected from MRI. For 
example, grade 1 and 2 Pfirrman scores were determined with SUVmax lower than 15 
at all lumbar levels. As the lumbar disc graded higher in MRI, the SUVmax increased 
significantly. However, several advanced cases with structural disc abnormality had 
grade 8 Pfirrman scores, but showed decreased SUVmax values corresponding to low 
18F-NaF uptake on the PET/CT scan. 
 
This asymmetry observed in the relationship between PET and MRI could be related 
to the disc degeneration stages. Although inactive or stable disc calcification would 
not present as high 18F-NaF uptake in PET images, it can still be identified as an 
abnormal disc structure on an MRI. This does not mean that severe disc degeneration 
would appear as a normal disc in PET imaging; however it more likely that these 
calcified discs become stable, and therefore have low SUVmax values. A limited 
number of studies have compared 18F-NaF PET/CT and MRI in the spine; however, 
the findings in this study can be compared to the findings of other joints areas, where 
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both PET scans and MRI have been used. Fischer et al. compared the distribution of 
increased bone tracer activity on PET with edema on MRI in the spine and sacroiliac 
joints (SIJ) for ankylosing spondylitis patients 182. The study found that MRI detected 
more spinal lesions in comparison to what was detected in 18F-NaF PET/CT (68 vs. 
38), whereas there was a similarly positive results at SIJ in both modalities (19 vs 17). 
This is consistent with the findings in this chapter, indicating that active and inactive 
end-stage disc degeneration is more likely be noted in MRI compared to PET scans. 
Draper et al. 136 compared increased 18F-NaF uptake on the PET images to cartilage 
damage visualised on MRI at the patellofemoral region; increased bone tracer 
detection did not always correspond to structural damage seen on MRI. Both Draper 
et al. 136 and Fischer et al. 183 found around 40% agreement between 18F-NaF PET/CT 
and MRI. Another study was correlating increased bone uptake in 99mTc-MDP 
SPECT/CT image with MRI in the knee region 116. In that study, a moderate correlation 
was found between bone tracer uptake and subchondral region, osteophytes and 
cartilage defects 116.  
 
4.5 Summary  
 
Advanced molecular imaging techniques such as 18F-NaF PET/CT and MRI can detect 
and quantify early IVD changes in AKU patients. Lumbar disc degeneration of patients 
with ochronotic arthropathy was associated with increased 18F-NaF uptake on PET 
images and high Pfirrmann scores on MR images. In AKU patients, disc degeneration 
is associated with increased ochronotic pigment in the joints and articular cartilage 
causing increased calcification in the IVD regions. Disc calcification will increase 
calcium hydroxyapatite crystals or calcium pyrophosphate dihydrate crystals at the 
affected area. In the early-stage of disc calcification, more binding sites would be 
available to bind with the 18F-NaF radiotracer, therefore high SUVmax would be 
detected. Lumbar disc SUVmax values increased gradually with age following by a 
reduction in the later years. The age factor strongly influenced MRI scoring values at 
all DVU levels. Male AKU patients have a mild tendency to develop more severe 
lumbar disc degeneration than female patients. Several advanced grade 8 Pfirrmann 
score discs in MR images showed low 18F-NaF uptake on PET/CT images. These cases 
were more likely to have fusion at that DVU level with inactive calcification or no 
clear bone formation at the intervertebral spaces. This study demonstrates the 
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correlation between functional PET images and anatomical MRI findings until IVD 




This study has some limitations, which must be pointed out. First, the evaluation of 
interobserver and intraobserver reliability has not been tested. Lumbar disc Pfirrmann 
scoring was performed only once by one MRI radiologist experienced in 
musculoskeletal disease. Likewise, SUVmax for each lumbar DVU was also measured 
once. The agreement of detection and scoring the lumbar DVU between PET images 
and MRI by two or more viewers was not possible due to limited time and availablilty 
of experienced radiologists who collaborated in this study. Second, no control group 
was available to statistically compare the results of non-AKU patients with AKU 
patients.  
 
4.7 Future work  
 
Future work is needed to further exam the correlation between molecular PET and 
morphological MRI evaluations. Evaluation of the interobserver and intraobserver 
reliability of SUVmax assessments from PET image and Pfirrmann score from MR 
images for each lumbar DVU would be necessary to support the measurement methods 
which were used in this chapter. A modified MRI scoring system or a new grading 
system which can expand visual representation of the disc and minimise ambiguity for 
ochronotic patients would improve results. The modified scoring system for AKU 
patients could still follow the same principle criteria of the previously used method. It 
would be more valuable and precise if both PET and MR images are compared using 
the same qualitative principle measurement methods, such as grading both images with 
the same scoring system. Grading PET/CT images would need the collaboration from 
nuclear medicine specialists in 18F-NaF PET/CT scans. Additionally, adding a control 





4.8 Conclusion  
 
This chapter has shown: 
 
 Abnormal 18F-NaF PET/CT scan manifestations were detected at lower spine 
joints in AKU patients as an area of increased 18F-NaF uptake, reflecting disc 
degeneration. 
 The values of SUVmax across the lumbar DVUs increased gradually with age 
following by a decline in the later years. 
 Increased SUVmax at the lumbar disc site indicates high osteoblastic activity in the 
pathological area. 
 Stable or inactive calcification in severe long-term disc degeneration was not 
identified as an area of high SUVmax, likely due to stable bone remodelling. 
 Lumbar intervertebral disc degeneration was associated with high Pfirrmann 
scores on MR images. 
 There were no statistically significant differences in SUVmax value between males 
and females across all lumbar DVUs except at L5/S1.  
 Male patients have a statistically higher Pfirrmann score compared to the female 
patients at all lumbar DVUs except at L5/S1.  
 Age was noted to have a positive, statistically significant effect on Pfirrmann 
scores at all lumbar disc levels.  
 A positive, statistically significant correlation between SUVmax and Pfirrmann 
scores at most lumbar levels was observed. 
 Several advanced disc degeneration cases had grade 8 Pfirrmann scores on MRI 
with low SUVmax on 
18F-NaF PET/CT scan, indicating fusion at that DVU lumbar 




















5 Determining treatment efficacy of nitisinone on spine ochronotic 








In the previous chapters, ochronotic arthropathy in the spine and hip have been 
identified and quantified using different imaging techniques in patients with AKU. In 
Chapter 3, low bone density and active bone turnover have been identified in AKU 
patients by measuring HUmean and SUVmax from lumbar vertebrae bodies and femoral 
heads using 18F-NaF PET/CT. Then, in Chapter 4, lumbar intervertebral discs were 
quantified and scored from 18F-NaF PET/CT and MR images.  
 
This study examines the changes in 18F-NaF PET/CT semiquantitative values across 
five visits for AKU patients who were part of the SONIA 2 clinical trial. The aim of 
this study was to investigate whether 18F-NaF can be used as an imaging biomarker of 
regional treatment efficacy by evaluating the changes in the lumbar spine for AKU 
patients who were treated with nitisinone for four years. This chapter of the thesis is 
designed to assess the disease progression and effectiveness of nitisinone by evaluating 
the changes in HUmean and SUVmax values measured from the lower spine using 
18F-
NaF PET/CT scans.  
 
The current chapter is divided into four main sections. The first section examines bone 
density by following the changes in lumbar spine HUmean values measured from CT 
images for nitisinone treated and non-treated groups. The second section investigates 
the change in bone 18F-NaF uptake by evaluating the changes in the mean lumbar 
vertebrae SUVmax values for both groups. The third section assesses the lumbar disc 
change by investigating the changes in SUVmax for the lumbar IVD regions. The fourth 
section evaluates the individual changes in the measured semiquantitative values 
between the visits for the nitisinone-treated patients and non-treated patients 
individually across the visits.  
 
Recently, in July 2020, nitisinone received positive opinons from the European 
Medicines Agency for its use in alkaptonuria 39, and has since been approved as a 
therpay for AKU by the European Commission 49. Nitisinone is a competitive inhibitor 
of hydroxyphenylpyruvic acid oxygenase, which is the second enzyme in the tyrosine 
catabolic pathway. Inhibiting this enzyme prevents production of the culprit molecule 
HGA, and should prevent or slow the progression of disease in patients with AKU 
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(Figure 1.1- Introduction). The main challenge faced to prove the efficacy of nitisinone 
is to stop or slow down the progression of ochronosis. It has been confirmed that 
nitisinone reduces plasma and urinary HGA levels 7,38,45–48,51. Previous studies have 
noted this promising event in AKU patients 48 and also in the AKU mouse models 46 
suggesting the beneficial effects of nitisinone in patients with ochronosis. It is 
suggested that early-stage treatment of AKU patients with nitisinone could prevent 
pigment deposition occurring, including within cartilage and joint tissues. The key 
research question here is whether or not the significant reduction in HGA levels after 
taking nitisinone has a significant impact in patients with AKU by stopping or slowing 
down the progression of ochronotic arthrophathy in the spine.  
 
As pointed out in the introduction Chapter, SONIA 2 patients underwent a number of 
scans to monitor the disease progression, including scintigraphy, MRI and DEXA 
scans. In SONIA 2, scintigraphy was qualitatively evaluated to identify ochronotic 
arthropathy by counting the number of joints with increased or abnormal tracer uptake 
throughout the whole body. The results show that the number of joints involved were 
increased in both treatment and non-treatment groups. Looking at the spine result, the 
number of spinal regions with osteoarticular disease was also increased over time in 
both groups. DEXA scan reported a reduction in the hip T-score value over time in 
both groups, indicating reduced hip bone density. Regarding MRI results, the number 
of fractures was increased in both groups. SONIA 2 final analysis scan results are 
shown in the appendix (see section 9.4). In all the scans reviewed in the SONIA 2 trial, 
there were no significant differences in the mean change in imaging results between 
nitisinone-treated and non-treated patients. These analyses have failed to confirm the 
benefit of nitisinone on stopping ochronotic arthropathy for those patients who took a 
daily dose of nitisinone over four years. In fact, the previous SONIA 2 investigations 
have mostly foucsed on qualitative analyses which is a subjective assessment method. 
The current study aimed to detect any statistically significant differences in spinal bone 
or discs between nitisinone-treated patients and non-treated patients using reliable and 
sensitive quantitative methods.  
 
With the development of new potential treatment for AKU patients, there is an 
increasing need to develop a new reliable method to examine drug efficacy, 
particularly in the early phases of clinical trials. In any clinical trial, it is important to 
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use accurate assessment methods to evaluate the success or failure of the treatment. 
Generally, bone mass is a major area of interest within the field of drug development 
for any bone or bone-related disorder due to the strong correlation between bone loss 
and disability. However, evaluating bone density changes using a traditional DEXA 
scans can be challenging because the changes in bone are usually mineral changes and 
may need years or decades to be visualise by conventional imaging techniques. 
Additionally, as was highlighted previously in Chapter 3, the calcified disc may 
strongly overestimate the DEXA scan BMD values. In the past decade, more recent 
attention has focused on bone biomarkers in clinical trials of therapies for various bone 
disorders. Although biochemical bone markers are widely used to measure bone 
turnover, they only reflect total skeletal function 138. It would be more useful if the 
regional bone formation is monitored during the course of treatment wich will provide 
a better understanding of the treatment impact on bone for AKU patients.  
 
18F-NaF PET/CT can offer novel information about the drug efficacy at specific sites 
of the skeleton, by overcoming the major weakness of the conventional methods. A 
number of studies utilized bone isotopes to assess the direct effects of pharmacological 
therapies at different sites of the skeleton for many metabolic bone disorders, where 
the treatment response was tested using different semiquantitative assessment methods 
98,138–142.  
  
As mentioned earlier, 18F-NaF PET/CT scan was part of the SONIA 2 clinical 
investigations, which were employed to evaluate the changes of clinical features in the 
skeleton over four years in order to track the progression of the disease and/or assess 
the response to treatment in the long term. This study may provide a better 
understanding of the impact of nitisinone on bone and joint disease in AKU patients, 
and evaluates the disease progression rate using a positron bone radiomarker.  
 
5.2 Design of study 
 
5.2.1 Patient group 
 
In this study, 34 AKU patients including 22 males and 12 females who enrolled in the 
SONIA 2 clinical trial and attended the Liverpool AKU Trial Centre were used. All 
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participants were aged between 30 and 68 years old at the beginning of the trial. The 
participants were divided randomly into a treatment group and non-treatment group 
(control patient group). Participants in the treatment group were treated with 
nitisinone, 10 mg once a day, for four years. Table 5.1 shows the number of patients, 
age and gender at the baseline visit for both treatment and non-treatment groups who 
participated in this study. The trial period consisted of four years, during which each 
patient underwent a 18F-NaF PET/CT scan annually for five consecutive visits; Visit 1 
(at baseline, pre-treatment), Visit 3 (one year), Visit 4 (two-year), Visit 5 (three years), 
and Visit 6 (four years) (see section 2.2.1). In Visit 2, which was at 3 months follow 
up, no 18F-NaF PET/CT scan was requested for all participants. Some patients dropped 
out of the SONIA 2 study therefore not all of the participants had a series of five 18F-
NaF PET/CT images. Patients with at least one recorded whole body 18F-NaF PET/CT 
scan at baseline were included in this analysis. Table 5.2 shows the number of 18F-NaF 
PET/CT images available and analysed at each visit for both groups. 
 
Table 5.1. Age and gender of the 34 AKU patients who were part of the SONIA 2 clinical 
trial and involved in this study classified by treatment arm.  
Not all of the SONIA 2 participants had a series of five 18F-NaF PET/CT images.   
Statistic Untreated Treated with nitisinone 
Number of patients 17 17 
Age 
Mean 
Range of age 
 
47.88 ± 10.88 
30 - 67 
 
48.88 ± 10.42 
30 - 68 












Table 5.2. Number of 18F-NaF PET/CT images for AKU patients who were part of 
SONIA 2 per annual visit for nitisinone treatment and non-treatment groups.  
Not all of the SONIA 2 participants had five serial 18F-NaF PET/CT images.   
Statistic Untreated patients  
Nitisinone-treated 
patients 





























5.2.2 Image analysis 
 
18F-NaF PET/CT images were analysed using Horos medical software (see section 
2.4.1.2). A semiquantitative comparison was performed by measuring HUmean and 
SUVmax for lumbar vertebral bodies (L1-L5) and SUVmax for lumbar disc units 
(T12/L1-L5/S1) for each patient (section 2.5 and 2.7). The measurement was obtained 
for each ROI at three sagittal sections, then the average value for each patient was 
generated for each visit. The longitudinal changes in the semiquantitative values for 
both groups over four years were tested. Kruskal-Wallis test was used to compare the 
data between treatment arms. 
 
The patients were classified into four groups based on their age to investigate the 
treatment effect and evaluate the progression of the disease in each age group; 30-39 
years, 40-49 years, 50-59 years and above 60 years. The individual changes in HUmean 
and SUVmax over the serial visits in the average lumbar vertebrae and lumbar DVU 
was also evaluated for the nitisinone-treated patients and non-treated patients for 
accurate response assessment in individual cases. Any patient who has two or more 







5.3 Results  
 
5.3.1 Change in semiquantitative values across 5 visits 
 
HUmean value was obtained from average lumbar vertebrae (L1-L5), and SUVmax was 
obtained from average lumbar vertebrae (L1-L5) and average lumbar DVU (T12/L1-
L5/SI) for both nitisinone-treated and non-treated AKU patients across five annual 
visits.  
 
5.3.1.1 Change in HUmean measured from lumbar vertebrae body across 5 visits 
 
Over time, the change in bone density was tested by investigating the mean change of 
vertebral HU measurements over four years (~48 months). Figure 5.1 and Table 9.23 
(appendix) summarise the mean HUmean values for the average lumbar vertebrae bodies 
(L1-L5), which were measured from CT images from Visit 1 at the baseline to Visit 6 
at 48 months in the treatment group and non-treatment group. At the baseline, there 
was no significant difference in the mean lumbar spine HUmean values between 
nitisinone-treated patients and non-treated patients (174.1 ± 104.3 and 152.7 ± 61.0, 
respectively). It is clear from the graph (Figure 5.1) that the mean lumbar HUmean 
measurements were generally consistent across the visits in both groups. The mean 
plotted data for the treatment group showed little change in bone density in the lumbar 
vertebrae following treatment with nitisinone. In the same way, there was minimal 
change in the bone density for those patients in the control group over four years. 
Figure 5.2 shows the mean change from baseline to each visit for lumbar vertebrae 
body HUmean values, for both groups. This data is also described in detail in Table 9.24 
(appendix). At month 12, nitisinone-treated patients showed a significantly greater 
reduction in the mean lumbar HUmean value (median change -5.3, range -48.7 to 35.9), 
compared with increase in the mean lumbar HUmean value for non-treated patients 
(median change 6.1, range -38.5 to 50.8). Nitisinone-treated patients experienced a 
8.64% mean reduction in vertebrae spine HUmean values, compared with a 9.5% mean 
increase in HUmean values in non-treated AKU patients (P = 0.036) at one year of 
follow up. After that, HUmean values in the non-treated group started to decrease from 
190.6 ± 111.4 in Visit 3 to 171.9 ± 112.2 in Visit 6. In nitisinone-treated AKU group, 
there was a slight rise in the HUmean of lumbar vertebrae from 139.5 in Visit 3 to 144.4 
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in Visit 6. It can be clearly seen from the data in Figure 5.2 and Table 9.24 (appendix) 
that there were no statistically significant differences between treatment and non-
treatment groups in the mean change in lumbar HUmean measurements at neither month 
24, month 36, nor month 48 (P = 0.739, 0.120, and 0.681, respectively). Overall, a 
clear impact of nitisinone in the HU could not be identified in this analysis. 
 
 
Figure 5.1. Mean lumbar vertebrae HUmean values for nitisinone treated and untreated 
AKU patients who were part of the SONIA 2 clinical trial across 5 annual visits.  
Blue line represents the non-treated SONIA 2 group; the orange line represents the nitisinone-
treated SONIA 2 group. Each visit was one year apart, V1; baseline data (pre-nitisinone), V3; 
after 12 months, V4; 24 months, V5, 36 months and V6; 48 months. Error bars represent SD, 
dash line represents untreated group and solid line represents treated group.  Table 9.23 
(appendix) shows the summary statistics for HU values across the treatment and non-treatment 
AKU groups visits. At the baseline, there was no significant difference in mean lumbar spine 
HUmean value between treatment and non-treatment group (174.1 ± 104.3 and 152.7 ± 61.0, 
respectively). Over four years, there were minimal changes in HUmean values for nitisinone-





















Figure 5.2. Changes in lumbar HUmean from baseline to month 48 for nitisinone-treated 
and untreated AKU patients.  
Blue represents the non-treatment SONIA 2 group; orange represents the nitisinone-treated 
SONIA 2 group. The graph shows the changes in HU values measured from CT images for 
lumbar vertebrae bodies (L1-L5) from baseline and the four follow up visits. Table 9.24 
(appendix) shows the summary statistics for the changes in HU values for nitisinone-treated 
AKU patients and untreated patients who were part of the SONIA 2 clinical trial over four 
years. The changes in the mean HU values between the two groups were compared using the 
Kruskal-Wallis test. At month 12, nitisinone-treated AKU patients experienced a significant 
reduction in vertebrae spine HUmean values, compared with non-treated AKU patients (P = 
0.036). At month 24, month 36, and month 48, there were no statistically significant 
differences between treatment and non-treatment groups in the mean change in lumbar HUmean 
measurements (P = 0.739, 0.120, and 0.681, respectively). *P-value < 0.05 indicate a 
statistically significant difference between treatment and non-treatment. In box and whisker, 




5.3.1.2 Change in SUVmax measured from lumbar vertebral body across 5 visits 
 
The change in bone 18F-NaF uptake during four years was investigated by following 
the changes in the mean lumbar spine SUVmax values. Figure 5.3 shows the mean 
lumbar SUVmax value comparison from Visit 1 at the baseline to Visit 6 at month 48 
for each group. Table 9.25 (appendix) displays the summary statistics for SUVmax 
measured from the PET scans for lumbar vertebrae bodies (L1-L5) for both the 
treatment and non-treatment groups for each visit. Mean lumbar spine SUVmax results 
at the baseline for the treatment group was similar to the non-treatment group value 
(12.6 ± 4.2, 11.9 ± 2.0, respectively), with no statistically significant differences (P > 
0.05). Looking at Figure 5.3, it is apparent that both groups reported no clear changes 
in SUVmax measurements from baseline to Visit 3 at month 12. After that, there was a 
gradual increasing trend in the mean vertebrae SUVmax measurement for the nitisinone-
treated group. In the non-treated group, there was a rise in SUVmax from 12.7 at Visit 
3 to 14.5 at Visit 5, and then the value slightly dropped to 13.9 at Visit 6. The change 
from baseline for the average lumbar vertebrae SUVmax for each group are displayed 
in Figure 5.4 and summarised in Table 9.26 (appendix). Using a Kruskal-Wallis test, 
there was no observed statistically significant difference in the mean change from 
baseline in vertebrae SUVmax values at neither month 12, 24, nor 36 (P-value = 0.206, 
0.678, and 0.310, respectively). A clear influence of nitisinone in the bone 18F-NaF 
uptake at the spine was noted by the end of the trial. At month 48, nitisinone-treated 
patients presented a significant higher increment in the mean lumbar vertebrae SUVmax 
values (median change 2.3, range -0.8 to 11.8) compared with non-treated patients 
(median change 0, range -2.2 to 5.0). Patients in the treatment group experienced a 
26.89% mean increase in SUVmax measurements, compared with a 10.32% mean 








Figure 5.3. Mean lumbar SUVmax values for nitisinone-treated and untreated AKU 
patients who were part of the SONIA 2 clinical trial across 5 annual visits.  
Blue line represents the non-treatment SONIA 2 group; the orange line represents the 
nitisinone-treat SONIA 2 group. Each visit was one year apart: V1; baseline (pre-nitisinone), 
V3; after 12 months, V4; 24 months, V5, 36 months and V6; 48 months. Error bars represent 
SD, dash type represents untreated group and solid represents treated group.  Table 9.25 
(appendix) shows the summary statistics for SUVmax values across the visits for both treatment 
and non-treatment AKU groups. At the baseline, there was no difference in mean lumbar spine 
SUVmax value between nitisinone-treated patients and non-treated patients (12.6 ± 4.2, 11.9 ± 
2.0, respectively). There were no changes in SUVmax values for treated and non-treated AKU 
patients from baseline at Visit 3 (month 12), then the value increased for both groups from 
Visit 3 to Visit 4. After that, the value increased for the nitisinone-treated group and decreased 



















Figure 5.4. Changes in lumbar SUVmax from baseline to month 48 for nitisinone-treated 
patients and untreated patients.  
Blue represents the non-treatment SONIA 2 group;  orange represents the nitisinone-treat 
SONIA 2 group. The data summarises the change in SUVmax values measured from the PET 
images for lumbar vertebrae bodies (L1-L5) from baseline and the four follow up visits. Table 
9.26 (appendix) summarises the statistics for the changes in SUVmax values for nitisinone-
treated AKU patients and untreated patients who were part of the SONIA 2 clinical trial over 
four years. Kruskal-Wallis test shows that there was no statistically significant difference in 
the mean change from baseline in vertebrae SUVmax values at neither month 12, 24, nor 36 
months (P-value = 0.206, 0.678, and 0.310, respectively). At month 48, patients in the 
treatment group presented a significant higher increment in the mean lumbar vertebrae SUVmax 
values compared with the control AKU group (P = 0.045). *P-value < 0.05  indicates a 
statistically significant difference between treatment and non-treatment. In box and whisker, 




5.3.1.3 Change in SUVmax measured from lumbar disc vertebral unit DVU across 5 
visits 
 
The change in the regional joint was also evaluated by investigating the change of the 
lumbar intervertebral disc 18F-NaF uptake over 48 months of treatment. Figure 5.5 
displays the mean lumbar DVU SUVmax comparison from Visit 1 to Visit 6 for each 
patient group. Table 9.27 (appendix) compares the summary statistics for SUVmax 
measured from the PET scans for the average lumbar DVU (T12/L1-L5/S1) for each 
visit for both treatment and non-treatment groups. As can be seen from Figure 5.5, 
there was no significant difference in the mean SUVmax values in the lumbar DVUs 
between treatment and non-treatment AKU groups at baseline (17.7 ± 5.4, 14.6 ± 2.9, 
respectively) (P > 0.05). Generally, there were consistent SUVmax values for both 
groups with few changes across the five visits. The mean change from baseline for 
lumbar DVUs SUVmax are highlighted in Figure 5.6 and Table 9.28 (appendix). Close 
inspection of the figures shows that DVU SUVmax values for the nitisinone-treated 
patients reduced 5.48% from 14.6 at Visit 1 to 13.8 at Visit 4 (at month 36), then 
increased by 4.79% to 15.3 by month 48 at Visit 6. On the other hand, it appears that 
untreated patients experienced a 13.6% mean increase in lumbar DUV SUVmax value 
from baseline to month 24, then the value reduced back to the baseline pointt by month 
48. In this section of the study, there were no statistically significant differences 
between treatment and non-treatment groups in the adjusted mean change from 
baseline in SUVmax values at any of the visits (P-value = 0.885, 0.124, 0.633 and 0.280, 
respectively). From this analysis, there was no clear evidence that nitisinone can 









Figure 5.5. Mean SUVmax values for average lumbar DVUs (T12/L1-L5/S1) for 
nitisinone-treated and untreated AKU patients who were part of the SONIA 2 clinical 
trial across 5 annual visits.  
Blue line represents the non-treated SONIA 2 group; the orange line represents nitisinone-
treated SONIA 2 group. Each visit was one year apart, V1; baseline (pre-nitisinone), V3; after 
12 months, V4; 24 months, V5, 36 months and V6; 48 months. Error bars represent SD, dash 
type represents untreated group and solid represents treated group. Table 9.27 shows the 
summary statistics for SUVmax values across the visits for both the treatment and non-treatment 
AKU groups. At baseline, there was no significant difference in the mean SUVmax values in 
the lumbar discovertebreal unit between the treatment and non-treatment AKU groups (17.7 ± 
5.4, 14.6 ± 2.9, respectively). There was very little change in lumbar DVU SUVmax values for 



















Figure 5.6. Changes in lumbar DVU SUVmax from baseline to month 48 for nitisinone 
treated and untreated AKU patients.  
Blue represents the non-treated SONIA 2 group; orange represents the nitisinone-treat SONIA 
2 group. The graph shows the changes in SUVmax values measured from the PET images for 
average lumbar DVUs (T12/L1-L5-S1) from baseline followed by up four visits. Table 9.28 
(appendix) shows the summary statistics for the change in lumbar DVU SUVmax values for 
nitisinone treated AKU patients and untreated patients over four years. Kruskal-Wallis test 
indicates that there was no statistically significant difference between treatment and non-
treatment group in the mean change from baseline in lumbar disc vertebrae SUVmax values to 
any of the visits (P-value = 0.885, 0.124, 0.633 and 0.280, respectively). In box and whisker, 





5.3.2 Individual change in quantitative values across five visits 
 
The individual changes in the measured values for the nitisinone-treated patients and 
non-treated patients were monitored individually.   
 
5.3.2.1 HUmean lumbar vertebral body 
 
Figure 5.7 and Figure 5.8 display the individual changes in the mean lumbar vertebrae 
(L1-L5) HUmean across the annual visits in the four age groups for both nitisinone-
treated and non-treated patients, respectively. As can be seen from Figure 5.7, most of 
the nitisinone-treated patients had no significant change in HU values across the serial 
visits in all age groups. Of the nitisinone-treated patients, 9 patients had reduced 
lumbar HUmean values, 7 had a small increase, and 1 had an almost consistent value 
over the four years. Likewise, most of the non-treated patients also showed a similar 
pattern in which no significant differences in lumbar HUmean measurements were noted 
over the 4 years (Figure 5.8). One patient (43 year old female) in the control AKU 
group had a remarkably high lumbar HU value compared to other patients. Of the non-
treated patients, 5 patients had experienced a reduction in baseline lumbar HUmean 
value, 2 experienced an increase in the value, and 9 patients had almost the same value 
at Visit 6. It is apparent from this data that there was no direct trend in bone density 
for neither treatment or non-treatment patients across the visits. As seen in Chapter 3 
(section 3.3.2.1.2), the oldest AKU patients (≥ 60 years old) had the lowest HUmean 
values compared to the patients in the other AKU age groups. Generally, there was 
little change in (L1-L5) HUmean in the 30-39, 40-49, and ≥ 60 age groups in both treated 
and non-treated patients across the visits. These changes were not statistically 
significant. In the 50-59 age group, the HUmean value fluctuated for nitisinone treated 
patients as well as for non-treated patients across the visits. Data shows that when the 
measured HU value was high initially at the beginning of the trial (Visit 1), it was 






Figure 5.7. The average lumbar vertebrae bodies (L1-L5) HUmean across the visits in the individual AKU patients who were part of the SONIA 2 clinical 
trial and treated with nitisinone classified by age.  
The key defines the gender and age of each AKU patient. M-male, F-Female, yrs-years-old, V1- baseline, V3- at month 12, V4- at month 24, V5 at month 36, 
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Figure 5.8. The average lumbar vertebrae bodies (L1-L5) HUmean across the visits in the individual AKU patients who were part of the SONIA 2 clinical 
trial and been in control group classified by age.  
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5.3.2.2 SUVmax in the lumbar vertebral body 
 
Figure 5.9 and Figure 5.10 demonstrate the individual changes in the mean lumbar 
vertebrae (L1-L5) SUVmax across the four age groups from annual visits for treated 
and non-treated patients, respectively. Looking at the individual differences in the 
lumbar vertebrae SUVmax measurements for nitisinone-treated AKU patients among 
the four age groups (Figure 5.9), the mean lumbar SUVmax values were very consistent 
with little changes between the visits for most of the treated patients. It appears from 
the figures that the patients in the youngest and oldest age groups had consistent 
SUVmax across the visits with minimal changes between Visit 1 and Visit 6. Closer 
inspection of the figures shows that there was little difference in lumbar SUVmax values 
between Visit 1 and Visit 4 for most of the patients in the 40-49 and 50-59 age groups; 
the values started to increase between Visit 4 and Visit 6. Lumbar SUVmax value 
increased in 9 treated patients and remained the same in 8 patients. No clear reduction 
trend was noted in the lumbar SUVmax value for nitisinone-treated patients. 
  
In the non-treatment group, the individual changes in the lumbar spine SUVmax 
measurements over time followed a similar pattern to that noted in the nitisinone-
treated patients (Figure 5.10). As seen from the non-treated patient figures, some of 
the 40s and 50s patients showed fluctuations in the SUVmax during the visits. No 
significant difference in SUVmax for most of the 30s and 60s patients was noted. As 
shown un the Figure 5.10, 7 non-treated AKU patients showed increases in lumbar 
SUVmax values, 7 patients showed a decrease in the values, and 3 patients had almost 
the same values.  
 
It is apparent that in most cases when the initial lumbar vertebrae SUVmax value was 
low at the beginning of the trial, it was more likely to be low across the visits. In 
general, elderly patients (≥ 60 years old) in both groups had low SUVmax values 
compared to other age groups with little change from the Visit 1 to Visit 6. This finding 
was noted earlier in Chapter 3 (section 3.3.1.1.2), where it been found that elderly 
patients had low 18F-NaF uptake at lumbar vertebral bodies compared to other age 
groups. Generally speaking, there was no direct trend in the individual changes for 
both treatment and non-treatment patients having very consistent lumbar SUVmax with 




Figure 5.9. The average lumbar vertebrae bodies (L1-L5) SUVmax across the visits in the individual AKU patients who were part of the SONIA 2 clinical 
trial and treated with nitisinone classified by age. 
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Figure 5.10. The average lumbar vertebrae bodies (L1-L5) SUVmax across the visits in the individual AKU patients who were part of the SONIA 2 
clinical trial and been in control group classified by age.  
The key defines the gender and age of each patient. M-male, F-Female, yrs-years-old, V1- baseline, V3- at month 12, V4- at month 24, V5 at month 36, V6- at 
month 48.  
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5.3.2.3 SUVmax in the lumbar discovertebral unit  
 
Figure 5.11 and Figure 5.12 show the individual changes in the mean lumbar 
discovertebral unit (T12/L1-L5/S1) SUVmax values for treatment and non-treatment 
patients across the annual visits among the four age groups, respectively. It can be seen 
from Figure 5.11 that the lumbar DVU SUVmax measurements for the nitisinone-
treated AKU patients in the 30-39, 40-49 and ≥ 60 age group were remarkably 
consistent across the five visits with little change between the visits. Treated patients 
in the 50-59 age group had constant SUVmax values between Visit 1 and Visit 5; after 
that the values started to increase from Visit 5 to Visit 6 for most of the cases. SUVmax 
at lumbar DVU increased in 8 nitisinone treated patients, decreased in 6 patients and 
remained the same in 3 patients. 
 
In the non-treatment group, the lumbar disc SUVmax value fluctuated across the visits 
in all the age groups except in the oldest age group (≥ 60 years old), in which the 
SUVmax value was generally consistent across the five visits. As shown in Figure 5.12, 
6 non-treated AKU patients showed increases in DVU SUVmax values,6 showed 
decreases in values, and 5 had no clear change in values.  
 
From these findings, concerning the 18F-NaF uptake in the IVD area, there seems to 
be no direct trend across the visits between the nitisinone-treated and non-treated AKU 
patients. Again, as with what was noted in lumbar vertebrae, when the SUVmax at the 
disc area was high initially at the baseline evaluation, it appears to be high across the 






Figure 5.11. The average lumbar DVUs (T12/L1-L5/S1) SUVmax across the visits in the individual AKU patients who were part of the SONIA 2 clinical 
trial and treated with nitisinone classified by age.  





Figure 5.12. The average lumbar DVUs (T12/L1-L5/S1) SUVmax across the visits in the individual AKU patients who were part of the SONIA 2 clinical 
trial and been in control group classified by age.  




5.4 Discussion  
 
In reviewing the literature, no previous data was found on the association between the 
changes that can be noted in scintigraphy and potential disease-modifying therapy in 
AKU patients. Previously, 18F-NaF PET has been used as an isotopic imaging 
biomarker in a number of studies detecting the effect of pharmacological treatment on 
regional bone formation during drug development for various metabolic bone 
disorders, including osteoporosis138–141. Different PET semiquantitative methods were 
successfully utilised for identifying the changes in PET images over time.  
 
This is the first longitudinal study investigating the effect of nitisinone in bone and 
cartilage for patients with AKU by quantifying 18F-NaF PET/CT scans over four years. 
In the SONIA 2 clinical trial, serial 18F-NaF PET/CT scans were performed to 
understand the disease progression better and/or assess possible responses to 
treatment. The progression of spinal arthrophathy in response to nitisinone was 
monitored annually by evaluating the changes in HUmean values from CT scans and 
SUVmax values from PET scans in order to assess the longitudinal change throughout 
treatment. In this chapter, the methods described previously in Chapter 3 and Chapter 
4, for quantifying the baseline 18F-NaF PET/CT scans have been repeated over the 
other visits.  
 
5.4.1 Annual change in the lumbar vertebrae HUmean value  
 
The first objective in this study was to determine the change in bone density over four 
years for those patients who received a daily dose of nitisinone and those who were 
treatment free. Although CT scans cannot detect early active bone biological 
processes, CT might still provide valuable information regarding the progression of 
the ochronotic arthrophathy during the course of treatment. There are few studies that 
evaluated the impact of nitisinone on osteopenia in AKU patients. To date, no previous 
study has investigated the impact of nitisinone on HU values. In this study, HU 
measurements from CT scans have been measured to assess the changes in bone 
density after receiving nitisinone for four years. The annual change in the mean HUmean 
values in the lumbar spine was monitored, representing the change in the spine bone 
density (Table 9.23 and Table 9.24). As previously proposed, ochronosis alters the 
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bone matrix and interferes with bone metabolism causing loss in bone mass. Based on 
that assumption, it was expected to see a reduction in bone density with age in AKU 
patients who are in the control group compared to those in the nitisinone treatment 
group. Contrary to expectation, minimal annual changes in the mean bone density 
measurements over the visits have been noted in nitisinone-treated patients, as seen in 
Figure 5.1. In this four-year clinical trial, nitisinone did not change the mean lumbar 
spine HU measurements significantly for treated AKU patients. A clear benefit of 
nitisinone in preventing osteoporosis or preventing weakened bones was not detected 
in CT images by evaluating the changes in HU measurements. This indicates that it 
may not have a direct effect on bone density, or the impact of therapy on the bone may 
take more than four years to be noted. The results here further support the idea that 
rebuilding bone density/bone mass may not be possible once a significant amount of 
bone density has been lost. In the non-treatment group, no significant changes have 
also been noted over four years, suggesting that average bone density change in AKU 
patients may take years or decades to be detectable. The minimal HU changes in the 
non-treatment group represents the rate of bone density progression over time in AKU 
patients. Kruskal-Wallis tests revealed that the changes in HU values between the two 
groups was only statistically significant different after 12 months. Generally speaking, 
this study did not detect clear evidence regarding the differences between the treatment 
and non-treatment group in the mean changes of HU values between visits. This 
finding accords with the observations of Introne et al. 48, who evaluated the effect of 
nitisinone for 40 AKU patients over 36 months. In that study, although Introne 
observed HGA reduction in urine and plasma, total hip range of motion and 
musculoskeletal function did not improve following the medication. Ranganath et al. 
51 suggested that the inconclusive results in that study may be due to insufficient 
nitisinone dosage (2 mg once daily). In the SONIA 2 trial, Ranganath and colleagues 
suggested giving SONIA 2 participants in the treatment group higher nitisinone dose 
of 10 mg once daily (based on the 4 week SONIA 1 study). Although the treatment 
group in SONIA 2 trial received five times more nitisinone than used in the Introne et 
al. 48 treatment group, the findings in the current chapter are in line with those of the 
Introne study; study duration is likely the common factor that has led to no effects on 
bone being detected. In another study, Suwannarat et al. 47 investigated the effect of 
nitisinone with a regular diet over the course of 3 to 4 months, and also found a 
consistent reduction of HGA in urine and plasma. That paper also provided little 
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evidence of positive therapeutic intervention on joints. Suwannarat noted that the pain 
in the affected joints was reduced, and that mobility improved in 6 out of the 7 patients. 
However, Suwannarat et al. only investigated a small number of cases and failed to 
use quantitative methods to assess the clinical effectiveness of nitisinone. The lack of 
quantitative outcome in that study makes it difficult to interpret these findings with 
confidence.  
Comparing the findings in this Chapter with those of Ranganath et al. 53, confirms that 
nitisinone may be ineffective in bone tissue suggesting that co-therapy is required to 
prevent bone loss in AKU patients. In 2020, Ranganath investigated the relationship 
between potential therapy and bone density in the largest group of AKU patients. In 
this longitudinal study, Ranganath et al. examined the data from 87 AKU patients who 
attended the NAC between 2007 and 2020 and underwent serial clinical evaluations, 
including DEXA and CT densitometry. In that study, patients were classified into three 
groups: the nitisinone-treatment group, the nitisinone plus antiresorptive treatment 
group, and the non-treatment group. To determine the effect of treatment, the change 
in bone density values at the femoral neck, total hip and lumbar spine from DEXA and 
CT were examined in all groups. A group of AKU patients who undertook 2 mg daily 
dose of nitisinone showed a significant reduction in CT values measured at femoral 
and hip sites (P < 0.05) and slightly increased lumbar CT values (P > 0.05). Only 
patients on nitisinone plus antiresorptive had improved bone density values at all 
measured ROI (P < 0.001) and surprisingly had significantly more fractures than the 
nitisinone-treatment group and non-treatment group. These results also seem to be 
consistent with SONIA 2 final analysis scans results (appendix), which found 
increased fracture for both groups and no significant differences in hip bone density 
values from DEXA scans between treatment and non-treatment groups.  
 
5.4.2 Annual change in SUVmax in the lumbar vertebrae and lumbar intervertebral 
disc 
 
The second investigation in this chapter was to evaluate the change in 18F-NaF uptake 
in the lower spine at the bone and joint regions over the four years for those nitisinone-
treated and non-treated AKU patients. In this study, the annual changes in maximum 
SUV values measured from lumbar vertebrae bodies (L1-L5) and the lumbar 
intervertebral discs (T12/L1-L5/S1) for SONIA 2 patients were monitored for both 
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treatment and non-treatment groups, as shown in section 5.3.1.2 and 5.3.1.3. Looking 
at the annual changes in PET semiquantitative values, the results of this study show 
that there were very little changes in the mean SUVmax values for the average lumbar 
vertebral bodies across the visits. Kruskal-Wallis test revealed no statistically 
significant differences between nitisinone-treated and non-treated AKU patients in the 
mean changes from baseline in vertebrae SUVmax values at month 12, month 24, and 
month 36 (P-value = 0.206, 0.678, and 0.310, respectively); the only significant 
differences were noted at month 48 (P = 0.045). These results would seem to suggest 
that the effect of nitisinone in the lower spinal bone could not be noted in 18F-NaF 
PET/CT scan before 48 months post-treatment. The finding in this section broadly 
supports the idea that it is hard to reproduce new bone after significant bone tissue 
damage. Further observations for a longer period may clarify these findings.  
 
Regarding the effectiveness of the nitisinone on the spinal joints, the IVD changes 
were also not significant between the treatment arms. What can be clearly seen in this 
analysis is that nitisinone had no apparent benefit in treating disc degeneration in AKU 
patients. There were no statistically significant differences between nitisinone 
treatment and non-treatment groups at any visits in the adjusted mean change from 
baseline in lumbar DVU SUVmax values (P > 0.05). Generally, the SUVmax 
measurements for the average lumbar DVUs were remarkably stable for both groups. 
It is more likely that this observation can be explained by the molecular mechanisms 
of 18F-NaF deposition in the calcified soft tissue, including calcified intervertebral disc 
lesions. Previously Chapter 4 shows that the relationship between increased SUVmax 
and disc damage was asymmetric in the severe disc degeneration cases and that 
increased 18F-NaF uptake on PET scans did not always correspond to the structural 
disc damage in MRI. Patients with end-stage disc degeneration with structural disc 
abnormalities had a grade 8 Pfirrmann score but not a correspondingly high SUVmax. 
The change in 18F-NaF uptake at the DVU was strongly associated with disc 
degeneration stages and whether the calcification was still active or had become stable. 
In the normal disc structure, no calcium deposition would be found in IVD area; 
therefore, no bone radiotracer accumulation at the non-calcified IVD would be 
expected. During the development of disc degeneration, the disc becomes thinner with 
unclear distinction between the vertebrae, causing a deformation of the vertebral bone. 
It is likely that calcium deposits in the IVD spaces in AKU patients increases with 
224 
 
disease progression, driving more 18F ion binding sites, therefore high 18F-NaF uptake. 
In severe disc degradation, it is more likely that most of the disc levels have complete 
calcification, causing the IVDs to begin to fuse together, which would lead to reduction 
of 18F-NaF uptake due to an inactive and stable degeneration stage; therefore, low SUV 
could be noted at the end-stages of disc degeneration. Because of that, it was expected 
to see a significant reduction in SUV value over time for patients who received 
nitisinone as an indicator for a successful treatment before IVDs collapse at the end 
disc degenerative stage. It was also expected to identify increased 18F-NaF uptake in 
the non-treated AKU group, which would indicate increased disc calcification before 
severe disc degeneration appears. Contrary to expectation, data did not show any 
significant differences in the SUV values between one visit and others in treatment 
and non-treatment AKU groups. It was surprising that the SUVmax values for the 
treatment group did not differ significantly from those of the non-treated AKU group. 
It may be challenging to explain this finding. However, a possible explanation for this 
result may be due to mineral calcium deposition over four years, which leads to few 
availability of -18F-ion binding sites; therefore, no changes were noted in 18F-NaF 
uptake during the trial. Also, nitisinone might not have the ability to treat stable disc 
calcification, which built up years ago. In fact, the severe damges in the spine tissues 
specifically in the disc area may not be treated by stopping or slowing down the 
ochronotic pigment deposition. Additionally, these results may demonstrate the 
stabilisation of the disease over four years.   
 
Generally, the 18F-NaF PET/CT results at lumbar vertebral and lumbar DVU of non-
treated AKU patients are similar to those AKU patients who were treated with 
nitisinone, following a similar pattern over four years. In accordance with the present 
results, scintigraphy qualitative data from SONIA 2 trial have found no significant 
differences between treated and non-treated AKU patients, which showed that the 
number of affected joints in whole body and spine were increased over visits for both 
treatement and non-treatment groups. Although more accurate, reliable and sensitive 
semiquantitative PET methods have been used in the current study, similar finding 
have been observed in both groups. It is possible that bone turnover, vascularity and 
osteoblastic activity in the lumbar spine is increased over a few years, but the changes 
are minimal, therefore, 18F-NaF uptake was almost stable in the measured sites. 
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According to these data, the effectiveness of nitisinone on 18F-NaF uptake measured 
from the lower spine was inconclusive.  
 
It was hypothesised that therapeutic interventions on bone disorders could be noted by 
evaluating the changes in 18F-NaF uptake in bone and cartilage. However, the findings 
of the current study did not support this. Overall, the longitudinal changes in 18F-NaF 
images in response to nitisinone were not significant, and minimal changes in bone 
and cartilage were observed over the period of four years. This observation may be 
explained by the fact that the number of patients was not enough to study the 
effectiveness of nitisinone on 18F-NaF uptake for a long period. Although continued 
HGA deposition in cartilage leads to osteoarthropathy, monitoring the change using 
bone radiotracer uptake seems to need more years to be noted. As mentioned in the 
previous section (5.4.1), the PET findings were consistent with that of Introne et al. 48 
who found that nitisinone did not appear to influence bone over a three-year clinical 
trial. The results observed in this study contradict with a previous preclinical study 
which suggested that taking nitisinone can completely prevent pigment deposition in 
cartilage tissues. Preston et al. 46 investigated the effectiveness of nitisinone in the knee 
joint using the AKU mouse model, and reported a beneficial impact of long-term 
treatment with nitisinone. Preston noted that ochronotic pigment was completely 
prevented in AKU mouse. It is important to point out that the observed impact of 
nitisinone in preventing ochronotic pigment in the cartilage or soft tissues is easier to 
assess and identify in preclinical studies, and it may be difficult to evaluate in human 
joints pre- and post-treatments with nitisinone. There is not currently a method that 
can assess deposition of HGA within human joints. Because of that, the alternative 
evaluation method in human research involves the use of imaging techniques as 
demonstrated here in this thesis.  
 
5.4.3 Individual changes in the quantitative values across the visits 
 
Due to the low number of patients in each age group, the trend of the change in the 
mean age group values may not be statistically convincing. The changes in lumbar 
vertebrae and IVD units from individual patients were plotted to examine any trends 
between the 18F-NaF PET/CT semiquantitative values and age in both treatment and 
non-treatment AKU patients. This section aimed to investigate what is happening to 
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these semiquantitative values over four years on an individual basis. Are all nitisinone-
treated AKU patients following the same pattern over the four years? These 
observational investigations helped to deliver an accurate assessment and show the 
disease progression in individual AKU patients. It is possible that the biological 
behaviour of the drug in the individual cases differs. In Chapter 3 and Chapter 4, the 
differences between the HUmean and SUVmax for the lumbar vertebrae and SUVmax for 
the DVU in each age group were tested respectively to assess the age effect for the 
baseline data. Chapter 3 identifies that generally, there were no significant differences 
in lumbar vertebrae (L1-L5) HUmean values between the age groups; also, no significant 
differences in lumbar vertebrae SUVmax between the age groups were observed. An 
interest finding has been noted in Chapter 4, in which lumbar disc SUVmax increased 
gradually with age following by a declined in the later years. 
 
This study found little change in bone semiquantitative values (HUmean) measured from 
the 18F-NaF PET/CT image for the lumbar vertebrae across the five visits for most of 
the cases. Figure 5.7 and Figure 5.8 represent the individual changes in the mean 
lumbar vertebrae HU value for both nitisinone-treated and non-treated AKU patients 
across the five visits in four age groups (30-39, 40-49, 50-59, and ≥ 60). When the 
mean HU values were plotted for lumbar vertebrae across the visits, little change was 
noted from one year to the next for nitisinone-treated AKU patients and non-treated 
AKU patients. No definitive trends were observed in most of the cases. Although 
HUmean values were fluctuating between visits for most of the AKU patients, the values 
in Visit 1 were very similar to the value in Visit 6. 
 
The individual changes in 18F-NaF uptake for lumbar bone have also been evaluated 
from Visit 1 to Visit 6. Figure 5.9 and Figure 5.10 show the individual changes in 
lumbar vertebrae SUVmax values in both nitisinone-treated and non-treated AKU 
patients. The results were similar to those shown in lumbar vertebrae HUmean figures. 
Again, the lumbar vertebrae SUVmax remains stable across the five visits with minimal 
changes in most cases. Although small fluctuations were noted in lumbar bone SUVmax 
across the visits, no definitive trends were noted in AKU patients.   
 
Regarding individual changes in the cartilage at the spine region, this study also 
observed small changes in the average SUVmax measured from the lumbar disc across 
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the five visits, as shown in Figure 5.11 and Figure 5.12. The lumbar DVUs SUVmax 
values were particularly stable with very little change in the values across the visits for 
most of the AKU cases. It was noted that if the SUVmax for the lumbar vertebral was 
high, it is likely that disc SUVmax value would also be high. It seems possible that these 
results were due to the inclusion of the endplate region in DVU measurements. As 
described in Chapter 2, it was impossible to define only the disc region in most of the 
spine levels, so the ROI was encompassed the DVU, covering the disc area and the 
endplate of the two adjacent vertebrae. Therefore, it is probable that the maximum 
SUV value was measured from the bone region rather than disc region.  
 
Overall, it is somewhat surprising that the HUmean and SUVmax measured from the 
lumbar spine for those AKU patients who undertook nitisinone and those who did not 
remained similar, with very little change in the measured values for most of the cases 
across the visits. Individually, no definitive trends were observed in any age groups. 
The similarites between the nitisinone-treated AKU patients and non-treated AKU 
patients was not expected but may be explained by several possible reasons. In the 
younger patients, the unchanged values may be explained by the fact that the 
deposition of the ochronotic pigment in spinal tissues is minimal in the third decade. 
These results are likely to be related to the stabilisation of the disease over four years 
for young patients. The reason for this is not clear but, it is possible that the effect of 
early-stage treatment for young AKU patients by nitisinone could prevent the 
development of ochronotic arthropathy and may be noted later in the 40s or 50s. In the 
40s and 50s age groups, the HU and SUV values can be seen fluctuating; however, in 
most patients, the values of Visit 1 and Visit 6 were very similar. It is possible that the 
progression of the disease is active in the 40s and 50s, causing inconsistent results. On 
the other hand, the oldest patients have very stable quantitative values across the visits. 
These results may be explained by the fact that they have severe inactive bone turnover 
and inactive disc calcification in the spine region caused by a high level of ochronotic 
deposition. As explained in the previous chapters, the low SUVmax in the lumbar spine 
for elderly patients is expected due to inactive local osteoblastic reaction of bone which 
reduces -18F ion binding sites, therefore low 18F-NaF uptake. It is probably challenging 
to prevent or treat ochronotic arthropathy in elderly patients who already have severe 
degeneration, but it may have a beneficial impact in young patients. It has been widely 
argued that nitisinone might slow the progression of the ochronosis by arresting 
228 
 
ochronotic pigment; however, it is unlikely for nitisinone to reverse ochronosis, and 
importantly, reverse joint damage. 
 
5.5 Summary  
 
In summary, the ability of 18F-NaF PET/CT to assess the early response in spinal 
arthropathy for AKU patients treated with nitisinone was limited. The semiquantitative 
evaluation of 18F-NaF PET/CT reported a stable disease progression in the nitisinone-
treat and non-treat groups over four years. Therefore, it seems that the effect of 
nitisinone in the lumbar spine was not confirmed due to unclear trends in nitisinone-
treated and non-treated AKU patients. Patients who received nitisinone showed an 
absence of significant radiographic improvements; likewise, non-treated patients 
showed no evidence of substantial structural or molecular damage over four years. In 
fact, nitisinone might slow the progression of the ochronosis by arresting further 
ochronotic pigment deposition; however, it is unlikely to treat stable bone turnover or 
severe disc damage associated with a high level of pre-treatement ochronosis.  
 
Whilst this study did not confirm the positive effect of nitisinone in the spine of AKU 
patients, it enhanced the understanding of disease progression over four years. The 
results raise the possibility that four years undertaking nitisinone may not be long 
enough to show bone and cartilage changes in the spinal tissues, particulary in patients 
who already had severe disease when treatment was initiated. It would not be 
unreasonable to expect a change in HUmean and SUVmax, which represents the treatment 
effect or disease progression over a period of four years in AKU patients. However, 
there is a possibility that the outcome would be clearer in longer term evaluations. 
Additionally, the spinal regions may not represent the global progression of ochronotic 
arthrophathy among the skeletal sites. It is therefore likely that further investigation is 
needed to assess the longer-term impacts of nitisinone in reducing arthritis features for 
AKU patients to establish the effectiveness of the treatment. This study encourages 
further investigation into using isotopic imaging biomarkers as a response assessment 
method in the skeleton in a variety of treatment options for AKU patients. Close 
monitoring of individual treated and non-treated patients would be important to 






The findings of this study are subject to certain limitations. First of all, interobserver 
and intraobserver reliability have not been tested due to limited time and clinical 
collaboration. Second of all, only one skeletal site was evaluated. It is more likely that 
one skeletal site does not represent the progression of the entire skeleton. Third of all, 
not all of the patients had all serial five scans due to withdrawal from the trial or 
technical issues in the PET/CT scanner or cyclotron on the scheduled day for imaging. 
These unmeasured scans may cause a source of error which should be considered 
carefully. Also, there were no control non-AKU patients to identify normal bone 
metabolism changes in the spine with age for the general population. Therefore it was 
not be possible to know whether the changes in the 18F-NaF PET/CT semiquantitative 
values over four years in AKU patients is following the average changes in the general 
population and in-line with age. These limitations mean that the findings in this study 
need to be interpreted cautiously.   
 
5.7 Future work  
 
Further work is needed to support the 18F-NaF PET/CT findings in regard to the 
effectiveness of nitisinone in bone and cartilage for AKU patients. More work is 
required to examine the interobserver and intraobserver agreements on the measured 
values. It would be more precise if other bones and joint sites such as the shoulder or 
knee are quantified to investigate the effect of nitisinone and assess the progression of 
the disease in more than one body site. This would represent a better understanding if 
nitisinone has a global and /or regional impact on bone and cartilage tissues. 
Additionally, more work is needed to develop a full picture of the correlation between 
nisitisone-treated and non-treated AKU patients over a long-term period. 
5.8 Conclusion  
 
This chapter has shown: 
 
 There were no significant differences between the nitisinone treatment and 




 There were no significant differences between nitisinone-treated patients and 
non-treated patients in the adjusted mean changes in SUVmax values for lumbar 
vertebrae and lumbar disc SUVmax across the visits. 
 There was no direct trend in the individual changes for both treatment and non-
treatment patients having very consistent lumbar HU and SUV values, with 
little change across five visits.  
 Four years undertaking nitisinone may not be long enough to detect the clear 
changes in the spinal tissues. 
 Nitisinone might slow the progression of the ochronosis by arresting 

























6  Cross-sectional study of cardiovascular calcification at baseline 
in alkaptonuria patients from the SONIA 2 study using 








Thus far, this thesis has focused on evaluating ochronotic arthropathy from 18F-NaF 
PET/CT scans in AKU patients. The previous chapters have shown increased 18F-NaF 
uptake in abnormal bone lesions and active calcified disc lesions in AKU patients. 
After that, spine arthropathy progression in response to nitisinone was evaluated. The 
final study of this thesis will move on to consider cardiovascular ochronosis in patients 
with AKU. This cross-sectional study describes the prevailing characteristics of 
cardiovascular involvements in AKU patients from the SONIA 2 trial using 18F-NaF 
PET/CT scans. The presence of abnormal cardiovascular calcifications were seen 
incidentally in the heart area while evaluating 18F-NaF PET/CT scans in the previous 
studies. Initial observations suggested that calcified vessels can be analysed and 
quantifed using existing data without adding extra cost or radiation to those patients. 
18F-NaF PET/CT images was available for SONIA 2 patients but not been used 
previously to assess cardiac involvements in AKU patients. This study is the first study 
to evaluate and analysis the distribution of a bone radiotracer within the heart region 
of AKU patients. The main reason for this initial investigation was to evaluate whether 
measuring 18F-NaF uptake in the heart could be used as a valuable imaging method to 
quantify molecular calcification in the cardiac vessels in order to identify calcified 
vessels and detect future cardiovascular risk in AKU patients. The current study set 
out to detect regional cardiac calcification by measuring the 18F-NaF uptake from PET 
images and the attenuation coefficient from CT images.  
 
In AKU, ochronotic pigment deposit in various body tissues, including cardiovascular 
tissues. It is understood in AKU that vessels become pigmented and calcified as part 
of the disease pathophysiology. The severe symptomatic cardiac disorder usually 
needs surgical intervention, so early diagnosis of cardiovascular disease could prevent 
surgical complications 28. Several cases of cardiovascular disorder associated with 
ochronosis have been reported 28–32. Additionally, numerous studies have been done 
to understand cardiovascular health in patients with AKU. In 1963, it was reported that 
there was no significant difference between the incidence of coronary artery disease 
in a patient suffering from AKU and those in the general population 184. However, 
AKU patients may be more susceptible to cardiovascular disease. Theoretically, there 
is concern that ochronosis could lead to early heart diseases associated with ochronotic 
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pigment, including cardiovascular calcification and inflammation. In a study of 58 
AKU patients, fifty percent of patients showed evidence of coronary-artery 
calcification detected from a non-contrast CT scan by the age of 59 years 7. 
Interestingly, no correlation between the severity of aortic valve disease and urine 
HGA levels has been found. In that study Phornphutkul et al. 7 reported that, the mean 
age of detecting cardiovascular involvements, including cardiovascular calcification, 
was 54 years, with no cardiac abnormalities noted before the fifth decade. On the other 
hand, Pettit et al. 34 and Hwaida et al. 27 suggested a role for cardiac scans such as 
echocardiographic surveillance for AKU patients above 40 years old in order to assess 
the early cardiovascular involvements. 
 
Although CT remains a gold standard to identify coronary artery calcification, it is a 
structural imaging modality which likely characterises vascular plaques and only 
detects macrocalcification. Detecting cardiovascular calcification before it becomes 
macroscopically visible will enable clinians to initiate further evaluation. Thus, for 
years, molecular imaging techniques have been employed to detect early abnormal 
cardiovascular lesions using isotopic biomarkers. Recently, 18F-NaF has been reported 
as a promiseing non-invasive method to detect and identify active microvascular 
calcification by many researchers. Due to the strong biological similarities between 
vascular calcification and bone formation, 18F-NaF can be used as a novel imaging 
biomarker for identifying early vascular calcification. Active vascular calcification 
commonly appears as hydroxyapatite deposits in the vascular walls, making it the best 
place for the exchange between the -18F ions and the hydroxyl group of hydroxyapatite 
after incorporating it into hydroxyapatite crystals. 
 
6.2 Design of study 
 
In this chapter only baseline scans for SONIA 2 participants were analysed. SONIA 2 
patients had subsequent scans; however, the analysis is beyond the scope of this thesis. 
 




Forty AKU patients including 24 males and 16 females who were part of the SONIA 
2 trial and had undergone 18F-NaF PET/CT scans to evaluate a variety of bone and 
joint abnormalities were analysed in this study. The exclusion criteria included 
previous myocardial surgery. The mean age of the patients involved in the current 
study was 50.25 ± 10.81 years old (range from 30 to 68), with no significant age 
difference between the gender groups; male mean age 50.92 ± 10.3 years old (range, 
30-67) and female mean age 49.25 ± 11.8 years old (range 30-68). The demographic 
characteristic of this population is summarised in Table 6.1. As in previous chapters, 
the cohort was divided into four groups according to their age as shown in shows in 
Table 6.2, including 7 patients (17.5%) between 30 and 39 years old, 13 (32.2%) 
between 40 and 49 years old, 10 (25%) between 50 and 59 years old, and 10 (25%) 
above 60 years old.  
 
Table 6.1 Demographic baseline characteristics of AKU patients who were part of the 
SONIA 2 clinical trial and analysised in this chapter. 




Age ± SD 
years 
Age range  
Total 40 50.25 ± 10.81 30 – 68 
Male 24 (60 %) 50.92 ± 10.3 30 – 67 
Female 16 (40%) 49.25 ± 11.8 30 – 68 
 
Table 6.2 The number of AKU patients at the beginning of the SONIA 2 clinical trial classified by gender and 
age who were included in this chapter.  
The participants were stratified by the decade of life into four age groups 30-39, 40-49, 50-59 
and ≥ 60 years old. 
Age group Gender Patient no. 
30 – 39 years old 
Total  7 
Male 3 
Female 4 
40 49 years old 
Total  13 
Male 8 
Female 5 
50 – 59 years old 
Total  10 
Male 6 
Female 4 
≥ 60 years old 





6.2.2 Image analysis 
 
Baseline 18F-NaF PET/CT data were analysed using Horos software, which allowed 
simultaneous display and analysis of PET, CT, and fusion PET/CT images in sagittal, 
coronal, and transverse planes. In this chapter, cardiac calcification was assessed in 
two main areas: coronary vessles and the aorta. The cardiac calcification assessment 
methods were described in detail in sections 2.8 and 2.8.2. Figure 6.1 briefly illustrates 
the assessment method which was applied in this chapter to quantify cardiovascular 
calcification. The main cardiac arterial regions, including coronary and aortic arterial 
regions, were evaluated and quantitatively analysed by measuring 18F-NaF uptake 
from PET images and the mean HU from CT images. For coronary arteries analysis, 
the arteries were visually recognised in a CT image, and ROIs were placed over the 
area of the four main branches of coronary arteries, including left coronary artery-left 
main stem (LCA), left anterior descending artery (LAD), left circumflex artery (LCA) 
and right coronary artery (RCA). For aortic artery analysis, ROIs were placed over 
ascending aorta (AA) and descending aorta (DA) (see Figure 6.2). The same ROIs, 
which were drawn in CT images, then copied to the 18F-NaF PET images to measure 
SUV values. 
 
Maximum SUV and mean HU were generated from 18F-NaF PET/CT images from the 
main coronary and aortic regions. Although the blood pool activity was minimal, it 
was more accurate excluding them from the measured uptake value. Background 
activity based on 18F-NaF activity in the blood pool was measured from inferior vena 
cava (IVC) and superior vena cava (SVC). After that, the maximum target to 
background ratio (TBRmax) for each ROI was generated to avoid overestimating the 
SUVmax value. TBRmax was calculated by dividing the SUVmax value for each ROI with 
a mean SUV of the blood pool 148,150. 
 
6.2.3 Correlation  
 
SUVmax, TBRmax, and HUmean values from main coronary and aortic branches were 
correlated with gender and age to assess the degree of cardiac calcification in relation 
to sex and age. Differences between gender and age were tested using the Pearson 
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correlation coefficient. One-way ANOVA analysis was conducted to assess the 
differences between age groups.  
 
 
Figure 6.1. The assessment methods used in this chapter to quantify cardiovascular 
calcification from 18F-NaF PET/CT images.  
First step; HUmean measurements from CT images by manually placing an individual circular 
ROI on axial CT slices over the four main coronary and aorta branches. Second step; SUVmax 
measurements from 18F-NaF PET images. The same ROI, which was drawn in the CT image, 
was copied to the PET image to generate the SUVmax value. Third step; blood pool activity 
measurements. Blood pool SUVmean was measured from SVC and IVC. Final step; background 
activity extraction. TRBmax was generated by dividing the value from the second step by the 
value of the third step for each ROI. HUmean; mean Hounsfield unit, SUVmax; maximum 
standardised uptake value, TBRmax; maximum target to background ratio ; is linear 
attenuation coefficient of ROI, ; is linear attenuation of distilled water, Am; maximum 
activity concentration (kBq/ml), Ao; mean activity concentration (kBq/ml), D; injected dose 
(kBq), W; body weight. 
Background 18F-NaF activity extraction




Evaluation of 18F-NaF activity in the blood pool in PET image




Evaluation of 18F-NaF uptake in PET image




Evaluation of the main arteries in CT image








Figure 6.2. Three-dimensional reconstruction image of the heart depicting the main 
arteries and veins.  
AO; aorta, SVC; superior vena cava, IVC; inferior vena cava, LCA; left coronary artery or left 
main stem, CA; left circumflex artery, RCA; right coronary artery, LAD; left anterior 
descending artery. Image done using BioRender.com  
 
6.3 Results  
 
6.3.1 SUVmax measurements 
 
In the 18F-NaF PET images, abnormal distribution of 18F-NaF was visibly noted within 
the chest area in AKU patients. Intense focal tracer uptake was identified in the heart 
region having bone-like radiotracer intensity. In some cases, abnormal vascular 
involvement was more noticeable in the fused 18F-NaF PET/CT images.  
 
In the first part of this study, the 18F-NaF uptake was analysed and quantified from 
coronary and aortic arteries by measuring maximum SUV from the main coronary 
arteries for 40 AKU patients. Figure 6.3 and Figure 6.4 show SUVmax measurements 
from the four main coronary arteries, aortic artery, and blood pool vessels. Table 9.29 
(appendix) summarises the measured values for each ROI. The average SUVmax value 
of all measured coronary arteries was 1.39 ± 0.49 (range 0.73 – 2.55). Average SUVmax 
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was 1.57 ± 0.59 (range 0.78 – 3.73) at LCA; 1.12 ± 0.35 (range 0.55 – 1.97) at LAD; 
1.18 ± 0.50 (range 0.45 – 2.64) at CA and 1.68 ± 1.04 (range 0.6 – 6.02) at RCA. The 
highest coronary arteries SUVmax value was detected at the RCA. The average SUVmax 
value at aortic artery was 2.06 ± 0.84 (range 0.94 – 4.76). Average SUVmax was 1.78 
± 0.57 (range 0.89 – 3.6) at AA and 2.38 ± 1.29 (range 0.99 – 7.1) at DA. Although 
DA value was slightly higher than AA, the t-test indicates no significant statistical 
difference between SUVmax measured from AA and DA. Blood pool 
18F-NaF uptake 
was also measured from IVC and SVC to generate TBRmax for the next section. The 
mean blood pool SUVmax was 0.82 ± 0.27 (range 0.43 – 1.83). Average SUVmax was 
0.77 ± 0.30 (range 0.37– 1.79) at IVC and 0.86 ± 0.28 (range 0.43 – 1.86) at SVC. 
Among all measured ROIs, the highest SUVmax value was detected at the DA and the 
lowest at the blood pool vessels, showing statistical significance differences between 
the two values (P < 0.05). 
 
6.3.1.1 Cardiovascular SUVmax and gender  
 
To assess the gender effect, the differences in SUVmax values between male and female 
patients were tested. Figure 6.3 and Figure 6.4 demonstrate the SUVmax at all ROIs for 
male and female AKU patients. The average SUVmax value for all four measured 
coronary arteries was 1.52 ± 0.51 (range 0.76 - 2.55) for males and 1.23 ± 0.49 (range 
0.6 – 2.25) for females. The SUVmax value at aorta was 2.14 ± 0.78 (range 1.18- 4.7) 
for males and 1.94 ± 0.93 (range 0.94– 4.76) for females. The blood pool SUVmax was 
0.76 ± 0.21 (range 0.43- 1.2) for male and 0.90 ± 0.33 (range 0.53 - 1.83) for female. 
It can be seen from the charts and the data in Table 9.29 (appendix) that, SUVmax value 
at most of the ROIs were similar in both genders. Male patients had slightly higher 
SUVmax at coronary arteries and aorta than female patients, while the female patients 
had higher SUVmax values at blood pool vessels. The statistical analysis using an 
independent t-test indicated that males had significant higher SUVmax at the average 
four main coronary arteries than females (P = 0.036). As the data show, there was no 
significant difference between the two groups at the average aortic artery nor average 
blood pool vessels (P = 0.471 and P = 0.123, respectively). 
 
Closer inspection of the figures show that regionally, there were significant 
confounding differences between coronary SUVmax value for males and females at 
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RCA only (P = 0.022), and at IVC (P = 0.003). No statistically significant differences 
in SUVmax values between males and females at LCA, LAD, CA, AA, DA, and SVC 





Figure 6.3. Mean SUVmax obtained from 18F-NaF PET scan at each cardiac artery for 40 AKU patients who were part of the SONIA 2 clinical trial 
stratified by gender.  
The results show the analysis of the baseline 18F-NaF PET data for 24 males and 16 females from four main branches of coronary arteries, including left coronary 
artery-left main stem (LCA), left anterior descending artery (LAD), left circumflex artery (CA) and right coronary artery (RCA), average coronary arteries 
(ACA), and aortic artery analysis, ascending aorta (AA) and descending aorta (DA), average aortic artery (AAA). Table 9.29 (appendix) shows the statistical 
correlation between gender at all ROI. SUVmax was highest at the DA in both male and female. Independent sample t-test revealed that males tend to have 
significantly higher SUVmax value at RCA and ACA than females (P = 0.022, P = 0.036, respectively). No statistically significant differences between males 
and females across the aortic artery were noted (P < 0.05). *Groups which showed significant difference (P < 0.05). In box and whisker, x is the mean value, 
and the line is the median. 




Figure 6.4. Mean SUVmax obtained from 18F-NaF PET scan at blood pool vessels for 40 AKU patients who were part of the SONIA 2 clinical trial 
stratified by gender.  
The results show the analysis of the baseline 18F-NaF PET data for 24 males and 16 females from blood pool vessels; inferior vena cava (IVC), superior vena 
cava (SVC), and average blood pool (ABP). Table 9.29 (appendix) shows the statistical correlation between gender at all ROI. Females tend to have a 
significantly higher SUVmax value at IVC than males (P = 0.003). No statistically significant differences between males and females at SVC nor ABP were noted 





6.3.1.2 Cardiovascular SUVmax and age 
 
The correlation between cardiovascular SUVmax values and age was tested in this 
section. Figure 6.5, Figure 6.6 and Figure 6.7 show the changes in SUVmax against age 
for 40 AKU patients at each cardiovascular region. Figure 6.5 shows that SUVmax 
values at the coronary arteries increased slightly with age. In the average four coronary 
arteries, age had a significant statistical influence on SUVmax measurements (R = 0.39, 
P = 0.013). Regionally, there was a significant correlation between the SUVmax values 
and age at the RCA only (R = 0.367, P = 0.02). No significant difference between the 
SUVmax values and age was found at LCA, LAD, nor CA (R= 0.276, R = 0.196, R = 
0.281, respectively, all P > 0.05). Likewise, as shown in Figure 6.6, aorta SUVmax 
values were not substantially correlated with age at neither AA nor DA (R = 0.17, R = 
0.144, and P = 0.293, P = 0.376, respectively). On the other hand, as shown in Figure 
6.7, the blood pool SUVmax value shows a moderate statistically significant correlation 
between age and SUVmax value at IVC (R = 0.372, P = 0.04), while no significant 
differences at SVC (R = 0.115, P = 0.482) were observed. 
 
The SUVmax from all cardiovascular regions for each age group were analysed, as 
shown in Figure 6.8, Figure 6.9, and Figure 6.10. The SUVmax data for all ROIs is 
displayed in detail in Table 9.30 (appendix). The SUVmax at the average four main 
coronary arteries was 1.13 ± 0.25 for 30-39 age group patients, 1.31 ± 0.63 for 40-49 
age group patients, 1.35 ± 0.34 for 50-59 age group patients and 1.71 ± 0.40 for 60 
years old patients and above. Although the SUVmax at coronary arteries increased from 
the youngest age group patients to the oldest group of patients, it was not statistically 
significant between the 30s and 40s patients or between 40s and 50s. Statistically, there 
was significant differences for the average coronary arteries SUVmax between patients 
in their 50s and above 60 only (P = 0.05). The average SUVmax at the AA and DA was 
1.73 ± 0.52 for 30-39 age group patients, 2.00 ± 0.93 for 40-49 age group patients, 
2.28 ± 0.78 for 50-59 age group patients and 2.15 ± 0.98 for ≥ 60 years old patients. 
The youngest age group patients had slightly lower aortic SUVmax values than the other 
three age groups, but statistically, it was not significant (P > 0.05). Similarly, there 
were no significant differences in blood pool SUVmax among the age group patients (P 
> 0.05). The average blood pool SUVmax was 0.87 ± 0.47 for 30-39 age group patients, 
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0.77 ± 0.17 for 40 - 49 age group patients, 0.86 ± 0.23 for 50-59 age group patients 




Figure 6.5. Scatter plots illustrating the correlation between SUVmax obtained from 
18F-NaF PET/CT and age at four main coronary arteries for 40 
AKU patients who were part of the SONIA 2 clinical trial.  
The results display left coronary artery-left main stem (LCA), left anterior descending artery (LAD), left circumflex artery (CA) and right coronary artery (RCA), 
average coronary arteries (ACA) in individual AKU cases with age. Multiple linear regression analysis identified no statistically significant correlation between 
regional  SUVmax value and age in AKU cases measured at LCA, LAD, and CA (P = 0.084, P = 0.227, and P = 0.079, respectively). Age was noted to have a 


































Figure 6.6. Scatter plots illustrating the correlation between SUVmax obtained from 18F-NaF PET/CT and age at aortic artery for 40 AKU patients who 
were part of the SONIA 2 clinical trial.  
The results display SUVmax of ascending aorta (AA) and descending aorta (DA), average aortic artery (AAA) in individual AKU cases with age. Multiple linear 
regression analysis identified that there was no significant correlation between SUVmax of AA nor DA and age in AKU cases (R = 0.17 and P = 0.293, R = 0.144 





























Figure 6.7. Scatter plots illustrating the correlation between SUVmax obtained from 18F-NaF PET/CT and age at blood pool vessels for 40 AKU patients 
who were part of the SONIA 2 clinical trial.  
The results display SUVmax of inferior vena cava (IVC), superior vena cava (SVC), and average blood pool (ABP) in individual AKU cases with age. Only 
SUVmax of IVC had shown a moderate correlation with age (R = -0.372, P = 0.043). At the same time, there was no correlation at SVC (R = 0.115, P = 0.48). 
P = 0.904
R = - 0.020
P = 0.043




























Figure 6.8. SUVmax measurements at the main coronary arteries measured from baseline 18F-NaF PET/CT scan for 40 AKU patients who were part of 
the SONIA 2 clinical trial stratified by decade of life. 
Table 9.30 (appendix) shows the coronary ROI and age groups which indicated a statistically significant difference between subgroup analyses. *Groups which 
showed significant difference (P < 0.05). One-way-ANOVA revealed no statistically significant difference between subgroup analyses at regional coronary 
arteries. There were substantial differences for SUVmax value between patients in their 50s and above 60 years only (P = 0.05) in the average four coronary 
arteries. Left coronary artery-left main stem (LCA), left anterior descending artery (LAD), left circumflex artery (CA) and right coronary artery (RCA), average 











Figure 6.9. SUVmax measurements at the aortic artery measured from baseline 18F-NaF PET/CT scan for 40 AKU patients who were part of the SONIA 
2 clinical trial stratified by the decade of life. 
Table 9.30 (appendix) shows the aortic ROIs and age groups which indicated a statistically significant difference between subgroup analyses. One-way-ANOVA 
revealed no statistically significant difference between subgroup analyses at regional aortic arteries. Ascending aorta (AA) and descending aorta (DA), average 



















Figure 6.10. SUVmax measurements at the blood pool vessels measured from baseline 18F-NaF PET/CT scan for 40 AKU patients who were part of the 
SONIA 2 clinical trial stratified by the decade of life. 
Table 9.30 (appendix) shows the blood pool vascular ROIs and age groups which indicated a statistically significant difference between subgroup analyses. 
One-way-ANOVA revealed no statistically significant difference between subgroup analyses at regional blood pool vessels. Inferior vena cava (IVC), superior 




6.3.2 TBRmax measurements 
 
The next section critically assesses the 18F-NaF uptake from the cardiovascular region, 
excluding the background activity accumulated in blood pool vessels. The result of 
coronary arteries and aortic artery TBRmax for 40 SONIA 2 patients are shown in 
Figure 6.11, and in Table 9.31 (appendix). Among the coronary arteries, the RCA had 
the highest TBRmax with 2.21 ± 1.60, then LCA with 2.12 ± 1.44. Mean TBRmax at the 
LAD and CA was 1.45 ± 0.51 and 1.53 ± 0.77, respectively. No statistical differences 
between the four main coronary arteries TBRmax values were detected. Regarding the 
aortic artery, the DA showed a significantly higher TBRmax (3.03 ± 1.74) than the AA 
(2.31 ± 1.06) (P = 0.002). The average TBRmax was 1.80 ± 0.80 for coronary arteries 
ranging from 0.94 to 4.59, and 2.7 ± 1.24 for aortic artery ranging from 1.22 to 6.76. 
Statistically, aortic TBRmax values were considerably higher than coronary arteries 
TBRmax values (P < 0.005). 
 
6.3.2.1 Cardiovascular TBRmax and gender  
 
Figure 6.11 compares the SUVmax across the coronary arteries for male and female 
AKU patients. Table 9.31(appendix) summarises the coronary arteries TBRmax for 
each gender group. Independent t-test identified that male AKU patients had 
significantly higher TBRmax in the ACA than the female AKU patients (P = 0.012). 
The average TBRmax for coronary arteries for the male patient was 2.06 ± 0.93, while 
for the female patients was 1.42 ± 0.31. Regionally, there were differences in TBRmax 
between males and females at LAD and RCA (P = 0.018, P = 0.012, respectively). In 
contrast, there was no apparent difference in the TBRmax values at LCA nor CA 
between males and females (P = 0.1, P = 0.219, respectively).  
 
Regarding the aortic artery, male patients had slightly higher aortic TBRmax values at 
both AA and DA regions, as shown in Figure 6.11 and Table 9.31. However, 
statistically, using an independent t-test, they were not significant (P = 0.175 and P = 
0.275, respectively). The average TBRmax within the aorta was 2.94 ± 1.44 for male 
AKU patients ranging from 1.63 to 6.76 compared to 2.34 ± 0.80 for female AKU 




Figure 6.11. Mean TBRmax obtained from 18F-NaF PET scan at each cardiac artery for 40 AKU patients who were part of the SONIA 2 clinical trial 
stratified by gender.  
Baseline PET data for 24 males and 16 females from four main branches of coronary arteries, including left coronary artery-left main stem (LCA), left anterior 
descending artery (LAD), left circumflex artery (CA), and right coronary artery (RCA), average coronary arteries (ACA), and aortic artery analysis of the 
ascending aorta (AA) and descending aorta (DA) and average aortic artery (AAA). Table 9.31 (appendix) shows the statistical correlation between gender at all 
ROIs. TBRmax was highest at the DA and lowest at LAD at both male and female patients. *Groups which showed significant difference (P < 0.05). Statistically, 
aortic TBRmax values were considerably higher than coronary arteries TBRmax values (P < 0.005). Independent sample t-test revealed statistically significant 
differences between males and females at LAD, RCA, and ACA (P = 0.01, P = 0.012, P =0.012 respectively). There was no apparent difference in the TBRmax 
values between both genders at LCA, CA, AA, DA, nor AAA (P = 0.1, P = 0.219, P = 0.175, P = 0.275, P = 0.141, respectively). In box and whisker, x is mean 






6.3.2.2 Cardiovascular TBRmax and age 
 
The TBRmax values were plotted against age, as shown in Figure 6.12 and Figure 6.13. 
Multiple linear regression analysis identified that there was no correlation between 
TBRmax obtained from the average four coronary arteries and age (R = 0.095, P = 
0.268). Looking at each individual coronary artery, a moderate correlation was noted 
between TBRmax and age at RCA only (R = 0.336, P = 0.034). No correlation between 
TBRmax and age was observed at LCA, LAD, and CA  (R = 0.76, R = 0.16, R = 0.148 
respectively, all P > 0.05,). Similarly, there was no evidence that age had an influence 
on aortic TBRmax measurements, as shown in Figure 6.13. No statistically significant 
correlation coefficients were found between aorta TBRmax and age at neither AA nor 
DA (R = 0.006, P = 0.732 and R = 0.033, P = 0.971, respectively). From this result, it 
appears that age has no direct influence on the TBRmax measurements at both coronary 
and aortic arteries.  
 
The mean TBRmax of the measured cardiovascular regions of each age group are 
compared in Figure 6.14 and Figure 6.15. The data are presented in detail in Table 
9.31 (appendix). The TBRmax at the average four main coronary arteries was 1.62 ± 
0.52 for 30-39 age group patients, 1.69 ± 0.96 for 40-49 age group patients, 1.59 ± 
0.32 for 50-59 age group patients and 2.29 ± 0.97 for 60 years old patients and above. 
In terms of the aorta, TBRmax at the average value was 2.65 ± 1.44 for 30-39 age group 
patients, 2.64 ± 1.30 for 40-49 age group patients, 2.77 ± 1.35 for 50-59 age group 
patients and 2.73 ± 1.10 for 60 years old patients and above. Generally, patients with 
increased coronary and aortic arteries TBRmax values were more likely to be in the 
older groups. However, statistical analysis revealed that there was only a significant 
difference for the average coronary arteries TBRmax between patients in their 50s and 
above 60 years (P = 0.04). No statistically significant differences in the average aortic 






Figure 6.12. Scatter plots illustrating the correlation between TBRmax obtained from 18F-NaF PET/CT and age at four main coronary arteries for 40 
AKU patients who were part of the SONIA 2 clinical trial. 
TBRmax of left coronary artery-left main stem (LCA), left anterior descending artery (LAD), left circumflex artery (CA) and right coronary artery (RCA), average 
coronary arteries (ACA) in individual AKU cases with age. Using multiple linear regression, coronary arteries showed no significant correlation between TBRmax 


































Figure 6.13. Scatter plots illustrating the correlation between aorta TBRmax obtained from 18F-NaF PET/CT and age at aortic artery for 40 AKU 
patients who were part of the SONIA 2 clinical trial.  
TBRmax of ascending aorta (AA) and descending aorta (DA), average aortic artery (AAA) in individual AKU cases with age. Multiple linear regression analysis 




























Figure 6.14. Mean main coronary arteries TBRmax among four decadal age groups measured from baseline 18F-NaF PET/CT scan for 40 AKU patients 
who were part of the SONIA 2 clinical trial. 
Table 9.31 (appendix) shows the four main coronary arteries and age groups which indicated a statistically significant difference between subgroup analyses. 
*Groups which showed significant difference (P < 0.05). There was a statistically significant difference between the 50s and 60s only at average coronary 
arteries (P = 0.04). Left coronary artery-left main stem (LCA), left anterior descending artery (LAD), left circumflex artery (CA) and right coronary artery 












Figure 6.15. Mean aortic TBRmax among four decadal age groups measured from baseline 18F-NaF PET/CT scan for 40 AKU patients who were part 
of the SONIA 2 clinical trial. 
Table 9.31 (appendix) shows the aortic ROI and age groups which indicated a statistically significant difference between subgroup analyses. There was no 
statistically significant difference between subgroup analyses at aorta arteries. Ascending aorta (AA) and descending aorta (DA), average aortic artery (AAA) 




6.3.3 Mean HU measurements 
 
So far, this study has focused on quantifying 18F-NaF uptake at the cardiovascular 
regions in PET images. In CT investigations, abnormal vascular calcification signs 
were observed within the heart region having bone-like attenuation coefficient 
intensity. Some of the dense vascular areas in the CT image were adjacent to the 
existing intensive radiotracer in the PET image, which was cleared in the fused 18F-
NaF PET/CTT image. These high dense calcium lesions were quantitatively analysed 
by measuring HUmean from CT images. 
 
The results of the four main coronary arteries and aortic artery are shown in Figure 
6.16 and Figure 6.17, and displayed in detail in Table 9.33. The mean HU value of all 
measured coronary arteries was 138.18 ± 139.41 (range 11 – 711). Average HUmean 
was 127.42 ±153.91 (range -2– 700) at LCA; 115.75 ±124.66 (range 7 – 502) at LAD; 
125.89 ±177.40 (range 3 – 937) at CA and 197.2 ±239.88 (range -29 – 1217) at RCA. 
The highest coronary arteries HUmean value was detected at the RCA, as shown in 
Figure 6.16. This result correlates with the SUVmax data, where the highest SUVmax 
value at the RCA was found (see results section 6.3.1). The HUmean value at the aorta 
was 133.71 ±143.48 (range 68.5 – 940). The average HUmean was 134.33 ±141.74 
(range 70 – 899) at AA and 133.1 ±147.11(range 67 – 981) at DA. Independent  t-test 
indicates no significant differences in HUmean values between the AA and DA regions. 
Mean blood pool HUmean measured from IVC and SVC were 99.85 ± 15.99 and 92.9 
± 19.98, respectively, with no significant differences between the two values (P > 
0.05).  
 
6.3.3.1 Cardiovascular HUmean and gender  
 
The differences between male and female HUmean values at all coronary and aortic 
ROIs are shown in Figure 6.16 and Figure 6.17 and summarised in Table 9.33 
(appendix). The average HUmean value for the four coronary arteries was 166.68 
±154.47 (range 43 - 711) for males and 95.44 ± 103.43 (range 11 - 370) for females. 
The HUmean value at the aorta was 115.04 ± 64.68 (range 68.5 - 409) for males and 
161.72 ± 213.81 (range 76.5 - 940) for females. The blood pool HUmean was 92.75 ± 
13.71 (range 66.5 - 126) for males and 100.54 ± 15.66 (range 83 - 133) for females. 
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Closer inspection of the figures show that male patients had slightly higher HUmean at 
coronary arteries than female patients, while female patients had higher aortic and 
blood pool HUmean values than male patients. However, an independent t-test indicated 
that there were no significant confounding differences in coronary arteries HUmean, 
aortic artery HUmean, and blood pool HUmean values between males and females AKU 








Figure 6.16. Mean HUmean obtained from the CT  scan at each cardiac artery for 40 AKU patients who were part of the SONIA 2 clinical trial stratified 
by gender.  
The results show the analysis of the baseline PET data for 24 male and 16 female from four main branches of coronary arteries, including left coronary artery-
left main stem (LCA), left anterior descending artery (LAD), left circumflex artery (CA) and right coronary artery (RCA), average coronary arteries (ACA), and 
aortic arteries analysis, ascending aorta (AA) and descending aorta (DA) and average aortic artery (AAA). Table 9.33 (appendix) shows the statistical correlation 
between gender at all cardiovascular ROIs. HUmean is highest at the RCA in male patients and DA in female patients. Independent sample t-test revealed no 
statistically significant differences between males and females at all measured ROIs (all had P > 0.05). In box and whisker, x is the mean value, and the line is 





Figure 6.17. Mean HUmean obtained from the CT  scan at the blood pool vascular region for 40 AKU patients who were part of the SONIA 2 clinical 
trial stratified by gender.  
The results show the analysis of the baseline PET data for 24 males and 16 females from blood pool vessels, including inferior vena cava (IVC) and superior 
vena cava (SVC), and average blood pool measurement (ABP). Table 9.33 (appendix) shows the statistical correlation between gender at all ROIs. Independent 
sample t-test revealed no statistically significant differences between males and females at AA, DA, nor ABP (P = 0.172, P = 0.246, and P = 0.129 respectively). 
In box and whisker, x is the mean value, and the line is the median.  
261 
 
6.3.3.2 Cardiovascular HUmean and age 
 
Figure 6.18, Figure 6.19, and Figure 6.20 shows the correlation between age and 
HUmean across cardiovascular arteries. It is clear that HUmean values were positively 
increased with age at all ROIs. The average coronary arteries HUmean value was 
significantly correlated with age (P = 0.006, R = 0.427). Regionally, LCA, LAD, and 
RCA had a significant correlation with age with P-values of 0.003, 0.002, and 0.029, 
respectively. In contrast, there was no significant correlation between CA HUmean 
values and age (P = 0.087, R = 0.274). The average aortic HUmean value was also 
positively correlated with age (P = 0.022, R = 0.36), as shown in Figure 6.19. 
Regionally, both AA and DA HUmean value had a positive trend with age (P = 0.017, 
R = 0.375 and P = 0.031, R= 0.341, respectively). Blood pool HUmean measurement 
was not affected by age (P > 0.05), as shown in Figure 6.20. 
 
Subgroup age analysis for the cardiac HUmean was compared in Figure 6.21, Figure 
6.22, and Figure 6.23 and presented in Table 9.34 (appendix). Generally, the youngest 
age group patients had low HUmean values, while the oldest age group had the highest 
HUmean values. The average HUmean from the four measured coronary arteries was 
78.32 ± 32.93 for 30-39 age group patients, 113.37 ± 182.69 for 40-49 age group 
patients, 100.63 ± 66.84 for 50-59 age group patients and 249.90 ± 124.18 for ≥ 60 
year old patients. Statistically speaking, there were significant differences between the 
50s and 60s age groups only for the HUmean values, which were measured from LAD, 
LAD and RCA (P = 0.03, P = 0.05, and P = 0.02, respectively).  
 
Subgroup age analysis from the aorta shows that the average HUmean was 108.07 ± 
23.62 for 30-39 age group patients, 92.92 ± 11.39 for 40-49 age group patients, 100.40 
± 10.45 for 50-59 age group patients and 238.00 ± 268.92 for ≥ 60 year old patients. 
Although aortic HUmean values correlated with age, there was no clear trend between 
sub-age group values. The only statistically significant evidence was shown between 
the HUmean values measured from AA for the youngest and the second youngest age 
groups (P = 0.04). On the other hand, most adolescent patients had significantly higher 
average blood pool HUmean values (110.00 ± 15.22) compared with the patients in the 
40-49 age group (86.83 ± 10.87), as shown in Figure 6.23. Regarding blood pool 
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vessels, no apparent differences were detected at the blood pool regions between the 






Figure 6.18. Scatter plots illustrating the correlation between HUmean obtained from CT scan and age at four main coronary arteries for 40 AKU 
patients who were part of the SONIA 2 clinical trial.  
The results display HUmean of left coronary artery-left main stem (LCA), left anterior descending artery (LAD), left circumflex artery (CA) and right coronary 
artery (RCA), average coronary arteries (ACA)  in individual AKU cases with age. Age had a positive, statistically significant effect in average main coronary 
arteries HUmean value ( R = 0.427, P = 0.006). Multiple linear regression analysis identified a statistically significant correlation between regional HUmean and 
age in AKU cases measured at LCA, LAD, and RCA (R = 0.338, 0.465, and 0.346, respectively, all P > 0.05). No significant correlation between HUmean values 



































Figure 6.19. Scatter plots illustrating the correlation between aorta HUmean obtained from CT scan and age for 40 AKU patients who were part of the 
SONIA 2 clinical trial.  
The results display HUmean of ascending aorta (AA) and descending aorta (DA), average aortic artery (AAA) in individual AKU cases with age. Multiple linear 
regression analysis identified that there was significant correlation between HUmean and age in AKU cases at AA and DA (R = 0.375, P = 0.017, and R = 0.341, 




























Figure 6.20. Scatter plots illustrating the correlation between blood pool HUmean obtained from CT and age for 40 AKU patients who were part of the 
the SONIA 2 clinical trial.  
The results display the HUmean of inferior vena cava (IVC), superior vena cava (SVC), and average blood pool (ABP) in individual AKU cases with age. Multiple 
linear regression analysis identified that there was no significant correlation between HUmean and age in AKU cases at IVC and SVC (R = -0.074, P = 0.681 and 





























Figure 6.21. Mean coronary arteries HUmean value among four decadal age groups measured from CT scan for AKU patients who were part of the 
SONIA 2 clinical trial. 
Table 9.34 shows the ROI and age groups which indicated a statistically significant difference between subgroup analyses. *Groups which showed significant 
difference (P < 0.05). One-way-ANOVA revealed a statistically significant difference between the 50s and 60s age groups at LCA, LAD, CA, and ACA (P = 
0.03, P = 0.05, P = 0.02, and P = 0.001, respectively). Left coronary artery-left main stem (LCA), left anterior descending artery (LAD), left circumflex artery 
(CA) and right coronary artery (RCA), average coronary arteries (ACA). In box and whisker, x is the mean value, and the line is the median.  










Figure 6.22. Mean aortic HUmean values among four decadal age groups measured from CT scan for AKU patients who were part of the SONIA 2 
clinical trial. 
Table 9.34 shows the ROI and age groups which indicated a statistically significant difference between subgroup analyses. *Groups which showed significant 
difference (P < 0.05). One-way-ANOVA revealed a statistically significant difference between the 50s and 60s age groups at average coronary arteries, and 
between 30s and 40s at AA (P = 0.04), and between 50s and 60s at AA, DA, and AAA (P = 0.009, P = 0.017, and P = 0.012, respectively). Ascending aorta 
(AA) and descending aorta (DA), average aortic artery (AAA). In box and whisker, x is the mean value, and the line is the median. 
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Figure 6.23. Mean blood pool HUmean among four decadal age groups measured from CT scan for AKU patients who were part of the SONIA 2 clinical 
trial. 
Table 9.34 shows the ROI and age groups which indicated a statistically significant difference between subgroup analyses.*Groups showed significant difference 
(P < 0.05). One-way-ANOVA revealed a statistically significant difference between the 30s and 40s age groups at SVC and ABP (P = 0.0001 and P = 0.04, 





6.3.4 Examples of some cases  
 
Part of this chapter aimed to highlight the distribution of 18F-NaF throughout the 
cardiac region in AKU patients. In a normal event, no coronary 18F-NaF activity in the 
PET image nor coronary calcium in the CT image was noted, as shown in Figure 6.24. 
As the images show, the radiotracer was distributed homogeneously throughout the 
skeleton in the PET image with no abnormal accumulation of activity in the heart area. 
In the same way, normal soft tissue density had appeared in the CT image. A 
significant difference can be noted between bone intensity in vertebra, ribs and 
sternum and the cardiac soft tissue intensity. This indicates a typical young AKU case 
who had healthy cardiovascular arteries. 
 
In abnormal cardiovascular events, three observations were noted in 18F-NaF PET/CT 
scan. First, increased 18F-NaF uptake in the PET image with the absence of local 
calcium in the CT image as shown in Figure 6.25 and Figure 6.26. The 18F-NaF activity 
was pointed out in the aortic at both AA and DA walls, with no abnormal calcification 
signs in the CT image  (Figure 6.25). Figure 6.26 shows intense 18F-NaF uptake in the 
PET image in the femoral artery with no femoral artery calcium in the CT image. In 
those cases, uptake was identified as focal in nature, but the impact may be localised 
to individual plaques. Second, regional coronary calcification in CT images with no 
18F-NaF uptake. Area of coronary calcification and without any 18F-NaF absorption 
was widely seen in AKU patients. Figure 6.27 shows an example of calcium in the AA 
wall with no unusual 18F-NaF activity in PET image. Third, the focal distribution of 
radiotracer in PET images in the area adjacent or overlying to existing extensive 
calcification in the CT images. Figure 6.27 shows an advanced active cardiovascular 
calcification event. The patient had extensive calcification in LAD and DA in the CT 
image adjacent to a mineral 18F-NaF uptake in the PET image. The affected area was 
clearly observed in the fused 18F-NaF PET/CT. In that case, increased and intense focal 
18F-NaF uptake was observed in the RCA in the PET image overlaying with existing 
extensive calcification in that area in the CT image. Also, increased 18F-NaF uptake 
was present in the abdominal aorta adjacent to the existing abdominal calcification 
area in the CT image. In that case, abnormal tracer distribution with bone-like tracer 
intensity in the PET image and bone-like intensity in the CT images was identified in 




Figure 6.24. 18F-NaF PET/CT images for a 33 year old, male AKU patient.  
A. PET/CT image shows a normal distribution of 18F-NaF throughout the skeleton, soft tissues 
and vessels. No abnormal 18F-NaF uptake nor high-density region in the heart region was noted 
in PET/CT image. B) axial 18F-NaF PET/CT image of aorta shows no abnormal 18F-NaF 
uptake nor aortic calcification at neither AA nor DA. Note the intensity and activity in the 






Figure 6.25. 18F-NaF PET/CT image of the heart for a 44 year old, female AKU patient, 
showing high background activity in soft tissues, specifically in the heart region.  
In the PET image, increased 18F-NaF uptake was noted in AA and DA. In the CT image, the 
calcification in both AA and DA were not visible. In the fused 18F-NaF PET/CT image, the 
abnormal uptake in both AA and DA were clearly noticeable. Arrows indicate increased 18F-
NaF uptake in PET image, which indicate micro-calcified vessels. In the previous chapter, it 
was noted that this patient had very high bone mineral density values in DEXA scan, high HU 
in CT images and high SUV values in PET images at lumbar spine lesions. Note the intensity 




Figure 6.26. 18F-NaF PET/CT image for a 56 year old, female AKU patient, showing high 
activity in the thigh. 
A) Coronal B) Sagittal C) Axial 18F-NaF PET/CT scan. In the PET image, increased 18F-NaF 
uptake was noted in the femoral arteries. In the CT image, no calcification was identified. In 
the fused 18F-NaF PET/CT image, the abnormal 18F-NaF uptake in both femoral sides was 
clearly noted. Arrows indicated increased 18F-NaF uptake in PET image and fused 18F-
NaFPET/CT image, indicating micro-calcified vessels in the right and left femoral sides. Note 






Figure 6.27. Axial 18F-NaF PET/CT images for a 62 year old, male AKU patient.  
The first upper row of images show extensive calcification in LAD in CT image adjacent to a 
minimally increased 18F-NaF uptake in the PET image. The second-row of images show 
extensive calcification in DA, which was clearly noted in CT image and fused 18F-NaF 
PET/CT image with no apparent abnormal 18F-NaF uptake in PET image. The third-row of 
images show calcification in the AA wall in CT image and fused 18F-NaF PET/CT image, with 
no intense 18F-NaF activity in PET image. The fourth-row of images shows an intense focal 
18F-NaF uptake in PET image in RCA overlaying with existing extensive calcification in CT 
image. The bottom row of images shows intense focal 18F-NaF uptake in PET image adjacent 
to an area of existing extensive calcification in the abdominal artery. Note the intensity and 
activity in the vertebra, ribs and sternum. 
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6.4 Discussion  
 
This is the first study to describe vascular calcification in the main arteries in patients 
with AKU using 18F-NaF PET/CT scan. While the 18F-NaF PET/CT scan was 
performed to detect joint and bone abnormalities, cardiac involvements were 
accidentally noted in SONIA 2 participants, and the event has been investigated. 
Spotty hot areas and dense lesions were noted in 18F-NaF PET/CT images, indicating 
vulnerable plaques which may be associated with cardiac ochronosis in AKU patients. 
Even minimal bone radiotracer uptake in coronary vessels was a piece of strong 
evidence for molecular cardiovascular calcification, which may lead to severe 
consequences if not treated. The purpose of this investigation came after noting 
unexpected bone radiotracer uptake in the heart area in AKU patients during 18F-NaF 
PET/CT evaluation. This study aimed to determine 18F-NaF uptake in the coronary 
arteries and aorta in order to assess early molecular calcification before detecting 
structural calcification by standard CT scan. 
 
6.4.1 Cardiovascular calcification analysis method 
 
In the present study, a novel method using a bone imaging radiomarker was employed, 
to quantify active cardiovascular calcification which may help to understand coronary 
artery disease in ochronotic patients. The assessment methods were chosen based on 
the previous studies in this area and the available resources, including data and 
software. The evaluation of coronary and aortic artery calcification using 18F-NaF as 
a biomarker was previously tested in several non-AKU studies reporting successful 
findings 148,150,152,156,157. 
 
In this study, it was not possible to identify the exact border of small vascular structures 
using non-contrast CT nor 18F-NaF PET images. From this point, using maximum 
SUV would be the best value to choose, presenting abnormal 18F-NaF uptake within 
small vessels. Clinically, there were no fixed or standard method to quantitatively 
analyse cardiovascular calcification in 18F-NaF PET/CT images. Exciting efforts are 
ongoing to establish the optimal method for creating a standard protocol to use 18F-
NaF tracer as a microcalcification imaging biomarker. Several studies supported the 
analysis method, which has been selected in this chapter to quantify the vascular 
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uptake using maximum SUV 155,158. In contrast, some studies preferred quantifying the 
cardiovascular 18F-NaF uptake using mean SUV 185. It is important to mention that a 
small fraction of the administered 18F-NaF dose will remain in the plasma 152. 
Therefore, this remaining background activity in the blood may affect the SUV 
measurements causing overestimation of the values. In order to avoid this issue, 
SUVmax was divided by the mean SUV of the blood pool to generate TBRmax..  
 
The primary purpose of combining the CT scanner with the PET scanner is to improve 
the structural identification of the imaged regions. In this study, the CT image was 
used to identify the dense regions in the heart visually and analyse them quantitively 
by measuring HU values. Based on the HU scale, high HU values defined dense 
tissues, which are usually detected from bone or calcified soft tissue lesions. Therefore, 
detecting high HU values in cardiac vessels indicated an abnormal cardiac event, 
increasing the possibility of calcified vessels, which more likely caused by calcium 
deposition. 
 
6.4.2 Increased 18F-NaF uptake in the cardiovascular system.  
 
Focal high intense 18F-NaF activity was identified and localised at multiple sites within 
the coronary circulation in AKU patients. To understand the 18F-NaF uptake within 
the cardiovascular system in AKU patients, the main arteries were identified and 
quantified in AKU patients. Although the evaluation of vascular calcification using 
18F-NaF PET/CT for AKU patients has not been described previously, the abnormal 
cardiac manifestations in ochronotic patients are well-known 7,25,28. Over the last few 
years, cardiovascular 18F-NaF uptake has been described in the general population and 
patients with heart disease using 18F-NaF PET/CT scan. The precise mechanism of 
18F-NaF accumulation in the cardiovascular tissue is not clearly understood or 
established yet; however, it can be extrapolated from 18F-NaF uptake in osseous tissue, 
which has been described previously by many studies over the decades. 18F-NaF is a 
bone radiotracer which detects high-risk lesions of active bone formation and 
remodelling. After administration of 18F-NaF, the -18F ion binds to the calcium 
pyrophosphate dihydrate crystals, including those in the arterial walls. Calcification in 
the vascular tissues likely shows increased 18F-NaF uptake, which can be indicated by 
the increase of SUV and TBR values. There is an assumption that 18F-NaF uptake 
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represents an active and ongoing microcalcification, which usually occurs at the 
earliest stage of vascular calcium deposition. So, the focal spot areas of increased 18F-
NaF uptake in the AKU patients may reflect an active and ongoing cardiovascular 
calcification. This corroborates these earlier findings 148,150,152,155–157,186. According to 
these observations, it is likely, therefore, to identify early cardiac involvements in 
AKU patients associated with active microvascular calcification before it becomes 
symptomatic. Increased 18F-NaF uptake in the calcified vessels is a valuable finding 
which can predict future cardiovascular events in AKU patients, allowing earlier 
intervention and treatment of cardiac diseases.  
 
Regarding the four main coronary arteries which have been measured in this chapter, 
the higher SUVmax was measured in the RCA followed by the LCA then CA and LAD 
(1.68 ± 1.04, 1.57 ± 0.59, 1.18 ± 0.05, and 1.12 ± 0.35, respectively). Dweck et al. 148 
measured SUVmax and TBRmax in the RCA, LCA, CA, and LAD for 119 volunteers 
(age ± SD; 72 ± 8 years old) with and without aortic valve disease who underwent 18F-
NaF PET/CT. Dweck et al. reported the SUVmax of RCA, LCA, CA, and LAD to be 
1.27 ± 0.41, 1.36 ± 0.4, 1.32 ± 0.46, and 1.38 ± 0.42, respectively. Interestingly, the 
mean SUVmax and TBRmax for the average four coronary arteries in that study reported 
being 1.56 ± 0.5 and 1.59 ± 0.48, respectively, which was very similar to the mean 
SUVmax and TBRmax for the average four coronary arteries of the AKU patients in this 
chapter, which had SUVmax of 1.39 ± 0.45 and TBRmax of 1.80 ± 0.8. In another study 
reporting coronary arteries SUVmax, Blomberg et al. and his co-workers 
154 evaluated 
18F-NaF uptake in 89 healthy patients who been imaged by different PET/CT scanners, 
and they found that average coronary arteries SUVmax were 3.75 ± 0.91, which was 
higher than AKU patients here.  
 
In the current study, descending aorta  SUVmax values were higher than ascending aorta 
values (2.06 ± 0.84 and 1.78 ± 0.57, respectively), the same findings with almost 
similar values to those reported in both Dweck et al. 148 and Derlin et al. 155 studies. 
On the other hand, the descending aorta TBRmax was 3.03 ± 1.74 in AKU patients 
compared to ascending aorta value, which was 2.31± 1.06. This data is slightly higher 
than that reported in Derlin et al. 155 where he found that DA TBRmax was 2.06 ± 0.35 
and AA was 2.01 ± 0.3, and also in Li et al. 147 who found that DA TBRmax was 1.57 
± 0.56 and AA was 2.0 ± 0.72. The results of this chapter revealed that SUVmax of the 
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aorta at both AA and DA regions for those patients with AKU were similar to the 
general population subjects, which have been published in the literature. This finding 
suggests that generalised rates of microvascular calcification in AKU and general 
population patients are very similar, reflected by arterial 18F-NaF uptake.  
 
From Figure 6.3 and Figure 6.11, 18F-NaF introduced by SUVmax and TBRmax in the 
aortic artery were higher than those measured in coronary arteries. Li et al. 147 and 
Dweck et al. 148 reported the same finding in their studies. In contrast, Blomberg et al. 
154 found different results in regard to the differences between coronary and aorta 18F-
NaF uptake. He found that coronary arteries had slightly higher SUVmax than the 
ascending aorta and descending aorta (3.74 ± 0.91, 3.32 ± 1.17 and 3.22 ± 0.88, 
respectively). In the current study, coronary arteries and aortic artery data were 
significantly lower than the previously published study. The possible explanation for 
this is that there were no active calcified regions, so there were few -18F binding sites 
to bind with 18F-NaF. Blomberg et al. found that both blood activity and the PET/CT 
system had a significant effect on the 18F-NaF uptake measurements. In that study, a 
higher uptake was detected in patients who were imaged by Discovery 690/710 than 
those imaged by Discovery STE, VTC or RX. So, the differences in the values between 
the data in the literature and the current study could be due to the different PET/CT 
systems which have been used.   
 
In general, less observation of calcification in coronary arteries compared to the aorta 
may be due to a few possible reasons. First of all, PET scanners have a limited spatial 
resolution, which could reduce the sensitivity to evaluate 18F-NaF uptake in small 
arteries. Secondly, both cardiac and respiratory movements can further decrease the 
sensitivity of PET scans in the detection of small arteries. Another possible reason may 
be correlated with the partial volume effect, which interferes with evaluating the small 
size of the ROI. Anatomically, the proximal coronary arteries are surrounded by 
vascular structures, such as the heart valves, aorta, and pulmonary artery. These areas 
are highly susceptible to calcium deposition, which can easily affect the interpretation 
of radiotracer accumulation in coronary arteries. Generally, aortic calcification has 
been found to have high specificity in recognising severe coronary atherosclerosis in 
coronary artery disease patients 187. Several studies suggested that cardiac calcification 
is more detectable in the aorta than coronary arteries because of its higher prevalence 
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and earlier onset 187. Although no control patients have been analysed in this chapter, 
there is a high probability that AKU patients have higher cardiovascular 18F-NaF 
uptake than healthy patients due to ochronosis. Dewck et al. found that patients with 
atherosclerosis had higher 18F-NaF uptake than control patients, describing a 
progressive rise within coronary artery plaques 148.  
 
6.4.2.1 Cardiovascular 18F-NaF uptake and gender  
 
The difference between cardiovascular 18F-NaF uptake between males and females 
was tested. Male AKU patients had higher vascular 18F-NaF uptake compared to 
female patients, demonstrated by  higher SUVmax and TBRmax values at all measured 
coronary arteries and aortic artery. Higher 18F-NaF uptake in cardiac vessels for males 
compared to females was expected due to several reasons. Based on the National 
Cholesterol Education Programme (NCEP), men have a higher risk of developing 
coronary heart disease ten years younger than women 188. Although the difference was 
noted in this chapter, it was not significant in all coronary arteries. Statistically, no 
significant differences in SUVmax values have been identified between males and 
females at most of the coronary arteries except at RCA, where the P-value was 0.022. 
In regard to the TBRmax, there were substantial differences between males and females 
at LAD (P = 0.018), and at RCA only (P = 0.012). No statistically significant 
differences in SUVmax and TBRmax was noted at aortic artery at neither AA nor DA 
between males and females. The possible reason for that could be the odd 18F-NaF 
distribution between the AKU patients throughout the body, which may be correlated 
to specific individual factors. For patients with AKU, cardiovascular calcification may 
be linked to the ochronosis process and pigment deposition in cardiac tissues. The 
gender difference regarding cardiovascular disease for AKU patients is incompletely 
understood. The results from this section suggest that when looking at the overall 
cardiovascular 18F-NaF uptake to assess abnormal cardiac distribution in 18F-NaF 
PET/CT image, gender should not be considered as a direct factor affecting 
cardiovascular uptake in AKU patients. Some published papers argue that aortic and 
coronary calcification is independently correlated with gender. In regard to the 
difference in 18F-NaF uptake among males and females in the arteries, Derlin et al. 155 
reported that the presence of arterial calcification and vascular uptake were more 
present in male patients compared with female patients. However, he pointed out that 
279 
 
this difference was not significant. This finding supports the results of this chapter. On 
the other hand, sex was found to have a significant impact in the cardiovascular 
calcification in elderly patients with severe aortic stenosis 188.  
 
6.4.2.2 Cardiovascular 18F-NaF uptake and age  
 
Regarding age, a slight rise in the 18F-NaF uptake of the average coronary arteries with 
age was observed. From Figure 6.5, and Figure 6.11, age was not statistically 
associated with increased regional SUVmax or TBRmax at LCA, LAD, and CA, in 
contrast to the theory indicating that age is one of the main risk factors for coronary 
artery calcification. Only one coronary artery out of the four measured arteries in this 
study, RCA, had a significant relationship between 18F-NaF uptake and age, showing 
increased coronary arteries SUVmax and TBRmax with age. This result suggests that 
cardiovascular 18F-NaF uptake is not always correlated with age in AKU patients.  
 
In the current study the youngest age group of patients had minimal 18F-NaF uptake, 
having low SUVmax and TBRmax values at all coronary arteries compared with the other 
age groups. The average SUVmax and TBRmax of the coronary arteries were increased 
slightly from 30s to the 60s; however, these increases were only significant between 
the 50s and 60s. The possible explanation for that might be due to the disease stages. 
It is more likely that the vascular calcifications are more common and progress faster 
between 50s and 60s in patients with AKU. 
 
Generally, in the first four decades of life, cardiac vessels are likely to be healthy with 
no abnormal calcium deposition within the cardiovascular system. It seems possible 
that this result was due to a non-pigmented artery and/or non-calcified artery in young 
patients. Therefore, 18F-NaF is rapidly cleared from the blood circulation and 
deposited in calcium-rich tissues, which are usually bone tissues and not a soft-tissues 
or vascular arteries. In young patients, the measured vascular regions expected to have 
low 18F-NaF uptake due to a healthy vascular structure with no calcium deposits, 
therefore no or few 18F-ion binding sites would be available in the vessels. This means 
that these AKU patients with healthy vessels would be more likely have low SUV and 
TBR values. With aging, ochronotic pigment is beginning to build up in all body 
tissues, including cardiac tissues. This deposition is usually linked with calcium 
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deposition in the cardiovascular wall. Due to this, increased 18F-NaF uptake with age 
in the PET image was expected. As explained previously in this thesis, increased 18F-
NaF uptake can be detected in active and ongoing calcified area. It is important to bear 
in mind that the inactive or stable calcified artery may also have significantly low 18F-
NaF absorption. This does not mean that there is no vascular calcification, but that 
means, it may become undetectable by 18F-NaF PET scan. The reason for this 
phenomenon is that 18F- ion is usually bound to newly laid down hydroxyapatite in the 
affected artery, which generally has more binding sites due to the active disease 
processes. Stable and inactive macrocalcifications, which been established months or 
years before, usually have a large volume but small surface area compared to ongoing 
and active microcalcifications, which have a small volume but large surface area 149. 
Since the degree of 18F-NaF absorption depends on the calcification surface area and 
cannot absorb through the outer calcification layer without a deeper penetration, it is 
more likely that 18F-NaF-PET/CT imaging detects microcalcifications only. Therefore, 
in macrocalcifications, 18F-NaF signals are low. Several other researchers reported 
this, resulting in an expanded interest for using 18F-NaF to image the 
microcalcification phase and visualise ongoing mineral deposition in the calcified 
vessels 147,152,153. 
 
Aortic 18F-NaF uptake values, which were measured by SUVmax and TBRmax, were 
also not correlated with age. In contrast, Beheshti et al. found a significant correlation 
between aortic SUVmean and age 
152. The aortic SUV values in Beheshti et al. study 
were 0.72 ± 0.12 for a patient younger than 40 years old, 0.81 ± 0.06 in 40s years old 
patients, 0.86 ± 0.07 in 50s years old patients, and 0.99 ±  0.03 in patients more aged 
than 60, whereas in this chapter, the result was significantly higher. In the current 
study, the aortic SUV values were 1.73 ± 0.52, 2.00 ± 0.93, 2.28 ± 0.78 and 2.15 ± 
0.98 for 30s, 40s, 50s, and 60s, respectively. Although Beheshti et al.’s research 
indicated a relationship between age and aortic calcification, which contrasts with the 
current findings, the differences may be due to several reasons. First of all, Beheshti 
and his co-workers measured mean SUV values, while here, the maximum SUV has 
been measured. The second significant difference between the two studies was the 
patients tested; Beheshti et al. evaluated the cardiovascular uptake for cancer patients, 
while in this study, AKU patients were evaluated. So, the pathological differences 
between cancer and AKU may cause those differences. Derlin et al. 155 also found that 
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both arterial calcification and 18F-NaF accumulation was significantly associated with 
age. Although the early results are difficult to compare due to differences in inclusion 
criteria, the literature can provide us with approximate average 18F-NaF uptake values, 
which can be useful for co-localisation of radiotracer uptake and calcification, 
specifically in patients at high risk of developing cardiac diseases such as AKU 
patients.  
 
6.4.3 Increased HUmean in the cardiovascular system 
 
In the CT images, white spots were clearly noted in the heart region for many of the 
SONIA 2 patients, which indicates a structural macroscopic arterial calcification. CT 
images visually pointed out the presence of a calcified vessel, defined as high-density 
mural regions. Based on the measured attenuation coefficient values from coronary 
and aortic arteries areas, HU values were significantly higher than what would be 
expected from soft tissues and healthy vascular tissues. To our knowledge, this is the 
first study in which CT images have been used to quantify regional cardiovascular 
involvements in AKU patients by measuring HU from main arteries, making the 
results of this section in this thesis novel. 
 
It was clear from the data that in the average measured coronary arteries and aortic 
artery, HUmean were higher than 130 HU. Regionally, the HUmean for AKU patients 
exceeded 115 in all coronary and aorta arteries. A study by Allison et al. 188 defined 
coronary calcification as a plaque with a density of more than 130 HU and an area 
larger than 2 pixels (0.67 mm2) from the electron-beam computed tomography (EBCT) 
image. Derlin et al. 158 also defined calcified plaques in the wall of arteries from 
PET/CT studies, having high-density mural areas with HU higher than 130. The 
maximum HU in some AKU patients involved in this study exceeded 700 HU, 
indicating severely calcified vessels. The minimum HU for some of the measured 
arteries was below zero, which indicated fat present in the blood vessels. In regard to 
the coronary arteries, the highest HUmean value was measured from RCA, which 
matched with the previous SUVmax and TBRmax findings. In contrast to the results in 
SUVmax and TBRmax, HUmean of coronary arteries was almost the same as HUmean of 




6.4.3.1 Cardiovascular HUmean and gender  
 
This study demonstrated that male AKU patients have higher HUmean than female AKU 
patients at all measured coronary arteries; however, this was not statistically significant 
(P > 0.05). A possible reason for that could be that men generally have a higher risk 
of coronary heart disease than women 188. Therefore, male patients have denser arterial 
walls due to increased calcium deposition in the vessel walls, which begin as a plaque 
with high HU. Allison et al. 188 tested risk factors that strongly correlate with prevalent 
coronary artery calcification for 6086 consecutive patients. In that study, they found 
that coronary calcium score, which had been measured from EBCT for the male 
patients, was higher than female patients, with evidence of having a more substantial 
amount of plaque appearing at an earlier age. To avoid other risk factors contributing, 
Allison and co-workers adjusted other cardiovascular risk factors such as age, 
cholesterol levels, smoking, hypertension, and diabetes, and the same finding was 
reached. Although the previous study was designed differently from the current study, 
similar outcomes were noted where male AKU patients tend to have higher HU values 
than female patients. Another study done for very elderly patients found that male 
patients had significantly higher coronary artery calcification and aortic valve calcium 
than female patients 189. Raggi et al. reported that female patients had lower 
calcification scores and a lower prevalence of coronary calcification than men (P < 
0.0001) 190. However, he found higher cumulative risk-adjusted mortality at five years 
for women than men despite controlling for other risk factors such as age, 
hypertension, and diabetes mellitus. 
 
As presented in 18F-NaF uptake section, males had higher SUVmax and TBRmax in 
coronary and aortic artery than females. Likewise, coronary arteries had higher HUmean 
values for male patients compared to female patients. In contrast to 18F-NaF uptake 
findings, aortic arteries had higher HUmean values for female patients compared to male 
patients. The possible explanation for that could be due to the mechanism of 






6.4.3.2 Cardiovascular HUmean and age 
 
In regard to age, the results describe a rise in HUmean value measured from coronary 
arteries and aortic artery with age, as shown in Figure 6.18 and Figure 6.19. The current 
study found that age was positively correlated with vascular HUmean values at most of 
the ROIs. Consistent with findings published by Allison et al. 188, which demonstrated 
age-associated coronary calcification measured by EBCT, which showed increased 
HU values at the calcified arteries with age. In that study, quantitative values measured 
from CT showed a significant correlation between age and Coronary Calcification 
Score (CCS) for both genders. The positive trend between age and CCS in that study 
was twice that of the next most significant correlation between CCS and body fat. 
Additionally, Allison et al. 188 noted that patients under 45 years old were not 
exhibiting any calcified plaques, and their EBCT test was negative. 
 
On the other hand, Hwaida et al. 191 investigated the presence of vascular calcifications 
for 40 AKU patients who underwent non-contrast CT scans. In that study, it was found 
that the prevalence of vascular calcifications was significantly increased with age. 
These results supported the findings in this study showing a clear positive trend 
between non-contrast CT results and age in AKU patients. In general, age is one of the 
cardiovascular risk factors which cause calcium deposition in the arterial wall.  
 
6.4.4 Relationship between 18F-NaF uptake and calcification noted in CT images 
 
The current study found that the results of PET and CT may vary such that the 
abnormality may be only visible in either PET or CT image depending on the 
calcification stage, as shown in Figure 6.25 and Figure 6.27. In the early calcification 
stage, 18F-NaF uptake was noted in the PET image with no apparent calcification in 
the CT image. The 18F-NaF activity was pointed out in some ROI, with no abnormal 
calcification signs observed in the CT image, as shown in Figure 6.25. In contrast, in 
stable macrocalcification, evident of vascular calcification was noted in the CT image 
without unusual 18F-NaF activity in the PET image, as shown in the AA area in Figure 
6.27. In advanced cases with very severe calcified plaques, intense 18F-NaF activity 
was noted in the affected regions overlaying and adjacent with existing extensive 
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calcification in the CT image, which was observed in fused the 18F-NaF PET/CT image 
as abnormal tracer distribution having bone-like intensity in calcified vessels. 
 
These results suggested that the relationship between CT and PET images may not 
always be perfectly matched and correlated. This finding broadly supports the work of 
other studies in this area, demonstrating the mismatch between 18F-NaF PET and CT 
images 148,149,155,157. In fact, the mismatch between the two modalities might be 
expected due to the calcification stage, whether it is active or inactive. This finding 
was previously reported by Thang et al. 157 who evaluated 18F-NaF PET/CT images to 
investigate vascular calcification in carotid plaques. The correlation between 18F-NaF 
uptake and HU was tested in that study, and they found no clear relationship between 
the TBRmax and HUmean (P > 0.05). Also, Derlin et al. 
155 did not find a significant 
correlation between SUVmax measured in PET images and the calcification score 
measured from the CT scan. In another study done by Dwech et al. 148, he noted that 
41% of his patients with high coronary calcium score (CAC >1000), had no significant 
increased 18F-NaF activity; in addition, high activity has been observed in an area 
remote of calcification on CT image. In contrast, Li et al. 147 reported a strong 
correlation between 18F-NaF and CT calcification in most of the coronary and aortic 
arteries, except in the abdominal aorta.  
 
The previous results supported the findings in the current chapter which can be 
explained by the fact that 18F-NaF binds to active microcalcification areas, which can 
be observed in PET images; in contrast, in CT image, inactive macrocalcification and 
stable calcification can be detected. Therefore, due to the difference in the calcification 
stages, mismatch results between PET and CT would be possible and expected. Irkle 
et al. 149 also reported that 18F-NaF PET/CT imaging could distinguish between 
microcalcification and macrocalcification areas in carotid plaques. In that study, 18F- 
NaF was strongly dependent on the surface area of calcification, as large 
microcalcification areas showed high 18F-NaF uptake, in contrast to small 






6.5 Summary  
 
Ochronotic pigment can affect all human tissues, including blood vessels causing 
calcium deposition within the cardiovascular system. This research sheds new light on 
detecting early stage of vascular calcification in AKU patients using advanced 
molecular imaging modalities. 18F-NaF is a promising imaging biomarker for in vivo 
quantification and identification of calcified vessels which could be associated with 
ochronosis in AKU patients. 18F-NaF PET/CT identified the presence and the extent 
of calcium deposition in the coronary arteries in SONIA 2 patients without adding 
extra cost or radiation. Additionally, 18F-NaF PET/CT could distinguish between 
ongoing/active calcification process and those stable or structural calcification which 
may be established months or years before. In PET images, active and ongoing 
calcification was detected as an area of increased 18F-NaF uptake, while in the CT 
image, stable and inactive calcified vessel was detected as a dense area having bone-
like intensity. 
 
Overall, this study considers a snapshot of the key characteristics of cardiac 
calcification in AKU patients, which would guide further longitudinal study. 
Identifying cardiac involvements at its early stage would educate the patients and 
clinical staff about symptoms and regular follow-up care. Future studies investigating 
cardiovascular involvements in AKU patients would be very interesting to develop a 
deeper understanding of the relationships between ochronosis and cardiovascular 




Several limitations to this study need to be acknowledged. First, the 18F-NaF PET/CT 
image was scanned for detecting abnormal bone and joint regions and not for cardiac 
investigation; therefore, the images were not optimised with ECG gating. The degree 
of calcification may significantly be underestimated due to respiratory and cardiac 
motion, which can easily blur the coronary and aortic calcifications. Second, 
intraobserver and interobserver reliability and agreement were not tested due to time 
limitations. Third, this study was limited by the absence of non-AKU controls; 
therefore, the comparison between AKU patients and healthy patients without 
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coronary artery disease was not tested. Finally, since there are many cardiac risk 
factors such as obesity, smoking, dyslipidaemia, diabetes, cholesterol levels, and 
hypertension, the impact of these factors in AKU patients was not investigated. These 
traditional risk factors may increase calcium deposition in the vessels, which might 
influence the 18F-NaF uptake in PET images and HU in CT images.  
 
6.7 Future work  
 
In terms of directions for future research, a number of studies are strongly 
recommended. It would be important to correlate the semiquantitative results from 18F-
NaF PET/CT scan with different clinical outcomes such as HGA level, ECG changes, 
and cardiac ultrasound, which could provide a better link between increased tracer 
uptake and/or present of calcium in the vascular wall and the disease progression in 
AKU patients. It is strongly suggested that intraobserver and interobserver reliability 
is tested in the future studies, to support the methods which have been used here. It 
would be intresting to compare the cardiovascular structures of non-AKU patients with 
AKU patients to better understand the natural history of AKU. Also, a larger sample 
size at each age group would help to determine the peak age where the 
microcalcification could be built up in AKU patients. Another possible area of future 
research would be to investigate the impact of nitisinone in calcified vessels for 
SONIA 2 patients. The longitudinal changes in cardiovascular quantitative values over 
a long time period would be an interesting area to consider in order to assess disease 
progression and early treatment response. 
 
6.8 Conclusion  
 
This chapter has shown: 
 
 That the presence and extent of calcium deposition in the cardiac vessels can 




 Increased and intense focal tracer uptake at the cardiovascular regions in 18F-
NaF PET images reflected the early stage of microvascular calcification in 
AKU patients.  
 The same mechanism that underlies the 18F-NaF uptake in osseous tissue also 
occurs in the calcified vessels due to the strong biological similarities between 
vascular calcification and bone formation. 
 Although the SUVmax and TBRmax at the average four coronary arteries 
increased from the youngest age group patients to the eldest age group of 
patients, it was statistically significant between the 50s and 60s age groups of 
patients only.  
 An inactive calcified vessel identifies as an area of high HU value in CT image 
reflecting structural macrocalcification and plaque stability. 
 HUmean values were positively associated with age in most of the cardiovascular 
ROIs. 
 There were no statistically significant differences in HU values and 18F-NaF 
uptake between males and females across most of the cardiovascular ROIs in 
























This is the final chapter of the thesis, which will draw together the implications of the 
findings from the studies presented here. It will provide an overview of the main 
findings from the previous chapters in the light of the literature reviewed and the 
current knowledge, and examine and interpret key methodological strengths and 
limitations. This discussion chapter will show the unique contributions made by this 
thesis, reflect on the overall implications of these findings for future research and 
practice, and finally present an overall conclusion.  
 
7.1 Discussion  
 
This thesis has addressed four main questions, each investigated in one of the main 
result chapters. The specific questions are: 
 
 Whether 18F-NaF PET/CT scan can be used to assess and identify early 
regional bone formation for patients with AKU by measuring HUmean from CT 
and SUVmax from PET. 
 Whether there is a link between structural disc changes in MRI and increased 
18F-NaF uptake in PET images measured from lumbar disc units. 
 Whether 18F-NaF PET/CT can be used to assess the disease progression and 
evaluate the treatment response in the long term.  
 Whether 18F-NaF PET/CT can be used as a cardiovascular imaging biomarker 
to identify early cardiovascular calcification and assess future cardiovascular 
risk in AKU patients. 
 
The work presented in this thesis demonstrates the most comprehensive imaging 
investigation for patients with AKU to date, which has played a key part in growing 
our awareness of the natural history of AKU. In this thesis, the quantitative data 
achieved from 18F-NaF PET/CT images contributes in several ways to our 
understanding of AKU disease progression. The thesis was undertaken to investigate 
the utility of 18F-NaF PET/CT as a molecular imaging biomarker for detecting and 
identifying the early stages of bone turnover, early disc degeneration, early stages of 
microvascular calcification, and to evaluate the therapy response in the long term for 




With respect to the first research question, it was found that 18F-NaF PET/CT scans 
can be used as promising imaging technique to identify early musculoskeletal 
involvements in the lumbar spine and hip regions in AKU patients. In Chapter 3, low 
bone density was detected in the lower spine and hip regions from the CT images, 
indicating that there is a low bone density disorder in AKU patients. Also, high 18F-
NaF uptake was identified at spine and hip regions in AKU, indicating active bone 
turnover at the affected bone area. Although positive focal 18F-NaF uptake and dense 
lesions were visibly observed in PET/CT images, visual assessment is a subjective 
assessment method which mainly depends on the opinion of the assesser. Therefore, 
Chapter 3 tested the use of non-subjective PET/CT assessment methods, which clearly 
defined the boundary between the normal distribution of radiotracer and increased 
uptake in the skeleton. The ROI has been quantified to accurately evaluate the change 
in 18F-NaF uptake that may not clearly be detected by qualitative visual inspection. 
Although there are a number of PET quantitative methods, in this thesis, the data have 
been analysed and quantified using SUV; the most straightforward PET 
semiquantitative method. SUV reliably helped to accurately quantify active bone 
lesions in the lower spine and hip regions. Low SUVmax values and low HUmean in the 
lumbar vertebrae and head of the femur indicated bone loss which may be associated 
with ochronosis in AKU patients. Comparing the results of AKU with the literature 
showed that AKU patients had higher SUV values than the general population. This 
could support the hypothesis that AKU patients have more active bone turnover than 
the general population. 
 
On the question of gender effects, this study found that there was no significant 
difference between the quantitative values measured from males and females, 
suggesting that gender has no significant effect on bone 18F-NaF uptake nor bone 
density values in AKU patients. On the other hand, lumbar HU and SUV values 
significantly decreased with age, indicating reduced active bone turnover and 
decreased bone density and bone perfusion in AKU patients which is likely to also be 
associated with ochronosis.  
 
Regarding the correlation between HU and T-score values, in Chapter 3, a strong 
correlation was noted in the lumbar spine and hip regions. Thus, it can be suggested 
that HU values can be used to estimate BMD. Chapter 3 demonstrated that a CT scan 
291 
 
in a hybrid PET/CT system could be used as a valuable diagnostic tool to predict bone 
and bone-related disorders associated with low bone density. In fact, the quantitative 
data extracted from CT images was employed to predict osteoporosis using data which 
was available but rarely used for that purpose. The methods which have been proposed 
in Chapter 3 to measure regional bone density is a novel quantitative method that is 
generalisable. This method can be adopted for any other group of patients without 
exposing them to extra radiation when CT scans have been performed for other 
reasons. This would help to predict early fracture risk to high risk patients. The 
substantial evidence in the literature supports that HU measurements generated from 
diagnostic CT images may be utilised as a useful tool for determining regional bone 
density, therefore estimating early fracture risk. As pointed out, spinal DEXA 
measurements are influenced by severe disc calcification in AKU patients, and the 
results may not reflect a true representation of bone density. Some evidence suggests 
that quantitative CT can be used instead of DEXA to assess spinal density, although 
further work using this technique is required to confirm this finding. At this time, it 
may too soon to say that HU values can be a replacement for the gold standard bone 
mineral density measurements, which is clinically generated from the DEXA scan. 
Furthermore, the results in Chapter 3 provided a moderate correlation between lumbar 
HU and SUV values, suggesting further investigation to approve or reject the 
correlation between 18F-NaF PET and CT findings. 
 
The second question in this study sought to determine the link between structural disc 
changes and molecular changes in the intervertebral disc area. In Chapter 4, lumbar 
disc degeneration was identified from functional 18F-NaF PET/CT images and 
anatomical MR images in order to investigate the relationships between the 18F-NaF 
uptake and morphological intervertebral disc changes in the lumbar spine. The study 
was designed to detect disc degeneration by measuring SUVmax and Pfirrmann score 
for lumbar disc units from PET and MRI scans, respectively. Chapter 4 shows that 
high-quality molecular imaging modalities such as PET/CT and MRI may help to 
identify early and active bony changes and intervertebral disc degeneration before it 
progresses to severe symptomatic arthritis. Usually, advanced morphological bone 
changes caused by ochronosis and pigment deposition in the disc area may not be 
observed clearly by plain radiography, as most of these features appear in the late 
stages. The results of Chapter 4 reveal that lumbar intervertebral disc degeneration in 
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AKU patients was strongly associated with increased SUVmax in PET images and a 
high Pfirrmann score in MR images. Although male AKU patients had a statistically 
higher Pfirrmann score than the female patients at most lumbar DVUs, gender had no 
significant correlation to the 18F-NaF uptake across the lumbar disc regions, similar to 
that noted in the lumbar vertebrae bodies in Chapter 3.  
 
With regard to the age effect, the results in Chapter 4 indicated a strong correlation 
between age and Pfirrmann score in MRI. The most interesting finding to emerge from 
Chapter 4 is that the values of SUVmax across the lumbar DVUs increased gradually 
with age followed by a decrease in the later years. These results are likely to be related 
to degenerative disc disease progression. There is a high probability that disc 
calcification increased due to ochronotic pigment deposition within the cartilage, 
resulting in increased calcium hydroxyapatite deposition in the IVD area and therefore 
increased SUV values. In the early disc calcification stages,  more binding sites would 
be available to bind with 18F-NaF radiotracer; therefore, high SUVmax would be 
detected. As the disc become more calcified over time, it becomes more stable, and 
less binding sites will be available; therefore, low SUVmax would be detected in elderly 
patients.  
 
In addition, Chapter 4 highlights that several advanced cases had high Pfirrmann 
scores but low SUVmax values. These observations suggest that these advanced cases 
probably had fusion of discs at the interbody lumbar level with inactive calcification 
at DVU. The overlap between disease progression and age leads to fewer free binding 
sites, due to complete disc calcification, inactive calcification, and/or vertebral fusion 
at that stage. These factors may explain the relative correlation between low SUVmax 
values in PET scan and high Pfirrmann scores in MRI.  
 
Looking at the results from Chapter 3 and Chapter 4, it is apparent that the SUVmax 
across all lumbar vertebrae levels and lumbar DVUs of the male group was slightly 
higher than the female group; however, it is somewhat surprising that these differences 
were not statistically significant at most of the individual ROIs. It was expected to 
identify higher values in male patients compared to female patients. In the general 
population, males are more likely to have intervertebral disc degeneration, which 
appears with greater frequency than in females 177. A possible explanation for this 
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might be that females generally weigh less than males, which will cause less pressure 
on the lower spine region. This non-significant result in AKU patients might be related 
to menopause triggers in women, and physical inactivity in men which might have an 
equal effect on losing bone density and developing osteoporosis in both genders. In 
general, degenerative disc changes can be observed in both genders in the literature. 
 
A note of caution is also due here in this thesis since there was no comparison to a 
non-AKU control group. The 18F-NaF uptake in the bony vertebrae and IVD from 
Chapter 3 and Chapter 4 described ochronotic arthropathy in AKU patients; these 
results demonstrating the biochemical alterations of the disease, which cause the active 
bone formation and therefore increase new hydroxyapatite for -18F ion to bind to, thus 
increase SUV measurements in the bone and disc area. It can be assumed that the 
ochronotic pigment deposition within IVD areas could be the major factor causing disc 
calcification in AKU patients, increasing SUV values in the disc area. Also ochronotic 
pigment could alter the bone matrix and interfere with bone metabolism causing bone 
turnover and loss in bone density. Although AKU data in this thesis was not 
statistically compared with non-AKU patients, the initial observations from literature 
and unpublished data (Alawadhi- non-AKU patients from Kuwait) showed that non-
AKU patients tend to have lower SUV values in bony vertebrae and IVD areas than 
AKU patients. These findings suggest that AKU patients are more likely to have 
advanced spinal arthropathy than the general population. What is now needed is a 
further study to establish whether these differences between AKU and the general 
population are statistically significant or not.  
 
The third question in this research was whether 18F-NaF PET/CT can be used to assess 
the progression of the disease and assess the response of treatment in the long term for 
AKU patients. Chapter 5 was designed to determine the effect of nitisinone in AKU 
patients over four years by evaluating the changes in HUmean and SUVmax values 
measured from lumbar vertebrae and intervertebral disc units. At the beginning of the 
SONIA 2 trial, nitisinone had not yet been licensed to treat AKU, so this study aimed 
to detect the efficacy and effectiveness of nitisinone in AKU patients. Investigating 
the changes in bone and cartilage tissues over the years was one of the critical points 
which would strongly confirm or reject the efficacy of nitisinone in ochronotic 
arthropathy. Prior to the studies in this thesis, it was difficult to make an accurate 
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prediction about how nitisinone can treat or prevent the ochronotic arthropathy for 
those AKU patients treated with nitisinone for four years and whether there is a 
different response between AKU patients.  
 
The results in Chapter 5 shows no clear trend in HUmean nor SUVmax over the visits in 
neither the treatment nor non-treatment AKU groups. This also accords with SONIA 
2 final analysis scans results, which showed that there were no significant differences 
in scintigraphy, MRI nor DEXA results between treatment and non-treatment groups. 
Comparison of the findings in this thesis with those of the final trial analysis confirms 
that nitisinone may not have direct impact on bone or cartilage. It was surprising that 
the treatment group trends did not differ significantly from those in the non-treatment 
groups. The reason for this is not clear, but it may be related to several possibilities. 
First, nitisinone might slow the progression of the ochronosis by stopping further 
pigmentation, but it is unlikely to reverse ochronosis or treat the severe damage which 
has been caused by ochronosis, specifically in the lumbar spine. Second, it is probable 
that the chosen spinal regions may not represent the overall bone change among the 
whole skeletal sites.  
 
Although Chapter 5 did not confirm the positive impact of nitisinone in the spine for 
AKU patients, it enhanced the understanding of disease progression over four years. 
The results raise the possibility proposed that four years of taking nitisinone may not 
be long enough to reveal bone and cartilage changes in the spinal tissues. Since the 
biochemical efficacy had been confirmed previously by noting significant plasma and 
urine HGA reductions after receiving oral administration of nitisinone, it is probable 
that the clinical efficacy needs more time to be noticeable in bone. Therefore, it is 
likely that further investigation is required in order to assess the longer-term impacts 
of nitisinone in reducing arthritis features for AKU patients to establish the 
effectiveness of treatment.  
 
Cardiac and vascular calcifications were incidentally noted on 18F-NaF PET/CT scans 
in AKU patients who enrolled in SONIA 2 trial while evaluating bone and joint 
involvements in the previous studies. From this point, the aim of last study was to 
identify and quantify early cardiovascular calcification, allowing more in-depth insight 
into cardiac involvement in AKU patients without adding another dose of ionising 
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radiation to those patients. Chapter 6 found that 18F-NaF PET/CT is a potential 
application which can provide novel function and structure information about vessels 
at no additional cost. 18F-NaF was found to be a promising imaging biomarker for 
identifying and quantifying calcified vessels which could be associated with 
ochronosis in AKU patients. The vascular calcification appeared as a dense area in CT 
scans and focal hot spot area in 18F-NaF PET images. In recent years, 18F-NaF has 
been proposed as a sensitive imaging marker to identify early vascular calcification 
and has been developed for non-invasive coronary artery assessment in a promising 
way. This is possibly due to the strong biological similarities between bone formation 
and vascular calcification. The main structural component in both events is 
hydroxyapatite. Thus, this could likely mean that the mechanism of 18F-NaF 
absorption by osseous tissues is also found in the calcified vessels.  
 
In Chapter 6, the degree of coronary and aortic calcification was quantified by 
measuring SUVmax, TBRmax, and HUmean values from 
18F-NaF PET/CT images in order 
to define early features of cardiovascular ochronosis in main coronary and aortic 
arteries. High SUVmax, TBRmax, and HUmean values were detected from cardiovascular 
regions indicating vascular calcification in AKU patients. Although the coronary and 
aortic stenosis mechanism in AKU patients remains unclear, previous studies have 
identified pigment accumulation in various body tissues, including cardiovascular 
system tissues. The pigmentation pattern in the regions of higher pressures or 
turbulence indicates significant microvascular damage which introduces an optimal 
focus for HGA deposition. Damage linked to pigment tends to predispose the tissue to 
dystrophic calcification, even if these processes are not well understood. The most 
often diagnosed cardiac abnormality in AKU patients includes calcified aortic stenosis, 
for which patients often need a valve replacement. Early identification of 
cardiovascular calcification in AKU patients would prevent severe symptomatic 
cardiac disease and surgical complications. Therefore, early detection of these 
calcified vessels using a sensitive microcalcification marker would significantly 
benefit this area of research.  
 
The findings in Chapter 6 indicate that neither gender nor age correlated directly to the 
degree of cardiovascular calcification in AKU patients. This outcome is contrary to 
the theoretical notion indicating that age is one of the significant cardiovascular risk 
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factors, which is most likely linked with the severity of cardiovascular calcification. 
Several possible reasons can explain this finding. In the early stage of microvascular 
calcification, calcium starts to build up in the vessels wall, resulting in increased 
calcium hydroxyapatite crystals. Therefore, more -18F binding sites would be available 
in the vessels to bind with 18F-NaF radiotracer. In the case of active and ongoing 
vascular calcification, high SUVmax and TBRmax values would be expected. By time, 
active vascular calcification becomes inactive and stable, less binding sites are 
available resulting in low SUVmax values. Another possible explanation for this is that 
18F-NaF cannot effectively identify macrocalcification because in the advanced 
calcification phase, hydroxyapatite is distributed deeply within vascular layers, and 
18F-NaF cannot penetrate deeper into vascular tissues. This can explain the statistically 
significant differences in the average coronary arteries 18F-NaF uptake between the 
50s and 60s age group patients only. These interesting results suggest that the level of 
cardiac vessel calcification is strongly related to individual cases in AKU patients. 
Therefore, it is indicated that the level of calcified deposition on the vascular walls in 
AKU patients depends on disease progress and disease stage. 
 
The study done in Chapter 6 adds to the growing body of research by revealing a 
sensitive technique which could prevent the evolution of cardiac events by detecting 
early microvascular calcification using 18F-NaF radiotracer. The novel assessment 
methods used here to analyse the main cardiac vessels in AKU patients may be applied 
to other patients elsewhere who underwent 18F-NaF PET/CT for other reasons that 
include the heart area. In fact, 18F-NaF PET/CT scans can be used for the retrospective 
and prospective interpretative investigation of calcified vessels and predict the early 
stage of cardiovascular calcification without additional radiation exposure or cost. 
Additionally, other bone radiotracers such as 99mTc-MDP can also be adapted to 
identify vascular calcification for those patients who had 99mTc-MDP or 99mTc-HMDP 
bone scintigraphy instead of 18F-NaF PET/CT. 
 
7.2 Limitations   
 
The generalisability of this thesis is subject to a number of certain limitations. First, 
being limited to only one or two skeletal sites, this study lacks general progression for 
the entire skeleton. It is possible that the changes in 18F-NaF uptake and bone density 
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in the lower spine does not accurately reflect the changes in the whole skeleton. 
Second, the most significant limitation lies in the fact that interobserver and 
intraobserver reliability of the measurement values have not been tested due to limited 
time and clinical collaboration. There are obvious difficulties in accepting the 
reliability of self-reported information or single observer findings. Third, 18F-NaF 
PET/CT images were not designed to be used for cardiac investigation; therefore, the 
images have not been optimised by ECG gating or motion correction. Another major 
source of uncertainty in the data used to assess the progression of the disease and 
evaluate the response to treatment in Chapter 5 is that not all of the patients had all 
five serial scans making those unmeasured data sources of error. Finally, the thesis is 
also limited by the lack of a control non-AKU group; therefore, statistically comparing 
the values and evaluating the differences between the general population and AKU 
patients was not possible. Notwithstanding these limitations, this work offers valuable 
insights into the use of novel 18F-NaF PET/CT semiquantitative methods.  
 
7.3 Future work  
 
Despite these promising results, which were presented within this thesis, several 
questions remain unanswered at present. Therefore, it is recommended that further 
research be undertaken in the following areas: First, clinical investigation using a 
larger sample size would be required to support the findings which were reported in 
this thesis. Second, the proposed methods which have been introduced here in this 
thesis needs to be applied to different skeletal sites such as the cervical spine, thoracic 
spine, shoulder or knee. It would be interesting to know the results from other body 
sites and compare them with lumbar and hip results. Third, it would be very important 
to test the interobserver and intraobserver reliability of the measurement values. In 
fact, good and excellent interobserver and intraobserver agreement would strongly be 
relevant in deciding the correct prognosis, treatment, and follow up strategy. Fourth, 
investigating the longitudinal changes in cardiovascular measurements for SONIA 2 
patients is an important area for future research to evaluate disease progression over 
time. Finally, it would also be interesting to know the bone and joint progression over 
time in the general population and compare it with AKU patients in the SONIA 2 trial. 
Therefore, an additional investigation would be designed to examine the changes in 
18F-NaF PET/CT quantitative values for non-AKU patients over time. This 
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longitudinal comparison between non-AKU and AKU patients would be useful as it is 
highly expected that the non-AKU group will show the typical changes in bone density 
and 18F-NaF uptake over the years, while the AKU patients will show the disease 
progression. 
 
7.4 Conclusion  
 
In conclusion, this thesis contributes significantly toward the validation of 18F-NaF 
PET/CT as a sensitive and accurate molecular imaging biomarker for identifying and 
quantifying bone, disc and cardiovascular involvements in patients with AKU. The 
present studies support further investigations, which convey the metabolism of 
ochronotic arthropathy and cardiovascular ochronosis in patients with AKU. These 
studies establish a quantitative framework for detecting early bone turnover, early disc 
calcification and early microvascular calcification in AKU patients. Although the data 
presented here have not confirmed the positive effect of nitisinone in the spine for 
AKU patients, it enhanced our understanding of the natural history of AKU. This new 
understanding should help to improve predictions in the disease progression and the 
impact of therapy in AKU patients. 
 
Furthermore, this thesis proposes novel 18F-NaF PET/CT semiquantitative imaging 
methods using widely available data that is rarely used to identify co-existing 
pathology without additional radiation exposure or cost. These applications could 
serve as diagnostic tools for detecting regional bone density and early cardiovascular 
calcification when 18F-NaF PET/CT is undertaken for other purposes, notifying and 
guiding the clinicians to initiate additional investigation on those who otherwise are 
not suspected of metabolic bone or cardiac disorders. Future investigations are 
required to confirm and validate the findings and build up the full picture of the 
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9 Appendix  
9.1 Bone involvement results from the lumbar spine and femoral head site 
 
Table 9.1. Gender difference in the severity of lower spine and hip degeneration 
measured from baseline CT scans for 39 AKU patients who were part of the SONIA 2 
clinical trial.  
The results display HUmean ± SD, minimum, and maximum values at each lumbar vertebra 
body from L1 to L5, and head of the femur, for male and female patients. * Correlation is 
statistically significant between gender at the ROI (P < 0.05). L1- first lumbar vertebrae, L2- 
second lumbar vertebrae, L3- third lumbar vertebrae, L4- fourth lumbar vertebrae L5- fifth 
lumbar vertebrae, L1-L5 average lumbar vertebrae, RT F- right head of the femur, LT F- left 






Minimum Maximum  P-value 
L1 
Total 38 139.94 ± 60.06 -7.00 239.00   
M 23 138.25 ±57.00 2.00 239.00 0.83 
F 15 142.52 ±66.47 -7.00 221.00   
L2 
Total 39 141.22 ±63.85 9.00 310.00   
M 24 133.02 ±54.66 32.00 213.00 0.32 
F 15 154.33 ±76.54 9.00 310.00   
L3 
Total 39 133.06 ±53.67 15.00 209.00   
M 24 130.05 ±52.56 22.00 209.00 0.66 
F 15 137.87 ±56.91 15.00 205.00   
L4 
Total 39 146.04 ±61.92 27.00 236.00   
M 24 145.31 ±63.56 28.00 236.00 0.93 
F 15 147.22 ±61.37 27.00 222.00   
L5 
Total 39 182.41 ±64.95 55.00 390.00   
M 24 183.87 ±69.80 66.00 390.00 0.86 
F 15 180.08 ±58.62 55.00 285.00   
L1-L5 
Total 39 148.13 ±55.81 26.00 239.00   
M 24 145.46 ±54.33 30.00 239.00 0.71 
F 15 152.40 ±59.77 26.00 221.00   
RT F 
Total 31 235.08 ±59.78 127.91 334.16   
M 19 227.55 ±52.54 143.8 311.52 0.68 
F 12 247.02 ±59.25 127.91 334.16   
LT F 
Total 31 244.42 ±48.98 154.50 348.44   
M 19 230.27 ±46.93 154.50 313.84 0.04* 
F 12 266.84 ±45.20 185.79 348.44   
Average F 
Total 31 240.00 ±50.02 154.00 341.00   
M 19 229.00 ±52.07 154.00 295.00 0.09 
F 12 257.00 ±51.08 178.00 341.00   
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Table 9.2. Differences in R between multiple linear regression analysis and polynomial 
regression in relation to the correlation between age and HUmean obtained from the lower 
spine and femoral sites for 39 AKU patients. 
ROI Linear regression Polynomial 
L1 0.545 0.624 
L2 0.588 0.647 
L3 0.624 0.644 
L4 0.646 0.682 
L5 0.489 0.576 
L1-L5 0.632 0.69 
RT F 0.586 0.586 
LT F 0.366 0.501 





Table 9.3.HUmean measurements at the lower spine and femoral sites for 39 AKU patients 
who were part of the SONIA 2 clinical trial stratified by the decade of life. 
Data display the HUmean ± SD, minimum and maximum values and P-value obtained from the 
baseline CT scan at each lumbar vertebrae level, the mean of the lumbar levels measurement, 
right and left femurs and mean of femurs’ measurements in four age groups. * Correlation is 
statistically significant between age group at the ROI (P < 0.05). 






171.37 ± 25.54 
156.13 ± 50.87 
160.53 ± 42.67 

















184.67 ± 35.70 
173.07 ± 64.54 
126.69 ± 46.87 

















171.31 ± 38.32 
154.36 ± 38.36 
126.30 ± 51.35 

















185.61 ± 38.85 
179.45 ± 44.27 
134.96 ± 60.13 

















196.78 ± 26.90 
224.96 ± 71.99 
173.62 ± 48.80 

















181.95 ± 26.28 
177.59 ± 45.92 
142.44 ± 48.39 

















270.30 ± 42.63 
236.08 ± 38.01 
215.35 ± 56.14 

















289.79 ± 36.32 
223.58 ± 50.15 
242.31 ± 47.44 

















280.05 ± 38.68 
229.83 ± 42.36 
224.77 ± 50.71 















Table 9.4. Gender difference in the severity of the lower spine and hip degeneration 
measured from baseline 18F-NaF PET scan for 39 AKU patients who were part of the 
SONIA 2 clinical trial.  
The results display mean SUVmax ± SD, minimum, and maximum values at each lumbar 
vertebra body from L1 to L5, average lumbar vertebra levels (L1-L5), and head of the femur 
(right, left, and average sides) for males and females patients. No statistically significant 
differences in SUVmax values been found between male and female at any ROI was found (P 
> 0.05).  
ROI Gender Patient no. SUVmax (mean ±SD) Minimum maximum P-value 
L1 
Total 38 10.19 ± 2.30 3.86 14.84   
M 23 10.68 ± 2.27 4.87 14.07 0.10 
F 15 9.43 ± 2.21 3.86 14.84   
L2 
Total 39 10.67 ± 3.15 5.25 19.93   
M 24 10.97 ± 3.20 6.77 19.93 0.45 
F 15 10.18 ± 3.11 5.25 17.95   
L3 
Total 39 10.08 ± 2.15 5.64 17.24   
M 24 10.45 ± 2.25 6.99 17.24 0.17 
F 15 9.47 ± 1.91 5.64 12.70   
L4 
Total 39 10.59 ± 2.55 4.87 16.50   
M 24 11.06 ± 2.45 7.79 16.50 0.15 
F 15 9.84 ± 2.61 4.87 14.55   
L5 
Total 39 11.15 ± 2.62 6.37 18.98   
M 24 11.43 ± 2.73 7.83 18.98 0.41 
F 15 10.70 ± 2.47 6.37 17.05   
L1-L5 
Total 39 10.54 ± 2.17 5.20 15.91   
M 24 10.92 ± 2.10 7.07 15.91 0.17 
F 15 9.93 ± 2.22 5.20 14.64   
RT F 
Total 31 4.63 ± 2.36 1.90 8.23   
M 19 4.44 ± 1.97 2.55 8.23 0.68 
F 12 4.95 ± 2.06 1.90 8.07   
LT F 
Total 31 4.34 ±1.57 2.35 8.49   
M 19 4.09 ±1.48 2.35 8.49 0.25 
F 12 4.74 ±1.67 2.46 8.23   
Average F 
Total 31 4.50 ±  2.55 2.20 8.36   
M 19 4.28 ± 2.08 2.82 8.36 0.77 







Table 9.5. Differences in R between multiple linear regression analysis and polynomial 
regression in relate to the correlation between age and SUVmax obtained from the lower 
spine and femoral sites for 39 AKU patients. 
ROI Linear regression Polynomial 
L1 0.332 0.44 
L2 0.31 0.338 
L3 0.391 0.405 
L4 0.416 0.528 
L5 0.432 0.508 
L1-L5 0.438 0.51 
RT F 0.219 0.24 
LT F 0.12 0.235 





Table 9.6. SUVmax measurements at the lower spine and hip sites for 39 AKU patients 
who were part of the SONIA 2 clinical trial stratified by the decade of life.  
Data display the SUVmax ± SD, minimum and maximum values and P-value obtained from the 
baseline 18F-NaF PET/CT scan at each lumbar vertebrae level, the mean of the lumbar levels 
measurement, right and left femoral heads and average head of the femur measurement in four 
age groups. * Correlation is statistically significant at the level (P < 0.05). 






































































































































































4.13 ±  2.34 
4.57 ± 1.48 
4.57 ± 1.31 















Table 9.7. Gender difference in the severity of the lower spine and hip degeneration 
extracted from baseline DEXA reports for 39 AKU patients who were part of the SONIA 
2 clinical trial.  
The results show mean T-score ± SD, minimum, and maximum values at each lumbar vertebra 
body, average lumbar levels (L1-L4), and left femoral head for males and females patients. * 
Correlation is statistically significant at the ROI (P < 0.05). At L4, only male patients had 
statistically significant higher T-score values compared to female patients (P = 0.02). 
ROI Gender Patient no. T-Score (mean ±SD) Minimum Maximum P-value 
L1 





M 22 0.93 ±1.86 -2.60 5.30 
F 14 -0.23 ±1.63 -2.70 2.90 
L2 




M 23 0.39 ±1.76 -2.50 4.70 
F 14 -0.17 ±2.06 -3.60 3.60 
L3 




M 23 0.72 ±1.94 -2.78 5.80 
F 14 0.14 ±1.52 -2.60 3.50 
L4 




M 23 1.37 ±1.97 -1.70 5.60 
F 14 -0.22 ±1.76 -3.50 3.40 
L1-L4 




M 23 0.90 ±1.77 -1.60 5.40 
F 14 -0.09 ±1.70 -3.20 3.50 
Femur 




M 22 -1.72 ±0.90 -3.10 0.30 












Table 9.8. Differences in R between multiple linear regression analysis and polynomial 
regression in relate to the correlation between age and T- score obtained from the lower 
spine and femoral sites for 37 AKU patients. 
ROI Linear regression Polynomial 
L1 0.031 0.103 
L2 -0.311 0.159 
L3 -0.158 0.116 
L4 -0.009 0.172 
L1-L4 0.137 0.136 





Table 9.9. T-score measurements at the lower spine and femoral region extracted from 
DEXA reports for 37 AKU patients who were part of the SONIA 2 clinical trial stratified 
by the decade of life. 
Data display the T-score ± SD, minimum and maximum values and P-value obtained from the 
baseline DEXA scan at each lumbar vertebrae level, the average lumbar levels, and femoral 
region in four age groups. * Correlation is statistically significant at the ROI (P < 0.05). 
Statistically, there were substantial differences in T-score value measured from L2 between 
the 50s and 60s age groups only (P = 0.006). 






-0.300 ± 0.876 
0.592 ± 1.750 
1.189 ± 2.267 

















0.129 ± 0.936 
0.825 ± 1.954 
0.860 ± 1.847 

















0.154 ± 0.895 
1.033 ± 2.110 
0.840 ± 1.950 

















-0.300 ± 0.627 
1.350 ± 2.172 
1.380 ± 1.997 

















-0.029 ±  0.732 
1.075 ± 1.992 
1.130 ± 1.857 

















-0.486 ± 1.104 
-1.542 ± 0.812 
-1.880 ± 0.916 
















9.2 Lumbar DVUs results from 18F-NaF PET/CT scan and MRI 
 
Table 9.10. Gender difference in the SUVmax values for lumbar DVUs measured from 
baseline 18F-NaF PET/CT scan for 34 AKU patients (19 males, 15 females) who were part 
of the SONIA 2 clinical trial.  
The results show mean SUVmax ± SD, minimum, and maximum values at each lumbar DVU 
from T12/L1 to L5/S1 level for males and females. * Correlation is statistically significant 
between gender at the ROI (P < 0.05). A significant difference was found between male and 
female at L5/SI only (P = 0.02).  
 





14.38 ± 5.10 
15.85 ± 5.44 













15.84 ± 6.41 
15.67 ± 5.67 













14.78 ± 5.2 
15.46 ± 4.57 













14.23 ± 5.01 
15.21 ± 3.93 













14.46 ± 5.06 
15.83 ± 4.06 













17.11 ± 5.90 
18.87 ± 5.24 














15.12 ± 4.13 
16.15 ± 3.19 
















Table 9.11. SUVmax measurements at the lumbar DVU for 34 AKU patients who were 
part of the SONIA 2 clinical trial stratified by the decade of life. 
Data display the SUVmax ± SD, minimum and maximum values and P-value obtained from the 
baseline 18F-NaF PET/CT scan at each lumbar DVU level, from T12/L1 segment to the L5/S1 
segment in four age groups. * Correlation is statistically significant between age group at the 
DVU level (P < 0.05). 
 
DVU level Age group SUVmax DVU (mean – SD) Minimum Maximum P- value 
T12/L1 
30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
12.72 ± 4.34 
15.66 ± 4.54 
16.49 ± 5.76 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
13.46 ± 4.1 
18.15 ± 7.71 
16.79 ± 5.49 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
13.87 ± 4.71 
19.07 ± 4.79 
12.70 ± 3.28 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
12.26 ± 4.12 
15.65 ± 3.42 
16.42 ± 6.22 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
12.75 ± 4.61 
18.4 ± 4.91 
12.23 ± 3.41 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
12.83 ± 4.45 
19.10 ± 5.08 
18.57 ± 6.11 















30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
12.99 ± 3.92 
17.67 ± 3.97 
15.45 ± 2.65 















Table 9.12. Gender difference in the severity of DVU degeneration measured from 
baseline MRI scan at each lumbar DVU level for 34 AKU patients who were part of the 
SONIA 2 clinical trial stratified by gender.  
The results display the mean Pfirrmann grade ± SD, minimum, and maximum score from six  
lumbar DVU regions from segment T12/L1 to segment L5/S1 for both genders. The results 
show male patients have significantly higher Pfirrmann scoring grade in DVUs than female 
AKU patients. The independent sample t-test revealed statistically significant differences 
between males and females across the lumbar DVUs (P < 0.05) except at L5/S1 (P = 0.07) * 
Statistical significance (P < 0.05).  
 





6.4 ± 2.7 
7.4 ± 1.3 













6.6 ± 2.5 
7.5 ± 1.2 













6.5 ± 2.6 
7.3 ± 1.8 













6.3 ± 2.8 
7.2 ± 2.0 













6.4 ± 2.8 
7.3 ± 1.9 













6.6 ± 2.5 
7.3 ± 1.9 














6.5 ± 2.7 
7.3 ± 1.7 
















38.8 ± 15.5 
43.0 ± 9.5 














Table 9.13. The severity of DVU degeneration measured from baseline MRI scans at each 
lumbar DVU level for 34 AKU patients who were part of the SONIA 2 clinical trial 
stratified by the decade of life.  
The results display the mean Pfirrmann grade ± SD, minimum, and maximum score from six 
lumbar DVU regions from segment T12/L1 to segment L5/S1. * Correlation is statistically 
significant between 30-39 age group and 40-49 age group at all DVU level (P < 0.05). 
 
DVU level Age group Pfirmann DVU (mean±SD) Minimum Maximum P- value 
T12/L1 
30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
3.0 ± 2.7 
6.8 ± 2.5 
7.6 ± 1.0 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
3.6 ± 2.6 
6.8 ± 2.5 
7.8 ± 0.4 












30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
3.1 ± 2.6 
6.8 ± 2.5 
7.6 ± 1.0 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
2.4 ± 2.4 
6.8 ± 2.5 
7.5 ± 1.1 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
2.4 ± 2.4 
6.8 ± 2.5 
7.7 ± 0.5 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
3.1 ± 2.4 
7 ± 2.4 
7.9 ± 0.3 














30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
2.9 ± 2.3 
6.9 ± 2.5 
7.7 ± 0.4 













30-39 years old 
40-49 years old 
50-59 years old 
≥ 60 years old 
17.7 ± 13.6 
41.2 ± 14.9 
46.1 ± 2.6 
















9.4 SONIA 2 finial analysis scan results: osteoarticular disease of joints 
 
Table 9.14. Shows the summary statistics for the number of joints with osteoarticular 
disease detected from scantigraphy throughout the whole body from Visit 1 to Visit 6 for 
169 AKU patients who were part of SONIA 2 clinical.  
Data are summarised by the number of patients (n), mean HU (SD), median (IQR), the 













Baseline n 69  67  
 Mean 6.7  6.1  
 SD 3.2  3.1  
 Median 8.0  6.0  
 min 0  0  
 max 14  14  
Month 12 n 62 62 66 65 
 Mean 6.7 0.0 6.4 0.1 
 SD 3.2 0.4 3.2 0.5 
 Median 7.0 0.0 6.5 0.0 
 min 1 -1 0 -1 
 max 14 2 14 2 
Month 24 n 54 54 62 60 
 Mean 8.4 1.6 8.2 1.9 
 SD 3.3 3.0 3.3 2.8 
 Median 8.0 0.5 8.0 1.5 
 min 1 -4 0 -4 
 max 14 10 14 10 
Month 36 n 52 52 55 53 
 Mean 9.1 2.3 8.4 2.3 
 SD 3.2 3.1 3.5 3.4 
 Median 9.0 2.0 8.0 2.0 
 min 0 -3 0 -6 
 max 14 10 14 11 
Month 48 n 48 48 52 51 
 Mean 9.1 2.1 8.5 2.4 
 SD 3.3 3.1 3.6 3.4 
 Median 9.5 1.5 8.0 2.0 
 min 2 -4 0 -4 
 max 14 10 14 11 
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Table 9.15. Shows the change in the number of joints with osteoarticular disease for 
nitisinone treated AKU patients and untreated patients who were part of the SONIA 2 
clinical trial over four years.  
Data are summarised the change from baseline at each visit for number of joints detected from 







Month 12 Adjusted mean 0.1 0.1 
 95% CI 0.0; 0.2 0.0; 0.3 
 
Adjusted mean (difference 
nitisinone-untreated) 
 0.0 
 95% CI  -0.1; 0.2 
 p-value*  0.576 
Month 24 Adjusted mean 2.0 1.9 
 95% CI 1.2; 2.7 1.2; 2.7 
 
Adjusted mean (difference 
nitisinone-untreated) 
 -0.1 
 95% CI  -1.1; 1.0 
 p-value*  0.893 
Month 36 Adjusted mean 2.1 2.2 
 95% CI 1.3; 3.0 1.3; 3.1 
 
Adjusted mean (difference 
nitisinone-untreated) 
 0.1 
 95% CI  -1.1; 1.3 
 p-value*  0.911 
Month 48 Adjusted mean 2.2 2.1 
 95% CI 1.4; 3.1 1.3; 3.0 
 
Adjusted mean (difference 
nitisinone-untreated) 
 -0.1 
 95% CI  -1.3; 1.1 





Figure 9.1. Changes in the number of joints with osteoarticular disease detected from 
scintigraphy from baseline to month 48 for nitisinone treated and untreated AKU 
patients.  




Osteoarticular Disease of Spine 
 
Table 9.16. Shows the summary statistics for the number of spinal regions with 
osteoarticular disease detected from scantigraphy throughout the whole body from Visit 
1 to Visit 6 for 169 AKU patients who were part of SONIA 2 clinical.  
Data are summarised by the number of patients (n), mean HU (SD), median (IQR), the 












Baseline N 69  67  
 Mean 3.0  3.4  
 SD 2.1  2.1  
 Median 3.0  4.0  
 Min 0  0  
 Max 6  6  
Month 12 N 62 62 66 65 
 Mean 3.0 0.0 3.4 0.0 
 SD 2.1 0.0 2.2 0.0 
 Median 3.0 0.0 4.0 0.0 
 Min 0 0 0 0 
 Max 6 0 6 0 
Month 24 N 54 54 62 60 
 Mean 3.2 0.2 3.5 0.1 
 SD 2.0 1.2 2.0 1.2 
 Median 4.0 0.0 4.0 0.0 
 Min 0 -3 0 -2 
 Max 6 4 6 4 
Month 36 N 52 52 55 53 
 Mean 3.7 0.3 3.7 0.3 
 SD 2.0 1.2 2.0 1.3 
 Median 4.0 0.0 4.0 0.0 
 Min 0 -3 0 -2 
 Max 6 4 6 4 
Month 48 N 48 48 52 51 
 Mean 3.5 0.4 3.7 0.3 
 SD 2.1 1.3 2.0 1.3 
 Median 4.0 0.0 4.0 0.0 
 Min 0 -3 0 -2 




Table 9.17. Shows the change in the number of spinal regions with osteoarticular disease 
for nitisinone treated AKU patients and untreated patients who were part of the SONIA 
2 clinical trial over four years. 
Data are summarised the change from baseline at each visit for number of joints detected from 







Month 12 Adjusted mean 0.0 0.1 
 95% CI -0.2; 0.3 -0.2; 0.3 
 
Adjusted mean (difference 
nitisinone-untreated) 
 0.0 
 95% CI  -0.3; 0.4 
 p-value*  0.831 
Month 24 Adjusted mean 0.3 0.2 
 95% CI 0.0; 0.5 -0.1; 0.5 
 
Adjusted mean (difference 
nitisinone-untreated) 
 -0.1 
 95% CI  -0.4; 0.3 
 p-value*  0.641 
Month 36 Adjusted mean 0.4 0.4 
 95% CI 0.1; 0.6 0.1; 0.6 
 
Adjusted mean (difference 
nitisinone-untreated) 
 0.0 
 95% CI  -0.4; 0.3 
 p-value*  0.965 
Month 48 Adjusted mean 0.4 0.3 
 95% CI 0.2; 0.7 0.1; 0.6 
 
Adjusted mean (difference 
nitisinone-untreated) 
 -0.1 
 95% CI  -0.4; 0.3 







Figure 9.2. Changes in the number of spinal regions with osteoarticular diseas detected 
from scintigraphy from baseline to month 48 for nitisinone treated and untreated AKU 
patients.  




Osteopenia of the Hip 
 
Table 9.18. Shows the summary statistics for femur T-score values measured from DEXA 
scans from Visit 1 to Visit 6 for 169 AKU patients who were part of the SONIA 2 clinical.  
Data are summarised by the number of patients (n), mean HU (SD), median (IQR), the 













Baseline n 64  68  
 Mean -1.26  -1.30  
 SD 0.98  1.20  
 Median -1.25  -1.30  
 min -3.9  -3.5  
 max 1.3  2.8  
Month 12 n 59 59 66 66 
 Mean -1.28 0.03 -1.39 -0.13 
 SD 0.98 0.27 1.14 0.25 
 Median -1.20 0.00 -1.45 -0.10 
 min -3.3 -0.6 -3.4 -1.2 
 max 1.6 1.1 2.5 0.4 
Month 24 n 57 57 63 63 
 Mean -1.29 0.09 -1.37 -0.14 
 SD 0.99 0.32 1.12 0.28 
 Median -1.30 -0.10 -1.40 -0.10 
 min -3.2 -0.6 -3.3 -1.1 
 max 1.6 1.2 2.3 0.4 
Month 36 n 57 57 58 58 
 Mean -1.37 0.07 -1.18 0.01 
 SD 0.89 0.31 1.15 0.39 
 Median -1.40 -0.10 -1.25 -0.10 
 min -3.1 -0.7 -3.4 -0.8 
 max 0.7 0.8 2.5 1.6 
Month 48 n 50 50 53 53 
 Mean -1.41 -0.17 -1.22 0.04 
 SD 0.81 0.35 1.17 0.41 
 Median -1.50 -0.20 -1.30 -0.10 
 min -3.1 -0.8 -3.3 -1.0 
 max 0.2 0.8 2.9 1.6 
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Table 9.19. Shows the change in T-score values for nitisinone treated AKU patients and 
untreated patients who were part of the SONIA 2 clinical trial over four years.  
Data are summarised the change from baseline at each visit for number of joints detected from 







Month 12 Adjusted mean 0.06 -0.15 
 95% CI -0.13; 0.01 -0.21; 0.09 
 
Adjusted mean (difference 
nitisinone-untreated) 
 0.09 
 95% CI  -0.18; 0.01 
 P-value*  0.030 
Month 24 Adjusted mean -0.12 -0.15 
 95% CI -0.20; 0.04 -0.23; 0.08 
 
Adjusted mean (difference 
nitisinone-untreated) 
 0.03 
 95% CI  -0.13; 0.06 
 P-value*  0.490 
Month 36 Adjusted mean -0.10 0.02 
 95% CI -0.20; 0.01 -0.12; 0.07 
 
Adjusted mean (difference 
nitisinone-untreated) 
 0.08 
 95% CI  0.05; 0.21 
 P-value*  0.211 
Month 48 Adjusted mean -0.19 0.05 
 95% CI -0.29; 0.09 -0.15; 0.05 
 
Adjusted mean (difference 
nitisinone-untreated) 
 0.14 
 95% CI  0.00; 0.28 




Table 9.20. Shows the summary statistics for the number of patients with osteopenia of 
the hip detected from DEXA scan from Visit 1 to Visit 6 for 169 AKU patients who were 
part of the SONIA 2 clinical.  
Data are summarised by the number of patients (n), mean HU (SD), median (IQR), the 
minimum and maximum. This table is split by treatment arm and clinical trial visits. 
aOsteopenia/osteoporosis is categorised as Normal (T-score ≥-1.0), Osteopenia (T-score of -2.4 to -1.1) 
and Osteoporosis (T-score ≤-2.5). 
Visit Osteopenia/osteoporosis Untreated Nitisinone 
Baseline N (%) 64 (92.8) 68 (98.6) 
 Normal 22 (31.9) 22 (31.9) 
 
Pts. with osteopenia or 
osteoporosis 
42 (60.9) 46 (66.7) 
 Osteopenia 35 (50.7) 33 (47.8) 
 Osteoporosis 7 (10.1) 13 (18.8) 
 Missing 5 (7.2) 1 (1.4) 
Month 12 N (%) 59 (85.5) 66 (95.7) 
 Normal 18 (26.1) 21 (30.4) 
 
Pts. with osteopenia or 
osteoporosis 
41 (59.4) 45 (65.2) 
 Osteopenia 36 (52.2) 32 (46.4) 
 Osteoporosis 5 (7.2) 13 (18.8) 
 Missing 10 (14.5) 3 (4.3) 
Month 24 N (%) 57 (82.6) 63 (91.3) 
 Normal 18 (26.1) 19 (27.5) 
 
Pts. with osteopenia or 
osteoporosis 
39 (56.5) 44 (63.8) 
 Osteopenia 33 (47.8) 30 (43.5) 
 Osteoporosis 6 (8.7) 14 (20.3) 
 Missing 12 (17.4) 6 (8.7) 
Month 36 N (%) 57 (82.6) 58 (84.1) 
 Normal 18 (26.1) 23 (33.3) 
 
Pts. with osteopenia or 
osteoporosis 
39 (56.5) 35 (50.7) 
 Osteopenia 35 (50.7) 24 (34.8) 
 Osteoporosis 4 (5.8) 11 (15.9) 
 Missing 12 (17.4) 11 (15.9) 
Month 48 N (%) 50 (72.5) 53 (76.8) 
 Normal 15 (21.7) 19 (27.5) 
 
Pts. with osteopenia or 
osteoporosis 
35 (50.7) 34 (49.3) 
 Osteopenia 33 (47.8) 26 (37.7) 
 Osteoporosis 2 (2.9) 8 (11.6) 




Table 9.21. Shows the change in the number of patients with osteopenia of the hip for 
nitisinone treated AKU patients and untreated patients who were part of the SONIA 2 
clinical trial over four years.  
Data are summarised the change from baseline at each visit for number of joints detected from 







n (%) n (%) 
Month 12 Improved by 1 category 3 (4.3) 0 (0.0) 
 Unchanged 49 (71.0) 56 (81.2) 
 Worsened by 1 category 7 (10.1) 10 (14.5) 
 Missing 10 (14.5) 3 (4.3) 
 P-value*  0.226 
Month 24 Improved by 1 category 4 (5.8) 1 (1.4) 
 Unchanged 42 (60.9) 48 (69.6) 
 Worsened by 1 category 11 (15.9) 14 (20.3) 
 Missing 12 (17.4) 6 (8.7) 
 P-value*  0.379 
Month 36 Improved by 1 category 8 (11.6) 4 (5.8) 
 Unchanged 40 (58.0) 48 (69.6) 
 Worsened by 1 category 9 (13.0) 6 (8.7) 
 Missing 12 (17.4) 11 (15.9) 
 P-value*  0.874 
Month 48 Improved by 1 category 4 (5.8) 4 (5.8) 
 Unchanged 34 (49.3) 41 (59.4) 
 Worsened by 1 category 12 (17.4) 8 (11.6) 
 Missing 19 (27.5) 16 (23.2) 







Figure 9.3. Changes in the femoral T-score measured from DEXA scan from baseline to 
month 48 for nitisinone treated and untreated AKU patients.  






Table 9.22. Shows the summary statistics for the number of fractures detected from MRI 
from Visit 1 to Visit 6 for 169 AKU patients who were part of the SONIA 2 clinical. 
Data are summarised by the number of patients (n), mean HU (SD), median (IQR), the 
minimum and maximum. This table is split by treatment arm and clinical trial visits. Change 
from baseline is analysed using a generalised linear mixed model with an underlying Poisson 







Since last visit 
n (%) 









Baseline n 69 69 69 69 
 0 58 (84.1)  54 (78.3)  
 1 8 (11.6)  11 (15.9)  
 2 0 (0.0)  2 (2.9)  
 3 1 (1.4)  2 (2.9)  
 4 0 (0.0)  0 (0.0)  
 5 2 (2.9)  0 (0.0)  
 Missing 0 (0.0)  0 (0.0)  
Month 12 n 63 63 67 67 
 0 61 (88.4) 61 (88.4) 66 (95.7) 66 (95.7) 
 1 2 (2.9) 2 (2.9) 1 (1.4) 1 (1.4) 
 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Missing 6 (8.7) 6 (8.7) 2 (2.9) 2 (2.9) 
 P-value*    0.443 
Month 24 n 61 61 65 65 
 0 61 (88.4) 60 (87.0) 65 (94.2) 64 (92.8) 
 1 0 (0.0) 1 (1.4) 0 (0.0) 1 (1.4) 
 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Missing 8 (11.6) 8 (11.6) 4 (5.8) 4 (5.8) 
 P-value*    1.000 
Month 36 n 61 61 60 60 
 0 60 (87.0) 59 (85.5) 60 (87.0) 59 (85.5) 
 1 1 (1.4) 2 (2.9) 0 (0.0) 1 (1.4) 








Since last visit 
n (%) 









 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Missing 8 (11.6) 8 (11.6) 9 (13.0) 9 (13.0) 
 P-value*    0.998 
Month 48 n 53 53 55 55 
 0 48 (69.6) 46 (66.7) 53 (76.8) 52 (75.4) 
 1 5 (7.2) 6 (8.7) 2 (2.9) 3 (4.3) 
 2 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 
 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
 Missing 16 (23.2) 16 (23.2) 14 (20.3) 14 (20.3) 









Figure 9.4. Changes in the number of fractures detected from MRI scans from baseline 





9.5 Treatment efficacy of nitisinone on spine ochronotic arthropathy in 
SONIA 2 patients using 18F-NaF PET/CT scan 
 
Table 9.23. Shows the summary statistics for HU measured from CT images for average 
lumbar vertebrae bodies (L1-L5) from Visit 1 to Visit 6 for 34 AKU patients who were 
part of the SONIA 2 clinical trial and involved in this study.  
Data are summarised by the number of patients (n), mean HU (SD), median (IQR), the 







Visit 1 Baseline N 17 17 
  Mean (SD) 174.1 (104.3) 152.7 (61.0) 
  Median (IQR) 154.2 (108.5,207.8) 160.2 (106.7,196.9) 
  Min, max 49.1, 509.8 10.9, 242.0 
Visit 3 Month 12 N 15 15 
  Mean (SD) 190.6 (111.4) 139.5 (61.1) 
  Median (IQR) 171.2 (127.4,197.8) 150.3 (97.2,199.6) 
  Min, max 82.9, 560.6 17.5, 223.0 
Visit 4 Month 24 N 14 16 
  Mean (SD) 176.9 (119.5) 143.0 (58.1) 
  Median (IQR) 172.3 (80.0,202.9) 141.8 (104.1,190.3) 
  Min, max 49.7, 531.5 17.1, 232.9 
Visit 5 Month 36 N 15 15 
  Mean (SD) 178.5 (123.0) 134.2 (52.0) 
  Median (IQR) 153.6 (114.7,204.8) 131.2 (109.5,183.8) 
  Min, max 43.1, 573.3 -6.1, 191.0 
Visit 6 Month 48 N 14 12 
  Mean (SD) 171.9 (112.2) 144.4 (59.6) 
  Median (IQR) 152.1 (113.0,209.5) 165.6 (127.6,180.5) 
















Table 9.24. Shows the change in HU values for nitisinone treated AKU patients and 
untreated patients who were part of the SONIA 2 clinical trial over four years.  
Data are summarised the change from baseline at each visit for HU values measured from the 
CT image for lumbar vertebrae bodies (L1-L5) using a Kruskal-Wallis test. *P-value < 0.05 
indicate a statistically significant difference between treatment groups in the mean change 
from baseline in HU values. At month 12, nitisinone-treated patients showed significantly 
more reduction in the mean lumbar HUmean value than non-treated patients (P = 0.036). There 
were no statistically significant differences between treatment and non-treatment groups in the 
mean change in lumbar HUmean measurements at neither month 24, month 36, or month 48 (P 








Visit 3 Month 12 N 15 15  
  Mean (SD) 10.9 (22.1) -6.5 (21.1)  
  Median (IQR) 6.1 (-1.6,27.0) -5.3 (-19.0,6.7) *0.036 
  Min, max -38.5, 50.8 -48.7, 35.9  
Visit 4 Month 24 N 14 16  
  Mean (SD) -2.9 (21.4) -7.0 (18.9)  
  Median (IQR) -1.5 (-21.1,6.6) -7.0 (-14.8,8.2) 0.739 
  Min, max -33.8, 42.5 -51.0, 23.2  
Visit 5 Month 36 N 15 15  
  Mean (SD) -3.6 (30.6) -20.2 (23.7)  
  Median (IQR) -2.9 (-15.4,9.7) -16.9 (-40.3,4.0) 0.120 
  Min, max -63.9, 63.5 -64.5, 9.6  
Visit 6 Month 48 N 14 12  
  Mean (SD) -8.8 (24.0) -10.5 (37.4)  
  Median (IQR) -3.5 (-29.1,3.5) -20.7 (-36.0,9.0) 0.681 












Table 9.25. Shows the summary statistics for SUVmax measured from PET scan for 
average lumbar vertebrae bodies (L1-L5) from Visit 1 to Visit 6 for 34 AKU patients who 
were part of the SONIA 2 clinical trial and involved in this study. 
Data are summarised by the number of patients (n), mean SUVmax (SD), median (IQR), the 







Visit 1 Baseline N 17 17 
  Mean (SD) 12.6 (4.2) 11.9 (2.0) 
  Median (IQR) 11.9 (9.9,14.8) 11.9 (10.6,12.3) 
  Min, max 5.8, 20.3 7.5, 16.4 
Visit 3 Month 12 N 15 15 
  Mean (SD) 12.7 (3.5) 11.9 (2.4) 
  Median (IQR) 12.0 (10.8,14.5) 12.1 (10.3,14.2) 
  Min, max 6.1, 19.5 6.7, 16.0 
Visit 4 Month 24 N 14 16 
  Mean (SD) 14.5 (5.2) 12.7 (2.9) 
  Median (IQR) 13.2 (12.0,16.4) 12.7 (10.9,14.6) 
  Min, max 7.6, 27.0 6.5, 17.3 
Visit 5 Month 36 N 15 15 
  Mean (SD) 14.6 (5.5) 13.7 (3.5) 
  Median (IQR) 12.7 (11.3,16.8) 14.0 (11.5,15.8) 
  Min, max 7.4, 28.4 7.1, 20.7 
Visit 6 Month 48 N 14 12 
  Mean (SD) 13.9 (4.0) 15.1 (4.6) 
  Median (IQR) 13.0 (11.0,18.0) 14.0 (13.0,17.5) 
















Table 9.26. Shows the change in SUVmax values for nitisinone treated and untreated AKU 
patients who were part of the SONIA 2 clinical trial over four years.  
Data are summarised the change from baseline at each visit for SUVmax values measured from 
PET scan for lumbar vertebrae bodies (L1-L5) using a Kruskal-Wallis test. *P-value < 0.0,5 
indicate a statistically significant difference between treatment groups in the mean change 
from baseline in SUVmax values. At month 12, month 24, and month 36, there was no 
statistically significant change from baseline in vertebrae SUVmax values. At month 48, 
nitisinone-treated patients presented a significantly higher increment in the mean lumbar 








Visit 3 Month 12 n 15 15  
  Mean (SD) -0.5 (2.2) 0.2 (1.3)  
  Median (IQR) -0.5 (-2.0,0.9) 0.2 (-0.5,1.6) 0.206 
  Min, max -4.2, 4.0 -2.9, 2.4  
Visit 4 Month 24 n 14 16  
  Mean (SD) 1.5 (4.2) 0.8 (1.7)  
  Median (IQR) 1.1 (-0.5,2.1) 0.8 (-0.3,1.2) 0.678 
  Min, max -4.0, 14.3 -1.7, 4.7  
Visit 5 Month 36 n 15 15  
  Mean (SD) 1.3 (4.7) 1.7 (2.2)  
  Median (IQR) 0.7 (-1.1,1.8) 1.6 (-0.4,4.1) 0.310 
  Min, max -3.7, 15.7 -1.3, 5.2  
Visit 6 Month 48 n 14 12  
  Mean (SD) 0.5 (2.4) 3.0 (3.6)  
  Median (IQR) 0.0 (-1.6,1.6) 2.3 (0.5,4.6) *0.045 














Table 9.27. Shows the summary statistics for SUVmax measured from PET scan for 
average lumbar vertebrae disc units (T12/L1-L5/S1) from Visit 1 to Visit 6 for 34 AKU 
patients who were part of SINIA 2 clinical trial and involved in this study.  
Data are summarised by the number of patients (n), mean SUVmax (SD), median (IQR), the 







Visit 1 Baseline N 17 17 
  Mean (SD) 14.7 (5.4) 14.6 (2.9) 
  Median (IQR) 14.2 (10.6,18.0) 14.3 (13.3,16.0) 
  Min, max 6.9, 23.8 8.6, 19.8 
Visit 3 Month 12 N 15 15 
  Mean (SD) 15.1 (4.9) 14.3 (3.4) 
  Median (IQR) 14.8 (11.3,20.2) 14.3 (11.6,16.0) 
  Min, max 6.1, 22.4 7.5, 21.0 
Visit 4 Month 24 N 14 16 
  Mean (SD) 16.7 (6.5) 14.8 (3.7) 
  Median (IQR) 15.6 (12.2,21.1) 14.5 (13.0,17.0) 
  Min, max 7.5, 30.5 7.1, 21.8 
Visit 5 Month 36 N 15 15 
  Mean (SD) 15.7 (5.8) 13.8 (3.4) 
  Median (IQR) 14.7 (12.0,18.7) 14.7 (10.5,15.3) 
  Min, max 7.0, 29.8 7.3, 20.6 
Visit 6 Month 48 N 14 12 
  Mean (SD) 14.6 (3.9) 15.3 (4.7) 
  Median (IQR) 14.0 (12.5,17.9) 15.8 (12.6,18.2) 


















Table 9.28. Shows the change in lumbar DVU SUVmax values for nitisinone treated and 
untreated AKU patients who were part of the SONIA 2 clinical trial over four years. 
Data are summarised the change from baseline for SUVmax measured from PET scan for 
lumbar DVU (T12/L1-L5-S1) using a Kruskal-Wallis test. There was no statistically 
significant difference between treatment and non-treatment groups in the adjusted mean 







Visit 3 Month 12 N 15 15  
  Mean (SD) -0.4 (2.3) -0.4 (1.7)  
  Median (IQR) -0.5 (-2.2,2.1) -0.9 (-1.5,1.2) 0.885 
  Min, max -4.8, 3.0 -2.7, 2.5  
Visit 4 Month 24 N 14 16  
  Mean (SD) 1.8 (4.3) 0.2 (2.0)  
  Median (IQR) 2.0 (-0.5,2.9) 0.9 (-1.6,1.6) 0.124 
  Min, max -5.6, 13.8 -3.7, 3.6  
Visit 5 Month 36 N 15 15  
  Mean (SD) 0.5 (4.3) -0.6 (2.4)  
  Median (IQR) 0.8 (-1.9,2.0) -0.3 (-3.1,1.8) 0.633 
  Min, max -5.1, 13.2 -4.5, 2.4  
Visit 6 Month 48 N 14 12  
  Mean (SD) -1.1 (3.1) 0.5 (3.6)  
  Median (IQR) -0.3 (-3.8,1.0) 0.5 (-2.5,2.3) 0.280 







9.6 Cardiovascular calcification in alkaptonuria patients using quantitative 
analysis by 18F-NaF PET/CT 
 
Table 9.29. Gender difference in the severity of cardiovascular calcification measured 
from 18F-NaF PET/CT scan for 40 AKU patients who were part of the SONIA 2 trial. 
The results show mean SUVmax ± SD, minimum, and maximum values for main branches of 
arteries for males and females. * Correlation is statistically significant between gender at the 
ROI (P < 0.05). Left coronary artery-left main stem (LCA), left anterior descending artery 
(LAD), left circumflex artery (CA) and right coronary artery (RCA), ascending aorta (AA) 
and descending aorta (DA), inferior vena cava (IVC) and superior vena cava (SVC).   





1.57 ± 0.59 
1.67 ± 0.65 













1.12 ± 0.35 
1.2 ± 0.37 










Total 1.18 ± 0.50 0.45 2.64 
 
0.675 
Male 1.21 ± 0.45 0.45 2.39 
Female 1.14 ± 0.57 0.54 2.64 
RCA 
Total 1.68 ± 1.04 0.6 6.02 
 
0.022* 
Male 1.99 ± 1.20 0.7 6.02 
Female 1.23 ± 0.49 0.6 2.25 
All main coronary 
arteries 
Total 1.39 ± 0.49 0.73 2.55 
 
0.036* 
Male 1.52 ± 0.51 0.76 2.55 
Female 1.23 ± 0.49 0.6 2.25 
AA 
Total 1.78 ± 0.57 0.89 3.6 
 
0.222 
Male 1.87 ± 0.59 1.15 3.6 





2.38 ± 1.29 
2.43 ± 1.20 













2.06 ± 0.84 
2.14 ± 0.78 










Total 0.77 ± 0.30 0.37 1.79 
 
0.003* 
Male 0.64 ± 0.20 0.37 1.09 





0.86 ± 0.28 
0.84 ± 0.25 













0.82 ± 0.27 
0.76 ± 0.21 











Table 9.30. SUVmax measurements at the cardiac arteries for 40 AKU patients who were 
part of the SONIA 2 clinical trial stratified by the decade of life.  
Data display the SUVmax ± SD, minimum and maximum values, and P-value obtained from 
the baseline 18F-NaF PET/CT scan at the main coronary arteries (LCA, LAD, CA, and RCA), 
aorta (AA, and DA), and blood pool vessels (IVc, and SVC) in four age groups. * Correlation 
is statistically significant between age group at the ROI (P < 0.05). 
ROI Age group SUVmax ± SD Minimum  Maximum P-value 
LCA 
30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.20 ± 0.26 
1.60 ± 0.89 
1.57 ± 0.45 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
0.99 ± 0.34 
1.14 ± 0.40 
1.05 ± 0.32 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.06 ± 0.21 
1.07 ± 0.52 
1.16 ± 0.40 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.28 ± 0.32 
1.42 ± 1.14 
1.63 ± 0.53 














30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.13 ± 0.25 
1.31 ± 0.63 
1.35 ± 0.34 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.68 ± 0.52 
1.65 ± 0.50 
1.94 ± 0.67 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.94 ± 0.65 
2.34 ± 1.53 
2.61 ± 1.11 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.73 ± 0.52 
2.00 ± 0.93 
2.28 ± 0.78 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.09 ± 0.52 
0.76 ± 0.25 
0.71 ± 0.22 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
0.87 ± 0.49 
0.78 ± 0.15 
0.91 ± 0.26 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
0.87 ± 0.47 
0.77 ± 0.17 
0.86 ± 0.23 















Table 9.31. Gender difference in the severity of cardiovascular calcification measured 
from baseline 18F-NaF PET/CT scans for 40 AKU patients who were part of the SONIA 
2 clinical trial.  
The results show mean TBRmax ± SD, minimum, and maximum values for main branches of 
coronary arteries and aortic arteries for males and females. * Correlation is statistically 
significant between gender at the ROI (P < 0.05). A significant difference was found between 
male and female at LAD and RCA only (P = 0.018, P = 0.0 12, respectively). Left coronary 
artery-left main stem (LCA), left anterior descending artery (LAD), left circumflex artery (-
CA) and right coronary artery (RCA).  
 






















































































































Table 9.32. TBRmax measurements at the cardiac arteries for 40 AKU patients who were 
part of the SONIA 2 clinical trial stratified by the decade of life.  
Data display the TBRmax ± SD, minimum and maximum values and P-value obtained from the 
baseline 18F-NaF PET/CT scan at the main coronary arteries and aorta in four age groups. 
Statistically, no significant difference between the values of TBRmax of age groups at neither 
coronary nor aortic arterial regions (P > 0.05). 
ROI Age Group TBRmax ± SD Minimum Maximum P-value 
LCA 
30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.67 ± 0.64 
2.42 ± 2.38 
1.85 ± 0.47 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.34 ± 0.41 
1.49 ± 0.51 
1.25 ± 0.39 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.50 ± 0.63 
1.44 ± 0.92 
1.36 ± 0.40 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.76 ± 0.66 
1.83 ± 1.30 
1.91 ± 0.49 















30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
1.62 ± 0.52 
1.69 ± 0.96 
1.59 ± 0.32 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
2.41 ± 1.26 
2.10 ± 0.54 
2.41 ± 1.36 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
2.89 ± 1.87 
3.08 ± 2.25 
3.14 ± 1.50 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
2.65 ± 1.44 
2.64 ± 1.30 
2.77 ± 1.35 



















Table 9.33. Gender difference in the severity of cardiovascular calcification measured 
from CT scans for 40 AKU patients who were part of the SONIA 2 clinical trial.  
The results show mean HUmean ± SD, minimum, and maximum values for main branches of 
arteries for males and females. * Correlation is statistically significant between gender at the 
ROI (P < 0.05). Left coronary artery-left main stem (LCA), left anterior descending artery 
(LAD), left circumflex artery (CA) and right coronary artery (RCA), aortic arteries, including 
ascending aorta (AA) and descending aorta (DA), and blood pool vessels, including inferior 
vena cava (IVC) and superior vena cava (SVC).   





127.42 ± 153.91 
140.00 ± 150.30 












115.75 ± 124.66 
145.42 ± 138.54 












125.89 ± 177.40 
143.44 ±2 06.56 












197.2 ± 239.88 
238.21 ± 274.65 













138.18 ± 139.41 
166.68 ± 154.47 












134.33 ± 141.74 
116.67 ± 69.74 












133.1 ±1 47.11 
113.42 ± 61.92 












133.71 ± 143.48 
115.04 ± 64.68 












99.85 ± 15.99 



























95.57 ± 14.71 
92.75 ± 13.71 










Table 9.34. HUmean measurements at the cardiac arteries for 40 AKU patients who were 
part of the SONIA 2 clinical trial stratified by the decade of life.  
Data display the HUmean ± SD, minimum and maximum values, and P-value obtained from the 
CT scan at the main coronary arteries, aorta, and blood pool in four age groups. * Correlation 
is statistically significant between age group at the ROI (P < 0.05). 
ROI Age Group HUmean ± SD Minimum Maximum P-value 
LCA 
30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
84.00 ± 44.38 
112.77 ± 160.48 
71.00 ± 34.08 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
83.00 ± 68.74 
50.00 ± 25.42 
104.10 ± 135.05 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
71.14 ± 53.41 
132.31 ± 244.27 
62.60 ± 28.48 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
75.57 ± 33.07 
158.38 ± 323.72 
218.40 ± 228.39 















30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
78.32 ± 32.93 
113.37 ± 182.69 
100.63 ± 66.84 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
109.57 ± 29.14 
89.54 ± 12.28 
98.80 ± 9.58 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
106.57 ± 21.42 
96.31 ± 16.44 
102.00 ± 12.34 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
108.07 ± 23.62 
92.92 ± 11.39 
100.40 ± 10.45 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
107.00 ± 12.19 
97.90 ± 20.39 
100.67 ± 14.92 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
113.00 ± 19.07 
78.92 ± 10.28 
89.30 ±1 6.83 













30-39 years old 
40-49 years old 
50-59 years old 
> 60 years old 
110.00 ± 15.22 
86.83 ± 10.87 
95.59 ± 12.97 
98.80 ± 14.70 
93.00 
66.50 
80.00 
77.00 
133.00 
105.50 
126.00 
122.50 
0.00* 
0.11 
0.62 
 
 
